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Background: Hyperhidrosis is uncontrollable excessive sweating that occurs at rest, regardless of
temperature. The symptoms of hyperhidrosis can significantly affect quality of life. The management of
hyperhidrosis is uncertain and variable.
Objective: To establish the expected value of undertaking additional research to determine the most
effective interventions for the management of refractory primary hyperhidrosis in secondary care.
Methods: A systematic review and economic model, including a value-of-information (VOI) analysis.
Treatments to be prescribed by dermatologists and minor surgical treatments for hyperhidrosis of the
hands, feet and axillae were reviewed; as endoscopic thoracic sympathectomy (ETS) is incontestably an
end-of-line treatment, it was not reviewed further. Fifteen databases (e.g. CENTRAL, PubMed and
PsycINFO), conference proceedings and trial registers were searched from inception to July 2016. Systematic
review methods were followed. Pairwise meta-analyses were conducted for comparisons between
botulinum toxin (BTX) injections and placebo for axillary hyperhidrosis, but otherwise, owing to evidence
limitations, data were synthesised narratively. A decision-analytic model assessed the cost-effectiveness
and VOI of five treatments (iontophoresis, medication, BTX, curettage, ETS) in 64 different sequences for
axillary hyperhidrosis only.
Results and conclusions: Fifty studies were included in the effectiveness review: 32 randomised
controlled trials (RCTs), 17 non-RCTs and one large prospective case series. Most studies were small,
rated as having a high risk of bias and poorly reported. The interventions assessed in the review were
iontophoresis, BTX, anticholinergic medications, curettage and newer energy-based technologies that
damage the sweat gland (e.g. laser, microwave). There is moderate-quality evidence of a large statistically
significant effect of BTX on axillary hyperhidrosis symptoms, compared with placebo. There was weak but
consistent evidence for iontophoresis for palmar hyperhidrosis. Evidence for other interventions was of low
or very low quality. For axillary hyperhidrosis cost-effectiveness results indicated that iontophoresis, BTX,
medication, curettage and ETS was the most cost-effective sequence (probability 0.8), with an incremental
cost-effectiveness ratio of £9304 per quality-adjusted life-year. Uncertainty associated with study bias was
not reflected in the economic results. Patients and clinicians attending an end-of-project workshop were
satisfied with the sequence of treatments for axillary hyperhidrosis identified as being cost-effective.
All patient advisors considered that the Hyperhidrosis Quality of Life Index was superior to other tools
commonly used in hyperhidrosis research for assessing quality of life.
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Limitations: The evidence for the clinical effectiveness and safety of second-line treatments for primary
hyperhidrosis is limited. This meant that there was insufficient evidence to draw conclusions for most
interventions assessed and the cost-effectiveness analysis was restricted to hyperhidrosis of the axilla.
Future work: Based on anecdotal evidence and inference from evidence for the axillae, participants
agreed that a trial of BTX (with anaesthesia) compared with iontophoresis for palmar hyperhidrosis would
be most useful. The VOI analysis indicates that further research into the effectiveness of existing medications
might be worthwhile, but it is unclear that such trials are of clinical importance. Research that established a
robust estimate of the annual incidence of axillary hyperhidrosis in the UK population would reduce the
uncertainty in future VOI analyses.
Study registration: This study is registered as PROSPERO CRD42015027803.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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NICE National Institute for Health
and Care Excellence
NMA network meta-analysis
OR odds ratio
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PSA probabilistic sensitivity analysis
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Plain English summary
Hyperhidrosis is characterised by uncontrollable and excessive sweating that occurs at rest, regardless oftemperature, and has a major impact on quality of life.
The aim of this project was to summarise the evidence on the clinical effectiveness and cost-effectiveness
of treatments for primary hyperhidrosis and assess the need for and value of further research.
We systematically reviewed studies of the effectiveness of treatments to be prescribed by dermatologists
and minor surgical treatments for hyperhidrosis of the hands, feet and armpits; as ‘endoscopic thoracic
sympathectomy’ (ETS) surgery is established as an end-of-line treatment, we did not review this further.
We analysed the cost-effectiveness of the treatments for the armpit. We also investigated the value and
cost-effectiveness of conducting further research for the armpit. We consulted patients about our analysis
and findings.
The evidence on treatments for hyperhidrosis was of limited quality and insufficient to draw firm
conclusions. There was consistent weak evidence of some benefit from iontophoresis (a process in which
an electrical field is used to deliver drugs through the skin) for hyperhidrosis of the hands, and botulinum
toxin (BTX) injections were found to be effective for patients with hyperhidrosis of the armpit. For armpit
hyperhidrosis, our analyses suggested that using treatments in the following order would be the most
cost-effective: iontophoresis, BTX, medication, curettage, ETS.
Combining the evidence and patient advisor input, we established that further research on the clinical
effectiveness and cost-effectiveness of BTX (with anaesthetic) compared with iontophoresis for
hyperhidrosis of the hand would be useful. The Hyperhidrosis Quality of Life Index tool appears to be the
best questionnaire for measuring the impact of treatments on quality of life in future studies. The results
of ongoing studies of new technologies that damage the sweat glands, and of new formulations of
anticholinergic medications, may be informative.
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Scientific summary
Background
Hyperhidrosis is characterised by uncontrollable, excessive and unpredictable sweating that occurs at rest,
regardless of temperature. Primary hyperhidrosis has no discernible cause. It most commonly involves the
axillae, palms and soles, but may also involve the face, groin or any area of the body.
Primary hyperhidrosis is thought to affect approximately 1% of the UK population, with around 100 new
patients being referred to an average NHS dermatology department each year. The symptoms of
hyperhidrosis can significantly affect quality of life and can lead to social embarrassment, loneliness,
anxiety and depression.
There is significant variation in the treatment for primary hyperhidrosis available in secondary care and
current recommendations are not underpinned by robust evidence; there are many areas of uncertainty.
Objectives
The aim of this project was to establish the expected value of undertaking additional clinical studies to
determine the most effective interventions for the management of refractory primary hyperhidrosis
(excluding patients with social anxiety disorder) in secondary care.
The key objectives were:
1. to undertake an evidence synthesis by systematic review to estimate the clinical effectiveness and safety
of treatments that would be available in secondary care and inform key clinical parameters for a
decision model
2. to develop a decision model to estimate cost-effectiveness
3. using the decision model, to undertake a value-of-information (VOI) analysis to help inform the design
of future clinical studies.
Methods of the clinical effectiveness review
A systematic review was conducted to inform the clinical effectiveness and safety of treatments that would
be available for prescription by dermatologists and minor surgical treatments. The protocol included all
treatments for hyperhidrosis prescribed in secondary care. However, screening and selecting the relevant
literature revealed that endoscopic thoracic sympathectomy (ETS) could not be included in a comparative
review as the position of ETS in the treatment pathway is uncontestable; ETS is considered only as an
intervention of last resort because of its significant risks. Recent studies of ETS have focused on the details
of the surgical procedure, addressing a question that is beyond the remit of the current project.
Fifteen databases (e.g. CENTRAL, PubMed and PsycINFO) were searched in January 2016. Clinical advisors
were consulted for additional potentially relevant studies and reference lists of relevant systematic reviews
were manually searched. Information on studies in progress and unpublished research was sought by
searching conference proceedings and trial registers, in July 2016.
Studies assessing treatments for primary hyperhidrosis that would be available for prescription by
dermatologists and minor surgical treatments were eligible for inclusion. For each intervention, randomised
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controlled trials (RCTs), non-RCTs and large prospective case series were identified and the more robust
study designs were included in the review. Outcomes of interest included disease severity, sweat rate,
quality of life, patient satisfaction and adverse events.
Pairwise meta-analyses were conducted for comparisons between botulinum toxin (BTX) injections and
placebo for axillary hyperhidrosis. The evidence for other comparisons was too limited or too
heterogeneous to allow pooling; therefore, data were tabulated and synthesised narratively.
Results of the clinical effectiveness review
Fifty studies were included in the systematic review: 32 RCTs, 17 non-RCTs and one case series. Most
studies were small, rated as having a high risk of bias and poorly reported. The interventions in the
included studies were iontophoresis, BTX, anticholinergic medications, curettage and newer technologies
that damage the sweat gland (e.g. laser, microwave).
There is moderate-quality evidence of a large statistically significant effect of subcutaneous BTX on symptoms
of axillary hyperhidrosis in the short and medium term (up to 16 weeks) [pooled Hyperhidrosis Disease Severity
Scale (HDSS) response at 4 weeks: risk ratio 3.30, 95% confidence interval 2.46 to 4.43]. Short-term evidence
indicated that BTX may improve quality of life compared with placebo but is associated with adverse events,
notably injection site pain. Evidence comparing the effectiveness of BTX injections to the axillae with curettage
is very low quality and uncertain, although there is no evidence to suggest that curettage is more effective
than BTX in the short to medium term and there is evidence to suggest that there is a higher incidence of
adverse events with curettage. Trials are too short term to explore the potential curative nature of curettage
compared with the retreatment needed with BTX.
There is very low-quality evidence suggesting that BTX injections had a small positive effect on palmar
hyperhidrosis symptoms compared with placebo or no treatment, although there was a high incidence of
adverse events with BTX.
There is insufficient evidence to draw conclusions on the effectiveness and safety of topical BTX for primary
hyperhidrosis.
There were no studies assessing the clinical effectiveness of iontophoresis for axillary hyperhidrosis.
There is very low-quality evidence suggesting a short-term beneficial effect of tap water iontophoresis on
palmoplantar hyperhidrosis compared with placebo and of dry-type iontophoresis compared with no
treatment. Compared with tap water iontophoresis alone, the evidence for the effectiveness of combining
anticholinergic therapy with iontophoresis is mixed and inconclusive. There is low-quality evidence to
suggest that iontophoresis is less effective than BTX injections at reducing palmar hyperhidrosis symptoms
in the short term and that the effect duration is shorter than with BTX.
There were no studies assessing the clinical effectiveness of oral glycopyrrolate. There is very low-quality
evidence regarding the effectiveness and safety of topical glycopyrrolate for axillary and facial
hyperhidrosis. No evidence for other treatment sites was found.
There is low-quality evidence suggesting a short-term small benefit of other oral anticholinergics in
hyperhidrosis symptoms compared with placebo. Both oxybutynin and methantheline bromide are
associated with dry mouth symptoms. There were no studies assessing the clinical effectiveness of
propantheline bromide for hyperhidrosis.
The limited evidence precludes any conclusions regarding the effectiveness and safety of curettage, laser
epilation, fractionated microneedle radiofrequency, microwave or ultrasound.
SCIENTIFIC SUMMARY
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Review of quality-of-life measures/tools
A narrative review was conducted to identify the tools that are commonly used to measure quality of life in
studies of patients with hyperhidrosis. Study eligibility was not restricted to the interventions considered
in the separate systematic review of effectiveness: all studies that reported measuring quality of life or
described a quality-of-life measure/tool in the context of hyperhidrosis were included. Information on the
tools and their use in hyperhidrosis was summarised in a narrative synthesis.
The review included 184 studies, many of which used two or more tools for measuring quality of life.
Twenty-two individual tools were identified. In addition, 32 studies were identified that reported
quality-of-life outcomes, but the method used to measure quality of life was not reported.
The Dermatology Life Quality Index (DLQI), the HDSS and the Hyperhidrosis Quality of Life Questionnaire
(HQLQ) were used more often than any other tool for measuring quality of life in hyperhidrosis. The
Hyperhidrosis Quality of Life Index (HidroQoL©) is the most recent tool to be designed and validated for
measuring quality of life in patients with hyperhidrosis.
Development of a new cost-effectiveness model
The review of cost-effectiveness studies did not identify any modelling studies, so a de novo cost-effectiveness
model was developed to formally assess the cost-effectiveness of treatments for primary hyperhidrosis and to
estimate the VOI to aid decisions about further research. Cost-effectiveness analysis (CEA), expected value
of perfect information (EVPI) and expected value of partial perfect information (EVPPI) analyses were conducted
for the axillae body site only: insufficient evidence was available to warrant an analysis for any other body
site. A NHS and Personal Social Services perspective was adopted for the analysis. The axillae CEA was a
state-transition cohort model with a time horizon of 48 years. Quality-adjusted life-years (QALYs) and costs,
discounted at a rate of 3.5%, were calculated for 64 different treatment sequences. The treatments in the
sequences included: aluminium chloride, iontophoresis (sponge for axilla), medication, BTX, curettage and ETS.
Technologies such as laser, microwave, ultrasound and fractionated microneedle radiofrequency were not
included in the base-case model as they are not common practice in the UK. The model was based on
treatment response defined as at least a two-point reduction on the HDSS.
The clinical evidence was based on a network meta-analysis conducted on the studies identified in the
review of clinical effectiveness. When the response was reported as a continuous variable, a binary variable
was derived. Withdrawal rates for iontophoresis sponge and medication were obtained from a survey of
dermatologists conducted to inform the model parameters. EuroQol-5 Dimensions (EQ-5D) utility estimates
were derived from a primary study of EQ-5D at different levels of response with a small sample size.
Costs were mostly obtained from the national published sources.
Scenario, sensitivity and threshold analyses were conducted on the effectiveness of iontophoresis sponge,
NHS payment of home iontophoresis sponge, the long-term effectiveness of medication, the price of
medication, the probability of withdrawal due to adverse effects for BTX, the frequency of BTX injections,
the disease severity of people having surgery and the likelihood of retrying different treatments.
Cost-effectiveness, expected value of perfect information and expected
value of partial perfect information results
The base-case results indicated that iontophoresis, BTX, medication, curettage and ETS was the most
cost-effective sequence, with an incremental cost-effectiveness ratio of £9304 per QALY (probability of 0.8).
A total of 59 out of the 64 treatment sequences were either strictly dominated or dominated by extension.
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The next most cost-effective sequences involved those with medication either before BTX in the sequence
or not in the sequence at all. This reflects the uncertainty in the estimate of the effectiveness of medication
versus placebo.
The following scenarios had an effect on the results:
l If the cost of medication increased from the cost of propantheline bromide to an average of the cost
of propantheline bromide and glycopyrrolate bromide, then it would no longer be cost-effective to
include medication in the treatment sequence at a willingness-to-pay threshold of £30,000 per QALY
l If the effectiveness of medication declines over time, then it becomes significantly less cost-effective to
include medication in a treatment sequence.
l If the iontophoresis response rate were only half the placebo response rate of 0.13, then iontophoresis
would come after medication in the sequence; BTX would be first.
l If partial responders to non-surgical options as well as patients with no response at all had curettage
instead of only those that had no response at all to previous treatments, then curettage would come
after iontophoresis in the treatment sequence as it is relatively cost-effective compared with BTX and
medication given the assumptions in the model.
The EVPI has been calculated based on the model assuming that the NHS pays for home iontophoresis and
the iontophoresis device has a life expectancy of 10 years. This is the estimated difference between the
expected value of the decision made with perfect information and the decision made with current information.
The population EVPPI results indicate that the value of further research on any model parameter is
unlikely to be greater than the cost at a threshold of £20,000 per QALY. The exceptions are research on
withdrawal rates due to adverse effects if the annual incidence of axillary hyperhidrosis is 2%, and on
curettage compared with BTX effectiveness if the annual incidence of axillary hyperhidrosis is 2% and the
odds ratio (OR) of response of iontophoresis compared with placebo is 1.
If the cost-effectiveness threshold is £30,000 per QALY and the annual incidence of axillary hyperhidrosis is
2%, then the value of further research may be greater than the cost for research on medication compared
with placebo effectiveness. If the annual incidence is 2% and the OR of response of iontophoresis compared
with placebo is 1, then research on BTX compared with medication effectiveness may be cost-effective.
Patient and clinician perspective on research findings
In order to elicit the opinions of hyperhidrosis patients and clinicians, an end-of-project workshop was held
at Harrogate District Hospital with four patients and one dermatologist. Other clinicians provided advice
during telephone meetings.
Patients and clinicians were unsurprised by the positive findings regarding BTX for axillary hyperhidrosis
and did not consider that further research on iontophoresis for the axilla would be worthwhile. Despite
the lack of trial evidence, they believed that iontophoresis was effective in some patients. Patients
and clinicians agreed that a trial of BTX (plus anaesthetic) compared with iontophoresis for palmar
hyperhidrosis would be useful.
Patients and clinicians were satisfied with the sequence of treatments identified as being cost-effective in
the modelling exercise: iontophoresis, BTX, medication, curettage and ETS.
A trial comparing the different anticholinergic medications currently available for hyperhidrosis was
not considered to be worthwhile. Although there was interest in the new energy-based ‘destructive’
technologies as potential cures for hyperhidrosis of the axilla, patients and clinicians agreed that better
evidence was needed before a comparative trial against BTX was warranted.
SCIENTIFIC SUMMARY
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All patient advisors agreed that the HidroQoL tool was superior to the other tools commonly used in
hyperhidrosis research (HDSS, DLQI, HQLQ) for assessing quality of life. Patients considered that the
HidroQoL tool should be the primary outcome in future studies and that measuring the actual amount of
sweat produced should only be considered as a secondary outcome.
Conclusions
The evidence for the effectiveness and safety of second-line treatments for primary hyperhidrosis is limited
overall and few firm conclusions can be drawn. However, there is moderate-quality evidence to support
the use of BTX injections for axillary hyperhidrosis.
The cost-effectiveness analysis for axillary hyperhidrosis found that the treatment sequence of iontophoresis,
BTX, medication, curettage and ETS was most cost-effective. Despite high levels of uncertainty, iontophoresis
and BTX maintained their position as first and second treatment options in the majority of cost-effective
sequences. The VOI analyses included relative effectiveness parameters for BTX, medication and curettage,
and the results suggested that a trial on medication compared with placebo with a HDSS outcome measure
may be of value if the cost-effectiveness threshold is £30,000 and the annual incidence of axillary
hyperhidrosis is 2%. Given the level of uncertainty and its impact on the model, further research on the
annual incidence of axillary hyperhidrosis may be warranted.
Based on clinical and patient opinion, and inferences from findings from the evidence, a well-conducted,
adequately powered RCT of BTX (with anaesthesia), compared with iontophoresis, for palmar hyperhidrosis
may be warranted. The new HidroQoL tool appears appropriate for capturing hyperhidrosis-related
quality-of-life issues. BTX plus anaesthesia costs considerably more than iontophoresis and, therefore,
cost-effectiveness would also need to be assessed.
There are ongoing studies of the new ‘destructive’ technologies: microwave, laser, fractionated
microneedle radiofrequency and ultrasound. If the results of this ongoing research are promising, then
trials comparing these with BTX and with curettage for axillary hyperhidrosis may be warranted.
There are ongoing and recently completed trials of new oral and topical anticholinergic medication
formulations; therefore, it is unlikely to be worthwhile undertaking further research of the anticholinergic
medications currently available. There is little value in undertaking further studies of BTX compared with
placebo for hyperhidrosis of the axilla or iontophoresis compared with placebo for hyperhidrosis of the
hand.
Study registration
This study is registered as PROSPERO CRD42015027803.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of underlying health problem
Hyperhidrosis is characterised by uncontrollable, excessive and unpredictable sweating that occurs at rest,
regardless of temperature, and has a major impact on quality of life. It is caused by hyperfunction of the
exocrine sweat glands, which are controlled by the sympathetic nervous system via postsynaptic cholinergic
fibres.
Hyperhidrosis is a common condition that can be primary or secondary. Primary hyperhidrosis is excessive
sweating without any discernible cause. It most commonly involves the axillae, palms and soles, but may
also involve the face, groin or any area of the body. Secondary hyperhidrosis has an underlying cause, such
as an endocrine disorder (e.g. hyperthyroidism), secretory tumour (e.g. phaeochromocytoma), sympathetic
nervous system disorder, primary neurological condition (e.g. neuropathy), spinal disease or injury, or a
psychiatric disorder. It is usually generalised over the entire body (i.e. not restricted to any specific areas of
the body).
Primary hyperhidrosis is thought to affect approximately 1% of the UK population.1 Firm estimates of
prevalence for the UK or England, or England and Wales, are not available. Estimates of prevalence from
a large US study2 reported a figure of 2.1%, although a recent much smaller study reported a much higher
estimate of 4.8%.3 A recent study of prevalence in Sweden reported a figure of 1.4% for primary
hyperhidrosis [Hyperhidrosis Disease Severity Scale (HDSS) 3–4], whereas a study from Germany reported a
figure of 6.1% with frequent or continuous disturbing sweating.4,5 A study of two ethnically different cities
reported prevalence rates of 14.5% in Shanghai and 12.3% in Vancouver.6 It is unclear why the estimates
are so varied, but reasons may include differences in study design and definition of primary hyperhidrosis.
Primary hyperhidrosis normally develops in childhood and adolescence. In a few instances, it may improve
with age, but it usually persists for the majority of life, although it may resolve spontaneously in the
elderly. Although the cause of primary hyperhidrosis is unknown, it is likely that there is a genetic link,
with one study reporting 65% of patients having a positive family history.7
The symptoms of hyperhidrosis can significantly affect quality of life and can lead to social embarrassment,
loneliness, anxiety and depression. Functional problems may arise from skin maceration and soreness.
Severely affected patients also may have secondary microbial infections. Teenagers may be referred for
treatment because problems holding a pen and sweating ruining paperwork lead to an inability to do
schoolwork and examinations. Adults may find the condition affects employability and it may prevent
individuals having personal relationships. The unpredictable and uncontrollable nature of the condition can
make it very distressing for sufferers.
Description of current NHS service provision
Patients suffering from hyperhidrosis often have anxiety disorders or depression, which may exacerbate or
can in some instances be the cause of their hyperhidrosis.8 It is important to distinguish between primary
and secondary hyperhidrosis as the treatment options are different. Treatment for secondary hyperhidrosis
should be directed towards the underlying cause, rather than the hyperhidrosis itself.
The management of primary hyperhidrosis has been summarised in two non-systematic evidence
reviews.9,10 Therapy for primary hyperhidrosis differs depending on the site of the condition. The generally
accepted treatment pathway with the various treatment options is summarised as follows.
DOI: 10.3310/hta21800 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 80
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Wade et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
1
Primary care
Patients have often tried various over-the-counter remedies before presenting to their general practitioner
(GP). In primary care, an assessment of patients’ symptoms will include an assessment of the psychological
and social effects of the condition to the patient.
As hyperhidrosis can be exacerbated by foods containing stimulants, especially caffeine and theobromine,
dietary restriction of coffee, tea, caffeinated soft drinks and chocolate may improve mild cases of
hyperhidrosis. Other lifestyle changes that may reduce symptoms include avoiding clothing that can make
sweating worse, such as tight-fitting garments or man-made fibres, wearing clothing that absorbs sweat or
disguises its appearance, or using devices such as armpit guards.11 Hyperhidrosis can be associated with
weight gain, and overweight people may benefit from advice about weight reduction. Drugs and physiological
or disease-driven hormonal abnormalities may lead to secondary hyperhidrosis and should be excluded.
The first line of treatment for primary hyperhidrosis is topical pharmacological agents.8 Most patients try a
variety of topical antiperspirants and deodorants, but find no relief until they use 10% or 20% aluminium
chloride applied daily to dry skin. This dose of aluminium chloride has been shown to be effective in
clinical trials for mild to moderate hyperhidrosis.10 It is hypothesised that the metallic antiperspirants enter
the sweat gland duct and form an occlusive plug by combining with ductal keratin. Unfortunately, skin
irritation is very common with these antiperspirants and often forces discontinuation of the treatment.9
In UK clinical practice, for axillary hyperhidrosis, a 1-month trial of 20% aluminium chloride is the initial
treatment. Treatment is similar for plantar hyperhidrosis except that a month’s trial of 3% formaldehyde
solution to be applied to the soles can be offered. Failure of these treatments over the specified period
may be followed by referral to a secondary care dermatologist.
The evidence base for the use of aluminium chloride in primary care is weak. The National Institute for
Health and Care Excellence (NICE) Clinical Knowledge Summary found no placebo-controlled randomised
controlled trials (RCTs) and identified a limited evidence base comprising two small poor-quality RCTs, an
open-label trial, four small case series and expert opinion.8 However, this low-cost therapy is used mainly
as a first step, helping GPs discriminate between those who do and do not require referral for more
specialised care. Patients whose apparent primary hyperhidrosis is actually secondary to an anxiety disorder,
medication or a hormonal abnormality may also be identified in primary care and are referred for relevant
treatments or investigation, rather than treatments specific to hyperhidrosis. Consequently, there is little
decision uncertainty in relation to the treatment of hyperhidrosis in primary care, unlike the situation in
secondary care.
Dermatology
Dermatologists may prescribe any of a number of treatments: iontophoresis, botulinum toxin (BTX)
injections or systemic agents, such as anticholinergic (antimuscarinic) medications, depending on local
prescribing policies.8,10,12
Tap water iontophoresis is a process in which an electrical field drives the flow of ions in a medium and
enables drug delivery through the near impenetrable barrier of the skin.13 The technique involves
immersion of the palms of the hands or soles of the feet in a shallow tray of water through which a weak
electrical current is run. Sponges soaked in water can be used to treat the axillae. Iontophoresis can also
be used with solutions of anticholinergics, although there is little evidence this these are any more effective
than tap water.9 The exact mechanism of action behind the therapeutic effect in hyperhidrosis is unknown
and efficacy has been demonstrated only in small studies.9 Adverse effects are minor, including a tingling
‘pins and needles’ sensation at the treatment site and dryness of the skin, although bruising or blisters can
occur if the intensity of the current is too high.
Over the last few years, BTX injections have become an established licensed treatment for axillary
hyperhidrosis. BTX blocks neuronal acetylcholine release at the neuromuscular junction and in cholinergic
autonomic neurons, blocking the postganglionic sympathetic cholinergic nerve fibres to the sweat glands.9
BACKGROUND
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There is clinical trial evidence demonstrating the efficacy of BTX in hyperhidrosis, although this varies with
site of hyperhidrosis, is only temporary (only 3–6 months) and may be technique dependent.14 Potential
drawbacks are the expense of the toxin, the discomfort associated with the injections and the need for
repeated treatments.9
Administration of anticholinergic (antimuscarinic) agents and beta-blockers may address symptoms in mild
cases of hyperhidrosis. Oral propantheline (Pro-Banthine®, Kyowa Kirin Ltd) is licensed for this indication,
but the unlicensed drug oral glycopyrronium bromide is often used. Occasionally other anticholinergics are
used, such as oxybutynin and also methantheline bromide.10 The doses of oral anticholinergic medication
required to truly control abnormal sweating may cause significant adverse effects, including drowsiness,
dry mouth, dilated pupils, photophobia, blurred vision, acute glaucoma, impaired micturition, reduced
bronchial secretions, constipation, confusion, nausea, vomiting, giddiness, tachycardia, palpitations and
arrhythmias. Thus, some patients are forced to discontinue this avenue of treatment, or titrate the dose up
or down in accordance with tolerability in order to achieve a positive effect with minimal adverse effects.
The available medical treatments for primary hyperhidrosis are of uncertain efficacy and even when
effective are not curative. Current recommendations are not underpinned by robust evidence and there are
many areas of uncertainty. Importantly, the NICE Clinical Knowledge Summary on hyperhidrosis, updated
in July 2013, was limited by poor-quality evidence: recommendations were often based on expert opinion
in the absence of trial evidence.8 In particular, the relative effectiveness of treatments prescribed by a
dermatologist is uncertain.
Surgery
Thoracic sympathectomy involves interruption or ablation of the high thoracic sympathetic chain to
decrease sympathetic tone to the upper extremity and/or face.10 Open thoracic or cervical sympathectomy
is now rarely performed and the less invasive technique of endoscopic thoracic sympathectomy (ETS) is
preferred.10 ETS is carried out under general anaesthesia through one or more small insertion incisions
between the ribs. It is used for axillary, palmar, or facial hyperhidrosis. ETS can be performed at different
levels of the thoracic sympathetic chain with varying efficacy and safety.15 Adverse effects of thoracic
sympathectomy can be serious, such as pneumothorax. A common adverse effect of thoracic
sympathectomy is compensatory hyperhidrosis, whereby excessive sweating occurs in other parts of
the body after treatment; reported in 80% of patients in one large survey.16
Lower limb sympathectomy can also be performed as an open surgical procedure under general
anaesthesia, but more minimally invasive procedures are now usually preferred. An alternative is
endoscopic lumbar sympathectomy, which is less widely available but has been proposed to produce
a more reliable interruption of the sympathetic chain.17 Lower limb hyperhidrosis can be treated by
chemical sympathectomy, which involves injecting the lumbar sympathetic chain with a chemical
(phenol) to damage the nerve;18 however, it is rarely performed in the UK.
Guidance from NICE does specifically recommend ETS for primary hyperhidrosis of the upper limb
(NICE interventional procedures guidance 487),19 but only for those ‘suffering from severe and debilitating
primary hyperhidrosis that has been refractory to other treatments’. However, as for the dermatology
treatment options, this recommendation for ETS was based on limited quality evidence: a non-systematic
literature review, non-randomised comparative studies and case series; and focused on efficacy and safety
more than quality of life.
Given the reluctance of patients to undergo ETS and its apparently limited effectiveness in terms of
quality of life, alternative surgical options are required. Such procedures, for which guidance has not
been issued, include removal of sweat glands. Traditionally, this was achieved through excision of sweat
gland-containing skin (such as axillary skin), but now sweat gland clearance is more often done by
subcutaneous curettage by open techniques or superficial liposuction, rather than skin resection:20
the inside layer of the skin (which contains the sweat glands) is scraped (curetted) and/or suctioned under
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general anaesthesia to remove the sweat glands but preserve skin integrity.21–23 Adverse effects are not as
serious as for thoracic sympathectomy, but can include wound breakdown or infection. These less invasive
procedures are undertaken by only a few dermatology surgeons in the UK and are rarely available through
the NHS.
Other emerging treatments for hyperhidrosis of the axilla include energy-based technologies that damage
the sweat gland: laser, microwave, fractionated microneedle radiofrequency and ultrasound therapy.
Laser treatment involves using a long-pulsed diode-powered laser, under local anaesthesia, to apply
energy directly to the underside of the dermis to act on the hair follicle and surrounding sebaceous gland
epithelium, causing necrosis and subsequent disruption of the exocrine gland.24–26 The microwave device
has been developed to heat target tissue at the interface between the skin and subcutaneous tissue, under
local anaesthesia, causing irreversible thermolysis of apocrine and eccrine sweat glands that reside at that
interface.27 Fractionated microneedle radiofrequency uses energy to heat the tissue below the surface of
the skin at a depth of 2–3 mm.28 The microfocused ultrasound device uses high-intensity ultrasound to
produce small (approximately 1 mm3) lesions or thermal coagulation points within the subcutaneous soft
tissue layer of the dermis. At a depth of 4.5 mm within the subcutaneous tissue, the sweat glands can be
treated without surface effects and once damaged the sweat glands are unable to regenerate.29
Description of technologies under assessment
The technologies under assessment are those that are considered second-line treatments: iontophoresis,
BTX, anticholinergic (antimuscarinic) agents and minor surgery (such as curettage, laser, microwave,
fractionated microneedle radiofrequency and ultrasound).
As discussed in Description of current NHS service provision, topical aluminium chloride is a low-cost
therapy, used mainly as a first step, helping GPs discriminate between those who do and do not require
referral for more specialised care. Therefore, aluminium chloride has not been included in this assessment.
Sympathectomy is end-of-line treatment and NICE recommends ETS only for upper limb hyperhidrosis
patients ‘suffering from severe and debilitating primary hyperhidrosis that has been refractory to other
treatments’ (© NICE 2017, reproduced with permisison from NICE interventional procedures guidance
487).19 As sympathectomy is unlikely to be considered at the same point in the treatment pathway as
second-line treatments, it is not a comparator to the other treatments considered in this assessment.
Decision problem
Other than ETS, which is recognised as effective but to be reserved as a treatment of last resort, there is
significant variation in the treatment for primary hyperhidrosis available in secondary care and the order
in which they are prescribed. Current recommendations are not underpinned by robust evidence;
there are many areas of uncertainty. In particular, the relative effectiveness of treatments prescribed by a
dermatologist is uncertain and further research (both primary studies and evidence synthesis) may be
required to resolve this. With regard to the minor surgical treatments available, guidance on which are the
best alternative surgical options is needed, but the relative effectiveness of subcutaneous curettage and
targeted sweat gland removal has not been researched or reviewed comprehensively.
Given the lack of clear research evidence to guide clinical practice, new RCTs may be warranted. However,
RCTs can be difficult to conduct and extremely expensive to run. They are also demanding of both
clinicians and patients and should not be undertaken without careful consideration. The need for further
research is informed by both the clinical evidence and the cost-effectiveness of different treatments. The
value of any future research is related to the cost of making suboptimal treatment decisions. Furthermore,
in clinical practice a suite of interventions is available to patients; therefore, the decision problem also
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includes which treatment should be given to patients in the event that a treatment is not effective or a
patient withdraws due to adverse effects. Therefore, the decision problem includes a comparison of
treatment sequences.
This assessment included a systematic review to determine the relative clinical effectiveness and safety of
interventions used in the management of refractory primary hyperhidrosis in secondary care (iontophoresis,
BTX, anticholinergic agents and minor surgery), followed by a decision model to determine the most
cost-effective treatment sequence and a value-of-information (VOI) analysis.
Aims and objectives of the research
The aim of this project was to establish the expected value of undertaking additional clinical studies
(such as RCTs) to determine the most clinically effective and cost-effective interventions for the
management of refractory primary hyperhidrosis (excluding patients with social anxiety disorder) in
secondary care.
The key objectives were:
1. to undertake an evidence synthesis by systematic review to estimate clinical effectiveness and safety
of treatments that would be available in secondary care and inform key clinical parameters for a
decision model
2. to develop a decision model to estimate cost-effectiveness
3. using the decision model, to undertake a VOI analysis to determine the need for further research and to
help inform the design of future clinical studies.
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Chapter 2 Methods of the clinical effectiveness
review
A systematic review was conducted to inform the clinical effectiveness and safety of second-linetreatments that would be available for prescription by dermatologists and minor surgical treatments.
The protocol included all treatments for hyperhidrosis prescribed in secondary care. However, screening
and selecting the relevant literature revealed that ETS, although used as part of the treatment pathway for
hyperhidrosis, could not be included in a comparative review as the position of ETS in the treatment
pathway is uncontestable (ETS is considered only as an intervention of last resort because of its significant
risks). Furthermore, the scoping searches identified that the rapid review of ETS for the NICE interventional
procedures guidance 487 captured the relevant evidence on ETS.19 They also revealed that because ETS is
an established therapy, recent studies of ETS have focused on the details of the surgical procedure,
addressing a question that is beyond the remit of the current project. This was included as a protocol
amendment in our progress report.
The systematic review was conducted according to the general principles recommended in Centre for
Reviews and Dissemination (CRD)’s guidance on the conduct of systematic reviews30 and is reported
according to the general principles of the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses statement.31 The protocol was written in accordance with the new Preferred Reporting
Items for Systematic Review and Meta-Analysis – Protocols initiative32 and registered on PROSPERO,
the international database of prospectively registered systematic reviews in health and social care
(URL: www.crd.york.ac.uk/prospero/), as PROSPERO CRD42015027803.
Literature searches
To identify studies of effectiveness, an exhaustive systematic search of electronic databases was undertaken
in January 2016 using the following databases: Allied and Complementary Medicine Database (AMED),
British Nursing Index, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Central
Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews (CDSR), Database of
Abstracts of Reviews of Effects (DARE), EMBASE, Health Technology Assessment (HTA) database, MEDLINE,
NHS Economic Evaluation Database (NHS EED), PsycINFO and PubMed.
The search strategy combined relevant search terms with indexed keywords (such as medical subject
headings) and text terms that appear in the titles and/or abstracts of database records. Search strategies
included appropriate search terms for ‘hyperhidrosis’ combined with search terms for treatment types
(e.g. ‘botulinum toxin’, ‘iontophoresis’, ‘curettage’).
No date or language limits were applied.
Additional searches of EMBASE, MEDLINE and NHS EED were carried out to identify studies of
cost-effectiveness. A recognised ‘costs’ search filter was used in conjunction with topic terms when the
searches of the EMBASE and MEDLINE databases were undertaken.
Additional searches of AMED, British Nursing Index, CINAHL, CENTRAL, CDSR, DARE, EMBASE, HTA
database, MEDLINE, NHS EED, PsycINFO and PubMed were carried out to identify quality-of-life studies.
The search strategies used combined topic terms for hyperhidrosis with a recognised search filter for
‘quality of life’.
The search strategies are presented as Appendix 1.
DOI: 10.3310/hta21800 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 80
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Wade et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
7
Clinical advisors were consulted for additional potentially relevant studies; Julie Halford (nurse specialist
and patient representative) provided an extensive bibliography of publications and articles relating to
hyperhidrosis. Reference lists of relevant reviews were manually searched.
In addition, information on studies in progress, unpublished research or research reported in the grey
literature was sought by searching relevant resources in July 2016 [including Conference Proceedings
Citation Index: Science (ISI), ClinicalTrials.gov and the World Health Organization International Clinical
Trials Registry Platform Portal].
Two researchers undertook the screening of titles and abstracts obtained through the search, although the
library was split between the researchers, rather than each record being double screened. A sample of just
over 10% of records was double screened in order to assess the level of agreement between the researchers;
it was planned to undertake full double screening if the level of agreement was poor, but this was not
necessary. Any record for which a researcher was unsure of their decision was marked and screened by an
additional reviewer, in addition to the 10% of records double screened for quality assurance purposes.
Full manuscripts of potentially relevant studies were obtained and independently screened by two
researchers, using pre-defined eligibility criteria. Disagreements were resolved through discussion and,
when necessary, consultation with a third researcher. Relevant foreign language studies were translated
and included in the reviews.
A separate library was created for the records identified by the searches of conference proceedings and
trial registers (in July 2016) and all trials identified were deduplicated against the original library. The
records were then assessed for relevance by two researchers and any selected for full-text screening were
manually compared with the included studies from the original library to identify those that offered
additional data. The extra studies were then separated by trial status as ongoing or completed. An online
search of pharmaceutical websites and trial registration databases was performed for the completed
studies to identify any published reports or trial data. When contact details were available, an e-mail was
sent to the principal investigator to request research findings or published reports.
Inclusion and exclusion criteria
Population
Patients with primary hyperhidrosis (including adults and children). Patients with hyperhidrosis secondary to
other conditions, such as overactive thyroid or spinal cord injury, or social anxiety disorder, were not
eligible for inclusion.
Interventions
Treatments for hyperhidrosis that would be available for prescription by dermatologists and minor surgical
treatments for hyperhidrosis.
Comparators
A different active treatment for hyperhidrosis, placebo or no treatment.
Outcomes
Any of the following:
l disease severity (e.g. measured with the HDSS, or patient reported)
l sweating (e.g. measured by gravimetry, or iodine starch test)
l patient quality of life [e.g. assessed using Hyperhidrosis Impact Questionnaire (HHIQ), HDSS (which may
be used to measure patient quality of life as well as disease severity) or the Dermatology Life Quality
Index (DLQI)]
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l patient preference
l patient satisfaction
l patient compliance/adherence to treatment
l social functioning (e.g. measured by Social Functioning Questionnaire)
l adverse events [such as compensatory sweating (CS)]
l resource use.
In addition, the duration of treatment effect was also assessed when adequate data were available.
Study designs
For each intervention, we planned to include good-quality, up-to-date, directly relevant systematic reviews,
if they were available. In the absence of such a review, RCTs were included, when available. For
interventions for which RCT evidence was lacking, non-RCTs were included. In the absence of controlled
trials, large (> 100 patients) prospective case series (single-arm trials) were included.
Data extraction strategy
Data were extracted directly into a standard spreadsheet, which was initially piloted on a sample of studies
and refined. Data extraction was conducted by one researcher and checked by a second researcher for
accuracy, with any discrepancies resolved by discussion, or consultation with a third researcher, when
necessary. Authors of studies were contacted for clarification and missing data, as necessary. In cases of
multiple publications of the same study, the publication with the largest sample or longest follow-up was
treated as the main source. Data extracted included details of study methods (including study design,
country and year of publication), patient characteristics (including age, sex, body treatment site, previous
treatments and baseline severity), interventions (including treatment type, dose, frequency and duration),
relevant outcome measures (including outcome domain, measurement tool used and follow-up time points)
and results. When possible, we sought to include intention-to-treat data. When intention-to-treat data were
not available, we extracted and analysed the data as reported in the paper. When results data were missing
or limited (e.g. conference abstracts), authors were contacted and, when relevant, manufacturer trials
registers were consulted for further data. Where outcome data were presented only in graphical format,
authors were contacted to provide further information. If the authors did not respond, data from graphs
were extracted using Graph Grabber (version 1.5; Quintessa, Henley-on-Thames, UK) software. All data
extraction was performed with Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA).
Quality assessment strategy
The quality assessment of studies was conducted as part of the data extraction process using criteria
relevant to the study designs included. The quality of RCTs and non-RCTs was assessed using the Cochrane
risk of bias tool, which focuses on the domains shown to have an impact on the trial results in particular
(selection, performance and detection biases and attrition).33 An additional question relating to the similarity
of treatment groups at baseline was added.34 In addition, a question about ‘within-patient’ study designs
was added, owing to concerns about the validity of certain outcome measures in ‘within-patient’ study
designs, in which patients receive different interventions on different sides of the body (i.e. the left axilla
vs. the right axilla).
Studies without a control group were not formally quality assessed; however, study details are presented
and their impact on the reliability of the results is discussed in the relevant sections of this report.
Each controlled trial was given an overall risk of bias judgement: trials that were rated as having a low risk
of bias for all key domains (i.e. have a ‘yes’ response for each key domain) were judged to have a low
overall risk of bias; trials that were rated as having a high risk of bias for one or more key domains
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(i.e. have a ‘no’ response) were judged to have a high overall risk of bias; and trials that were rated as
having an unclear risk of bias (and no high risk of bias) for one or more key domains were judged to have
an unclear overall risk of bias. When relevant, the overall risk of bias judgement was made separately for
different outcomes, as certain outcomes are subjective (e.g. the HDSS), whereas other outcomes can be
measured more objectively (e.g. gravimetry).
Sequence generation and allocation concealment were both considered to be ‘key domains’; therefore,
non-randomised trials were all considered to have a high overall risk of bias. When prognostic factors were
considered to differ between treatment groups at baseline, this was also considered to be a key source of
bias. When prognostic factors were not reported, an ‘unclear’ response was not considered to be a key
source of bias. It is not always possible to blind care providers to different hyperhidrosis interventions;
therefore, blinding of care providers was not considered to be a ‘key domain’, nor was blinding of
outcome assessors. Blinding of patients was considered to be a ‘key domain’; this is particularly relevant
for subjective outcomes, which were assessed in many of the studies included in this review. Although it is
acknowledged that it is not possible to blind patients in studies comparing minor surgical interventions
with non-surgical interventions, or minor surgical interventions with more major surgery, blinding of
participants was still considered a ‘key domain’ in these studies. Whether or not missing outcome data
were balanced across groups or adjusted for was also considered to be a ‘key domain’. Whether or not the
report appeared to be free from selective outcome reporting was not considered to be a key source of
bias; the study protocol was unavailable for the majority of studies.
The final quality assessment question was about ‘within-patient’ study designs, in which patients received
different interventions on different sides of the body. Clinical advisors to the project considered that this
type of study was of limited use in hyperhidrosis research, particularly for outcomes, such as the HDSS, for
which patients are asked to judge the tolerability and impact of their hyperhidrosis on different parts of
their body separately. Therefore, ‘within-patient’ study designs were considered to be a key source of
bias when the HDSS was used to assess disease severity or for assessments of quality of life. However,
‘within-patient’ study designs were not considered to be a key source of bias for more objective outcomes,
such as gravimetry.
The quality of the body of evidence identified was classed according to a modified version of the Grading
of Recommendations Assessment, Development and Evaluation (GRADE) classification (very low, low,
moderate, high or insufficient) for each intervention and comparison, taking into account the following
criteria: study risk of bias, directness of evidence, heterogeneity, precision of effect estimates, risk of
publication bias and magnitude of effect.
Data analysis
The results for each of the different treatment types are presented in separate sections within Chapter 3,
Results of studies included in the review. Study characteristics and results are presented in a series of
structured tables in Appendix 2. Quality assessment results are discussed and tabulated in Chapter 3,
Quality of studies included in the review. The results were interpreted in the context of the quality of the
individual studies.
Results were pooled in a pairwise meta-analysis if at least two studies reported the same outcome and
were considered sufficiently similar for analysis to be appropriate and feasible. Otherwise, the results were
summarised in a narrative synthesis. Although a network meta-analysis (NMA) was required to conduct the
VOI analyses (see Chapter 6), the evidence was considered too heterogeneous and limited to perform a
NMA to address the clinical review questions.
When meta-analyses were performed, dichotomous outcomes were combined to estimate pooled risk
ratios (RRs) using standard random-effects DerSimonian–Laird meta-analyses35 and continuous outcomes
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were combined to estimate pooled mean differences (MDs) using standard random-effects inverse variance
meta-analyses. Heterogeneity was assessed using the I2-statistic and visual inspection of forest plots.
For studies that included two intervention groups with two different doses and used one control group,
data from each intervention group were entered separately to explore any dose response effect and the
number of participants in the control group was divided by two to reduce the risk of double-counting
data.36 Although this approach may artificially reduce the power of the study in the meta-analysis and does
not account for potential correlation between the two active treatment groups, a separate analysis
combining the two arms showed no significant difference in results.
Studies using different units of analysis (i.e. axilla in half-side comparisons vs. patients in between-patient
comparisons) were pooled where deemed appropriate and reported in separate subgroups. Meta-regressions
and other subgroup analyses were considered inappropriate due to the small number of studies. All analyses
were conducted using Review Manager 5.3 (The Cochrane Collaboration, The Nordic Cochrane Centre,
Copenhagen, Denmark).
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Chapter 3 Results of the clinical
effectiveness review
Flow of studies through the review of effectiveness
The electronic searches identified a total of 4057 records: 3572 records were identified from the clinical
effectiveness searches, 337 records were identified from the quality-of-life searches and 148 records were
identified from the cost-effectiveness searches. The 4057 records were inserted into an EndNote X8 library
(Thomson Reuters, CA, USA). Just over 10% of the records (423/4057) were double screened and the level
of agreement between the researchers was assessed. The level of agreement was 96.2% (407/423 records),
which was considered adequate, and, therefore, the remaining records were single screened for study inclusion.
The full papers of 435 potentially relevant primary studies were ordered for inclusion screening. Four
papers were unavailable and, therefore, 431 records were screened. A total of 276 studies were excluded
at the full-paper stage. Details of these studies, along with the reason for their exclusion, are provided in
Appendix 3.
Table 1 presents the 155 records that were eligible for inclusion in the systematic review to inform the
clinical effectiveness and safety of second-line treatments that would be available for prescription by
dermatologists and minor surgical treatments. For each specific intervention, we prioritised the more robust
study designs; this resulted in 93 small (< 100 participants) case series studies being excluded because
RCTs or non-randomised comparative studies were available for the specific intervention they assessed.
TABLE 1 Studies that met the inclusion criteria for the systematic review of effectiveness
Study details Intervention Study design
Dahl and Glent-Madsen 198937 Iontophoresis RCT
Dolianitis et al. 200438 Iontophoresis Non-RCT
Karakoç et al. 200239 Iontophoresis Case series (n= 112)
Karakoc et al. 200440 Iontophoresis Non-RCT
Shimizu et al. 200341 Iontophoresis RCT
Stolman 198742 Iontophoresis RCT
Na et al. 200743 Dry iontophoresis Non-RCT
Choi et al. 201344 Dry iontophoresis Non-RCT
Akbar et al. 201345 Iontophoresis Case series
Chia et al. 201046 Iontophoresis Case series
Hölzle and Alberti 198747 Iontophoresis Case series
Ohshima et al. 200848 Iontophoresis Case series
Shams and Kavanagh 201149 Iontophoresis Case series
Wollina et al. 199850 Iontophoresis Case series
Hyun et al. 201551 Glycopyrrolate RCT
continued
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TABLE 1 Studies that met the inclusion criteria for the systematic review of effectiveness (continued )
Study details Intervention Study design
Mehrotra et al. 201452 Glycopyrrolate RCT (linked study to Mehrotra et al. 201553)
Mehrotra et al. 201553 Glycopyrrolate wipes RCT
Hale et al. 201454 Glycopyrrolate Case series
Lee et al. 201255 Glycopyrrolate Case series
Mackenzie et al. 201356 Glycopyrrolate cream Case series
Costa et al. 201457 Oxybutynin RCT
Costa et al. 201558 Oxybutynin RCT (linked study to Costa et al. 201457)
Schollhammer et al. 201559 Oxybutynin RCT
Wolosker et al. 201260 Oxybutynin RCT
Try et al. 201261 Oxybutynin Case series
Wolosker et al. 201162 Oxybutynin Case series
Wolosker et al. 201163 Oxybutynin Case series
Wolosker et al. 201364 Oxybutynin Case series
Wolosker et al. 201465 Oxybutynin Case series
Wolosker et al. 201466 Oxybutynin Case series
Wolosker et al. 201567 Oxybutynin Case series
Hund et al. 200468 Methantheline bromide RCT
Müller et al. 201369 Methantheline bromide RCT
Fuchslocher and Rzany 200270 Methantheline bromide Case series
Glogau 200771 BTX (topical) RCT
Balzani et al. 200172 BTX RCT
Baumann et al. 200573 BTX RCT
Baumann et al. 200574 BTX RCT
Heckmann et al. 200175 BTX RCT
Lowe et al. 200276 BTX RCT
Lowe et al. 200777 BTX RCT
Lowe et al. 200278 BTX RCT (linked study to Naumann and
Lowe 200179)
Naumann and Lowe 200179 BTX RCT
Naumann et al. 200380 BTX RCT
Naver et al. 200081 BTX RCT
Odderson 200282 BTX RCT
Ohshima et al. 201383 BTX RCT
Schnider et al. 199784 BTX RCT
Schnider et al. 199985 BTX RCT
Naumann et al. 200286 BTX RCT (linked study to Naumann and
Lowe 200179)
Ibrahim et al. 201321 BTX vs. curettage RCT
Ibrahim et al. 201387 BTX vs. curettage RCT (linked study to Ibrahim et al. 201321)
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TABLE 1 Studies that met the inclusion criteria for the systematic review of effectiveness (continued )
Study details Intervention Study design
Rajagopal and Mallya 201488 BTX vs. iontophoresis RCT
Heckmann et al. 199989 BTX Non-RCT
Yamashita et al. 200890 BTX Non-RCT
Baker 201391 BTX vs. glycopyrrolate Non-RCT
Wachal et al. 200992 BTX vs. iontophoresis Non-RCT
Absar and Onwudike 200893 BTX Case series
Maltese et al. 201294 BTX SR
Naumann et al. 201314 BTX SR
Shayesteh and Nylander 201195 BTX SR
Aghaei 200796 BTX Case series
Baker and Hansen 201197 BTX Case series
Basciani et al. 201498 BTX Case series
Bechara et al. 200799 BTX Case series
Böger et al. 2000100 BTX Case series
Campanati et al. 2003101 BTX Case series
Campanati et al. 2011102 BTX Case series
Chattopadhyay et al. 2009103 BTX Case series
Chow and Wilder-Smith 2009104 BTX Case series
Coutinho dos Santos et al.
2009105
BTX Case series
D’Epiro et al. 2014106 BTX Case series
Glaser et al. 2007107 BTX Case series
Glaser et al. 2015108 BTX Case series
Glogau 1998109 BTX Case series
Gregoriou et al. 2010110 BTX Case series
Hanlon et al. 2006111 BTX Case series
Hasson et al. 2014112 BTX Case series
Heckmann et al. 1998113 BTX Case series
Ito et al. 2011114 BTX Case series
James et al. 2005115 BTX Case series
Karlqvist et al. 2014116 BTX Case series
Karlqvist et al. 2015117 BTX Case series
Kinkelin et al. 2000118 BTX Case series
Kouris et al. 2014119 BTX Case series
Kouris et al. 2014120 BTX Case series
Kouris et al. 2015121 BTX Case series
Krogstad et al. 2004122 BTX Case series
Krogstad et al. 2005123 BTX Case series
continued
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TABLE 1 Studies that met the inclusion criteria for the systematic review of effectiveness (continued )
Study details Intervention Study design
Lowe et al. 2003124 BTX Case series
Moffat et al. 2009125 BTX Case series
Naumann et al. 1998126 BTX Case series
Naver et al. 1999127 BTX Case series
Swartling et al. 2001128 BTX Case series
Nelson et al. 2005129 BTX Case series
Ogden et al. 2009130 BTX Case series
Paracka et al. 2015131 BTX Case series
Pérez-Bernal et al. 2005132 BTX Case series
Pinelli et al. 2000133 BTX Case series
Rosell et al. 2013134 BTX Case series
Salmanpoor and Rahmanian
2002135
BTX Case series
Scamoni et al. 2012136 BTX Case series
Schnider et al. 2001137 BTX Case series
Shelley et al. 1998138 BTX Case series
Solish et al. 2005139 BTX Case series
Solomon and Hayman 2000140 BTX Case series
Vadoud-Seyedi 2004141 BTX Case series
von Rhein et al. 2004142 BTX Case series
Weber et al. 2005143 BTX Case series
Wollina and Karamfilov 2001144 BTX Case series
Paracka et al. 2015145 BTX Case series
Wollina et al. 2002146 BTX Case series
Tronstad et al. 2014147 Liposuction curettage RCT
Rompel and Scholz 2001148 Curettage vs. BTX Non-RCT
Jemec 1975149 Curettage vs. excision Non-RCT
Bechara et al. 2008150 Liposuction curettage vs.
excision vs. Shelley’s
procedure
RCT
Leclere et al. 201524 Liposuction curettage vs.
laser epilation
RCT
Darabaneanu et al. 2008151 Curettage Case series
Feldmeyer et al. 2015152 Curettage Case series
Proebstle et al. 2002153 Curettage Case series
Bechara et al. 2008154 Liposuction curettage Non-RCT
Ottomann et al. 2007155 Liposuction curettage vs. BTX Non-RCT
Hasche et al. 1997156 Liposuction Case series
Bechara et al. 2007157 Liposuction curettage Case series
Bechara et al. 2007158 Liposuction curettage Case series
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TABLE 1 Studies that met the inclusion criteria for the systematic review of effectiveness (continued )
Study details Intervention Study design
Bechara et al. 201225 Laser epilation RCT
Letada et al. 201226 Laser epilation RCT
Caplin 2013159 Laser Case series
Chasin 2012160 Laser Case series
Fratila and Reckmeyer 2014161 Laser Case series
Goldman and Wollina 2008162 Laser Case series
Hoffmann 2012163 Laser Case series
Katz and Cangello 2014164 Laser Case series
Kim et al. 2010165 Laser Case series
Penrose et al. 2011166 Laser Case series
Yanes 2013167 Laser Case series
Canadian Agency for Drugs and
Technologies in Health 2015168
Laser SR
Tataru and Avram 2013169 Laser assisted lipolysis Case series
Abtahi-Naeini et al. 2015170 Fractionated microneedle
radiofrequency
Case series (linked study to Fatemi Naeini
et al. 201528)
Fatemi Naeini et al. 201528 Fractionated microneedle
radiofrequency
Non-RCT
Kim et al. 2013171 Fractionated microneedle
radiofrequency
Case series
Glaser et al. 201227 Microwave RCT
Kilmer et al. 2011172 Microwave RCT (linked study to Glaser et al. 201227)
Hong et al. 2012173 Microwave Case series
Lee et al. 2013174 Microwave Case series
Lupin et al. 2011175 Microwave Case series
Lupin et al. 2012176 Microwave Case series
Lupin et al. 2014177 Microwave Case series (linked study to Hong et al. 2012173)
Nestor and Park 201429 Microfocused ultrasound RCT (two RCTs reported in one publication)
Nestor and Park 2012178 Microfocused ultrasound RCT (linked study to Nestor and Park 201429)
Nestor and Park 2013179 Microfocused ultrasound RCT (linked study to Nestor and Park 201429)
Nestor and Park 2013180 Microfocused ultrasound RCT (linked study to Nestor and Park 201429)
Pinson et al. 2014181 Radiofrequency device Case series
Commons and Lim 2009182 VASER ultrasound Case series
Nicholas et al. 2015183 Dermatology and surgery SR
SR, systematic review.
Note
Studies highlighted in bold were included in the review (n= 48 studies reported in 57 papers).
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Five additional studies were excluded because they were systematic reviews that were not considered to be
of sufficiently good quality, up to date or directly relevant to be relied on.
Forty-eight studies identified by electronic searching were included in the systematic review (reported in
57 papers); the 57 included records are highlighted in bold in Table 1.
No additional studies were identified by screening reference lists of relevant systematic reviews or from
contact with clinical advisors. Figure 1 presents the flow of studies through the study selection process
from the main searches.
Records identified from searches of
electronic databases
(n = 4057)
Excluded on title/abstract
(n = 3622)
Full papers ordered
(n = 435)
Full paper unavailable
(n = 4)
Full papers screened
(n = 431)
Eligible for inclusion
(n = 155)
Excluded
(n = 276)
• Not primary hyperhidrosis patients, n = 14
• Surgical, rather than dermatology intervention
   (sympathectomy), n = 102
• Not a relevant dermatology intervention, n = 28
• Not a relevant dermatology comparator (e.g.
   sympathectomy/aluminium chloride), n = 8
• No intervention, n = 11
• Not a systematic review or primary
   prospective study, n = 105
• Not a comparative study (sequential
   treatment), n = 1
• Not a dermatology effectiveness study
   (quality of life/economics only), n = 3
• No effectiveness outcome, n = 1
• Duplicate report, n = 3
Included from electronic database
searches
n = 57 records (48 studies)
Excluded
(n = 98)
• Systematic review not considered to
   be sufficiently good quality, up to
   date or relevant, n = 5
• Study design superceded (case series
   with < 100 patients), n = 93
FIGURE 1 Flow diagram of the study selection process.
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The separate searches of conference proceedings and trial registers, conducted in July 2016, identified a
total of 306 records (80 of which were considered to be potentially relevant for the review). After the
80 records were de-duplicated against the original library, 31 were excluded as being duplicate reports,
leaving 49 potentially relevant records. Ten were identified from searches of conference abstracts and
39 were identified from searches of trial registers.
Further details of the 10 conference abstracts were obtained, resulting in eight records being excluded:
one had no intervention, one was found to be a duplicate report, three did not report an effectiveness
outcome and three were small case series. Therefore, two additional records relating to completed studies,
reported as conference abstracts, were included in the review.184,185
Further details of the 39 records identified from trial registers were sought. One record was found to be a
duplicate report, one was a study that was registered but later withdrawn (prior to recruiting participants),
and an additional two studies were very small case series, so were rejected from the review. Thirteen of
the records identified from trial registers were found to be ongoing trials; details are reported in Ongoing
studies.
Pharmaceutical company websites and trial registration databases were searched for additional information
on the remaining 22 studies and, when contact details were available, principal investigators were
contacted to supply research findings or published reports. One study was found to have been terminated
because of a high sham response, two studies were found to have been extended, with no data currently
available, and a further two studies were found to be case series studies of an intervention for which
several RCTs had already been identified. For eight records, no further information was found and principal
investigators did not respond to e-mail requests (when contact details were identified). For four records,
the investigators responded to e-mail requests, but did not offer any additional data. Five studies, relating
to the same intervention (DRM04), were conducted by the same pharmaceutical company, which
responded that their data were due to be presented at an upcoming conference. They agreed to share
their results after the conference; however, data were not supplied in time to be included in the review.
A separate flow chart is presented with further details of the searches of conference proceedings and trial
registers (Figure 2).
Characteristics of studies included in the review of effectiveness
There was substantial variation among the 32 RCTs, 17 non-RCTs and one case series study that were
included in the review. Sample sizes ranged from 472 to 339,69 with most studies including < 50 patients.
Studies were conducted in a range of different countries: 23 studies were conducted in European countries
[Germany (n = 925,68,69,75,89,148,150,154,155), the UK (n = 291,184), Denmark (n = 237,149), Austria (n = 284,85), Poland
(n = 192), Sweden (n = 181), France (n = 159), Italy (n = 172), Norway (n = 1147) and multiple European
countries (n = 324,79,80)], 15 studies were conducted in the Americas [USA (n = 1321,26,27,29,42,53,71,73,74,76,77,82)
and Brazil (n = 257,60)], 11 studies were conducted in Asian countries [Japan (n = 441,83,90,185), South Korea
(n = 343,44,51), Turkey (n = 239,40), India (n = 188) and Iran (n = 128)] and one study was conducted in Australia.38
Therefore, many of the study populations may not be representative of hyperhidrosis patients in the UK,
because of the differences in climate.
Studies were published between 1975149 and 2016;184 42 out of the 50 studies were published since
2000 and 19 of the 50 studies were published since 2010. Generally, studies of topical glycopyrrolate,
oxybutynin and the newer minor surgical devices (laser epilation, fractionated microneedle radiofrequency,
microwave and ultrasound) were the most recent (published after 2010), whereas some of the studies
of iontophoresis, BTX and curettage were > 15 years old; therefore, some of the devices, formulations and
procedures used in earlier studies may not be applicable to current practice.
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When reported, all studies included adults, although 10 studies included a small number of participants
aged < 18 years.38–40,44,53,80,82,88,155,184 The majority of patients in the studies that reported the sex of
participants were female; two studies included only female patients,57,72 while the rest of the studies
included both male and female patients. Inclusion criteria relating to disease severity were reported in
31 studies; baseline severity was usually moderate to severe, with a HDSS score of 3 or 4 points and/or a
sweat rate of at least 50 mg per 5 minutes.
As expected, the site of hyperhidrosis differed between studies of different interventions. Studies of
iontophoresis all included patients with palmar hyperhidrosis, some of whom also had plantar
hyperhidrosis.38,41 All the studies of curettage, laser epilation, fractionated microneedle radiofrequency,
microwave and ultrasound included only patients with axillary hyperhidrosis. All studies of BTX included
patients with hyperhidrosis of the axilla except for seven74,76,81,84,88,90,92 that studied plantar hyperhidrosis.
Studies of topical glycopyrrolate included patients with hyperhidrosis of the axilla53,91 or forehead.51
Records identified from searches of
conference proceedings and trial registers
(n = 306)
Excluded on title/abstract
(n = 226)
Potentially relevant records
(n = 80)
Potentially relevant records
(n = 49)
Excluded after deduplicating against the main
EndNote library from the original searches
(n = 31)
Excluded
(n = 8)
Excluded
(n = 39)
Identified from conference
abstract database
(n = 10)
Identified from trial registers
(n = 39)
Included
(n = 2)
Included
(n = 0)
• No intervention, n = 1
• Duplicate report, n = 1
• No effectiveness outcome, n = 3
• Small case series, n = 3
• Duplicate report, n = 1
• Study withdrawn (prior to
   enrolment), n = 1
• Small case series, n = 2
• Ongoing studies, n = 13
   (listed in Ongoing studies)
• Study terminated, n = 1
• Study extended, n = 2
• Study design superceded, n = 2
• No information found/no
   response to e-mail, n = 8
• No additional data supplied,
   n = 9
FIGURE 2 Flow diagram of the study selection process for conference proceedings and trial register searches.
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Studies of methantheline bromide included patients with axillary and/or palmar hyperhidrosis.68,69
Studies of oxybutynin included patients with hyperhidrosis of the axilla and palm,60 foot57 or generalised59
hyperhidrosis.
In the majority of comparative studies, the intervention was compared against a placebo/sham device or no
treatment, although some studies compared two or more active treatments, such as BTX, compared with
iontophoresis,88,92 BTX compared with glycopyrrolate,91 BTX compared with curettage,21,148,155,184 curettage
compared with laser epilation,24 or curettage compared with more radical surgery.149,150 Table 2 shows the
comparisons made in the included comparative studies.
Outcomes assessed in the studies included disease severity, sweat rate, patient-reported effectiveness,
quality of life, satisfaction and adverse events. However, methods of assessing outcomes varied between
studies. Disease severity was often assessed using the HDSS, although some studies also used a patient
or physician assessment of disease severity or improvement. Sweat rate was assessed using gravimetry,
iodine starch test, digitised ninhydrin-stained sheets, the Sakurai–Montagna sweating test, corneometry,
evaporimetry or a bespoke sweat reduction questionnaire or visual analogue scale (VAS); some studies
assessed sweat rate under stressful conditions, such as during a maths test. Some studies assessed
patient-reported treatment effectiveness and willingness to undergo repeat treatment. Quality of life was
assessed using a range of questionnaires, such as the DLQI, HHIQ and Short Form questionnaire-12 items
(SF-12). HDSS was also used as a quality-of-life tool in some studies. Further details of quality-of-life
tools used in hyperhidrosis studies are presented in Chapter 4. Patient satisfaction was assessed using
questionnaires. Some studies of BTX used a dynamometer to assess grip strength. Some studies of minor
surgical interventions also undertook histological analysis. Timing of the outcome assessment varied
between the studies, ranging from around 1 week to > 1 year. Outcome assessment tended to be shorter
for the shorter-lasting topical treatments and iontophoresis, and much longer for the longer-lasting BTX
injections and minor surgical treatments, as might be expected.
Summary study characteristics and results for the separate interventions assessed are presented in
Appendix 2. Interventions likely to be tried at the beginning of the treatment pathway are presented first
(iontophoresis, systemic agents, BTX), with minor surgical procedures (curettage, laser, etc.) at the end of
the tables.
Quality of studies included in the review
Thirty-two of the included studies were RCTs, 17 were non-RCTs and one study was a case series.
The results of the quality assessment of the RCTs and non-RCTs, using the Cochrane risk of bias tool, are
presented in Table 3. Each trial was given an overall risk of bias judgement, as described in Chapter 2,
Quality assessment strategy.
Generally, methods were poorly reported, with a high proportion of assessments having to be recorded as
unclear. It was clear that the allocation sequence was adequately generated in only eight RCTs;21,51,59,69,75,76,79,83
methods of sequence generation were unclear in the other 24 RCTs.24–27,29,37,41,42,53,57,60,68,71–74,77,82,84,85,88,147,150
Seventeen studies were non-RCTs;28,38,40,43,44,80,81,89–92,148,149,154,155,184,185 therefore, there was no randomised
sequence generation. Concealment of allocation was also poorly reported; only two RCTs reported adequate
methods, and methods were unclear in the remaining 30 RCTs. Again, this criterion was not relevant for the
17 non-RCTs. Study groups were generally similar at baseline in terms of most prognostic factors in only six
studies,21,40,57,59,69,77 although, for two of these studies, one of the prognostic factors differed at baseline,
which may have affected one of the outcomes reported.69,77 There were differences between groups in
important prognostic characteristics in five studies27,53,68,73,74 and insufficient data were available to assess
similarity of baseline characteristics in 38 studies.24–26,28,29,37,38,41–44,51,60,71,72,75,76,79–85,88–92,147–150,155,184,185
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TABLE 2 Comparisons made in the included comparative studies
Intervention Iontophoresis
a
Topical
glycopyrrolate Oxybutynin
Methantheline
bromide BTX Curettage
b
Laser
epilation
Radical
excision
Shelley’s
procedure
Fractionated
microneedle
radiofrequency Microwave Ultrasound Placebo
No
treatment
Iontophoresis
a
2
c
2 3 2
Topical
glycopyrrolate
1 2 1
Oxybutynin 3
Methantheline
bromide
2
BTX 2 1 4 13 4
Curettage
b
4 2
d
1
e
2 1
Laser epilation 1
e
1 2
Radical
excision
2
Shelley’s
procedure
1
Fractionated
microneedle
radiofrequency
1
Microwave 1
Ultrasound 2
Placebo 3 2 3 2 13 1 1 2
No treatment 2 1 4 2
a Includes iontophoresis with tap water, anticholinergics and dry-type iontophoresis.
b Includes curettage, suction curettage, tumescent suction curettage, curettage with aggressive shaving and curettage combined with laser therapy.
c Iontophoresis vs. iontophoresis with an anticholinergic.
d Comparisons between curettage and tumescent suction curettage, or curettage with aggressive shaving.
e Laser epilation vs. laser epilation with curettage.
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TABLE 3 Risk-of-bias assessment results
Study
Sequence
generation
adequate
(key domain)
Allocation
concealment
adequate
(key domain)
Prognostic
factors
similar at
baseline
(key domain)
Participants
blind to
treatment
allocation
(key domain)
Care
providers
blind to
treatment
allocation
Outcome assessors
blind to treatment
allocationa
Missing
outcome data
adequately
addressed
(key domain)
Report
free from
selective
outcome
reporting
Free from
‘within-
patient’
study
design
Overall risk
of bias
judgement
Choi et al. 201344 N/A N/A Unclear No No Unclear (sweat rate);
no (satisfaction)
Unclear Unclear No High
Dahl and Glent-Madsen
198937
Unclear Unclear Unclear Yes Yes Unclear Unclear Unclear No Unclear
Na et al. 200743 N/A N/A Unclear No No Unclear (sweat rate);
no (satisfaction)
Unclear No No High
Rajagopal and Mallya
201488
Unclear Unclear Unclear Unclear No Unclear No Unclear Yes High
Stolman 198742 Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear No Unclear
Wachal et al. 200992 N/A N/A Unclear No No No Unclear Unclear Yes High
Dolianitis et al. 200438 N/A N/A Unclear Yes No Yes Yes Unclear No High
Karakoc et al. 200440 N/A N/A Yes Yes No No Unclear Unclear No High
Shimizu et al. 200341 Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear Yes Unclear
Baker 201391 N/A N/A Unclear Unclear Unclear Unclear Unclear No Yes High
Mehrotra et al. 201553 Unclear Unclear No Yes Unclear Unclear (sweat rate);
yes (HDSS)
Yes Unclear Yes High
Hyun et al. 201551 Yes Unclear Unclear Yes Unclear Unclear (sweat rate);
yes (HDSS)
Yes No No Unclear
(gravimetry);
high (HDSS)
Wolosker et al. 201260 Unclear Unclear Unclear Yes Unclear Yes Yes No Yes Unclear
Costa et al. 201457 and
Costa et al. 201558
Unclear Unclear Yes Yes Yes Unclear (sweat rate);
yes (quality of life)
Unclear Unclear Yes Unclear
Schollhammer et al.
201559
Yes Unclear Yes Yes Unclear Yes Yes Yes Yes Unclear
Hund et al. 200468 Unclear Unclear No Unclear Unclear Unclear Yes No Yes High
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TABLE 3 Risk-of-bias assessment results (continued )
Study
Sequence
generation
adequate
(key domain)
Allocation
concealment
adequate
(key domain)
Prognostic
factors
similar at
baseline
(key domain)
Participants
blind to
treatment
allocation
(key domain)
Care
providers
blind to
treatment
allocation
Outcome assessors
blind to treatment
allocationa
Missing
outcome data
adequately
addressed
(key domain)
Report
free from
selective
outcome
reporting
Free from
‘within-
patient’
study
design
Overall risk
of bias
judgement
Müller et al. 201369 Yes Unclear Yesb (palm
sweat rate
differed
between
groups at
baseline)
Yes Yes Unclear (sweat rate);
yes (HDSS, quality of
life)
Yes No Yes Unclear (HDSS,
DLQI, axilla
gravimetry);
high (palm
gravimetry)
Balzani et al. 200172 Unclear Unclear Unclear Unclear No No Yes No Yes Unclear
Baumann et al. 200573 Unclear Unclear No Yes Yes Unclear (physician
assessment); yes
(quality of life)
No No Yes High
Glogau 200771 Unclear Unclear Unclear Yes Unclear Unclear Yes Unclear No Unclear
Heckmann et al. 199989 N/A N/A Unclear No No No Yes Unclear No High
Heckmann et al. 200175 Yes Yes Unclear Yes Yes Yes Yes Unclear No Low
Ibrahim et al. 201321 and
Ibrahim et al. 201387
Yes Yes Yes Noc No Unclear (sweat rate);
no (HDSS)
Yes Yes No High
Lowe et al. 200777 Unclear Unclear Yesb (DLQI
scores differed
between
groups at
baseline)
Yes Yes Unclear (sweat rate);
yes (HDSS, quality of
life)
Unclear Unclear Yes Unclear (HDSS,
gravimetry);
high (DLQI)
Naumann and Lowe
2001;79 Naumann et al.
200286 and Lowe et al.
200278
Yes Unclear Unclear Yes Unclear Unclear (sweat rate);
yes (quality of life,
satisfaction)
Yes Unclear Yes Unclear
Naumann et al. 200380 N/A N/A Unclear No No Unclear (sweat rate);
no (satisfaction)
Unclear Unclear Yes High
Odderson 200282 Unclear Unclear Unclear Yes Yes Yes Unclear Unclear Yes Unclear
Ohshima et al. 201383 Yes Unclear Unclear Yes Yes Yes Yes Unclear Yes Unclear
Rompel and Scholz
2001148
N/A N/A Unclear Noc No No No Unclear Yes High
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Study
Sequence
generation
adequate
(key domain)
Allocation
concealment
adequate
(key domain)
Prognostic
factors
similar at
baseline
(key domain)
Participants
blind to
treatment
allocation
(key domain)
Care
providers
blind to
treatment
allocation
Outcome assessors
blind to treatment
allocationa
Missing
outcome data
adequately
addressed
(key domain)
Report
free from
selective
outcome
reporting
Free from
‘within-
patient’
study
design
Overall risk
of bias
judgement
Schnider et al. 199985 Unclear Unclear Unclear Yes Yes Unclear (sweat rate);
yes (patient-assessed
sweating, satisfaction)
Unclear Unclear No Unclear
Vakili and Baker 2016184 N/A N/A Unclear Noc Unclear No Unclear Unclear Yes High
Wakugawa et al.
2001185
N/A N/A Unclear No Unclear Unclear Unclear No No High
Baumann et al. 200574 Unclear Unclear No Yes Yes Unclear (sweat rate);
yes (quality of life)
No No Yes High
Lowe et al. 200276 Yes Unclear Unclear Yes Yes Unclear (sweat rate);
yes (patient-assessed
sweating)
Unclear Unclear No Unclear
Schnider et al. 199784 Unclear Unclear Unclear Yes Yes Yes Yes Unclear No Unclear
Yamashita et al. 200890 N/A N/A Unclear No No Unclear No Unclear No High
Naver et al. 200081 N/A N/A Unclear No No Yes (sweat rate); no
(patient-assessed
sweating)
Yes Unclear No High
Bechara et al. 2008150 Unclear Unclear Unclear Noc No Unclear (sweat rate);
no (satisfaction)
Unclear Unclear Yes High
Bechara et al. 2008154 N/A N/A Unclear Unclear No Unclear Unclear No No High
Jemec 1975149 N/A N/A Unclear Noc No No Unclear Unclear Yes High
Leclere et al. 201524 Unclear Unclear Unclear Noc Unclear Unclear (sweat rate);
no (HDSS, satisfaction)
Yes No Yes High
Ottomann et al. 2007155 N/A N/A Unclear Noc Unclear Unclear (sweat rate);
no (quality of life)
Unclear Unclear Yes High
Tronstad et al. 2014147 Unclear Unclear Unclear Unclear No Unclear Yes No No Unclear
(gravimetry);
high (DLQI)
Bechara et al. 201225 Unclear Unclear Unclear No No Unclear (sweat rate);
no (satisfaction)
Yes Unclear No High
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TABLE 3 Risk-of-bias assessment results (continued )
Study
Sequence
generation
adequate
(key domain)
Allocation
concealment
adequate
(key domain)
Prognostic
factors
similar at
baseline
(key domain)
Participants
blind to
treatment
allocation
(key domain)
Care
providers
blind to
treatment
allocation
Outcome assessors
blind to treatment
allocationa
Missing
outcome data
adequately
addressed
(key domain)
Report
free from
selective
outcome
reporting
Free from
‘within-
patient’
study
design
Overall risk
of bias
judgement
Letada et al. 201226 Unclear Unclear Unclear No No Unclear (sweat rate);
no (patient-assessed
sweating)
Yes Unclear No High
Fatemi Naeini et al.
201528 and Abtahi-
Naeini et al. 2015170
N/A N/A Unclear Yes No No (sweat rate); yes
(HDSS, patient-
assessed sweating,
quality of life,
satisfaction)
Yes Unclear No High
Glaser et al. 201227 and
Kilmer et al. 2011172
Unclear Unclear No Yes No Yes Unclear Yes Yes High
Nestor and Park 2014;29
Nestor and Park 2012;178
Nestor and Park 2013179
and Nestor and Park
2013180
Study 1:
unclear;
study 2:
unclear
Study 1:
unclear;
study 2:
unclear
Study 1:
unclear;
study 2:
unclear
Study 1: yes;
study 2: yes
Study 1:
unclear;
study 2:
unclear
Study 1: unclear;
study 2: unclear
(sweat rate); yes
(HDSS, satisfaction)
Study 1: no;
study 2: no
Study 1:
no; study 2:
unclear
Study 1:
no; study 2:
yes
Study 1: high;
study 2: high
Total Yes, n= 8;
no, n= 17;
unclear,
n= 24
Yes, n= 2;
N/A, n= 17;
unclear,
n= 30
Yes, n= 6; no,
n= 5; unclear,
n= 38
Yes, n= 24;
no, n= 17;
unclear, n= 8
Yes,
n= 12;
no, n= 21;
unclear,
n= 16
Yes, n= 21 (for at
least one outcome);
no, n= 17 (for at
least one outcome);
unclear, n= 32 (for at
least one outcome)
Yes, n= 21;
no, n= 7;
unclear, n= 21
Yes, n= 3;
no, n= 14;
unclear,
n= 32
Yes, n= 26;
no, n= 23;
unclear,
n= 0
Low, n= 1;
high, n= 30
(an additional
4 ‘unclear’ risk
studies had a
high risk of bias
for one specific
outcome each);
unclear, n= 18
N/A, not applicable (study not a RCT).
a For subjective outcomes, the patient was considered to be the outcome assessor.
b Most of the important prognostic factors were similar between groups at baseline, but there were differences between groups in one prognostic factor; the overall risk of bias has been
presented separately for those outcomes that may have been affected by this difference between groups.
c It is not possible to blind patients in studies comparing minor surgical interventions with non-surgical interventions, or minor surgical interventions with more major surgery; however,
such studies were still considered to have a high risk of bias.
Note
Items in bold are when responses affected overall risk-of-bias judgement (i.e. when negative responses for the ‘key domains’ resulted in an overall high risk-of-bias judgement and when
positive responses for ‘key domains’ resulted in an overall low risk-of-bias judgement).
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Twenty-four studies reported blinding of participants to treatment group,27–29,37,38,40,51,53,57,59,60,69,71,73–77,79,82–85 in
17 studies participants were not blinded,21,24–26,43,80,81,89,90,92,148–150,155,184,185 and in eight studies it was unclear
whether or not participants were blinded.41,42,68,72,88,91,147,154 It is not always feasible to blind patients in
studies comparing minor surgical interventions with non-surgical interventions, or minor surgical
interventions with more major surgery; such studies were considered to have a high overall risk of bias,
owing to the potential effect on outcomes, many of which are subjective. Blinding of care providers was
reported in only 12 studies;37,57,69,73–77,82–85 in 21 studies it was clear that care providers were not blinded,21,
25–28,38,40,43,44,72,80,81,88–90,92,147–150,154 and in 16 studies it was unclear whether or not care providers were
blinded.24,29,41,42,51,53,59,60,68,71,79,91,155,184,185 Blinding of outcome assessors, for at least one outcome, was
reported in 21 studies (for subjective outcomes, the patient was considered to be the outcome assessor),
27–29,38,51,53,57,59,60,69,73–77,79,81–85 at least one outcome was assessed unblinded in 17 studies,21,25,26,28,40,43,44,72,80,81,89,
92,148–150,155,184 and in 32 studies it was unclear whether or not outcome assessors were blinded, for at least
one outcome.21,24–26,29,37,41–44,51,53,57,68,69,71,74,76,77,79,80,85,88,90,91,147,150,154,155,185
Either outcome data were complete or incomplete outcome data were adequately addressed in
21 studies;21,24–26,28,38,51,53,59,60,68,69,71,72,75,79,81,83,84,89,147 seven studies did not adequately address missing
outcome data,29,73,74,88,90,148 and in 21 studies it was unclear whether or not missing outcome data were
adequately addressed.27,37,40–44,57,76,77,80,82,85,91,92,149,150,154,155,184,185 Only three studies appeared to be free of the
suggestion of selective outcome reporting21,27,59 and it was unclear whether or not 32 studies were free of
the suggestion of selective outcome reporting; many studies did not have protocols available in order to
make this assessment.85,88–90,92,148–150,155,184 Twenty-three studies used a ‘within-patient’ study design,21,25,26,28,
29,37,38,40,42–44,51,71,75,76,81,84,85,89,90,147,154,185 in which patients received different interventions on different sides
of the body. Clinical advisors to the project considered that this type of study was of limited use in
hyperhidrosis research, particularly for subjective outcome tools, such as the HDSS, in which patients are
asked to judge the tolerability and impact of their hyperhidrosis on different sides of their body separately.
Overall, only one RCT,75 which compared botulinum toxin type A (BTX-A) with placebo in 145 patients
with hyperhidrosis of the axilla, was rated as having a low overall risk of bias, scoring ‘yes’ for all four key
domains. Although it was a ‘within-patient’ study design, the outcomes assessed were sweating (assessed
using gravimetry), patient satisfaction and adverse events; therefore, the ‘within-patient’ study design is
unlikely to have significantly biased these outcomes.75
Five studies51,59,69,79,83 scored reasonably well on the risk-of-bias assessment, achieving a ‘yes’ response in
three of the four ‘key’ domains and ‘unclear’ in the remaining key domain. All five studies were considered
to have an unclear overall risk of bias, although they appeared to be of better quality than most of the
other included studies. In all five studies, it was the method of allocation concealment that was not
adequately reported. Two of the studies, involving 32079, and 15283 patients with hyperhidrosis of the
axilla, compared BTX-A with placebo. One of the studies compared glycopyrrolate with placebo in
39 patients with facial hyperhidrosis. This study had a ‘within-patient’ study design and measured sweat
rate using gravimetry and disease severity using the HDSS. Therefore, in this study, overall risk of bias was
considered to be unclear for sweat rate, but high for the HDSS result, owing to the difficulty patients may
have had scoring different sides of their face separately for tolerability and interference with daily
activities.51 One of the studies compared oxybutynin with placebo in 62 patients with mostly generalised
hyperhidrosis.59 The final study that scored reasonably well on the risk-of-bias assessment compared
methantheline bromide with placebo in 339 patients with hyperhidrosis of the axilla and palm. In this
study, most patient characteristics were comparable between groups at baseline (including HDSS score,
DLQI score and axilla sweat rate), but palmar sweat rate (measured by gravimetry) was higher in the
placebo group than in the treatment group; therefore, in this study, overall risk of bias was considered be
unclear for most outcomes but high for the outcome palmar sweat rate.69
An additional 13 studies had an unclear overall risk-of-bias judgement (with at least two ‘unclear’ key domain
responses).37,41,42,57,60,71,72,76,79,82–85 Thirty studies had a high overall risk-of-bias judgement (plus an additional
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four ‘unclear’ risk studies that had a high risk of bias for one specific outcome each,21,24–29,38,40,43,44,53,68,73,74,80,
88–92,148–150,154,155,184,185 because of differences in baseline characteristics for one prognostic factor69,77 or because
they were ‘within-patient’ studies that assessed HDSS or DLQI,51,147 as described above).
The case series study should be considered as having a high overall risk of bias,39 as this type of study is
more susceptible to bias than a controlled trial. The study had a prospective study design. It was unclear
whether patients were recruited consecutively or were a selected group. In general, the descriptions of
patient characteristics, intervention and outcome assessment were adequate.
The quality of the studies for each of the individual interventions is summarised along with the results of
studies in Results of studies included in the review.
Results of studies included in the review
Iontophoresis
Ten studies of iontophoresis were included.37–44,88,92 Four studies were RCTs,37,41,42,88 five were
non-RCTs38,40,43,44,92 and one was a case series.39 Risk of bias was considered high in seven
studies38–40,43,44,88,92 and unclear in three studies.37,41,42
Two studies were conducted in South Korea43,44 and two in Turkey.39,40 The other studies were conducted
in Australia,38 Denmark,37 India,88 Japan,41 Poland92 and the USA.42
Study sample size ranged from 1043 to 11239 participants. All studies included adults and some also
recruited patients aged < 18 years.38–40,44,88 All studies included males and females. The majority of
participants were female in all studies except two.43,88 Inclusion criteria relating to patients’ baseline disease
severity were only reported in three studies; in one study patients had HDSS scores of 3–4,88 one study
stated that patients had excessive sweating resulting in a social or occupational handicap42 and in one
study patients rated their hyperhidrosis as ‘moderate to severe’.38
There were a number of differences in the interventions that were used. Most studies used iontophoresis
with tap water in at least one group,37–42 although two studies evaluated ‘dry-type’ hand-held devices.43,44
Iontophoresis was combined with glycopyrrolate (in the iontophoresis tray) in one study38 and with oral
oxybutynin in another.41 Another study used iontophoresis in combination with topical aluminium
chloride.88 One study compared the efficacy of using alternative current (AC) against the more
conventional direct current (DC).41 The frequency of iontophoresis sessions varied across the studies,
ranging from once daily to once weekly, and the electric current used ranged from 0 to 30 mA.
Iontophoresis was compared with BTX in two studies,88,92 with iontophoresis combined with an
anticholinergic in two studies,38,41 with placebo in three studies37,40,42 and with no treatment in two studies.43,44
Five studies treated hands only37,42–44,88 and four focused on both hands and feet.38–41 Another study
treated hands and it was not clear whether or not axillae were also treated with iontophoresis.92 There
were no studies identified that specifically treated hyperhidrosis of the axilla.
Iontophoresis compared with placebo
Three very small studies (two RCTs, one interrupted time series) compared tap water iontophoresis with
a placebo (see Appendix 2, Table 43).37,40,42
Dahl and Glent-Madsen37 was a half-side comparison RCT including 11 adult patients. Patients had one
hand randomised to tap water iontophoresis and the other to a sham treatment. Initial treatment involved
sessions of 15 minutes, repeated one to five times a week, and continued until ‘good subjective effect’
was reported. After the initial treatment (duration not reported), six patients continued on maintenance
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treatment every other week. Efficacy was evaluated with gravimetry, after the initial treatment and after
3 months of maintenance treatment. After the initial treatment, the median difference between treated
and placebo hand in sweat reduction was 32%, favouring the treated hand (p < 0.01). The six patients
who continued maintenance treatment had an 81% (median) reduction in sweating from baseline at
3 months (p < 0.05). No adverse events were observed.
Stolman42 was a half-side placebo-controlled randomised trial evaluating tap water iontophoresis to the
palm delivered for 20 minutes, three times per week, for 3 weeks, in 18 adults. Sweating was evaluated
with the iodine starch test. At the end of treatment, 83% patients experienced a ‘marked reduction’ in
sweating in the treated hand, whereas no change was noticed in the untreated hand. No serious adverse
events were reported.
Karakoc et al.40 was an interrupted time series study that included 15 patients who received a low-intensity
AC (designed as sham treatment) iontophoresis (with tap water) for 15 minutes, eight times over 28 days
on both hands, followed by iontophoresis DC (with tap water) 1 week later. Sweating was evaluated by
gravimetry up to 1 week after the end of each treatment. There was no reduction in sweating 1 week
after the end of the sham treatment, but there was a statistically and clinically significant reduction in
sweating 1 week following iontophoresis therapy (mean reduction of 88% in sweating from baseline, from
3.1 ± 0.4 g/hour to 0.4 ± 0.1 g/hour in the right hand and from 3.2 ± 0.3 g/hour to 0.4 ± 0.1 g/hour in the
left hand). No data on adverse events were reported.
Iontophoresis compared with no treatment
Two small non-randomised trials compared a ‘dry-type’ iontophoresis device for the hand with no
treatment (see Appendix 2, Table 44).43,44
Na et al.43 was a non-randomised study evaluating the effectiveness of a ‘dry’ hand-held iontophoresis
device. Ten patients were instructed to hold the device with one hand for 30 minutes daily for 1 week,
then every other day for another week. The other hand received no treatment. Results were assessed
with gravimetry at up to 28 days from treatment initiation. There was a statistically significant difference
(p < 0.001) in sweat reduction from baseline favouring the treated hand at the end of treatment (43% vs.
2%). At 2 weeks’ follow-up there was also a statistically significant difference in mean sweat reduction
from baseline favouring the intervention (18% vs. 2%), although it is unclear if this result can also be
considered clinically significant. The authors stated there were no serious adverse events.
Choi et al.44 was a non-randomised study evaluating a similar ‘dry’ hand-held device. Twenty-three patients
were instructed to hold the device with the left hand for 20 minutes daily for 4 weeks. The right hand
received no treatment. Effectiveness was evaluated by gravimetry, Investigator Global Assessment (IGA),
Patient Satisfaction Assessment and hydration capacitance. Improvement in IGA and hydration capacitance
from 2 to 8 weeks’ follow-up and after 8 weeks was significantly greater in the treated palm than in
the untreated hand (p < 0.05), but the clinical significance of this finding is unclear becuase of limited
reporting. There was no statistically significant difference between the two palms in gravimetry and
Patient Satisfaction Assessment. There were no serious adverse events.
Iontophoresis compared with botulinum toxin
Two studies (one RCT, one non-RCT) compared iontophoresis with BTX injections for palmar hyperhidrosis
(see Appendix 2, Table 45).88,92 It was not stated in the study reports whether tap water or anticholinergic
drugs were used in the water bath; however, given the recency of the studies, it is assumed that tap water
was used.
Rajagopal and Mallya 201488 compared the efficacy of iontophoresis with BTX (BTX-A formulation) for the
palm in a RCT of 60 patients. Thirty participants were randomised to sessions of iontophoresis (2 × 10 minutes)
combined with topical aluminium chloride (20% lotion) three times per week over 4 weeks, and 30 patients
received injections of BTX-A [100 units (U) per palm]. Efficacy was assessed 4 weeks after the intervention using
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HDSS. Patients were also asked to score improvement in their symptoms at follow-up (either mild, good,
excellent or no improvement). Participants without a HDSS score improvement from baseline at 4 weeks were
crossed over to the other group for another 4 weeks and those with improvement in HDSS were followed
up in the same group for 6 months. At 4 weeks, the proportion of reporting an improvement in HDSS of
≥ 2 points was 57% in the BTX-A group, compared with 27% in the iontophoresis group. This difference
was clinically and statistically significant (p= 0.037). Similarly, the proportion of patients who achieved a
reduction in HDSS of at least 1 point /was higher in the BTX-A group (80%) than in the iontophoresis group
(47%). Among non-responders, the rate of improvement was significantly higher in those switching from
iontophoresis to BTX-A than in those switching from BTX-A to iontophoresis. The study reported that the
effect duration in responders was greater with BTX than with iontophoresis plus topical therapy. There was a
statistically significant difference favouring BTX-A in the proportion of patients rating improvement as excellent
or good (80% vs. 47%; p= 0.037). There were no severe adverse events. Mild to moderate pain (n= 8)
and mild temporary motor weakness (n= 1) were reported in the BTX-A group.
Wachal et al.92 carried out a non-randomised study of 86 adults with hyperhidrosis of the hand and other
upper limb. Participants received one of three interventions: iontophoresis (n = 28), BTX-A (n = 22) or
sympathectomy (n = 36). Iontophoresis patients received treatment for 20 minutes every 2–3 days. The
total duration of treatment was not reported. Effectiveness and willingness to undergo retreatment were
assessed by patients at 1, 6 and 12 months’ follow-up, using two VASs, both ranging from 1 to 10 points
(with higher scores indicating greater effectiveness/willingness). The percentage of patients assessing
treatment as either good/very good (5–10 points on the VAS) was higher in the BTX-A group than in the
iontophoresis group at all follow-up points, but was statistically significant only at 1 month (90.9% vs.
35.7%). Similarly, the percentage of patients who were willing to undergo retreatment was greater in the
BTX-A group than in the iontophoresis group, although the difference was statistically significant only at
1 month (81.8% vs. 42.8%). The authors reported that there were no adverse effects associated with
iontophoresis and no adverse event data were reported for the BTX-A group.
Iontophoresis compared with iontophoresis with anticholinergics
Two studies (one RCT, one non-RCT) compared iontophoresis alone with iontophoresis combined with
anticholinergic therapy (see Appendix 2, Table 46).38,41
Shimizu et al.41 carried out a RCT of 52 adult patients randomised to one of three treatments for
palmoplantar hyperhidrosis: iontophoresis with AC, iontophoresis (AC) plus oral oxybutynin (4 mg/day)
or iontophoresis with DC. Iontophoresis therapy was delivered for 30 minutes once a week to both
hands and feet. Efficacy was measured by gravimetry and the results were presented after up to
15 treatment sessions. There was a statistically and clinically significant mean reduction from baseline
in all three treatment groups from after the second treatment (p < 0.05), but no statistically significant
difference in effectiveness between treatment groups at the end of follow-up (AC group from 0.73 to
< 0.25 mg/cm2/minute; AC + oxybutynin from 0.81 to < 0.25 mg/cm2/minute; DC group not reported).
No adverse events were reported other than small vesicles on palms in the DC group (n = 5) and dry
mouth and eyes in the group receiving oxybutynin (n = 2).
Dolianitis et al.38 conducted a non-randomised half-side comparison study in which patients acted as
their own control, comparing iontophoresis plus a glycopyrrolate solution with standard iontophoresis
plus tap water only. Of the 20 patients included, 19 had their palms treated and one had their soles
treated. All patients underwent two treatment sessions. In the first treatment, patients were blinded as to
which tray contained glycopyrrolate. Patients had one palm/foot treated with iontophoresis plus a 0.05%
glycopyrrolate solution and the other side received iontophoresis plus tap water only, for 10 minutes.
In a second visit, both palms or soles were treated for 10 minutes with 0.05% glycopyrrolate solution.
The interval between both visits was between 2 and 3 weeks for most participants. Patient daily
self-assessment was used to evaluate the total number of dry-hand days (total number of days during
which hands were totally dry). The intervention resulting in the highest median number of dry-hand
days was bilateral glycopyrrolate (11 days, range 0–31 days), followed by unilateral glycopyrrolate
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(5 days, range 0–17 days) and tap water (3 days, range 0–15 days). The incidence of dry/sore throat (n = 8)
was higher after bilateral glycopyrrolate than after unilateral treatment. The authors reported that there
were no other adverse events.
Non-comparative studies
The study by Karakoç et al.39 was a case series involving 112 patients who received iontophoresis for both
hands, eight times over 28 days. Sweating was evaluated by gravimetry 20 days after the end of treatment
(see Appendix 2, Table 47). A statistically significant reduction in sweat from baseline was reported for
81% of participants and there were no serious adverse events.
Evidence summary for iontophoresis
In summary, 10 studies (four RCTs, five non-RCTs, one case series) of iontophoresis were included.
All were rated as being at high or unclear risk of bias.
Three very small studies (two RCTs, one interrupted time series) compared iontophoresis with a
placebo37,40,42 and found a positive effect of iontophoresis. Two studies reported a statistically significant
difference in sweat reduction (measured by gravimetry) in the short term (approximately 1 to > 3 months
from treatment initiation), favouring iontophoresis.37,40 One RCT reported a marked reduction in hand
sweating at 5 days post treatment (iodine starch test) when treatment with iontophoresis was compared
with no treatment.42
Two small non-randomised half-side comparisons with no treatment, in which patients acted as their own
control, evaluated a hand-held ‘dry-type’ iontophoresis device;43,44 only one of them found a statistically
significant reduction in sweating (gravimetry) and a significant improvement in the treated palm compared
with the untreated palm at up to 28 days from treatment initiation.
Two studies (one RCT, one non-RCT) compared iontophoresis alone with iontophoresis combined with
anticholinergic therapy.38,41 One study found no significant difference in sweat reduction (gravimetry) of
the hands and feet between iontophoresis alone and iontophoresis combined with oral oxybutynin
by the end of the 6-week treatment period. Another study reported that iontophoresis with topical
glycopyrrolate resulted in a longer duration of effect (as well as a higher incidence of dry/sore throat)
than with iontophoresis alone.
Two studies (one RCT, one non-RCT)88,92 compared iontophoresis with BTX injections for palmar
hyperhidrosis. One RCT found a statistically and clinically significant difference in treatment response
(HDSS) and patient-reported symptoms between the two interventions favouring BTX at 4 weeks from
baseline. One non-RCT92 reported a statistically and clinically significant improvement in patient-reported
symptoms and willingness to undergo treatment at 1 month, but the difference was no longer statistically
significant at 6 or 12 months. This may reflect a waning of the effect following a single treatment with
BTX compared with regular use of iontophoresis, although the evidence is too limited to confirm this
hypothesis. There was limited evidence suggesting that effect duration following end of therapy with
iontophoresis was shorter than after BTX injection. Patients receiving BTX experienced pain more
frequently than with iontophoresis.
One additional case series reported a statistically significant short-term reduction in sweating (gravimetry)
for most patients undergoing standard tap water iontophoresis for the hand (20 days’ follow-up).39
Overall, there is very low-quality but consistent evidence suggesting a beneficial effect of iontophoresis in
the treatment of palmoplantar hyperhidrosis compared with placebo or no treatment and that the effect
of iontophoresis after treatment discontinuation is short-lived. Compared with iontophoresis alone, the
evidence for the effectiveness of combining anticholinergic therapy with iontophoresis is mixed and
inconclusive.
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There is very low-quality evidence to suggest that iontophoresis is less effective than BTX injections at
reducing palmar hyperhidrosis symptoms in the short term and that the effect duration following end of
treatment is shorter than with BTX.
Glycopyrrolate (topical)
Three studies of topical glycopyrrolate were included, including two RCTs51,53 and one non-RCT.91 Sample
sizes ranged from 3853 to 40.91 The risk of bias was considered as high across all outcomes reported in two
studies53,91 and unclear or high depending on the outcome reported in one study.51
Studies were conducted in the UK,91 the USA53 and South Korea;51 therefore, the populations of two of
the studies may not be representative of hyperhidrosis patients in the UK, notably because of differences in
climate. Studies were recent, published between 201391 and 2015.51,53
All of the studies included mostly adults, with ages ranging from 17 to 68 years. In two studies, the
majority of patients were female,53,91 whereas one study included mostly male patients.51 Inclusion criteria
relating to patients’ baseline disease severity were reported in two of the studies: in one study patients had
HDSS scores of 3–4 and a minimum sweat rate of 50 mg per 5 minutes,53 in the other study, patients had
HDSS scores of 3–4 and a minimum sweat rate of 100 mg per 20 minutes on each side of the forehead.51
Duration, dosage and intensity of treatment varied across the studies. Daily dosages ranged from 2% to
4%. Two of the studies compared two different dosages as well as comparing against a non-glycopyrrolate
treatment group.53,91 Glycopyrrolate was applied directly to the axillae in two studies53,91 and onto the face in
one study.51 There were no studies of oral glycopyrrolate.
Topical glycopyrrolate compared with placebo
Two small RCTs compared glycopyrrolate wipes with placebo, used for hyperhidrosis of the axilla for
4 weeks53 or the face for 10 days (see Appendix 2, Table 48).51
Mehrotra et al.53 carried out a three-arm randomised trial that compared 4 weeks of daily treatment
glycopyrrolate wipes for axillary hyperhidrosis (4% group or 2% group) with placebo in 38 patients.
Efficacy was evaluated with HDSS and gravimetry. At the end of week 4, patients receiving glycopyrrolate
experienced a statistically and clinically significant reduction in sweating from baseline (glycopyrrolate 4%,
59% reduction; glycopyrrolate 2%, 48% reduction), and this was significantly greater than the reduction
achieved in the placebo-treated group (16%). There was also a significantly greater proportion of
responders (i.e. HDSS score reduction of ≥ 2 points) in the glycopyrrolate groups (glycopyrrolate 4%,
50%; glycopyrrolate 2%, 35%) than in the placebo group (9%). Adverse event rates were similar
between groups, although it appears that blurred vision, dry mouth and application site discomfort
were more frequent in the groups receiving active treatment.
In the study by Hyun et al.,51 39 patients were treated with 2% topical glycopyrrolate on half of the
forehead, while the other half of the forehead was treated with a placebo. Efficacy was evaluated with
gravimetry and HDSS. At the end of the 10-day treatment, there was a statistically significant difference of
37% [standard deviation (SD) 11.4%] in reduction of sweat production rate favouring intervention versus
placebo (p < 0.025). There was no difference in mean change from baseline in HDSS scores between
treatment and placebo, although the risk of within-patient correlation cannot be excluded. One patient
reported a transient headache following the intervention and no other adverse events were reported.
Topical glycopyrrolate compared with botulinum toxin type A
One study non-RCT compared topical glycopyrrolate with BTX (see Appendix 2, Table 49). Baker91
allocated patients (n = 40) with axillary hyperhidrosis to one of four groups: glycopyrrolate spray
(2% or 1%), BTX-A injections or no treatment. Efficacy was evaluated using HDSS. At 6 weeks following
treatment, patients who had received glycopyrrolate 1% had less improvement in HDSS scores than
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the BTX group; the difference was statistically significant (p < 0.05), although it was not clear if it was also
clinically significant. There was no significant difference between glycopyrrolate 2% and BTX-A.
Evidence summary for topical glycopyrrolate
Three studies (two RCTs, one non-RCT) of topical glycopyrrolate were included. Two small, low-quality
(rated as having high or unclear risk of bias) RCTs evaluated short-term treatment with glycopyrrolate
wipes against placebo, used for hyperhidrosis of the axilla53 or the face.51 Both studies found that the
reduction in sweating (gravimetry) on the treated sides at the end of treatment was significantly greater in
the active treatment group than in the placebo group. Compared with placebo, there was evidence of a
significant short-term improvement in patient-reported disease severity (HDSS) in patients receiving
treatment for axillary hyperhidrosis, but not for facial hyperhidrosis. There was limited and inconclusive
evidence from one non-RCT91 regarding the relative effectiveness (HDSS) and safety of BTX injections
compared with glycopyrrolate spray for axillary hyperhidrosis.
Overall, there is very low-quality evidence suggesting a short-term benefit of topical glycopyrrolate for
axillary and facial hyperhidrosis. No evidence for other treatment sites was found.
Oxybutynin
Three placebo-controlled RCTs of oxybutynin were included (see Appendix 2, Table 50).57,59,60 Risk of bias
was considered unclear for all three studies. Sample sizes ranged from 3257 to 62.59
Studies were conducted in France59 and Brazil57,60 and were recent, as they were published between 201260
and 2015.59
When reported, studies included adult patients, with ages ranging from 18 to 62 years. One study
included female patients only,57 with the other two studies including mostly female patients.59,60 Inclusion
criteria relating to patients’ baseline disease severity were reported in only one of the studies; patients had
HDSS scores of ≥ 2.59 However, one of the other studies reported that patients had persistent hyperhidrosis
despite a previous sympathectomy.57
In all three studies, oral oxybutynin was prescribed in progressively increasing doses (starting at 2.5 mg
daily) throughout the treatment period, which lasted 30 days in one study57 and 6 weeks in two
studies.59,60 The maximum dose prescribed was 7.5 mg daily in one study59 and 10 mg daily in two
studies.57,60
The majority of patients in one study had generalised hyperhidrosis,59 whereas the other two studies
focused on specific body parts (including axilla and palm60 and the foot57).
Schollhammer et al.59 randomised 32 patients to oxybutynin and 30 patients to placebo. Efficacy was
assessed using HDSS and quality of life with DLQI. At the end of the treatment period, the percentage of
participants with an improvement in HDSS score of ≥ 2 points was higher in the treatment group (43%)
than the placebo group (7%). This difference was relatively small but statistically significant. Mean
improvement in DLQI score was small but statistically significantly higher in patients allocated to the
oxybutynin group (6.9) than those allocated to the placebo group (2.3) (p < 0.01). Dry mouth was
significantly more frequent in the oxybutynin group (41%) than in the placebo group (11%) (p < 0.01).
Wolosker et al.60 randomised 25 patients to a oxybutynin group and 25 patients to a placebo group.
Improvement in hyperhidrosis was assessed using a non-validated scale completed by patients ranging
from 0 (no improvement) to 10 (absence of hyperhidrosis), with higher scores indicating greater
improvements. Three outcomes, including improvement in palmar or axillary symptoms, improvement in
plantar symptoms and improvement in quality of life at the end of treatment, were each assessed using a
modified questionnaire by Amir et al.186 using a summed total score ranging from 20 to 100, with lower
scores indicating greater improvement from baseline. The study reported large and statistically significant
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differences in improvement favouring oxybutynin for all three outcomes at the end of treatment. However,
the proportion of patients reporting moderate or severe dry mouth was significantly higher in the
intervention group (35%) than in the placebo group (9%) (p = 0.038). Further results are reported in
Appendix 2, Table 50.
Costa et al.57 included patients with persistent plantar hyperhidrosis despite undergoing sympathectomy
> 6 months earlier. The study randomised 16 patients to the oral oxybutynin group and 16 patients to the
placebo group. Sweating was measured by evapometry, and improvement in quality of life at the end of
treatment was assessed using a modified questionnaire by Amir et al.186 and by imputing a summed
total score ranging from 0 to 100, with lower scores indicating greater quality of life. There was an
improvement from baseline measurements in sweating of the foot (38% reduction in the treated group
vs. 9% in the placebo group) at the end of 30 days of treatment that was statistically significant only in the
oxybutynin group, although the clinical relevance of these results may be limited. Statistically and clinically
significant reductions in sweat from the hands, back and abdomen were also reported. Quality-of-life
scores were significantly improved from baseline (p = 0.001) in the oxybutynin group (from ‘very good’ at
baseline to ‘excellent’ at follow-up), but not in the placebo group, although the clinical relevance of these
results is unclear. Dry mouth (100% vs. 44%), constipation (31% vs. 6%) and drowsiness (18% vs. 6%)
were all more common in the oxybutynin group than in the placebo group.
Evidence summary for oxybutynin
Three studies, all rated as having an unclear risk of bias, evaluated the effectiveness and safety of oral
oxybutynin against placebo for hyperhidrosis of the axilla and palm,60 foot57 and generalised
hyperhidrosis.59
One study reported statistically significant improvement in patient-reported symptoms compared with
placebo at the end of treatment, in both the axilla and palm, at 6 weeks.60 Another study reported a
statistically significant difference in sweat reduction (gravimetry) in the foot and the hand at 30 days,
although the reduction may be of limited clinical relevance.57 A third study reported a small difference
favouring active treatment compared with placebo in patient-reported disease severity improvement
(HDSS) at the end of 6 weeks of treatment, although, again, this reduction was small and may be of
limited clinical relevance.59 All three studies reported a short-term quality-of-life improvement favouring
oxybutynin, as well as a significantly higher incidence of dry mouth symptoms in patients receiving active
therapy.
Overall, there is low-quality evidence suggesting a short-term small benefit of oxybutynin in hyperhidrosis
symptoms and a short-term improvement in quality of life compared with placebo. There is insufficient
evidence to indicate whether or not the effectiveness of oxybutynin differs according to target area.
Oxybutynin is associated with a high incidence of adverse events, particularly dry mouth.
Methantheline bromide
Two placebo-controlled RCTs of oral methantheline bromide were included (see Appendix 2, Table 51).68,69
Risk of bias was considered high across all outcomes in one study68 and mostly unclear (except for one
outcome) in the other study.69
Sample sizes were 4268 and 339.69 Both studies were conducted in Germany. The studies were published in
200468 and 2013.69
One study was conducted in adults, with an age range of 18–54 years, the majority of whom were
female.68 The other study did not report the age range or sex of the included patients.69 Inclusion criteria
relating to patients’ baseline disease severity was reported in both studies; in one study, patients had a
minimum sweat rate of 50 mg per minute68 and, in the other study, patients had a minimum sweat rate of
50 mg per 5 minutes.69 Both studies included patients with axillary and/or palmar hyperhidrosis.
RESULTS OF THE CLINICAL EFFECTIVENESS REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
34
In one study, oral methantheline bromide was prescribed at a dose of 50 mg twice daily for 4 weeks,68
whereas the other study prescribed oral methantheline bromide at a dose of 50 mg three times daily for
4 weeks.69
Müller et al.69 evaluated the efficacy of a 4-week course of 50 mg of methantheline three times daily,
using gravimetry, HDSS and DLQI. Axillary sweat rates were significantly reduced at the end of treatment
in the intervention group compared with placebo (intervention group: 41% reduction, from 168 ± 146 mg
per 5 minutes at baseline to 99 ± 98 mg per 5 minutes at day 28; placebo group: 19% reduction, from
161 ± 119 mg per 5 minutes at baseline to 130 ± 119 mg per 5 minutes at day 28; p = 0.0013), but the
study found no differences in palmar sweat. There was also a statistically significant difference in reduction
in HDSS scores between groups, favouring methantheline bromide. A statistically significant difference in
DLQI score reduction favouring the intervention group was also reported (intervention group: 6.9 points
reduction, from 16.6 ± 5.3 at baseline to 9.7 ± 6.8 at day 28; placebo group: 4.2 points reduction, from
16.4 ± 5.6 to 12.2 ± 6.9 at day 28). However, both HDSS and DLQI score improvements were small when
compared with placebo and may not be clinically significant. The most common adverse event was dry
mouth, which occurred significantly more often in the intervention group (88 events) compared with the
placebo group (28 events). Twenty-one events were recorded as severe, although the authors did not
report rates by group or which events may have been related to the study medication.
Hund et al.68 assessed the efficacy of a 4-week course of 50 mg of methantheline twice daily using
gravimetry. They reported a statistically significant reduction in axillary sweating from baseline at the end
of treatment in patients allocated to methantheline bromide [40% reduction, from 89.2 (SD 73.4)
mg/minute to 53.3 (SD 48.7) mg/minute], compared with no change in the placebo group. The difference
between methantheline and placebo was clinically significant. There were no differences in palmar
sweating reduction between the intervention group and the placebo group at 4 weeks. The incidence
of dry mouth symptoms was significantly greater in the intervention group than in the placebo group
(intervention group: 47.8% at week 2 and 34.8% at week 4; placebo group: 11.1% at week 2 and
5.6% at week 4: between-group difference significant at p < 0.02).
Evidence summary for methantheline bromide
Two placebo-controlled RCTs of oral methantheline bromide were included.68,69 Both studies were rated as
being at a high or unclear risk of bias. They both reported relatively small reductions in axillary sweating
(gravimetry) after 4 weeks of active treatment compared with placebo, but no difference in sweating of
the palms. One study also reported small, non-clinically significant, differences in patient-reported disease
severity (HDSS) and quality-of-life improvement favouring treatment against placebo. Both studies reported
a statistically and clinically significant increase in dry mouth symptoms in patients receiving active treatment
compared with those receiving placebo.
Overall, there is low-quality evidence that, compared with placebo, methantheline bromide has a
short-term positive effect on axillary hyperhidrosis symptoms and quality of life, although this effect is
small and may not be clinically significant. There is no evidence that methantheline bromide improves
symptoms of the palm or any other body parts. There is evidence suggesting that methantheline bromide
is associated with a high incidence of dry mouth symptoms.
Botulinum toxin (topical)
One very small study evaluated the efficacy of topically applied BTX for axillary hyperhidrosis (see Appendix 2,
Table 52).71 The risk of bias was considered unclear. In the study by Glogau,71 12 patients had one axilla
randomly assigned to receive 200 U of BTX-A mixed with Cetaphil cream (Galderma, Fort Worth, TX, USA),
which was massaged into the axilla and remained on the skin for 60 minutes. The other axilla received a
placebo cream. Sweating outcomes were measured by gravimetry and iodine starch test at 4 weeks’ follow-up.
Two patients were excluded from the study analyses due to a significant imbalance in sweating (> 25%) at
baseline. Among the remaining 10 patients, the reduction in sweating from baseline was 40% greater in
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the BTX-A-treated axillae than the placebo-treated side (65% vs. 25%) at 4 weeks’ follow-up. The
difference was statistically significant. The authors stated that the results of the Minor’s iodine starch test
were consistent with the gravimetry results. Four minor localised adverse events were reported in the
treated axilla.
Evidence summary for topical botulinum toxin
Only one very small study (rated as having an unclear risk of bias) evaluated the efficacy of topically
applied BTX for axillary hyperhidrosis.71 There is insufficient evidence to conclude on the effectiveness and
safety of topical BTX for primary hyperhidrosis.
Botulinum toxin (subcutaneous injection)
Twenty-three studies of BTX administered by subcutaneous injection were included.21,72–77,80–85,88–92,148,155,184,185
Thirteen studies were randomised trials21,72–77,79,82–85,88 and 10 were non-randomised studies.80,81,89–92,148,155,184,185
Risk of bias was considered to be high across all reported outcomes in 14 studies,21,73,74,80,81,88–92,148,155,184,185
unclear in seven studies72,76,79,82–85 and low in one study.75 Another trial was rated as being at an unclear
risk of bias for all assessed outcomes except one (DLQI), which was rated as high risk.77
Two studies were conducted in multiple European countries.79,80 Among the other studies, six were
conducted in the USA,21,73,74,76,77,82 four in Germany,75,89,148,155 three in Japan,83,90,185 two in Austria,84,85 two
in the UK91,184 and one each in India,88 Italy,72 Poland92 and Sweden.81 Studies were published between
199784 and 2016;184 the BTX used in the earlier studies may not have the same effectiveness and adverse
event profile as newer formulations.
When reported, all studies included adults; five studies also recruited a small number of participants
aged < 18 years.80,82,88,155,184 However, age range was not reported in seven studies. The majority of the
participants in 12 of the studies were female; one study included only female patients.72 The majority of
the participants in seven studies were male. One study had 50% male participants and two studies did not
report the sex of the participants.
Inclusion criteria relating to patients’ baseline disease severity was reported in 13 studies; ranging from a
minimum sweat rate of 50 mg per 5 minutes77,79,80 to at least 100 mg per axilla per minute89 (when
reported in terms of sweat rate). Other inclusion criteria were used for baseline disease severity, including
HDSS score (generally patients had a score of 3–4), Haider 2005 criteria,187 described as ‘severely disabled
in regard to occupation and social activities’ or ‘socially handicapped by condition’.
Most studies used BTX-A and only two used botulinum toxin type B (BTX-B).73,74 Five studies used Botox®
(Allergan Inc., Irvine, CA, USA),77,81,90,92,184 three studies used Dysport®,84,89,185 one study used both brands148
and 14 studies did not state which brand was used.21,72–76,79,80,82,83,85,88,91,155 When stated, the most common
dosage of BTX-A was 50 U,21,77,79,80,82,83,92,155,185 although some studies used dosages as high as 250 U.72,89
Studies of BTX-B used dosages of 2500 U73 or 5000 U.74
Twelve studies compared BTX with placebo exclusively72–76,79,82–85 (including two studies77,80 that compared
different botulinum regimens with placebo) and four compared BTX with no treatment.81,89,90,185 Of the seven
studies that compared BTX with an active treatment, four studies compared it with curettage,21,148,155,184
two with iontophoresis88,92 and one with topical glycopyrrolate.91
Most studies (n = 16) used BTX for treating axillary hyperhidrosis exclusively21,72,73,75,77,79,80,82,83,85,89,91,148,155,184,185
and five used it to treat palms only.74,76,84,88,90 Two studies reported using the intervention for treating the
palm and/or axilla.81,92 None of the studies of BTX for treating axillary hyperhidrosis stated that anaesthesia
was used, whereas all studies of BTX for treating hyperhidrosis of the palm, or palm and/or axilla, reported
using local anaesthesia.
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Axillary hyperhidrosis
By far the most studied intervention/site combination was BTX for axillary hyperhidrosis: there were many
studies versus placebo or no treatment reporting various outcomes.
Botulinum toxin compared with placebo
Of the nine studies that compared subcutaneous injections of BTX with placebo for axillary
hyperhidrosis,72,73,75,77,79,80,82,83,85 eight were RCTs and one80 was an open-label continuation study of an
included RCT (see Appendix 2, Table 53).79
Two studies reported using HDSS as a measure of efficacy,77,83 six measured sweating using
gravimetry.75,77,79,80,82,83 Five studies measured quality of life.73,77,79,80,83 Patient satisfaction was assessed in
three placebo-controlled BTX studies, using four different tools.79,80,83 Three studies reported on duration of
effect.73,77,83 All studies reported data on adverse events.
Out of 10 studies, five were considered sufficiently similar to be pooled in a meta-analysis.75,77,79,82,83
A range of outcomes were reported as presented in the following sections.
Hyperhidrosis Disease Severity Scale Two studies estimated treatment response in terms of a
reduction in HDSS score of ≥ 2 points.77,83 These studies were pooled in a meta-analysis. Lowe et al.77
was a three-armed trial that compared two doses of BTX-A (50 U and 75 U) with placebo, and both active
treatment arms were considered sufficiently homogeneous to be pooled. Figure 3 shows that there was a
large and statistically significant difference in odds of response at 4 weeks favouring BTX-A [RR 3.30,
95% confidence interval (CI) 2.46 to 4.43]. There was no difference in response rates between the two
BTX-A doses in Lowe et al.77 (50 U and 75 U). There was no evidence of heterogeneity.
Ohshima et al.83 found that HDSS response rates were maintained in the intervention group at 16 weeks
and reported a similarly large difference compared with placebo at this time point (RR 5.96, 95% CI 2.87
to 12.39).
In the Ohshima et al. study,83 the initial treatment phase (which lasted 16–24 weeks) was followed by
an open-label second treatment phase; the entire study lasted until 40 weeks after first treatment.
Participants initially allocated to BTX received either a re-injection of BTX-A 50 U per axilla or no
re-injection. Participants initially allocated to placebo received either one injection of BTX-A 50 U per
axilla or no injection. Patients received a BTX-A injection during the second treatment phase if they met
‘re-injection criteria’: mean sweat production beyond 50% of baseline at any time between weeks 16 and
24 [of 78 patients allocated to BTX-A, 34 (44%) were included in the second treatment phase]. Treatment
response was defined as ≥ 50% reduction in mean sweat from baseline and a reduction from baseline of
≥ 2 points on the HDSS. Rates of adverse events were higher in the intervention group (54%) than in the
placebo group (30%). Duration of effect, defined as the number of days between the initial treatment
and the first recording of > 50% of baseline sweat production, was 273 days (95% CI 171 days to a
number of days that was not reported) for the BTX group compared with 35 days (95% CI 28 to 56 days)
for placebo.
Lowe et al.77 measured the median effect duration in the subgroup of responders, defined as time to
return to a HDSS score of 3 or 4 points after treatment. The study reported a median effect duration of
205 days in the 50-U group, 197 days in the 75-U group and 96 days in the placebo group. The difference
between each BTX-A group and placebo was statistically significant.
Sweating (gravimetry) Five RCTs were included in at least one meta-analysis evaluating the effect of
BTX on gravimetry against placebo75,77,79,82,83 and one unblinded continuation study of the Naumann et al.80
RCT was only summarised narratively.
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FIGURE 3 Botulinum toxin vs. placebo. Reduction of ≥ 2 points in HDSS at 4 weeks. df, degrees of freedom; IV, inverse variance. In Lowe et al.,77 the 75-U and 50-U groups
were presented separately to explore any dose–response effect and total n/N in the placebo group was 27/108; events and total sample size were divided by two to avoid
double counting. This artificially reduces the power of the study in the meta-analysis and does not account for correlation between the two active treatment groups.
However, a separate analysis combining the two arms showed no significant difference in results.
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Sweating (gravimetry) response (2–4 weeks’ follow-up) Figure 4 shows a pooled analysis of four
studies75,79,82,83 reporting a reduction of ≥ 50% sweating from baseline at 2–4 weeks’ follow-up and
suggests a large and statistically significant difference favouring BTX-A compared with placebo (RR 3.27,
95% CI 1.93 to 5.55).
There was evidence of heterogeneity (I2-statistic = 94.7%), which seems to be due to the Heckmann et al.75
study. Heckmann et al.75 used a higher dose than the other studies (200 U vs. 50 U) and had a half-side
comparison design. However, Figure 4 shows no evidence of a dose–response effect and suggests that the
results in Heckmann et al.75 were driven by a relatively lower overall response rate in the placebo group
(15% in Heckmann et al.75 vs. 40% overall in the other studies). The reason for the heterogeneity in
response rates across placebo groups is unclear. Notwithstanding the heterogeneity the treatment effect
favours BTX.
Figure 5 shows a meta-analysis of three studies75,77,82 and suggests a similarly large and statistically
significant difference in the odds of patients experiencing a reduction of at least 75% in sweat volumes
at 2–4 weeks’ follow-up (RR 6.74, 95% CI 2.84 to 16.03).
There was again evidence of heterogeneity (I2-statistic = 92.4%) due to the Heckmann et al.75 study
results, which had a higher RR than the other studies. As with Figure 4, Figure 5 shows no evidence of a
dose–response effect and suggests that the results in Heckmann et al.75 were driven by a relatively lower
response rate in the placebo group than in other studies (3% in Heckmann et al.75 vs. 18% overall in the
other studies), rather than a higher response rate in the intervention group (79% in Heckmann et al.75
vs. 76% overall in the other studies). As before, the reason for the heterogeneity in response rates across
placebo groups is unclear.
Sweating (gravimetry) response (16 weeks’ follow-up) Figure 6 shows a pooled analysis of three
studies79,82,83 reporting a reduction of ≥ 50% sweating from baseline at 16 weeks’ follow-up and suggests
a large and statistically significant difference favouring BTX-A (RR 2.87, 95% CI 1.94 to 4.26). There was
no evidence of heterogeneity.
Figure 6 suggests that the effect observed in patients undergoing BTX-A treatment at 2–4 weeks
(see Figure 4) is largely maintained at 16 weeks, albeit slightly reduced: the absolute rate of BTX-A
patients with ≥ 50% reduction in sweating at 2–4 weeks was 94% compared with 83% at 16 weeks.
Sweating (gravimetry): mean percentage sweat reduction (2–4 weeks) Figure 7 shows a
meta-analysis of four studies77,79,82,83 and suggests a large and statistically significant difference in mean
percentage sweat reduction from baseline favouring BTX-A. Compared with placebo, patients receiving
BTX-A had an approximately 57% greater reduction in sweating at 2–4 weeks’ follow-up (MD –56.83%,
95% CI –64.61% to –49.04%). There was no evidence of heterogeneity.
Sweating (gravimetry): mean percentage sweat reduction (16 weeks) Figure 8 shows a pooled
analysis of three studies,79,82,83 which suggests a slightly greater difference in mean percentage sweat
reduction at 16 weeks’ follow-up. Compared with placebo, patients receiving BTX-A had an approximately
67% greater reduction in sweating (MD –66.93%, 95% CI –82.76% to –51.10%). There was no evidence
of heterogeneity.
Naumann et al.80 was a 16-month open-label continuation study of the Naumann et al.79 RCT and was not
included in the meta-analyses. After 4 months of the initial trial, in which patients were randomised to
either BTX-A 50 U or placebo, participants could receive up to three further treatments with open-label
BTX-A over 12 months. Of the 207 participants enrolled during the entire 16-month period, 80 received
one treatment, 93 had two treatments, 30 received three treatments and four only received placebo
during the initial phase of the trial. Outcomes assessed included treatment response (gravimetry), patient
satisfaction and quality of life (bespoke questionnaires) and adverse events. The proportion of responders,
DOI: 10.3310/hta21800 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 80
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Wade et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
39
0.01 0.1 1
RR
IV, random, 95% CI
RR
IV, random, 95% CIWeightTotalEventsTotalEvents
PlaceboBTX
Study or subgroup
Between-patients comparison
Naumann and Lowe 200179 (50 U)
Odderson 200282 (50 U)
Ohshima et al. 201383 (50 U)
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 2.08, df = 2 (p = 0.35); I 2 = 4%
Test for overall effect: z = 8.36 (p < 0.00001)
2.61 (1.94 to 3.52)
4.49 (1.08 to 18.61)
2.09 (1.63 to 2.69)
2.33 (1.91 to 2.84)
227
12
75
314
242
12
78
332
28
1
34
63
78
6
74
158
30.4%
9.8%
31.3%
71.5%
Half-side comparison
Heckmann et al. 200175 (200 U)
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 9.13 (p < 0.00001)
6.09 (4.13 to 8.98)
6.09 (4.13 to 8.98)
134
134
145
145
22
22
145
145
28.5%
28.5%
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.22; χ2 = 21.23, df = 3 (p < 0.0001); I 2 = 86%
Test for overall effect: z = 4.39 (p < 0.0001)
Test for subgroup differences: χ2 = 18.75, df = 1 (p < 0.0001); I 2 = 94.7%
3.27 (1.93 to 5.55)
448
477
85
303 100.0%
10 100
Favours placebo Favours BTX
FIGURE 4 Botulinum toxin vs. placebo. Reduction in sweating from baseline to 2–4 weeks of ≥ 50%. df, degrees of freedom; IV, inverse variance. Follow-up duration was
2 weeks for Heckmann et al.75 and 4 weeks for Naumann et al.79 and Ohshima et al.83 Median follow-up duration in Odderson82 was 2 weeks (range 1–8 weeks). Data for
Odderson82 were extracted from figures.
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FIGURE 5 Botulinum toxin vs. placebo. Reduction in sweating from baseline to 2–4 weeks of ≥ 75%. df, degrees of freedom; IV, inverse variance. Follow-up duration was
2 weeks for Heckmann et al.75 and 4 weeks for Lowe et al.77 Median follow-up duration in Odderson82 was 2 weeks (range 2–8 weeks). Data for Odderson82 were extracted
from figures. In Lowe et al.,77 total n/N in the placebo group was 20/108; events and total sample size were divided by 2 to avoid double-counting.
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FIGURE 6 Botulinum toxin vs. placebo. Reduction in sweating from baseline to 16 weeks of ≥ 50%. df, degrees of freedom; IV, inverse variance. Follow-up duration was 16 weeks
for Naumann et al.79 and Ohshima et al.83 Median follow-up duration for Odderson82 was 16 weeks (range 10–21 weeks). Data for Odderson82 were extracted from figures.
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FIGURE 7 Botulinum toxin vs. placebo. Mean per cent reduction in sweating from baseline to 2–4 weeks. df, degrees of freedom; IV, inverse variance. Follow-up duration was
4 weeks for Lowe et al.,77 Naumann et al.79 and Ohshima et al.83 Median follow-up duration in Odderson82 was 2 weeks (range 1–8 weeks). Data for Odderson82 were extracted
and calculated from figures.
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FIGURE 8 Botulinum toxin vs. placebo. Mean per cent reduction in sweating from baseline to 16 weeks. df, degrees of freedom; IV, inverse variance. Follow-up duration was
16 weeks for Naumann et al.79 and Ohshima et al.83 Median follow-up duration for Odderson82 was 16 weeks (range 10–20 weeks). Data for Odderson82 were extracted and
calculated from figures.
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defined as those achieving ≥ 50% reduction in spontaneous sweating, was higher in the BTX groups than
in the placebo group both 4 weeks after treatments (BTX group: first treatment, 96.1%; second treatment,
91.1%; third treatment, 83.3%; placebo group: 34.7%) and 16 weeks after treatments (BTX group; first
treatment, 85.7%; second treatment, 87.3%; third treatment, 80.5%; placebo group: 20.6%).
Sweating (sweat area) Two studies evaluated sweat outcomes using non-gravimetric methods. Schnider
et al.85 measured sweat production by digitising and analysing ninhydrin-stained sheets using standardised
image analysis software. Balzani et al.72 used the Minor’s iodine starch test. Both studies reported clinically
relevant improvements in sweating at follow-up in the BTX group compared with the placebo group.
Quality of life Of the five studies that measured quality-of-life outcomes, two used DLQI,77,83 one used
SF-1279 and two used a bespoke questionnaire.73,80
Two studies were combined in a meta-analysis. Figure 9 shows that there was a statistically significant
difference in mean reduction in DLQI score from baseline to 4 weeks’ follow-up favouring BTX-A over
placebo (MD –4.80, 95% CI –5.67 to –3.94). There was no evidence of significant heterogeneity.
Ohshima et al.83 reported further results at up to 16 weeks following initial treatment, which suggested
that the effect was maintained over this period.
Naumann et al.79 reported a statistically significant difference in mean change in quality of life, measured
using SF-12 physical component summary (PCS) but not mental component summary (MCS) scores, from
baseline to 16 weeks, favouring BTX-A. However, the improvement in PCS appeared small and may not be
clinically significant. The two studies that used a bespoke unvalidated questionnaire73,80 both reported an
improvement in quality of life following BTX-A treatment, although it is unclear whether or not this
improvement was clinically significant.
Patient satisfaction Three studies reported data on patient satisfaction, using HHIQ79 and a global
assessment of treatment satisfaction questionnaire.79,80,83 Patients’ global assessment of treatment
satisfaction was measured on a scale ranging from –4 to 4, with negative values indicating worsening and
positive values indicating improvement. A score of 0 indicates no change from baseline, +1 indicates slight
improvement, +2 moderate improvement, +3 substantial improvement and +4 complete abolition of signs
and symptoms. Patient satisfaction, as measured by global assessment score, ranged from moderate (mean
score of 2.6)79,83 to substantial (mean score of 3.5)80 in patients receiving BTX-A and from unchanged
(mean score of 0.3)79,83 to slight (mean score of 1.4)80 in patients receiving placebo at 4–16 weeks’
follow-up.
Adverse events None of the studies reported serious or severe adverse events related to the intervention.
The most common treatment-related events reported included injection site pain and CS. Four studies
reported injection site pain events,73,75,77,80 with incidence rates ranging from approximately 1%75 to 12%.77
Six studies reported higher rates of non-axillary/CS in patients/axillae receiving BTX-A,77,79,80,82,83,85 with
event rates ranging from under 1%82 to 15%.85 One event of increased facial sweating was also reported
in one study.75 There was no evidence to suggest an increase in incidence or severity of treatment-related
adverse events in the two studies in which patients received repeated injections.80,83
Further study details and results not included in the meta-analysis are reported in Appendix 2, Table 53.
Botulinum toxin compared with no treatment
Three studies81,89,185 compared the effectiveness of BTX-A with no treatment (see Appendix 2, Table 54).
All were small non-randomised half-side comparison trials (in which patients acted as their own control).
Heckmann et al.89 included 12 patients. Participants initially received BTX-A 250 U in one axilla and the
same treatment on the contralateral side 14 days later. Sweating outcomes were assessed by gravimetry
and iodine starch test. Effect duration and patient satisfaction were assessed by patient questionnaire.
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FIGURE 9 Botulinum toxin vs. placebo. Mean reduction in DLQI score from baseline to 4 weeks. df, degrees of freedom; IV, inverse variance. In Lowe et al.,77 the total sample
size of the placebo group (n= 108) was divided by 2 to avoid double-counting.
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The study found a significant reduction in sweating at 7 days’ follow-up, confirmed by iodine starch test.
Most patients reported being symptom free for at least 9 months. Injection site stinging post intervention
was the only adverse event reported.
Naver et al.81 included 28 patients. Of those, 13 were treated for axillary hyperhidrosis with BTX-A.
Sweating outcomes were evaluated using evaporimetry and iodine starch test at 1–2 weeks’ follow-up.
The study found a significant reduction in sweating at follow-up with both measures. All patients reported
a marked reduction or complete disappearance of sweating symptoms. Two patients reported intense
pain from injection and reported that they would have preferred treatment under local anaesthesia.
Wakugawa et al.185 included 20 patients. Thirteen patients received BTX-A in both axillae and seven
patients received BTX-A (50 U) on one side only. Sweating was assessed by measuring sweating area with
the Sakurai–Montagna paper sweating test at 1 and 3 months’ follow-up.188 Test papers were digitised
and sweating areas measured using image analysis software. In the seven patients who were treated on
one side only, there was a statistically significant reduction in sweat area in the treated side, but not in
the non-treated contralateral side at 1 and 3 months. There were no serious adverse events.
Botulinum toxin compared with curettage
Four studies (one RCT, three non-RCTs) compared curettage with BTX (see Appendix 2, Table 55).21,148,155,184
Ibrahim et al.21 was a half-side comparison RCT involving 20 patients and comparing tumescent suction
curettage with injection of BTX-A (50 U). Efficacy was measured with HDSS and gravimetry. The reduction
in mean HDSS score from baseline was statistically and clinically significantly greater in BTX-A-treated
axillae than in curettage-treated axillae both at 3 months (MD 0.80; p = 0.0002) and at 6 months
(MD 0.90; p = 0.0017). There was no statistically significant difference in sweat reduction between the
two interventions at 3 months’ follow-up. There were few adverse events for curettage-treated axillae and
none reported for BTX-A.
Ottomann et al.155 carried out a non-randomised parallel-group study in 88 patients. Forty-one were
assigned to curettage and 47 to BTX-A (50 U). Sweating was assessed with gravimetry. Quality of life
was measured using a bespoke disease-specific questionnaire covering 10 items grouped under three
categories (psychosocial symptoms, activities, subjective perspective/others). Both sweating and quality
of life were measured at 2, 12 and 26 weeks’ follow-up. There were no significant differences between
the two groups in sweating reduction from baseline at any of the follow-up times. There were also no
significant differences between groups in quality-of-life improvement at 26 weeks (earlier follow-up results
were not reported). There were no severe adverse events. The incidence of adverse events associated with
treatment was higher in the curettage group (8.3%) than in the BTX-A group (1.7%).
Rompel and Scholz148 conducted a non-randomised parallel-group study in 113 patients. Ninety participants
received curettage under general anaesthesia and 23 patients were treated with BTX-A injections. Sweating
was measured with patient questionnaires at baseline, 6 months and the end of follow-up (median
28.2 months), when participants were asked to record the amount of axillary sweating based on a score
ranging from 1 (no axillary secretion) to 6 (maximum axillary secretion). General satisfaction with the
procedure was assessed using a four-item scale (from dissatisfied to very good). The study reported no
significant differences in sweating. In the curettage group, the overall score of axillary sweating at rest was
reduced to 40.0% of the baseline score after 6 months and to 45.7% of the baseline score at the end of
follow-up (median 28.2 months). In the BTX-A group, sweating at rest was reduced to 48.5% of the
baseline score after 6 months and to 68.8% at the end of follow-up (median 16.1 months). There was no
statistically significant difference in general satisfaction score between the two interventions: satisfaction
with treatment was rated as ‘very good’ or ‘good’ in 66% of curettage patients and 61% of BTX-A
patients. The overall complication rate after curettage was 17.8%. The study reported that there were no
adverse reactions after treatment with BTX-A except for minimal superficial haematoma. In the curettage
group, 12 patients required surgical revision and additional suction drainage.
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Vakili and Baker184 carried out a non-randomised parallel group study in 98 patients. The study was
reported only as a conference abstract with limited details. Twenty-three participants were treated
with microretrodermal curettage, and 75 received BTX-A. Efficacy was assessed using HDSS. The study
reported significant and similar improvement from baseline in mean HDSS scores in both groups at
6 weeks’ follow-up. Improvements in other patient-reported outcomes (including physical effects and
impact of psychological precipitating factors) were also equally significant in both groups at 6 weeks.
No data on adverse events were reported.
Palmar hyperhidrosis
Seven studies evaluated the effectiveness of BTX for palmar hyperhidrosis.74,76,81,84,88,90,92 Of those,
five targeted the palm only74,76,84,88,90 and two targeted the palms and/or axillae.81,92
Botulinum toxin compared with placebo
Three RCTs evaluated the effectiveness of BTX for palmar hyperhidrosis against placebo (see Appendix 2,
Table 56).74,76,84 Of those, two were half-side comparison trials.76,84 All patients underwent local anaesthesia
on both hands.
Baumann et al.74 studied 20 patients. Fifteen patients were randomised to BTX-B (5000 U) treatment for
both hands and five received a placebo. Sweating was assessed using iodine starch test, and the Palmar
Hyperhidrosis Improvement (P-HI) questionnaires. The P-HI questionnaire evaluates patient-perceived
improvement in symptoms. The lowest possible P-HI score is 2, representing great improvement in palmar
hyperhidrosis, and the highest possible score is 8, representing worsening hyperhidrosis. Quality-of-life
outcomes were evaluated using the Palmar Hyperhidrosis Quality of Life (P-HQOL) questionnaire. The
P-HQOL assesses interference of hyperhidrosis with daily life, with scores ranging from 4 (no interference
with daily life) to 15 (great deal of interference with daily life). Both questionnaires were unvalidated.
At 30 days’ follow-up there was no statistically significant difference in iodine starch test results between
the intervention and placebo groups. At 30 days, there was a statistically significant difference in mean
change from baseline in P-HI scores (p = 0.002) and P-HQOL scores (p = 0.010), favouring BTX-B; however,
owing to limited reporting (no mean scores or SDs), it is unclear whether or not these results were clinically
significant. There were 83 adverse events that were considered to be definitely related to the intervention,
including decreased grip strength (50% of participants), muscle weakness (60%), dry mouth (90%),
excessively dry hands (60%) and indigestion/heartburn (60%). There was no statistically significant
difference betwen groups in the incidence of injection site pain. The authors did not report on the
rate of severe/serious events.
In the study by Lowe et al.,76 19 patients were treated with BTX-A (100 U) in one hand. randomly assigned,
and placebo in the other hand. Sweating outcomes were measured by gravimetry at 28 days’ follow-up.
Hyperhidrosis severity was also assessed by physicians and patients. There was a reduction in gravimetric
measurements favouring BTX-A over placebo (p = 0.0027). The difference with placebo was statistically and
clinically significant (approximately 33% difference). The authors also reported significant improvements
from baseline in iodine starch test results in BTX-A-treated palms compared with placebo-treated palms.
Both physicians and patients considered the improvement in hyperhidrosis severity at 28 days to be
significantly greater in the BTX-A-treated hand than in the placebo-treated palms (p < 0.01) . Four patients
reported adverse events. There was no significant difference in grip strength between the BTX-A- and
placebo-treated hands.
Schnider et al.84 studied 11 patients in whom one hand was randomly assigned to BTX-A (120 U) treatment
and the other hand to placebo treatment. Sweating was assessed by digitisation of ninhydrin-stained sheets,
followed by image analysis to measure the stained area using a standardised algorithm. Subjective rating of
symptoms was performed using a VAS for each hand, with scores ranging from 0 (no sweating) to 100
(most severe sweating). All outcomes were assessed at 3, 8 and 13 weeks. The study reported a statistically
significant reduction in sweating area and a significant improvement in patient rating of symptoms in the
BTX-A group, compared with no significant change in the placebo group. Three patients reported minor
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handgrip weakness in the BTX-A-treated hand and three patients reported that injections were more painful
in hands receiving BTX-A than in the placebo-treated hands.
Botulinum toxin compared with no treatment
Two non-randomised half-side comparison studies (in which patients acted as their own control) compared
BTX with no treatment (see Appendix 2, Table 57).81,90
Naver et al.81 studies 28 patients, of whom 19 are relevant to this review and were treated for palmar
hyperhidrosis with BTX-A under local anaesthesia. Sweating outcomes were evaluated using evaporimetry
and iodine starch test at 1–2 weeks’ follow-up. The study reported a significant reduction in evaporation in
the treated side (57% reduction from baseline) and a significant reduction in area of colour reaction from
the palms at 1–2 weeks (p = 0.0002). Fifteen out of 19 patients reported marked reduction or complete
disappearance of sweating at 1–2 weeks. Twelve patients reported slight and transient reduction in power
of the fingers and six reported intense dryness of the skin.
Yamashita et al.90 administered BTX-A (60 U) to the right hand only in 27 patients. Sweating was
assessed by gravimetry monthly from 1 to 6 months and using the iodine starch test. The study reported a
statistically significant reduction from baseline in sweating in both groups at all follow-up points. Although
the reduction in sweating was larger in the intervention group, it is unclear whether or not there was a
statistically or clinically significant difference compared with the untreated hand. Larger decreases in
sweating were also reported with the iodine starch test, although it is unclear if differences between
BTX-A and no treatment were clinically significant. The study did not report whether or not the patients
experienced any adverse events.
Botulinum toxin compared with iontophoresis
Two studies88,92 compared BTX with iontophoresis (see Appendix 2, Table 45). Results are reported in the
Iontophoresis.
Summary of evidence for subcutaneous injection of botulinum toxin
Twenty-three studies of BTX used as subcutaneous injection were evaluated. More than two-thirds of the
studies focused on treatment for axillary hyperhidrosis exclusively and about a third focused on palmar
hyperhidrosis.
In the case of axillary hyperhidrosis, BTX was compared with placebo in nine studies (eight RCTs,72,73,75,77,79,82,83,85
one open-label continuation study80), no treatment in three studies81,89,185 (non-RCTs) and curettage in four
studies21,148,155,184 (one RCT, three non-RCTs). There was evidence that BTX, compared with placebo, resulted
in a clinically and stastically significant reduction in sweat production (gravimetry) (five pooled RCTs, one
open-label continuation study) and improvement in patient-reported symptoms (HDSS) (two pooled RCTs).
There was evidence to suggest that reductions in sweat production (three pooled RCTs) and improvements
in HDSS score (one RCT) were largely sustained at 16 weeks’ follow-up. There was also evidence of a
statistically significant improvement in some measures of quality of life in BTX-treated patients compared
with placebo-treated patients at 4 weeks’ (four RCTs)73,77,80,83 and 16 weeks’ follow-up (three RCTs, one
open-label continuation study).73,79,80,83 None of the studies of BTX for axillary hyperhidrosis reported
serious or severe adverse events that were considered to be related to the intervention by the investigators.
The most common treatment-related adverse events reported included injection site pain and CS.
Three non-randomised half-side comparison studies (in which patients acted as their own control) of BTX
and no treatment reported broadly similar results.81,89,185
Of the four studies (one RCT, three non-RCTs) that compared curettage with BTX,21,148,155,184 one small
half-side RCT21 found a difference in HDSS score (at 3 and 6 months’ follow-up) and gravimetric sweat
measurement improvements (3 months’ follow-up) favouring BTX, although the difference was statistically
significant only for HDSS score. Three non-randomised studies found no evidence of a significant
difference in gravimetric sweat measurements at up to 26 weeks (one non-RCT),155 patient-reported
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sweating or patient satisfaction at 6 months (one non-RCT),148 HDSS score improvement at 6 weeks
(one non-RCT)184 or in quality of life up to 26 weeks (one non-RCT),155 between curettage and BTX.
When reported, the incidence of adverse events was higher with curettage than BTX (one RCT,21
two non-RCTs148,155).
For the treatment of palmar hyperhidrosis, BTX was compared with placebo in three RCTs, no treatment in
two non-RCTs and iontophoresis in two studies (one RCT, one non-RCT). Compared with placebo, two
studies reported a small but statistically significant reduction in sweating outcomes at short-term follow-up
(3–13 weeks), measured either by gravimetry (one RCT)76 or by sweat area tests (one RCT),84 although one
study found no statistically significant difference compared with placebo using the iodine starch test.74
There was very limited evidence from a single study of a significant improvement in quality of life at
30 days’ follow-up favouring BTX.74 One study (BTX-B 5000 U) found a high incidence of treatment-related
adverse events.74 Two non-randomised half-side comparison studies (in which patients acted as their own
control) compared BTX with no treatment.81,90 Both studies reported a difference in at least one measure
of sweat reduction favouring the intervention, although the clinical significance of these results is unclear.
There were no serious adverse events.
As stated previously (iontophoresis evidence summary), two studies (one RCT, one non-RCT)88,92 compared
iontophoresis with BTX injections for palmar hyperhidrosis. One RCT88 found a statistically and clinically
significant difference in treatment response (HDSS) and patient-reported symptoms between the two
interventions, favouring BTX, at 4 weeks from baseline. One non-RCT92 reported a statistically and clinically
significant improvement in patient-reported symptoms and willingness to undergo treatment at 1 month,
but the difference was no longer statistically significant at 6 or 12 months. There was limited evidence
suggesting that effect duration following discontinuation from iontophoresis was shorter than after BTX.
Patients receiving BTX experienced pain more frequently than with iontophoresis.
Overall, there is moderate-quality evidence of a large effect of subcutaneous BTX on symptoms of axillary
hyperhidrosis in the short and medium term (up to 16 weeks), and of a small to moderate positive effect
on quality of life in the short term, compared with placebo. There is low-quality evidence to suggest
that BTX is associated with higher patient satisfaction in the short to medium term, as well as a higher
incidence of non-severe adverse events, notably injection site pain and CS, compared with placebo. There
is very low-quality evidence regarding the relative effectiveness of BTX injections to the axillae compared
with curettage and no evidence of a difference in longer-term effectiveness, and low-quality evidence
suggesting a higher incidence of adverse events in patients undergoing curettage.
There is very low-quality evidence suggesting that BTX injections have a small positive effect on palmar
hyperhidrosis symptoms compared with placebo or no treatment, although there is some very low-quality
evidence to suggest a high incidence of adverse events with BTX-B (5000 U). The evidence for an effect of
BTX injections for palmar hyperhidrosis on quality of life is insufficient.
As stated previously, there is very low-quality evidence to suggest that iontophoresis is less effective than
BTX injections at reducing palmar hyperhidrosis symptoms in the short term and that the duration of effect
is shorter than with BTX.
Curettage
Nine studies evaluating curettage for axillary hyperhidrosis were included: four were RCTs21,24,147,150
and five were non-randomised comparative studies.148,149,154,155,184 In one study, risk of bias was considered
unclear for gravimetric outcomes and high for all other outcomes.147 All other studies were considered to
be at a high risk of bias.
Study size ranged from 4154 to 113148 participants (total 526 individuals). One of the studies was conducted
in France, Germany and Spain.24 The other studies were conducted in the UK,184 Germany,148,150,154,155
Denmark,149 Norway147 and the USA.21 Studies were published between 1975149 and 2016,184 although
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most were published from 2007 onwards. The curettage procedures and equipment used in the later
studies are likely to have progressed since the procedures used in the study dating back to 1975.
When reported, all studies included adults, although two studies also recruited a small number of participants
aged < 18 years.155,184 Ages ranged from 16 to 57 years, when reported; age range was not reported in four
studies.24,148,149,154 In most studies the majority of participants were female, although three studies did not
report the sex of the participants. Inclusion criteria relating to patients’ baseline disease severity were reported
in six studies: in two studies patients had a minimum sweat rate of 50mg/minute,150,154 in one study patients
had HDSS scores of ≥ 2,155 in one study patients had HDSS scores of 3–4,24 one study21 used Haider 2005
criteria187 and one study stated that patients were severely disabled in regard to occupation and social
activities.148
Most studies reported using curettage with a liposuction method.21,147,150,154,155 When reported, the method
of anaesthesia included both local and general anaesthesia, although the older studies were more likely
than more recent studies to use general anaesthesia.148,149 Curettage was compared with a range of
therapies, including BTX-A (four studies21,148,155,184) and several surgical techniques, including Shelley’s
procedure (skin-sparing technique) (one study150), radical skin excision (two studies149,150), laser therapy
(with or without curettage) (one study24) and curettage with aggressive manual skin shaving (one study154).
One study compared curettage with two interventions (skin sparing and radical excision)150 and one study
compared curettage with tumescent suction curettage.147
Curettage compared with botulinum toxin
Four studies compared BTX with curettage (see Appendix 2, Table 55).21,148,155,184 Study results are reported
in Botulinum toxin.
Comparison of curettage with other minor surgical interventions
Five studies (three RCTs, two non-RCTs)24,147,149,150,154 compared suction curettage with other types of minor
surgery that are more radical (see Appendix 2, Table 58): radical skin excision, radical skin excision with
Y-plasty closure, Shelley’s procedure (skin-sparing technique) and curettage with aggressive manual
shaving.
Bechara et al.150 included a total of 40 patients who were randomised to one of three surgical interventions:
liposuction-curettage (n = 15), radical skin excision with Y-plasty closure (n = 14) and a skin-sparing
technique (n = 11). At 1-year follow-up, all three groups experienced significant mean reductions in sweat
rates from baseline and there were no statistically significant differences between the three interventions.
Aesthetic outcome was assessed by patients on a scale of 1 (very good) to 5 points (not good at all). The
mean aesthetic outcome score was 3.2 (range 2–5) in the skin excision group, 2.3 (range 1–3) in the
skin-sparing technique group and 1.5 (range 1–2) in the curettage group. The mean aesthetic outcome
score was significantly better in the curettage group than in the other groups (p < 0.05). The incidence of
haematoma was similar across groups, although one moderate to severe hematoma occurred in the
curettage group that resolved over 4 weeks. No other severe adverse events were reported.
Jemec149 carried out a non-randomised parallel group trial comparing curettage with radical skin excision
in a total of 41 participants. Patient satisfaction and adverse events were the only outcomes reported.
Follow-up data were reported between 6 and 9 months post intervention. Levels of patient satisfaction
were comparable between the two interventions. It was reported that there were no abscesses,
haematomas or wound defects. No other adverse event data were reported.
The study by Bechara et al.154 was a non-randomised half-side comparison trial in which patients acted
as their own control, comparing curettage with or without aggressive manual shaving. The trial was
stopped early after treatment of only four patients because of extensive skin damage associated with
aggressive shaving.
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Tronstad et al.147 compared tumescent suction curettage with curettage alone in a half-side randomised
comparison involving 22 patients. Sweating was assessed using gravimetry and skin conductance tests.
Patients also assessed their sweating using a VAS for each side at follow-up (no further details reported).
Quality of life was assessed using the DLQI questionnaire. All measurements were performed at 3, 6 and
12 months’ follow-up. The reduction in sweating (both objective and subjective measurements) was
statistically and clinically significant at 6 and 12 months compared with baseline in both treatment
groups (p < 0.05), and significantly greater with tumescent suction curettage than with curettage alone
(p < 0.05). Three-month follow-up results were similar, although the difference between interventions
was not statistically significant for gravimetry. Quality-of-life results were not reported. One patient from
the tumescent suction curettage group experienced postoperative neuropathic pain lasting through the
observation period. There were no haematomas or infections requiring antibiotics at 1 week and no other
adverse events were reported.
Curettage compared with energy-based sweat gland destroying (‘destructive’)
technologies
Leclere et al.24 (see Appendix 2, Table 59) conducted a RCT that included 100 patients and compared
four interventions: laser alone with a radiation of 975 nm, laser alone with simultaneous wavelengths of
924 nm and 975 nm, laser (924/975 nm) followed by curettage, and curettage alone. Effectiveness was
measured using the Starch-Iodine Scale Improvement, a four-point single-item questionnaire measuring
changes in sweating, with scores ranging from 0 points (no evidence of sweating by starch test) to
3 points (big dark area without changes), and HDSS. At both 1 and 12 months’ follow-up, the largest
reduction in mean HDSS and sweating scores was achieved in the the laser plus curettage group, followed
by the laser 924/975 nm only group, the curettage only group and the laser 975 nm group. Although the
results suggest a clinically relevant difference between laser plus curettage and the other interventions,
the authors did not state whether or not differences between the interventions were statistically significant.
Aesthetic outcomes were measured using the Global Aesthetic Improvement Scale (GAIS), a five-point scale
rating global aesthetic improvement, compared with baseline, as judged by the investigator. At 1 and
12 months’ follow-up mean scores on the GAIS were highest in the laser plus curettage patients, followed
by laser 924/975 nm, curettage alone and laser 975 nm groups. There were few adverse events in all
groups, and all had resolved within 1 month of follow-up.
Evidence summary for curettage
In summary, nine studies (four RCTs,21,24,147,150 five non-RCTs148,149,154,155,184) evaluated curettage for axillary
hyperhidrosis. All were rated as being at a high risk of bias.
Four studies (one RCT, three non-RCTs) compared curettage with BTX.21,148,155,184 One small half-side RCT21
found a difference in HDSS score (at 3 and 6 months’ follow-up) and gravimetric sweat measurement
improvements (3 months’ follow-up) favouring BTX compared with curettage, although the difference was
statistically significant only for HDSS score. Three non-randomised studies found no evidence of a significant
difference in gravimetric sweat measurements at up to 26 weeks (one non-RCT),155 patient-reported
sweating or patient satisfaction at 6 months (one non-RCT),148 HDSS score improvement at 6 weeks
(one non-RCT)184 or quality of life up to 26 weeks (one non-RCT),155 between curettage and BTX. When
reported, the incidence of adverse events was higher with curettage than with BTX (one RCT, two non-RCTs).
Among the five studies (three RCTs, two non-RCTs) that compared suction curettage with other surgical
interventions, one RCT150 found no difference in sweating (gravimetry) at 1 year of follow-up between
liposuction curettage, radical skin excision and a skin-sparing technique (Shelley’s procedure), although
patients undergoing curettage reported significantly greater satisfaction with aesthetic outcomes. One
non-RCT149 reported comparable levels of patient satisfaction and safety between curettage and radical
skin excision at 6–9 months’ follow-up. One small non-randomised half-side comparison trial (in which
patients acted as their own control), evaluating curettage with and without aggressive manual shaving,
was stopped early because of extensive skin damage associated with aggressive shaving.154 One RCT147
evaluated tumescent suction curettage against curettage alone in a half-side comparison. Reduction in
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sweating (gravimetry, skin conductance and patient reported) was statistically significantly greater with
tumescent suction curettage than with curettage alone at 6 and 12 months’ follow-up, although, owing
to limited reporting, it is not clear whether or not these results were clinically significant. One event of
neuropathic pain lasting throughout the 12 months’ follow-up was reported in the tumescent suction
curettage group. One four arm RCT24 found a clinically significant benefit in mean HDSS and sweating,
as well as better aesthetic outcomes, with laser plus curettage compared with two different regimens of
laser alone, or curettage alone. Few adverse events were reported in all groups.
Overall, there is very low-quality evidence regarding the relative effectiveness and safety of curettage
compared with other minor surgical interventions for axillary hyperhidrosis. Compared with the more
radical excision techniques, there is no clear evidence of a difference in sweat reduction, patient
satisfaction or safety. However, aggressive manual shaving was associated with extensive skin damage in
one very small study, which was stopped early. There is insufficient evidence to conclude whether or not
sweating symptoms are significantly more reduced with tumescent suction curettage than with curettage
alone in the medium term (up to 12 months).
There is low-quality evidence suggesting that curettage combined with laser treatment is more effective at
reducing hyperhidrosis symptoms and has better aesthetic outcomes than laser or curettage alone, and no
evidence of a difference in safety between these therapies.
As stated previously, there is very low-quality evidence regarding the relative effectiveness of BTX injections
to the axillae compared with curettage and no evidence of a difference in longer-term effectiveness, and
low-quality evidence suggesting a higher incidence of adverse events with curettage than with BTX.
Radical skin excision
Two studies of radical skin excision were included (see Appendix 2, Table 58). Results are reported in the
curettage results section.149,150
Shelley’s procedure (skin-sparing technique)
One study evaluated the effectiveness and safety of Shelley’s skin-sparing procedure (see Appendix 2,
Table 58).150 Results are reported in Curettage.
Laser epilation
Three RCTs evaluated the efficacy and safety of laser epilation for axillary hyperhidrosis.24–26 All three
studies were considered as being at a high risk of bias.
Sample sizes ranged from 626 to 100.24 Studies were conducted in Germany,25 the USA26 and France,
Germany and Spain.24 Studies were recent, published between 201225,26 and 2015.24
Only one study reported the age range of participants, which was 24–66 years.25 The majority of participants
in two of the studies were female,25,26 whereas the other study did not report the sex of the participants.24
Inclusion criteria relating to patients’ baseline disease severity were reported in two of the studies; patients
had HDSS scores of 3–4 in one study24 and patients met Hornberger 2004 criteria189 in the other.25
The wavelength used varied between the studies. Leclere et al.24 compared four interventions: (1) laser
alone with a wavelength of 975 nm, (2) laser alone with simultaneous wavelengths of 924 nm and
975 nm, (3) laser (924/975 nm) followed by curettage, and (4) curettage alone. Bechara et al.25 and Letada
et al.26 both evaluated the efficacy of a long-pulsed laser using a half-side controlled trial; the wavelength
was 800 nm, delivered in five treatments at 4-week intervals, in one study25 and 1064 nm, delivered in six
treatments at monthly intervals, in the other.26
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Laser epilation compared with no treatment
Two RCTs comparing laser epilation with no treatment were included (see Appendix 2, Table 60).
The studies by Bechara et al.25 and Letada et al.26 were both half-side RCTs that evaluated the efficacy of a
long-pulsed laser. Bechara et al.25 found a significant reduction in sweat rate measured by gravimetry on
the laser-treated side and the untreated contralateral side, but no significant difference in reduction
between treated and non-treated sides at 12 months’ follow-up (p = 0.10). Participant satisfaction with
reduction in sweating was measured using a VAS score ranging from 0 to 10 (0 = not satisfied at all,
10 = absolute satisfaction). Patients reported a mean score of 5.9 after the last laser treatment and 4.1 at
follow-up. No serious adverse events were reported.
Letada et al.26 reported visibly reduced sweating in the laser-treated axilla, as measured by iodine starch
test, in all six patients compared with the contralateral side at 1 month follow-up. All patients at 1 month,
and two out of the three patients with results at 3 months, reported good or excellent improvement in
Global Assessment Questionnaire. No adverse events were reported.
Laser epilation compared with laser epilation with curettage
The results of the Leclere et al. study,24 which compared different laser interventions with curettage,
are reported in Curettage and in Appendix 2, Table 58.
Evidence summary for laser epilation
Two small RCTs of half-side comparisons between laser epilation and no treatment were included;
both were rated as being at high risk of bias.25,26
One study25 found no significant difference in sweat reduction measured by gravimetry between the
treated and non-treated sides at 12 months. The other study26 found that sweating was visibly more
reduced at 1 month according to the iodine starch test in the treated axillae. Both studies reported no
serious adverse events.
Overall, there is insufficient evidence to suggest that laser epilation alone is more effective than no
treatment at reducing hyperhidrosis symptoms or improving quality of life. There was insufficient evidence
regarding the safety of laser epilation, although no evidence was found to suggest the intervention was
not safe. As stated previously, there is low-quality evidence suggesting that curettage combined with laser
treatment is more effective at reducing hyperhidrosis symptoms and has better aesthetic outcomes than
laser or curettage alone, and no evidence of a difference in safety between these therapies.
Fractionated microneedle radiofrequency
Only one study evaluating the efficacy of fractionated microneedle radiofrequency was included
(see Appendix 2, Table 61).28 Fatemi Naeini et al.28 compared a therapy of three sessions of fractionated
microneedle radiofrequency with a sham treatment in a half-side comparison trial in 25 patients with
axillary hyperhidrosis (baseline severity HDSS 3–4) in Iran. The study was not randomised and considered
as being at high risk of bias.
Fatemi Naeini et al.28 reported significantly better results in mean HDSS scores (p < 0.001) and sweating
intensity (p < 0.001) at 21 weeks’ follow-up in the treated axillae than on the sham-treated side. Most
patients experienced transient side effects, but there were no severe adverse events. One patient
experienced tingling and numbness in the treated group, which resolved after 2 months of discontinuing
treatment.
Evidence summary for fractionated microneedle radiofrequency
Overall, there is insufficient evidence regarding the relative effectiveness and safety of fractionated
microneedle radiofrequency for axillary hyperhidrosis.
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Microwave
Only one study of a microwave device for axillary hyperhidrosis was included (see Appendix 2, Table 62).27
Glaser et al.27 conducted a RCT (risk of bias rated as high) that evaluated the effect of two sessions of
microwave therapy for axillary hyperhidrosis under local anaesthesia, delivered over approximately 2 weeks,
compared with a sham intervention. A third procedure was allowed for non-responders. The microwave-based
device included integrated vacuum and cooling (DTS G2 System; Miramar Labs, Sunnyvale, CA, USA). Few
other details were provided. The study included 120 patients and was conducted in the USA. Patients’ baseline
disease severity was a HDSS score of 3 or 4 points and a minimum sweat rate of 50 mg per 5 minutes. The
majority of participants were female.
Efficacy was evaluated using HDSS and gravimetry. Placebo group patients had follow-up visits at 30 days,
3 and 6 months and then exited the study. Active group participants had follow-up visits at 30 days and
3, 6, 9 and 12 months after treatment. The proportion of participants with reduction in HDSS score of
≥ 2 points was significantly higher in the microwave group at 30 days, 3 months and 6 months (p < 0.001).
There was no statistically significant difference in the percentage of patients with ≥ 50% reduction in sweat
rate between the intervention and control groups at any of the follow-up points. There was a statistically
significant difference favouring microwave therapy in the percentage of patients with ≥ 75% reduction in
sweat rate at 30 days only (p = 0.01). There were 45 procedure-related adverse events in 28% of active
group participants and 13% of sham patients. None of these adverse events were classed as serious and all
were considered transient except for one case of compensatory facial hyperhidrosis in a participant in the
active group, which was still present after 6 months.
Evidence summary for microwave
Only one study of a microwave device for axillary hyperhidrosis was included.27 Overall there is very
low-quality evidence suggesting that microwave therapy is more effective than placebo at reducing
patient-reported disease severity, although there was no evidence of a significant difference in sweat
reduction at up to 6 months. The evidence regarding the safety of microwave therapy is insufficient.
Ultrasound
Two RCTs of microfocused ultrasound were included, reported in a single publication (see Appendix 2,
Table 63).29 Sample sizes were 14 and 20, and both studies were conducted in the USA. Both were rated
as being at high risk of bias. In both studies, two sessions of microfocused ultrasound were given, 30 days
apart, for axillary hyperhidrosis (baseline severity HDSS 3–4 and sweat rate at least 50 mg/5 minutes), and
compared with a sham treatment.
The first study was a half-side comparison RCT that included 14 patients. Most participants were female.
Only three patients received local anaesthesia. Treatment response was assessed with gravimetry
(≥ 50% reduction in sweating from baseline). The study reported that all except one patient had a
response in the treated side at 90 days’ follow-up, but did not state whether or not there were any
differences with untreated axillae. Treated axillae were associated with significantly higher rates of adverse
events (primarily axilla tenderness/soreness), although most were mild and transient and there were no
serious adverse events.
In the second study, 12 patients were randomised to ultrasound therapy for both axillae and eight to
placebo. All patients received local anaesthesia. Treatment response was assessed with HDSS (defined
as reduction from 3 or 4 points at baseline to 1 or 2 points at follow-up) and gravimetry (≥ 50% sweat
reduction from baseline), at multiple time points (30, 60, 90 and 335 days from the end of treatment).
At 30 days’ follow-up, the HDSS-response rate was approximately 67% in the intervention group,
compared with 27% in the placebo group. The effect of the intervention and superiority over placebo
appeared to be maintained until 1 year from baseline. Gravimetric response (≥ 50% reduction from
baseline) was achieved in 83% patients in the intervention group, compared with 0% in the placebo
group, across all time points (p < 0.0001 at all follow-up points). Adverse events were more commonly
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reported in the treatment group. Most were transient and mild (most commonly axilla tenderness/soreness)
and none were serious.
Evidence summary for ultrasound
Two small RCTs of microfocused ultrasound were included.29 Overall, there was insufficient evidence
regarding the safety and effectiveness of ultrasound therapy for axillary hyperhidrosis.
Ongoing studies
Thirteen ongoing studies were identified from the searches of trial registers in July 2016. Details of the
studies are presented in Table 4.
Conclusions of the effectiveness of interventions for hyperhidrosis
The evidence for the effectiveness and safety of second-line treatments of primary hyperhidrosis is limited
overall. Most studies were small, rated as being at high risk of bias and poorly reported. There was
insufficient evidence to draw firm conclusions regarding the relative effectiveness and safety of any active
second-line treatments for hyperhidrosis.
There is very low-quality but consistent evidence suggesting a short-term beneficial effect of tap water
iontophoresis in the treatment of palmoplantar hyperhidrosis compared with placebo and of dry-type
iontophoresis compared with no treatment. Compared with tap water iontophoresis alone, the evidence
for the effectiveness of combining anticholinergic therapy with iontophoresis is mixed and inconclusive.
There is low-quality evidence to suggest that iontophoresis (assumed to be tap water iontophoresis,
although not specified in the studies) is less effective than BTX injections at reducing palmar hyperhidrosis
symptoms in the short term and that the effect duration is shorter than with BTX. There were no studies
assessing the clinical effectiveness of iontophoresis for hyperhidrosis of the axilla.
There is very low-quality evidence suggesting a short-term benefit of topical glycopyrrolate for axillary and
facial hyperhidrosis. No evidence for other treatment sites was found. There were no studies assessing the
clinical effectiveness of oral glycopyrrolate.
There is low-quality evidence suggesting a short-term small benefit of oral oxybutynin in reducing
hyperhidrosis symptoms and a short-term improvement in quality of life compared with placebo, although
there is insufficient evidence to determine whether or not the effectiveness of oxybutynin differs according
to target area. There is low-quality evidence that, compared with placebo, oral methantheline bromide has
a short-term positive effect on axillary hyperhidrosis symptoms and quality of life, although this effect is
small and may not be clinically significant. There is no evidence that methantheline bromide improves
symptoms of the palm or any other body parts. There is evidence suggesting that both oxybutynin and
methantheline bromide are associated with a high incidence of dry mouth symptoms. There were no
studies assessing the clinical effectiveness of propantheline bromide for hyperhidrosis.
There is insufficient evidence to draw conclusions on the effectiveness and safety of topical BTX for primary
hyperhidrosis.
There is moderate-quality evidence of a large effect of subcutaneous BTX on symptoms of axillary
hyperhidrosis in the short and medium term (up to 16 weeks), and of a small to moderate positive effect
on quality of life in the short term (up to 4 weeks), compared with placebo. BTX may be associated with
higher patient satisfaction in the short to medium term, as well as a higher incidence of adverse events,
notably injection site pain and CS. The evidence regarding the effectiveness of BTX injections to the axillae
compared with curettage is of very low quality and uncertain, although there is no evidence to suggest
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TABLE 4 Study characteristics for ongoing studies
Study
Sample size and
study location Patient characteristic Intervention Comparator
NCT02673619, 2016,190 randomised placebo-
controlled double-blind trial
55; USA and
Canada
Palm Umeclidinium Placebo
ACTRN12615000873527, 2015,191 randomised
crossover study
21; Austria Axilla and/or palmar
hyperhidrosis
THVD-102 (a combination of
oxybutynin and pilocarpine)
Placebo
NCT02633371, 2015,192 single-group
assignment, open label
7; USA Axilla, adolescents and young
adults
Topical oxybutynin 3% gel N/A
EUCTR2015-002163-42-DE, 2015,193 open-label
long-term safety study
660; USA and
Germany
Axilla Glycopyrronium topical wipes (DRM04) Placebo
NCT02553798, 2015,194 single-group
assignment, open label
660; USA and
Germany
Axilla DRM04 topical wipes N/A
JPRN-UMIN000015874, 2014,195 randomised
placebo-controlled double-blind trial
3; Japan Hyperhidrosis 0.2% rapamycin gel Placebo base gel
JPRN-UMIN000020647, 2016,196 randomised,
double-blind, placebo-controlled study
45; Japan Palmar OSD-001 (0.2% sirolimus gel, 0.4%
sirolimus gel)
Placebo
EUCTR2011-003132-30-SE, 2011,197
randomised, double-blind, placebo-controlled
crossover study
588; Sweden Inguinal, palmar or plantar
hyperhidrosis (BTX-A), truncal
or craniofacial hyperhidrosis
(BTX-B)
BTX-A/BTX-B Placebo
CTRI/2015/06/005935, 2015,198
non-randomised comparative study
20; India Axilla BTX-A injections Suction curettage
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TABLE 4 Study characteristics for ongoing studies (continued )
Study
Sample size and
study location Patient characteristic Intervention Comparator
NCT02105753, 2014,199 randomised efficacy
study, single-group assignment within-patient
control, open label
10; USA Axilla 1210 nm diode laser treatments × 1 per
axilla
1210 nm diode laser treatments × 2
per axilla
NCT02823340, 2016,200 single-group
assignment, open label
20; China Axilla Fractionated microneedle
radiofrequency
N/A
NCT02295891, 2014,201 non-randomised
efficacy study, single-group assignment, open
label
24; USA Axilla MiraDry® (Miramar Labs, Inc., Santa
Barbara, CA, USA)
N/A
NCT02286765, 2014,202 randomised clinical trial 40; USA Axilla Ulthera ultrasound system treatment in
a 3 × 4 grid, 12 treatment squares,
60 lines of treatment per square, at
one treatment depth (2.0 mm), at
0.30 J of energy
Ulthera ultrasound system
treatment in a 3 × 4 grid,
12 treatment squares, 40 lines
of treatment per square, at
one treatment depth (2.0 mm),
at 0.30 J of energy
N/A, not applicable.
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that curettage is more effective than BTX in the short to medium term and there is evidence to suggest a
higher incidence of adverse events with curettage. Trials are too short term to explore the potential
curative nature of curettage, compared with the retreatment needed with BTX.
There is very low-quality evidence suggesting that BTX injections had a small positive effect on palmar
hyperhidrosis symptoms compared with placebo or no treatment, although there was some very
low-quality evidence to suggest a high incidence of adverse events with BTX-B (5000 U). The evidence
for the effect of BTX injections for palmar hyperhidrosis on quality of life is insufficient.
There is very low-quality evidence suggesting that curettage combined with laser treatment is more
effective at reducing hyperhidrosis symptoms and has better aesthetic outcomes than laser or curettage
alone, and no evidence of a difference in safety between these therapies. There is insufficient evidence
to conclude whether or not sweating symptoms are significantly more reduced with tumescent suction
curettage than with curettage alone in the medium term (up to 12 months). There is also very low-quality
evidence suggesting that the use of aggressive skin shaving with curettage is associated with extensive
skin damage.
There is very low-quality evidence regarding the relative effectiveness and safety of curettage compared
with other minor surgical interventions for axillary hyperhidrosis. Compared with more radical excision
techniques, there is no clear evidence of a difference in sweat reduction, patient satisfaction or safety.
There is evidence suggesting that patients undergoing suction curettage are more satisfied with aesthetic
outcomes than those undergoing radical skin excision or Shelley’s procedure, although the limited
evidence precludes any firm conclusions.
There is low-quality evidence suggesting that microwave therapy is more effective than placebo at
reducing patient-reported disease severity, although there was no evidence of a significant difference in
sweat reduction at up to 6 months. The evidence regarding the safety of microwave therapy is insufficient.
The limited evidence precludes any conclusions regarding the effectiveness and safety of laser epilation,
fractionated microneedle radiofrequency or ultrasound.
Gaps in the clinical evidence
Botulinum toxin for hyperhidrosis of the axilla
There is sufficient evidence demonstrating the clinical effectiveness of BTX for hyperhidrosis of the axilla
and, therefore, no more trials of BTX compared with placebo in the axilla are warranted. Future trials of
interventions for hyperhidrosis of the axilla should use BTX as an active comparator.
Iontophoresis for palmar hyperhidrosis
There are three studies of tap water iontophoresis compared with placebo37,40,42 and two studies of
dry-type iontophoresis compared with no treatment.43,44 Although they have methodological limitations,
they all consistently show that iontophoresis is more effective than placebo/no treatment for hyperhidrosis
of the palm; therefore, no further trials of iontophoresis compared with placebo/no treatment are
warranted. Iontophoresis is currently standard practice for palmar hyperhidrosis in many dermatology
units.
Iontophoresis compared with botulinum toxin for palmar hyperhidrosis
There is limited evidence for the effectiveness of BTX for palmar hyperhidrosis. Although the studies of
iontophoresis for palmar hyperhidrosis are of poor quality, there is sufficient evidence to indicate a real,
albeit limited, effect of iontophoresis. To date there have been two reasonably small, poor-quality,
studies88,92 comparing BTX with iontophoresis (one of which also prescribed topical aluminium chloride
lotion to the iontophoresis group88) for palmar hyperhidrosis. BTX looks promising for palmar hyperhidrosis,
but the current evidence is not sufficiently reliable to draw firm conclusions; therefore, further research
is required. A well-conducted, adequately powered RCT of BTX (with anaesthesia) compared with
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iontophoresis for palmar hyperhidrosis is warranted. The cost of BTX plus anaesthesia is considerably
higher than the cost of iontophoresis; therefore, cost-effectiveness should also be assessed.
Microwave, laser, fractionated microneedle radiofrequency and ultrasound
These new, energy-based, ‘destructive’ technologies offer the prospect of the benefits of curettage for
hyperhidrosis of the axilla, but with fewer risks. Some small, poor-quality, studies have shown promising
results for these interventions compared with placebo or no treatment; however, these studies cannot
be considered reliable, so there may not be sufficient promise to warrant further research. Studies of
microwave, laser, fractionated microneedle radiofrequency and ultrasound therapies are ongoing, but the
numbers of participantsare low (≤ 40) and the interventions are not being ompared against other active
treatments or placebo. If the results of this ongoing research are consistent with the existing study results,
then a trial comparing these new energy-based technologies with BTX for hyperhidrosis of the axilla may
be warranted.
Curettage compared with botulinum toxin for hyperhidrosis of the axilla
Botulinum toxin has been shown to be effective for hyperhidrosis of the axilla. However, the procedure
has to be repeated at regular intervals (at least annually). Curettage offers the prospect of a single
treatment. There are currently a few small and/or non-randomised trials comparing curettage with BTX
for hyperhidrosis of the axilla. The short- to medium-term evidence suggests that these two interventions
are comparable in terms of effectiveness, or that BTX may be superior to curettage. In view of the
ongoing research into less invasive, energy-based, technologies (microwave, laser, fractionated microneedle
radiofrequency and ultrasound), a trial comparing BTX with curettage for hyperhidrosis of the axilla
may not be warranted at this time. When further evidence is available on the newer energy-based
technologies, then it will be clearer whether or not further research on curettage is warranted.
Comparison of different oral/topical medications: propantheline bromide, glycopyrrolate,
oxybutynin, methantheline bromide and newer medications
The oral medications have not been well studied in trials; there are no placebo-controlled trials of oral
glycopyrrolate (thought to be the most effective) or of propantheline bromide (the cheapest available).
There are no direct comparisons of the different oral/topical anticholinergic medications for hyperhidrosis.
However, there are ongoing and recently completed trials of new oral and topical formulations; therefore,
it may not be relevant to undertake further research of these specific drugs at this time. Although different
medications may work better for some patients than others, it may be difficult to power a study to find
any statistically significant differences between treatments.
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Chapter 4 Review of quality-of-life measures/tools
Background
The aim of this review was to identify the tools commonly used to measure quality of life in studies of
patients with hyperhidrosis. An assessment of the most appropriate tool for use in studies of hyperhidrosis
is beyond the scope of this review, although a brief overview of data related to the reliability and validity
of the tool has been provided, when such data were available.
Methods of the quality-of-life measures review
To locate quality-of-life measures/tools relevant to hyperhidrosis, studies were identified as part of the
literature searching conducted for the review of clinical effectiveness of treatments for hyperhidrosis.
The searches were undertaken in January 2016 and the full search methods are reported in Chapter 2,
Literature searches. For the review of quality-of-life measures, the search strategies combined topic terms
for hyperhidrosis with a recognised search filter for ‘quality of life’. The full list of search terms is presented
in Appendix 1, Hyperhidrosis quality-of-life literature searching.
Inclusion and exclusion criteria
Study eligibility was not restricted to the interventions considered in the separate systematic review of
effectiveness: all studies that reported measuring quality of life or described a quality-of-life measure/tool
in the context of hyperhidrosis were included. These studies were identified at the abstract screening stage
or from the full papers ordered for the review of effectiveness. It is acknowledged that some papers
excluded from the effectiveness review at the abstract stage may have mentioned quality of life in the full
paper and such studies will have been missed. However, we consider that it is unlikely that any important
quality-of-life tools have been missed because of this, because of the large number of studies screened.
Population
Patients with primary hyperhidrosis (including adults and children). Patients with hyperhidrosis secondary
to other conditions, such as overactive thyroid or spinal cord injury, or social anxiety disorder, were not
eligible for inclusion.
Outcomes
Any quality-of-life-related outcome measure was included. Quality-of-life outcomes can be measured using
a variety of tools: disease specific, such as the HDSS and HHIQ; discipline specific (dermatology), such as
the DLQI or Skindex-29; or more general health or utility, such as the Short Form questionnaire-36 items
(SF-36).
Study designs
Any study design was eligible for inclusion in this review.
Data extraction
All quality-of-life measures reported in the included studies were extracted into Microsoft Word® (2013;
Microsoft Corporation, Redmond, WA, USA). The data extract comprised details of the quality-of-life tool
or tools used, whether or not the tool was disease specific for hyperhidrosis, disease specific for skin
disease or a generic tool for health-related quality of life (HRQoL), and any description of reliability and
validity of the tool, when available.
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Details of the identified studies (reference, country, study design and body part affected by hyperhidrosis)
were extracted by two reviewers. Details of the quality-of-life outcome measures and tools used in studies
were extracted by a single reviewer and checked by a second reviewer.
The quality-of-life studies were not quality assessed as they did not necessarily evaluate the effectiveness
of interventions, and the data extracted from these studies were not effectiveness data. Although it has
been suggested that the COnsensus-based Standards for the selection of health Measurement INstruments
(COSMIN) checklist suggests it could be useful when selecting a measurement instrument’,203 it was found
that it could not be readily used for the following reasons. First, the checklist requires a high level of
detailed information about how a tool was developed, far more than was available for this review;
the studies found did not provide sufficient information to enable such a detailed assessment of
methodological quality. Second, in order to apply the COSMIN checklist, a level of expertise and
understanding about tool development is required, which was beyond the remit of the project.
The information on the tools and their use in hyperhidrosis was summarised in a narrative synthesis
describing the quality-of-life tool, the associated studies and the target of the tool.
Results of the quality-of-life measures review
The searches for studies or reviews that recorded quality-of-life outcomes identified 337 publications in
total; the study selection process found 183 studies that were relevant for inclusion into the review of
quality-of-life measures grouped as follows:
l Dermatology (n = 75). Studies presenting a dermatology intervention for hyperhidrosis that included a
measure of quality of life; interventions included iontophoresis, BTX injections, topical treatments
and/or oral treatments.
l Surgery (n = 82). Studies presenting a surgical intervention, including local surgical interventions, such
as the removal of the sweat glands, or more major surgery, such as ETS.
l Dermatology and surgery (n = 6). Studies involving both dermatological and surgical interventions.
l Economics (n = 7). Studies excluded from the clinical effectiveness review, but which presented an
economic analysis.
l Quality-of-life measure only (n = 13). Studies that reviewed quality-of-life measures or reported the
development of a quality-of-life tool and which were excluded from the systematic review of
effectiveness but presented methods for the measurement of quality of life.
Some studies reported outcomes from more than one quality-of-life measure; therefore, the review
recorded a total of 240 measures from the 183 studies: 202 measures from intervention studies, nine from
economic analyses and 29 from reviews or reports that discussed quality of life only. The frequency of use
for the most frequently used tools by type of study is shown in Figure 10.
Twenty-two individual tools for measuring quality of life were identified from the selected studies,; a
further 32 studies reported quality-of-life outcomes, but the method used to measure quality of life was
not reported or was unique to the single study. These are summarised in Table 5. As acknowledged in
Methods of the quality-of-life measures review, this is not the result of a totally comprehensive search for
all studies using these tools and, therefore, the data should be considered only indicative of the relative
frequency of use of the identified tools, when tools were available. New tools recently designed and
validated, such as the Hyperhidrosis Quality of Life Index (HidroQoL©) tool,204 are likely to be used in only a
very few studies, if any, because of their relative novelty.
A brief description follows of the tools used to measure quality of life and the associated studies identified
for the quality-of-life review. Each tool is described separately and grouped depending on the target
patient group (disease specific for hyperhidrosis, disease specific for skin disease and generic tools to
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FIGURE 10 Most frequently used quality-of-life tools by treatment type: surgery, dermatology, surgery and
dermatology, economics, or quality of life only. HQLQ, Hyperhidrosis Quality of Life Questionnaire.
TABLE 5 Frequency data for the use of quality-of-life measures in 182 studies of hyperhidrosis
Description Tool Surgery Dermatology
Surgery and
dermatology
Economics
only
Quality
of life
only Total
Hyperhidrosis Disease Severity
Scale (Kowalski et al.205)
HDSS 27 27 2 4 3 63
Dermatology Life Quality Index
(includes children’s version:
Children’s Dermatology Life
Quality Index)
DLQI 11 28 2 2 5 48
Hyperhidrosis Quality of Life
Questionnaire
HQLQ 17 13 0 0 1 31
Short Form questionnaire-36
items
SF-36 6 3 1 0 3 13
Keller Hyperhidrosis Scale Keller scale 7 1 0 0 2 10
Hyperhidrosis Impact
Questionnaire
HHIQ 0 7 0 0 1 8
Short Form questionnaire-12
items
SF-12 1 2 0 2 2 7
Quality-of-life measure for
people with skin disease
Skindex 1 3 0 0 2 6
A short disease-specific health-
related questionnaire for people
suffering from hyperhidrosis
Amir 2000186 2 1 0 0 2 5
Hyperhidrosis Quality of Life
Index
HidroQoL© 0 0 0 1 2 3
Hyperhidrosis Questionnaire HQ 0 0 0 0 2 2
Illness Intrusiveness Rating Scale IIRS 0 0 0 0 2 2
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measure HRQoL). Any original validation work was also identified and is described and a reference cited
when available. When the tool used was not described in the methods or the researchers designed their
own method to evaluate quality of life, the data were recorded as ‘not reported’ (n = 32).
Characteristics of disease-specific tools identified to measure quality of life in patients
with hyperhidrosis
Hyperhidrosis Disease Severity Scale
The HDSS was identified as the most commonly used tool. The HDSS was used in 63 studies in total:
for surgical research in 27 studies,17,24,27–29,159–161,164,167,171,174–176,179,181,207–217 for dermatological research in
27 studies,2,45,51–53,59,61,77,91,97,102,106–108,119,125,131,136,139,145,180,218–223 for surgery and dermatology combined in two
studies,21,224 for three quality-of-life-only studies225–227 and in four economic evaluation studies228–231 for
measuring quality of life in patients with hyperhidrosis. The HDSS was often used in combination with the
DLQI, with 18 studies using both tools (10 dermatology studies,61,77,102,106,107,119,139,221–223 five surgical
studies,176,208,210,214,217 two quality of life studies225,227 and one economic assessment230).
Studies that were found to use the HDSS tool were conducted globally, including the USA and Canada
(n= 2121,27,29,52,77,107,108,139,159,160,164,175,176,179,180,208,209,218,225,226,229), Spain (n= 6167,207,210,224,230,231), the UK (n= 591,97,125,
222,232), Germany (n= 52,131,145,161,227), Italy (n= 5102,106,136,214,223), France (n= 359,61,211), South Korea (n= 351,171,174),
Australia (n= 253,221), Egypt (n= 2213,219), Iran (n= 228,220), the Netherlands (n= 2215,217), Turkey (n= 2212,216),
Austria (n= 117), Europe (n= 124), Greece (n= 1119), Pakistan (n= 145) and Russia (n= 1181). The majority of
TABLE 5 Frequency data for the use of quality-of-life measures in 182 studies of hyperhidrosis (continued )
Description Tool Surgery Dermatology
Surgery and
dermatology
Economics
only
Quality
of life
only Total
Leibowitz Social Anxiety Scale Liebowitz
1987206
1 0 0 0 0 1
A French-language scoring
instrument validated for chronic
skin diseases
VQ-Dermato
scale
1 0 0 0 0 1
Questionnaire of Quality of Life
(adapted from the Caregiver
Questionnaire)
QQL 0 1 0 0 0 1
University of California, Los
Angeles Loneliness Scale
UCLA V3 0 1 0 0 0 1
Nottingham Health Profile NHP 0 0 0 0 1 1
Freiburg Life Quality Assessment FLQA 0 0 0 0 1 1
Patient Benefit Index PBI 0 0 0 0 1 1
The Everyday Life Questionnaire EDLQ 1 0 0 0 0 1
State–Trait Anxiety Inventory STAI 1 0 0 0 0 1
International quality of life
assessment
EQ-5D-5L 0 0 0 1 0 1
Tool used NR or unique to only
one study
NR 21 10 1 0 0 32
Total 97 97 7 9 30 240
EDLQ, Everyday Life Questionnaire; EQ-5D-5L, EuroQol-5 Dimensions, five-level version; FLQA, Freiburg Life Quality
Assessment; HQ, Hyperhidrosis Questionnaire; HQLQ, Hyperhidrosis Quality of Life Questionnaire; IIRS, Illness Intrusiveness
Rating Scale; NHP, Nottingham Health Profile; NR, not reported; PBI, Patient Benefit Index; QQL, Questionnaire of Quality of
Life; STAI, State–Trait Anxiety Inventory; UCLA V3, University of California, Los Angeles Loneliness Scale version 3.
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studies were case series (n= 2717,45,61,97,102,106,107,119,125,131,136,139,145,159–161,164,167,171,174–176,181,207–210). There were
15 RCTs,21,24,27,29,51–53,59,77,87,108,179,180,218,220 and the remainder were non-RCTs, retrospective observational studies
or reviews (n= 222,28,91,211–217,219,221–227,229–232). The HDSS was used in studies to measure quality of life in patients
with sweating in various areas of the body; studies of axillary sweating were most common (n= 362,21,24,27–29,52,53,
77,91,97,107,108,125,136,139,159–161,164,167,171,174–176,179–181,209,212,214,218,219,221,223,229), with an additional seven studies102,106,119,131,145,
207,213 examining sweating of the palm and axilla combined. Eleven studies17,45,61,208,211,215,222,224,225,230,231 were
identified of the foot and/or palm combined and nine of the face, palm and/or foot or generalised
hyperhidrosis.51,59,210,216,217,220,226,227,232
The HDSS is a disease-specific tool considered important for diagnostic use in clinical practice and for
research to identify and quantify the severity of disease in patients with hyperhidrosis and also to assess
treatment effects over time.12,205 The HDSS allows researchers to measure the impact of hyperhidrosis on
those suffering from excessive sweating by using a four-point scale:
1. My sweating is never noticeable and never interferes with my daily activities.
2. My sweating is tolerable but sometimes interferes with my daily activities.
3. My sweating is barely tolerable and frequently interferes with my daily activities.
4. My sweating is intolerable and always interferes with my daily activities.
Information on the original design of the HDSS is lacking, although it was possibly created by Kowalski in
2004 (Lisa Pieretti, International Hyperhidrosis Society, 5 June 2016, personal communication). Efforts have
been made to justify the use of the tool in hyperhidrosis research; for example, Kowalski et al.205 presented
work that examined the validity and reliability of the HDSS as a conference abstract in 2004.205 The study
presented data from a longitudinal clinical trial and a cross-sectional national survey of 150,000 US
households. The HDSS score at 4 weeks post treatment was found to correlate well with the DLQI and
relevant activity items from the HHIQ (r = 0.35 to 0.77; p < 0.001). Kowalski et al.205 also presented data
on construct analysis, which suggested that a reduction (improvement) in the HDSS score correlated well
with a reduction in gravimetric results, a clinical test used to measure quantity of sweating in patients with
hyperhidrosis, and that patients reported an increase in HDSS score with increases in limited daily activity
due to sweating. The test–retest reliability coefficient was also found to be within an acceptable range
(r = 0.82; p < 0.05).205
Studies of hyperhidrosis were found to use the HDSS more frequently than any other method for
measuring quality of life. The tool’s simple design has raised questions about its value as a tool to measure
patient-reported quality of life (Lisa Pieretti, personal communication), and a consensus exercise by the
Canadian Hyperhidrosis Advisory Committee considered the HDSS more appropriate as a measure of
disease severity.12 Furthermore, Panhofer et al.233 published a survey and validation guide for tools used to
measure quality of life in patients undergoing surgical interventions for hyperhidrosis and the HDSS was not
considered as part of this work. This reflects the fact that the HDSS is not viewed purely as a quality-of-life
tool; it is also possible the patient may complete the tool based on an improvement in quality of life or
simply a perceived reduction in sweating (with an assumption that this will improve their quality of life).
Disease-specific health-related questionnaire for hyperhidrosis (Amir et al.186)
The disease-specific health-related questionnaire for hyperhidrosis was designed and validated by a
research team in Israel, Amir et al.,186 to assist with clinical decision-making and to measure the efficacy of
surgical interventions in reducing sweat production in patients with hyperhidrosis. The questionnaire was
designed and validated with a patient population who were considering surgery for the treatment of their
excessive sweating.
The Amir et al.186 questionnaire was found in five studies identified for the review of quality-of-life
measures: the original development and validation work, integrated with a surgical study with a focus on
quality of life,186 and four additional studies, all from the same team in Brazil (three surgical studies234–236
and one dermatology study237).
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The Amir et al.186 tool development was conducted in two stages. First, 10 patients aged between 15 and
35 years were interviewed by two psychology students using a semistructured interview method with
questions that focused on the ways in which hyperhidrosis limits the daily life of patients. The responses
were analysed by the same psychology students, a clinical psychologist and a surgeon. Participants were
encouraged to discuss the effect on their leisure activities, social interactions, work or interpersonal
relationships. From the responses, four domains were identified (functional, social, interpersonal and
emotional). Functional included driving, writing and sports; social included shaking hands or being in public
places; personal involved being intimate with a partner; and emotional was split between the patient’s own
feelings about their condition (emotional self) and how they think others view them (emotional other).
The authors note that not all patients would find all questions relevant (e.g. those who do not drive).
The questionnaire was designed with 35 questions separated into the five domains with a 7-point Likert
scale for each response, where a score of 6–7 indicated a very low quality of life, 3–5 a medium level of
quality of life and 1–2 a high level of quality of life. The validation found a high level of internal reliability
(Cronbach’s α = 0.84).
The results suggest that patients felt impaired in many facets of life, both intimate and practical, and that
the effect of heat and stress played a major part in the patients’ quality of life. The authors found no
differences between the body area (hands, feet and axilla) and quality of life. Analysis of variance for the
quality of life domains in relation to sex and duration since onset found that females reported a lower
quality of life in all domains except emotional other. In addition, patients in whom onset of hyperhidrosis
occurred during childhood had a lower quality of life. A limitation of the validation work noted by the
authors is that only patients waiting for surgery were used in the survey and these may be patients whose
symptoms are at the more severe end of the spectrum.186 Another point to mention is that the tool was
validated in Israel and reported in studies conducted in Brazil, both countries with a very hot climate that
could have an impact on the patient population and subsequent outcome.
Hyperhidrosis Quality-of-Life Questionnaire
The Hyperhidrosis Quality of Life Questionnaire (HQLQ) was designed by de Campos et al.238 in 2003 as a
disease-specific tool to assess the effect of surgical intervention for patients with hyperhidrosis. The design
built on the previous validation work of Amir et al.186 and tested the tool on a large patient population
(n = 378), with the aim of replacing more generic measures.
The HQLQ was used in 31 studies included in the quality-of-life review. Seventeen studies, including the
validation work, had a surgical intervention,234,236,238–252 13 dermatology studies55,57,60,62–67,237,253–255 and one
quality-of-life review.227 The tool was used in Austria (n = 6240–242,248,249,251), Brazil (n = 2157,60–67,234,236–239,243,244,246,
247,252–255), Germany (n = 1227), Italy (n= 1245), South Korea (n = 155) and India (n = 1250).
de Campos et al.238 used their questionnaire to evaluate preoperative HRQoL and postoperative improvement
in symptoms of hyperhidrosis in all patients undergoing surgical intervention between 1995 and 2002. The
development study included 386 hyperhidrosis patients who underwent video-assisted thoracic surgery.238
The survey response rate was 91% (344 patients). Patients included in the study suffered with either palmar
and plantar (57.4%), palmar, axillary and plantar (25%), axillary (15.7%) or facial (6.5%) sweating.
The HQLQ consists of a single question to start ‘How would you rate your quality of life before and after
treatment?’, to which the patient is asked to respond with a score between 1 and 5, with 5 being very
poor/much worse. This is followed by 20 questions selected for relevance from the 36 items taken from
the Amir et al.186 questionnaire, again scored between 1 (excellent) and 5 (very poor), and further
separated into domains (again as described previously by Amir et al.186), including (1) functional or
social life, (2) personal life, (3) emotional self and (4) special circumstances (such as climate or stress).
Therefore, the final score for quality of life can range from 20 (excellent/much better after surgery) to
100 (very poor/much worse after surgery). No validation or reliability statistics or cross-validation with
other tools was reported.
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Keller Hyperhidrosis Scale
The Keller Hyperhidrosis Scale256 was cited in 10 studies in total: seven surgical studies,240–242,248,249,251,257
one dermatology study55 and two quality-of-life reviews.227,256 The tool was designed by an American team,
although, apart from the one South Korean dermatology study,55 all studies using the Keller tool appear to
come from the same team in Austria and all studies except one257 used both the Keller and the de Campos
et al. HQLQ238 methods combined to measure quality of life.
The Keller scale was designed by Keller et al.256 to measure preoperative and postoperative quality of life in
patients receiving bilateral ETS for palmar and plantar hyperhidrosis and appears to be a popular tool in
the field. The validation work compared patient score against the SF-36 and validation work reported a
strong level of reliability (Cronbach’s α = 0.89). The Keller Hyperhidrosis Scale measures quality of life
on a scale of 0 (mild) to 10 (severe). A total of 71 patients were entered into the study with a mean
preoperative Keller score of 6.85, which decreased significantly (p < 0.001) to 1.79, 1.53 and 1.91 at
2 weeks, 6 months and 1 year post surgery, respectively. Keller et al.256 reported no significant MD
between preoperative and postoperative scores for the SF-36 (p = 0.70) and concluded that standard
quality-of-life instruments do not accurately assess the benefits of surgery to patients with palmar and
plantar hyperhidrosis.
Hyperhidrosis Impact Questionnaire
The HHIQ was designed by Teale et al.258 in 2002 to assess the impact of hyperhidrosis on the daily lives
of patients and measure the effect of treatment. The HHIQ development and validation were performed
by a team of researchers funded by Allergan Inc. (Irvine, CA, USA), a large international pharmaceutical
company and significant producer of BTX-A for the treatment of hyperhidrosis. The relatively high
frequency of use of this tool reflects its use in Allergan-sponsored research. The validation work was not
available as a full publication, but does appear as a conference abstract presented at the ninth Annual
Conference of the International Society for Quality of Life Research (ISOQOL) in 2002.258
Eight studies selected for inclusion into the quality-of-life review used the disease-specific HHIQ for their
quality-of-life assessment or review: the original validation work by Teale et al.258 in 2002 and seven
additional studies that examined the effect of BTX-A on axillary or palmar hyperhidrosis.76,78,80,86,88,107,139
The study by Rajagopal and Mallya88 was conducted on behalf of the Indian armed forces and focused on
the use of BTX to treat palmar hyperhidrosis and appears independent of the other six studies, all of which
were conducted in either Europe or the USA/Canada and were funded or supported by Allergan Inc.
A review of the literature and interviews with key stakeholders (patients and physicians in the UK and
Germany) informed the design of the tool; a pilot study with the same stakeholders then tested the validity
and linguistic equivalence of the questionnaire.258 The questionnaire contained four sections: (1) disease
and treatment background; (2) direct impact on medical and non-medical resource utilisation; (3) indirect
impact on employment and productivity; and (4) intangible impacts on emotional status. Forty-one
questions measured baseline impact of the disease and a furtehr 10 questions were included in the
follow-up assessments. The final design of the HHIQ was validated against the SF-12 health survey and
the DLQI, using a population of 345 patients and 145 non-hyperhidrosis controls. A test–retest of the
10 follow-up questions using a cohort of clinical patients found consistent reliability and responsiveness of
the HHIQ. The authors conclude that the tool is a valid and reliable instrument for measuring disease and
treatment effects in patients with hyperhidrosis.
Hyperhidrosis Questionnaire
The Hyperhidrosis Questionnaire is a disease-specific instrument identified from a quality-of-life-only study
published in 2004 by Kuo et al.259 describing the tool’s design and validation. Although the development
and design of this tool appears to be quite comprehensive, the tool has been used in only one other
study selected for the quality-of-life review, a review paper of quality-of-life tools for hyperhidrosis by
Rzany et al.227
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The development study reported a review of the literature, to inform the elements to include in the
instrument’s design, followed by interviews with patients, nursing staff and clinicians. The pilot
questionnaire content was then validated by a panel of patient experts before being tested. The pilot
questionnaire contained 34 questions answered using a Likert scale of 1 (least disturbance) to 5 (most
disturbance). The final questionnaire contained 29 questions across five factors (domains): (1) functional,
(2) psychological, (3) social, (4) affective and (5) physical.
The study included 85 patients suffering from a combination of plantar, palmar, axilla or generalised
hyperhidrosis attending a thoracic surgery outpatient clinic in southern Taiwan between April 2002 and
March 2003. Internal reliability and construct validity was reported (Cronbach’s α = 0.95, range 0.71–0.94
across domains). There was no investigation of whether or not the scale reflects changes in disease
severity, nor was any cross-validation with other scales reported.
Hyperhidrosis Quality of Life Index
The HidroQoL was not identified in any of the studies selected for the quality-of-life review apart from
those published to describe its design and validation, probably because these are relatively recent
(2012 and 2015).204,260,261
The tool was developed as a disease-specific aid to both clinical practice and research to assist with
hyperhidrosis patient and clinician communication. The HidroQoL was not developed for any specific
body site or intervention. The HidroQoL tool was created using responses to interviews and focus group
discussions. In 2012, Kamudoni et al.204 recruited an online cohort of 71 patients from a number of social
networking sites to participate in initial interviews. From this, a prototype of the HidroQoL was created.
It contained 47 questions with a six-point patient response scale: (1) not at all, (2) a little, (3) somewhat,
(4) quite a bit, (5) very much and (6) not relevant. A panel of experts, including patients suffering from
focal or generalised hyperhidrosis (n = 7) and dermatology clinicians (n = 5), was recruited to validate the
content of the prototype tool using a questionnaire administered by e-mail. Further work in 2015261 used
modern test theory to examine differential item functioning, which allowed the researchers to assess if the
tool would function in different ways for different groups or test-takers.
The second stage of validation involved a cross-sectional cohort of 595 patient volunteers recruited using
prespecified inclusion criteria (age > 18 years, self-reported hyperhidrosis, HDSS score of ≥ 2 points and
disease onset prior to early adult years). The participants completed a number of questionnaires for
comparison (HDSS, DLQI and Skindex-17). Construct validity, reliability and responsiveness were assessed
using an online longitudinal study (n = 260 patients), for which patients were required to complete the
tool on three occasions over a period of time (7–21 days), using the final version of the questionnaire.
Construct validation found that the HidroQoL correlated well with the DLQI (r = 0.6; p < 0.01) and HDSS
(r = 0.59; p < 0.001), and showed correlation to the Skindex-16 scale, but to a lesser extent. The change
in HDSS score recorded by participants over time was also indicated in the HidroQoL scores from the
longitudinal study, suggesting that the tool could identify slight change or small responses to treatment
over a period of time. Reliability, tested using baseline measures and a test–retest method, showed strong
reproducibility (internal consistency, Cronbach’s α overall scale = 0.89; test–retest reliability, intraclass
correlation = 0.93).
Characteristics of disease-specific tools identified to measure quality of life in patients
with skin disease
Dermatology Life Quality Index (includes children’s version)
Described as a practical technique for routine clinical use, this questionnaire is a short and concise tool
(10 questions) for use in the management of chronic skin disorders.262 Developed by Finlay and Khan262 to
provide a patient-centred method for comparison between different types of skin disease, the questionnaire
records the impact each disease has on a patient’s quality of life and the relative effectiveness of treatment.
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The DLQI was found in 48 studies for reporting quality-of-life measures in patients with hyperhidrosis. The
study selection process found 28 dermatology studies,54,56,61,69,77,101–103,106,107,116,117,119–121,128,134,139,221–223,263–269
11 surgical studies,147,158,170,173,176,208,210,214,217,270,271 two dermatology/surgery combined,272,273 two economic
assessments230,274 and five studies or reviews of quality of life.225,227,261,262,275 As mentioned previously
(see Hyperhidrosis Disease Severity Scale), the DLQI was often used alongside the HDSS in dermatology
studies (n = 1061,77,102,106,107,119,139,221–223), surgical studies (n = 5176,208,210,214,217), studies of quality of life only
(n = 2225,227) and also economic assessments (n = 1230).
The DLQI was identified in studies conducted globally, including in the UK (n = 9103,232,261,262,267,268,275), the
USA and Canada (n = 877,107,139,173,176,208,222,263), Italy (n = 7101,102,106,214,223,266,272), Germany (n = 569,158,227,270,271),
Sweden (n = 4114,116,117,128), Greece (n = 3119–121), Ireland (n = 2265,274), Iran (n = 2170,264), Spain (n = 2210,230),
Australia (n = 1221), Austria (n = 1273), France (n = 161), India (n = 1269), the Netherlands (n = 1217) and
Norway (n = 1147). The studies included 24 case series,54,56,61,101–103,106,107,114,116,117,119–121,128,139,158,170,173,176,208,210,
214,266 nine retrospective observational studies,217,221,222,230,263,265,268,270,271 six quality-of-life or non-experimental
studies227,232,261,262,274,275 and three RCTs;69,77,223 the remainder were non-RCTs (n = 3264,269,272) or surgical
reviews or reviews of surgery compared with dermatology (n = 3147,267,273). The DLQI was used in studies to
measure quality of life on various areas of the body; studies of axillary sweating combined with other parts
of the body, such as palms or feet, were most common (n = 2654,56,69,77,101,103,106,107,114,119–121,139,147,158,170,173,176,
214,221,223,263,266,273,274). Studies were identified of the palm or palm and foot combined (n = 1161,128,208,222,230,264,
265,269–272) and of other combinations including the face, palm and/or foot or generalised hyperhidrosis
(n = 11116,117,210,217,227,232,261,262,267,268,275).
The DLQI was validated by Finlay and Khan262 using a survey of 128 patients aged 15–70 years who
attended a dermatology clinic. Patients were asked to document how certain aspects of their skin disease
affected their life, for example any effects the condition had on their work life, social life or personal
relationships. The results were combined and a questionnaire developed based on the 10 most commonly
reported aspects of impaired quality of life. The answers to each of the 10 questions were scored from
0 to 3, where a total maximum score of 30 and minimum score of 0 could be achieved: the higher the
score, the greater the impairment in quality of life. Once designed, the questionnaire was tested for use
on 200 outpatients and 100 healthy volunteers and reliability was further validated using a cohort of
53 patients by means of measuring the correlation of test–retest results over a 10-day period.
A recent review of the DLQI reported that repeatability, internal consistency and sensitivity to change have
all been demonstrated for this tool and it has been cross-validated against a number of other dermatology
tools (though mainly for psoriasis and acne).276 The DLQI instrument is licensed for use and, therefore,
permission is required from the authors to use the tool.
Skindex: a quality-of-life measure for people with skin disease
The Skindex suite of tools includes the original Skindex questionnaire, Skindex-29, Skindex-17 and Skindex-16.
The tools are dermatology-specific HRQoL instruments, originally based on the DLQI. The original tool was a
61-question survey refined to a 29-item questionnaire (Skindex-29),277 to reduce the time needed to complete
the questions and to improve the tool’s evaluative properties.278 Further refinement included using patients’
perspective responses to create a 16-item questionnaire (Skindex-16)279 for use in longitudinal research to
measure changes over time in patient quality of life in addition to reducing the tool to one page. Finally, a
study in 2006 created Skindex-17. A Rasch-reduced tool was created using a response theory model to
address issues such as response order and differential item functioning,280 and resulted in a reduction of the
Skindex-29 item tool to a 17-item instrument. The questions in the Skindex-16 and Skindex-17 differ;
however, a simple comparison conducted by Nijsten et al.280 found that the different reduction approaches
(patient opinion vs. statistical modelling) resulted in very similar instruments.
The Skindex-29 tool was used in five of the six studies identified for the group of Skindex instruments by
the hyperhidrosis quality-of-life review.143,227,281–283 The Lessa et al.284 study used Skindex-16. The studies
included two quality-of-life reviews, a RCT, a single case series, a case report and a surgical observational
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study. Two studies were carried out in Germany and the other four studies in the Netherlands, Turkey,
Spain and the USA.
The Skindex-61 item questionnaire was first created by Chren et al.278 in 1996; the validation of the tool
was later published in 1997. Cronbach’s α (0.71–0.94) was calculated to measure the reliability of the
psychometric test.285 The tool’s design was based on findings from a review of the literature and focus
group interviews with patients and clinicians to construct the initial framework for the ways in which
patients are affected by skin disease. The tool has eight scales (cognitive, social, discomfort, limitations,
depression, fear, embarrassment and anger) within three domains (symptoms, emotions and functioning).
Patients are asked to respond to the questions with one of five responses (never, rarely, sometimes, often,
all the time), and the score is reported as three values, one for each domain, calculated by averaging the
patient’s responses from each of the questions within each of the three domains.
In a study of 201 patients, scale scores were reproducible after 72 hours and were internally consistent
(Cronbach’s α = 0.76–0.86). Construct validity was also demonstrated. However, physicians’ judgement of
disease severity did not consistently correspond with Skindex scores and Skindex does not appear to have
been cross-validated against other quality-of-life measures.
The authors suggest that the Skindex-29 tool is more suited to research for which a comprehensive
overview of HRQoL is required and the goal may be to understand the response to treatment.285 The
Skindex-16 was designed to serve longitudinal data collection. As patients may be required to complete
the same survey many times over the course of a study, it was considered that it would be better if this
was a shorter exercise. The Skindex instruments are copyrighted and, therefore, permission is required
from the authors to use either of the tools.
VQ-Dermato scale: a French-language scoring instrument validated for chronic skin
diseases – Grob et al.286
The VQ-Dermato scale was designed and validated to provide a French-language dermatology-specific
instrument for routine use to assess the quality of life of patients with ‘chronic skin disorders’.286 The scale
was identified in one article selected for inclusion into the quality-of-life review, a retrospective analysis of
a 142 patient study to examine the long-term (> 5 years) effects of ETS on patient satisfaction and quality
of life for patients with palmar hyperhidrosis between 1994 and 2005.211
The VQ-Dermato scale is a self-administered 28-item instrument developed from interviews with patients.
Grob et al.286 tested the tool on a population of 231 hospital and private practice patients in France
suffering from chronic skin conditions and reported the instrument was validated in terms of content,
construct, reliability/reproducibility and internal consistency. A strong correlation was reported by authors
between the VQ-Dermato and the SF-36 (Cronbach’s α = 0.67–0.88).
Freiburg Life Quality Assessment
The Freiburg Life Quality Assessment was designed and validated as a set of dermatology-specific modules.
The first module addresses the core issues of all skin diseases. The additional questions are more specific to
distinct diseases. The tool was found to have satisfactory discriminatory power and validation data were
published in 2004.287 This tool was found to be used in only one hyperhidrosis quality-of-life review.288
Patient Benefit Index
The Patient Benefit Index created by Augustin et al.289 is an instrument to identify patient-reported needs
and benefits of dermatology research and treatment. Assessment is a two-step process; the first captures
data on the patients’ needs prior to treatment, and this is followed by assessment of improvement after
treatment. The result is an index of patient benefit in response to treatment. The measure was validated in
2009 by the authors using a large cohort of patients (n = 500) with many different skin diseases, including
some with hyperhidrosis (n = 50).289 Use of this tool was identified in only one quality-of-life review of
patients with hyperhidrosis.288
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Characteristics of non-disease-specific tools
Illness Intrusiveness Rating Scale
The Illness Intrusiveness Rating Scale (IIRS) was developed by Devins290 in 1994 to measure the impact of
illness based on its intrusion on valued lifestyle activities. Devins produced a follow-up publication in 2010
describing the use of the tool and validating how it can contribute to the understanding of HRQoL in
chronic disease.291 The IIRS was identified in only one other study from 1999.292 This study of 68 patients
found that total IIRS score correlated well with other disease severity measures (r = 0.61; p < 0.001) and
reflected improvements post surgery. The tool is a 13-item survey scored on a Likert scale from 1 (not very
much) to 7 (very much). The tool can be used as a 13-item scale or divided into three subsets with a score
calculated for each subset. The subsets are relationships and personal development (may include family or
social relationships), intimacy (with partner) and instrumental considerations (such as work).
The IIRS validation was informed by a qualitative review of literature examining the results of studies in
which it has been used, and describes the value of the tool for studies measuring patient-reported quality
of life in 36 chronic disease groups.291 Hyperhidrosis was considered in the review, with data on 223
patients provided by Claudio Cina.291 Cronbach’s α coefficient for the total scale was 0.97, for relationships
and personal development was 0.94, for intimacy was 0.92 and for instrumental considerations was 0.93.
Although the results presented by Devins290 suggest that the IIRS is potentially useful and valid for
measuring quality of life in patients with hyperhidrosis, it is possible that it is too general to be popular for
measuring quality of life in studies of hyperhidrosis, as reflected by its limited presence in such studies
since 1999.
Medical Outcomes Study short forms (Short Form questionnaire-36 items and Short Form
questionnaire-12 items)
The Medical Outcomes Study (MOS) was a large US cross-sectional study (n = 22,462 patients) conducted
in 1989 to examine the impact that different systems of care and clinician expertise may have on patient
outcomes, with the aim of developing better tools to monitor patients in clinical care.293 The study worked
with a conceptual framework considering the structure of care, the process of care and the subsequent
outcome of care. Patient-reported outcomes contributed significantly to the study and ‘short-form’ surveys
(MOS short forms) were designed to facilitate data collection.
Short Form questionnaire-36 items
The SF-36 is a widely used generic health survey designed over a 7-year period using data gathered from
the MOS.294 The SF-36 tool was designed to address general health, such as basic daily functioning and
emotional status, rather than disease-specific outcomes or any specific disease-related issues. The purpose
of the survey was to measure patient-centred outcomes and examine the relative burden of disease and
the benefits of treatment within diverse populations. The health concepts examined are common to other
health surveys and include physical, social and role function; mental health; general health; and measures
of pain and vitality, such as energy or fatigue.295
Further work included the International Quality of Life Assessment project,296 a project to produce versions
of the SF-36 into validated health questionnaires for patient-reported outcomes in multiple countries:
Canada, France, Germany, Italy, Japan, the Netherlands, Sweden, Spain, the UK and the USA. Within each
country the SF-36 was adapted and then validated using methods of forward and backward translation
and focus groups. The aim was to conserve the validity of the questionnaire while providing a culturally
relevant and standardised method of measuring HRQoL.
Thirteen studies identified for the review of measures of quality of life in patients with hyperhidrosis
reported using the SF-36, including six studies of surgical interventions,251,297–301 three studies examining
dermatology interventions,55,57,97 one study of dermatology and surgery combined272 and three
quality-of-life-only studies.225,256,288
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Short Form questionnaire-12 items
The SF-12 tool302 was developed as a shorter version of the SF-36 form, and was designed to be used in
large-scale UK and US health trials to reduce the number of data generated while still providing a practical
and valid summary score for mental and physical health outcomes. The validation utilised regression models
to select and score 12 items from the original MOS SF-36 and the authors performed cross-sectional
and longitudinal validation tests to compare the results of the two surveys between patient groups.
Cross-validation results suggest that downsizing reduced the length of time needed to complete the survey
to 2 minutes while still maintaining the accuracy of the measures, which compared well with the SF-36
survey results.295,302 The authors suggest that the survey may be better suited to large-scale studies
particularly focused on physical and mental health outcomes.
Seven studies identified for the review of measures of quality of life in patients with hyperhidrosis reported
using the SF-12: two economic assessments,303,304 one surgical intervention,305 two studies examining
dermatology interventions80,86 and two quality-of-life-only studies.258,288 Study designs included one case
series,305 two RCTs,80,86 two economic studies303,304 and two of quality of life only.227,256
Everyday Life Questionnaire or Fragebogen des täglichen Lebens
The Everyday Life Questionnaire (EDLQ) was designed by a German research team, Bullinger et al.306 The
EDLQ (or Fragebogen des täglichen Lebens) was created from responses to open-ended questions given to
patients and healthy control subjects as a process to measure behavioural disease-specific quality of life.
Questions consider issues such as mental health, physical well-being, social life and medical care. The
authors suggest that it is more useful if the tool is used alongside the Munich Life quality Dimensions
List.307 The review found that the EDLQ was used in only one surgical study of palmar hyperhidrosis.308
State–Trait Anxiety Inventory
The State–Trait Anxiety Inventory was originally developed in the early 1960s to measure anxiety in healthy
populations, but then became useful as a tool for measuring anxiety disorders in patients. The review
found use of the State–Trait Anxiety Inventory in only one surgical study of generalised hyperhidrosis.305
The tool is designed to measure anxiety caused by certain situations (state anxiety) and also the tendency
to perceive situations as threatening (trait anxiety).309
International quality of life assessment (EuroQol-5 Dimensions, five-level version) or
EuroQol-5 Dimensions
The international quality of life assessment (EuroQol-5 Dimensions, five-level version; EQ-5D-5L), or
EuroQol-5 Dimensions (EQ-5D), is a HRQoL measure developed in 1990 by the EuroQoL group310 from the
results of a postal survey conducted in England, the Netherlands and Sweden. The EuroQoL was designed
to be used alongside other quality-of-life measures as a health status index for reference purposes.
The group has since expanded from 23 academic contributors to 75 and has become an international
multilingual and multidisciplinary team producing a suite of copyright-standardised generic instruments for
describing HRQoL. Use of the EuroQoL tool was identified only in one study, an economic assessment of
the burden of hyperhidrosis on the patient, by Kamudoni et al.228 in 2014.
Leibowitz Social Anxiety Scale
The Leibowitz Social Anxiety Scale206 measures fear, anxiety and avoidance of social situations before and
after treatment.311 The questionnaire is completed by a clinician asking the patient a list of questions:
11 questions relating to social interaction and 13 questions related to public performance. It has also been
validated in a modified version as a patient (self-) reported outcome measure.312 Use of this tool was
identified in only one study of hyperhidrosis, a surgical case series examining sweating problems in patients
in Finland.313
University of California, Los Angeles, Loneliness Scale
The University of California, Los Angeles, Loneliness Scale was developed in 1978 by Russell et al.314 in the
USA. The purpose of the scale is to measure loneliness in patients participating in social psychological
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research where they may suffer from limited social interaction or feel lonely as a result of their disease.
The search identified its use in a single dermatology study from Greece,121 which used both the University
of California, Los Angeles, Loneliness Scale and the DLQI together to measure quality of life in patients
receiving BTX to treat palmar and axillary hyperhidrosis.
Nottingham Health Profile
The Nottingham Health Profile was first designed in 1975 at Nottingham University using survey responses
from a cohort of 700 people asked to describe typical ill health. The tool was developed as a generic and
standardised HRQoL tool to measure the health status of a population. The tool can also be used as an
outcome measure for interventional management alongside a clinical assessment.315 The Nottingham
Health Profile was discussed in a review of quality of life by Rzany et al.227 in 2012, along with 12 other
tools for measuring quality of life in patients with hyperhidrosis, but was not found in any other studies.
The Questionnaire of Quality of Life adapted from the Caregiver Questionnaire
The Questionnaire of Quality of Life is an adaptation of the Caregiver Questionnaire which was developed
by Geabler-Spira and adapted by Schneider et al.316 The Caregiver Questionnaire is a disease-specific
measure of HRQoL developed for children with spastic quadriplegic cerebral palsy who were to undergo
treatment at the Rehabilitation Institute of Chicago, IL, USA.316 Developed as a HRQoL and functional
outcome measure for children, particularly those with disabilities, this tool was adapted by Coutinho dos
Santos et al.105 to measure quality of life in children and adolescents treated with BTX-A for palmar
hyperhidrosis.
Studies identified where the tool used to measure quality of life was not described
Thirty-two additional studies of hyperhidrosis published between 1978 and 2009 mentioned the collection of
quality-of-life data but did not describe how these data were captured, describe which tool was used or
provide more than only minimal details (quality-of-life tool not reported) (Table 6).58,73,74,81,95,111,118,137,155,182,317–336
Summary of review of measures of quality of life
The aim of this review was to identify the tools commonly used to measure quality of life in patients
suffering from hyperhidrosis. The studies were reviewed to identify measures of patient-reported HRQoL in
studies of the treatment and/or management of hyperhidrosis.
The DLQI, the HDSS and the HQLQ were used more often than any other tool for measuring HRQoL in
hyperhidrosis. The DLQI has a patient-centred approach, but it is criticised in the context of quality-of-life
measures for hyperhidrosis for being too general and its inability to capture hyperhidrosis-specific problems
or concerns.261 The HDSS appears to have value for researchers of clinical effectiveness of treatments for
hyperhidrosis as it is often used to measure response to treatment. It is unclear from the literature what
measures were used to design or validate the tool, although attempts have been made to quantify the
tool’s value as a measure of HRQoL in patients with hyperhidrosis. However, the HDSS is not highly
regarded by all as a comprehensive tool for measuring of HRQoL, suggested by continued work on
developing better tools. In the UK and the USA, the DLQI and HDSS are commonly used in combination in
both surgical and dermatology studies. The HQLQ is designed specifically for surgical interventions of
hyperhidrosis, making it a popular choice for surgical studies, although the majority of users are in Brazil,
where the tool was originally developed, with none of the studies we identified being UK based.
Of interest is the newly developed HidroQoL tool, developed by UK researchers as a scoring system with
more focus on patient-relevant measures than most quality-of-life tools used for hyperhidrosis research,
for both research and clinical practice.260,261 Use of this tool was not found in any studies identified for the
review, although this may be because it is still relatively new.
In summary, the tools identified from studies of hyperhidrosis differ in their method and validation, with a
significant degree of overlap. The tools appear to take the patients’ quality of life into consideration in
most cases, although with the lack of standardisation in method or validation it is not clear from this
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review which tools should be used in studies of clinical efficacy and/or patient-reported quality of life in
hyperhidrosis. The tools most commonly used, such as the HDSS, appear to lack any form of published
validation during development. The combined use of two or more tools is common, but again there is a
lack of clear standardisation for which combinations should be used or work best together. The type of
intervention (surgery or dermatology) and geographical location may also be a factor in tool selection and
it was not uncommon to find colleagues using the same tool. The HidroQoL is the most recent tool to be
designed and validated for measuring the quality of life of patients with hyperhidrosis.
TABLE 6 Studies where the method for measuring quality of life was not described or not explained fully (n= 32)
Number Study Year Intervention Body site Country
1 Bachmann et al.317 2009 Surgery Palm and axilla Germany
2 Bogokowsky et al.318 1983 Surgery Not stated Israel
3 Boley et al.319 2007 Surgery All USA
4 Cardoso et al.320 2009 Surgery Palm Spain
5 Chan et al.321 2007 Surgery Palm, axilla and/or foot China
6 Commons and Lim182 2009 Surgery Axilla USA
7 Costa et al.58 2015 Dermatology Foot Brazil
8 Currie et al.322 2011 Surgery Palm, axilla and face UK
9 Divisi et al.323 2013 Surgery Generalised Italy
10 Garcia et al.324 2011 Surgery Facial blushing Spain
11 Hanlon et al.111 2006 Dermatology Axilla Ireland
12 Jeganathan et al.325 2008 Surgery Palm, axilla and face UK
13 Kinkelin et al.118 2000 Dermatology Forehead Germany
14 Maric´ et al.326 2014 Surgery Face, palm and axilla Unknown
15 Munia et al.327 2008 Surgery Axilla Brazil
16 Munia et al.328 2007 Surgery Axilla Brazil
17 Naver et al.81 2000 Dermatology Palm, axilla or palm plus axilla Sweden
18 Ottomann et al.155 2007 Dermatology and surgery Axilla Germany
19 Rathinam et al.329 2008 Surgery Not stated UK
20 Schnider et al.137 2001 Dermatology Axilla and palm Austria
21 Shalaby et al.330 2012 Surgery Palm and axilla Egypt
22 Shayesteh and Nylander95 2011 Dermatology Not stated Sweden
23 Shi et al.331 2015 Surgery Palm China
24 Steiner et al.332 2007 Surgery Palm Israel
25 Xiao et al.333 2015 Surgery Palm China
26 Baumann et al.73 2005 Dermatology Axilla USA
27 Baumann et al.74 2005 Dermatology Palm USA
28 Baumann et al.73 2005 Dermatology Axilla USA
29 Baumann et al.74 2005 Dermatology Palm USA
30 Cheng et al.334 2015 Surgery Palm USA
31 Flores335 2012 Surgery Palm and axilla Brazil
32 Jaffer et al.336 2007 Surgery Palm and face UK
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Chapter 5 Review of cost-effectiveness evidence
Methods
A review of full economic evaluations was conducted as part of the review of the clinical effectiveness of
treatments for hyperhidrosis. The purpose of the review of economic evaluations was to identify economic
evaluations that modelled the management of patients with hyperhidrosis in order to inform the model in
this study.
Search strategy
The search strategy is outlined in Appendix 1, Hyperhidrosis cost-effectiveness literature searching.
Study selection
Two researchers undertook the screening of titles and abstracts obtained through the search, although the
library was split between the researchers, rather than each record being double screened, as described in
Chapter 2, Literature searches. All potentially relevant articles were obtained for scrutiny against the full
selection criteria, with any disagreements resolved by discussion. The criteria were:
l study design – full economic evaluations involving a decision model-based analysis
l population – patients with primary hyperhidrosis (including adults and children)
l intervention – treatments for hyperhidrosis available for prescription by dermatologists and defined
surgical treatments for hyperhidrosis
l comparator – alternative treatment or no treatment for primary hyperhidrosis
l outcome – cost-effectiveness, cost estimates, utilisation estimates, quality-of-life estimates.
Data extraction and quality assessment strategy
Data on the following, when available, were extracted from included studies by one reviewer and checked
by another:
l study characteristics, such as study question, form of economic analysis, population, interventions,
comparators, perspective, time horizon and form of modelling used
l clinical effectiveness and cost parameters, such as effectiveness data, health state valuations (utilities),
resource use data, unit cost data, price year, discounting and key assumptions
l results and sensitivity analyses.
Studies were to be quality assessed using tools as part of the data extraction process, namely the
Consensus on Health Economic Criteria list337 for economic evaluations and the checklist by Philips et al.338
for model-based analyses.
Results
A total of eight records were identified as potentially relevant.227–230,272,304,339,340 No duplicates were
identified. Full copies were obtained for scrutiny against the inclusion criteria for the review. No records
were found to meet the inclusion criterion of involving a decision model-based analysis. A flow diagram
presenting the process of selecting studies can be found in Figure 11.
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Conclusion
No model-based economic evaluations of treatments for patients with primary hyperhidrosis were
identified.
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FIGURE 11 Flow diagram showing study selection for the economic evaluations review.
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Chapter 6 Development of new cost-effectiveness
model
Overview
The review did not identify any modelling studies, so a de novo cost-effectiveness model was developed to
formally assess the cost-effectiveness of treatments offered by the NHS for the management of primary
hyperhidrosis and to estimate the VOI to aid decisions about further research. VOI analysis can quantify the
expected gain in net benefit from obtaining further information to inform a decision. The model was written
in the R version 3.2 software (The R Foundation for Statistical Computing, Vienna, Austria). The model code
is reported in Appendix 4. As outlined earlier (see Chapter 1, Description of underlying health problem),
hyperhidrosis is an unpredictable, uncertain condition with unknown aetiology and an uncertain disease
natural history. Given these uncertainties, when there was no, or very limited, effectiveness evidence,
it was considered to be of little additional value to conduct VOI analysis. Therefore, although effectiveness
evidence was sought for all hyperhidrosis body sites, a model was developed only for body sites for
which there was sufficient effectiveness evidence identified to warrant a VOI analysis. From the clinical
effectiveness review reported in Chapter 3, sufficient evidence was identified to warrant a model-based
cost-effectiveness analysis (CEA) of the axilla body site only. A NHS and Personal Social Services (PSS)
perspective was adopted for the analysis. The price year was 2015 and the costs used were in Great British
pounds.
The structure of the model was developed based on the outcomes reported in the clinical studies identified
in the review of the literature (see Chapter 3). The most common clinical outcomes were gravimetry sweat
rates and HDSS response. The HDSS clinical outcome enabled a treatment response model using HDSS as
a proxy for response in a clinical setting. Response was defined as at least a two-point decrease on the
HDSS scale. EQ-5D utility data were available for HDSS levels, so a state-transition cohort model was
developed with states defined by treatment and progression to different treatments in the treatment
sequence determined by response. As the long-term costs and quality of life depend(s) on the treatments
available after treatment failure, treatment sequences were modelled.
Costs and utilities were discounted by an annual discount rate of 3.5% per year, which is the current
discount rate recommended by NICE.341 The outcomes of the analysis were cost per quality-adjusted
life-year (QALY) gained and the VOI. The QALYs were calculated using EQ-5D utility values. The benefit
of hyperhidrosis is gain in quality of life and the EQ-5D index measures quality of life using health state
preference values. The CEA met the NICE reference case.342 All stages of the work were informed by
discussions with clinical and patient advisors, who provided feedback on the model assumptions, including
the prescribed treatments, resource use, referral decisions and treatment side effects.
Both deterministic and probabilistic models were developed. The deterministic model was used to perform
sensitivity and scenario analyses on particular parameters, and groups of parameters, in order to identify
the key drivers of the model. The probabilistic model was used to account for non-linearity in the model
and correlations in parameters, and to characterise the decision uncertainty. The probabilistic model
simulated a cohort of 5000 people with primary hyperhidrosis referred for secondary care. The probabilistic
model also enabled the estimation of the expected value of perfect information (EVPI) in order to inform
whether or not there is value in further research.
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The following sections outline the key elements of the modelling and any associated assumptions:
l population, treatment sequences and model structure
l formulae of the transition probabilities and proportions of patients on different treatments
l effectiveness data used in the model
l utility data used in the model
l cost data used in the model
l EVPI methods
l model results.
Population, treatment sequences and model structure
The decision problem investigated in this study is whether or not further research is required on
interventions for hyperhidrosis. The need for further research is related to the cost of making suboptimal
treatment decisions. This requires an evaluation of the cost-effectiveness of different treatment sequences
and the identification of the optimal treatment sequence to be offered to patients with primary axillary
hyperhidrosis. The decision question is not simply, ‘Which of the available treatments should be given to
patients?’. It is also ‘which treatment should be given to patients in the event that a treatment is not
effective or a patient has to withdraw from treatment due to adverse effects?’. As, in practice, patients are
offered different treatments, modelling treatment sequences also accounts for the costs and effects of
treatment after treatment failure. This section describes the population and the model structure developed
to assess cost-effectiveness.
Population and time horizon
The population in the model is assumed to be people with primary axillary hyperhidrosis who have an
equal mix of scores 3 and 4 on the HDSS scale. Patients are assumed to enter the model at 18 years of
age. Hyperhidrosis is assumed to spontaneously resolve after the age of 65 years, so the model has a time
horizon of 48 years. Resolution of the condition at the age of 65 years is a model assumption based on
advice provided by the clinical experts on the project; however, it is worth noting that in clinical practice a
significant number of patients may experience resolution later on in life.
Individual treatments and treatment sequences
The candidate treatments for each body site are listed in Table 7. Although treatments for each body site
are listed, the economic model focuses solely on the axillae due to a lack of data associated with
treatments for other body sites.
Clinical expert advice was that curettage or ETS would not be offered before non-surgical treatments such
as iontophoresis, oral medication or BTX. The reason for this was the invasive nature of the surgical
interventions. It was also advised that ETS would not be offered before curettage for axillary hyperhidrosis.
TABLE 7 Candidate hyperhidrosis treatments by body site
Axillae Hand Foot Craniofacial
Iontophoresis sponge Iontophoresis liquid tray Iontophoresis liquid tray Oral medication
Oral medication Oral medication Oral medication BTX
BTX BTX BTX ETS
Curettagea ETS
ETS
a Curettage or other minor surgery (e.g. laser, fractionated microneedle radiofrequency).
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The rationale given for this was that there is a significant risk of CS from undergoing ETS, whereas the risk
is believed to be minimal for curettage.
With these two constraints imposed on the possible treatment sequences, there were 64 possible
treatment sequences for axillary hyperhidrosis, including aluminium chloride antiperspirant acting as a
‘no secondary care’ comparator. The full list of sequences is presented in Table 8. The interventions are
abbreviated by their first letter: aluminium chloride antiperspirant (A), ETS (E), curettage (C), BTX (B),
iontophoresis (I) and medication (M). For this analysis, medication is assumed to be oral medication, which
is considered to be a class of treatment in terms of clinical effectiveness (i.e. the effectiveness of no one
medication was incorporated in the model). The available data on topical medications were considered
insufficient available and, thus, these medications were not included in the analysis.
The number of treatment sequences was lower for the other body sites, as curettage is not used for
the hand, foot or craniofacial sites, ETS is not used for the foot and iontophoresis is not used for the
craniofacial site. However, as modelling was undertaken only for the axillae, only treatments for the axillae
are presented here.
Minor surgery for the axilla
Minor surgery for the axilla includes curettage, microwave, fractionated microneedle radiofrequency,
ultrasound and laser interventions. However, as there is insufficient evidence relating to microwave,
fractionated microneedle radiofrequency, ultrasound and laser, only curettage is included in the model.
If sufficient effectiveness evidence had been available, minor surgery would have been compared in a
separate model. The treatment sequences evaluated would have included each of these minor surgery
procedures (with or without ETS following failure of the minor surgery).
TABLE 8 The treatment sequences evaluated in the model (hyperhidrosis of the axilla)
Number Sequence Number Sequence Number Sequence Number Sequence
1 A 17 MB 33 IM 49 MIB
2 E 18 MBE 34 IME 50 MIBE
3 C 19 MBC 35 IMC 51 MIBC
4 CE 20 MBCE 36 IMCE 52 MIBCE
5 B 21 BM 37 MI 53 MBI
6 BE 22 BME 38 MIE 54 MBIE
7 BC 23 BMC 39 MIC 55 MBIC
8 BCE 24 BMCE 40 MICE 56 MBICE
9 M 25 IB 41 IMB 57 BIM
10 ME 26 IBE 42 IMBE 58 BIME
11 MC 27 IBC 43 IMBC 59 BIMC
12 MCE 28 IBCE 44 IMBCE 60 BIMCE
13 I 29 BI 45 IBM 61 BMI
14 IE 30 BIE 46 IBME 62 BMIE
15 IC 31 BIC 47 IBMC 63 BMIC
16 ICE 32 BICE 48 IBMCE 64 BMICE
A, aluminium chloride antiperspirant; B, BTX; C, curettage; E, ETS; I, iontophoresis; M, medication.
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Treatment failure (failure to respond to any treatment)
Treatment response is defined as at least a two-point reduction on the HDSS scale. It is assumed in the
model that a patient who achieves only a partial response (a reduction of one point on the HDSS scale)
tries the next treatment because the level of response is not deemed satisfactory. However, having
exhausted all available treatments (and if the patient is still deemed to be a non-responder), the patient
returns to one of the treatments to which they exhibited a partial response. The section Derivation of
different Hyperhidrosis Disease Severity Scale level responses describes the estimation of the treatment
response and partial response.
If a patient fails to respond to any treatment, the treatment in the sequence chosen as the fall-back
treatment depends on a hierarchy of treatments as follows: medication, iontophoresis, BTX, aluminium
chloride.
Medication and iontophoresis sponge were chosen as the first fall-back treatment options because they
afford clinicians potentially more flexibility in their use. They can be used at different doses/intensity or
used only before specific occasions. Only non-surgical treatments are considered as fall-back options.
This is to reflect the current clinical practice in which many patients never progress to surgery and to
incorporate the assumption that any patient achieving a partial response to curettage would no longer
have hyperhidrosis sufficiently severe to warrant having ETS. The effect on the results of changing the
order to ‘iontophoresis, BTX, medication and aluminium chloride’ was tested in a scenario analysis. The
treatment received as a fall-back option is the treatment in the particular sequence (at any point) that is
highest up the hierarchy (medication, iontophoresis, BTX, aluminium chloride antiperspirant). For example,
in the sequence:
iontophoresis sponge→ oral medication→ BTX→ curettage→ ETS, (1)
the treatment received would be medication as it is the treatment in the sequence that is highest in the
hierarchy. A patient who experienced no benefit from medication or stopped taking medication because
of adverse effects would receive the next treatment in the hierarchy, which, in this case, is iontophoresis.
If the patient experiences no benefit from iontophoresis or stops using iontophoresis because of side effects,
they would then be offered BTX. The next treatment to try would be aluminium chloride perspirants.
A patient who does not tolerate aluminium chloride antiperspirant would not receive any treatment.
This assumption was also maintained for shorter treatment sequences. For instance, in the sequence:
iontophoresis sponge→ curettage, (2)
the first fall-back treatment option would be iontophoresis sponge. A patient who fails to respond to
iontophoresis or stops because adverse effects would be offered aluminium chloride antiperspirants.
A patient who does not tolerate aluminium chloride antiperspirant would not receive any treatment.
State transitions
During the first year of the model, patients try the different treatments in sequence until they find a
treatment that works for them, or they enter the treatment failure state and retry an intervention that gave
them a partial response. A patient may die at any time according to the general population mortality risk.
In order to model the transitions between the treatments, a monthly cycle length is adopted during the
first year of the model. The monthly treatment states during the first year associated with each treatment
are reported in Table 9.
Patients are entitled to a free 1-month trial of an iontophoresis device at a NHS clinic, so it is assumed that
response can be determined within 1 month of starting iontophoresis treatment. If the patients who
respond then move to the iontophoresis responder state and remain there. Clinical expert advice was that
there are no long-term adverse effects from iontophoresis use, so it is also assumed that withdrawal
because of adverse effects would also occur within the first month.
DEVELOPMENT OF NEW COST-EFFECTIVENESS MODEL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
In the case of oral medication, clinical and patient group advice suggested that response can be
determined within 3 months of starting medication. This is consistent with time to response reported by a
small survey of dermatologists that was conducted to inform the model parameters, although there was
considerable variation in response. The survey methods and results are outlined in Appendix 5. It was
assumed that withdrawal because of adverse effects would also occur within 3 months, although the lack
of evidence on long-term adverse effects from oral medication is an area of uncertainty.
In the case of BTX, it is assumed, based on expert clinical input, that response can be established within the
first month following BTX injections and that withdrawal because of adverse effects would occur within the
first month, as clinical expert advice was that there are no long-term adverse effects from BTX injections.
Curettage is a one-off treatment. If a patient is considered a responder, then the response is assumed to
be permanent and the patient enters the successful curettage state; there is no long-term evidence to
support this assumption. ETS is also a one-off treatment. ETS is assumed to be effective for treatment of
hyperhidrosis in all cases but may lead to CS. Following ETS, a patient enters one of the CS states: no CS,
mild CS, moderate CS, severe CS or CS so severe that the patient regrets having CS (regret CS).
From the second year onwards, patients are assumed to remain on a treatment for the remaining time in
the model. The cycle length changed to 1 year.
The basic set of state transitions is presented in Figure 12. After trialling a treatment for a month in the
case of iontophoresis and BTX, and 3 months in the case or oral medication, a patient responds to
treatment and remains on the treatment, moves on to the next treatment or dies. If the patient does not
respond to treatment and there are no more treatments in the sequence, then the patient enters the
treatment failure state and retries a previous treatment that provided partial response. Patients progress
to available surgical treatments only if they have received no benefit from any previous non-surgical
treatment. If they achieved a partial response from a previous treatment, then they enter the treatment
failure state and retry a treatment based on the hierarchy outlined previously. This assumption was made
based on expert clinical advice regarding the level of severity required before a patient would advance to
surgical treatment.
TABLE 9 Monthly cycles associated with each treatment
Treatment Monthly cycles associated with each intervention during the first year
Aluminium
chloride
Monthly use
aluminium
chloride
Iontophoresis 1-month
iontophoresis
trial
Continue on
iontophoresis
if responder
Oral
medication
Month 1 oral
medication trial
Month 2 oral
medication
trial
Month 3 oral
medication
trial
Continue on
medication if
responder
BTX First BTX injection Second
month after
BTX injection
Third month
after BTX
injection
Fourth month
after BTX
injection
Fifth month
after BTX
injection
Sixth month
after BTX
injection
Have next
set of BTX
injection if
respondera
Curettage Undergo
curettage in first
month
Successful
curettage
ETS Undergo ETS in
first month
No CS Mild CS Moderate CS Severe CS Regret CS
a Return to ‘second month after BTX injection’.
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Following ETS, all patients enter one of the CS states as described above. If they have CS then they retry
oral medication.
No half-cycle correction is required during the 1-month cycles as the cycle length is short compared to the
model time horizon. It was also not applied to the annual cycles because patients receiving BTX continued
to cycle through different BTX states despite the transition to annual cycles. The bias associated with this
was considered to be minimal as the only transition out of BTX treatment in each cycle was general
population mortality.
Summary of model data
This section provides a summary of the data included in the model, which are fully detailed in sections
Derivation of transition probabilities and reuse of treatments to Resource use and unit costs. A description
of the analyses conducted is then presented in Incremental cost-effectiveness analysis and scenario and
sensitivity analyses and Value-of-information analysis, and the results are presented in Chapter 7.
The data included in the model can be categorised as treatment/clinical outcome data, utility data and cost
data.
Treatment/clinical outcome data
A NMA was conducted to synthesise the HDSS outcome data from nine studies in order to provide
consistent relative effectiveness data for the economic model. These studies were identified as being at risk
of bias in the systematic review (see Chapter 3, Quality of studies included in the review). Change in HDSS
was the selected outcome as it was one of the most prevalent outcomes, treatment response could be
easily defined and utility data were available only for the HDSS outcome.
The key outcome variable required for the economic model was response, defined as a reduction in the
HDSS score of at least 2 points. Half of the included studies reported response and half reported mean
change from baseline. As there is no unique transformation from mean change to response, the following
process was conducted: (1) a simulation was conducted to derive the likely numbers of responders and
non-responders in each study that reported mean change, accounting for the uncertainty associated with
the process; (2) a NMA was then conducted to estimate the relative odds ratio (OR) of response from the
response numbers from each study; and (3) for the purpose of assigning utility values to different levels of
response and for estimating the likelihood of retrying a previous treatment after exhausting the possible
options (defined as a partial response of one HDSS point change), the likelihood of different levels of
response was derived for different probabilities of response obtained from the NMA.
No distributions were specified for the relative effect parameters in the economic model. Instead, the
model sampled from simulated results produced from the NMA. Summary statistics of the relative effects
are reported in Table 10.
Death Next treatment
Non-surgical
FIGURE 12 The basic set of state transitions.
DEVELOPMENT OF NEW COST-EFFECTIVENESS MODEL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
80
No evidence was identified on the long-term effectiveness of treatments for hyperhidrosis of the axillae.
In the base case, it was assumed that effectiveness was permanently sustained. Probabilities of continued
effectiveness were tested in sensitivity analyses. These are reported in Table 10.
Withdrawal rates due to side effects for different treatments were derived from a survey of UK
dermatologists. These are reported in Table 10 along with the probability distributions used in the model.
The likelihood of moving on to the next treatment in the sequence depends on both the probability of
response and the probability of dropping out because of side effects.
The likelihood of CS following ETS was obtained from a published study.16 These data and the probability
distribution used in the model are reported in Table 10.
Mortality rates were obtained from the Office for National Statistics.343
Utility data
Means and SDs for the sample distributions for HDSS levels 2–4 were obtained from a published
abstract.228 Sample sizes were obtained from the related thesis.232 These were bootstrapped to obtain beta
distributions on a transformed scale of 0–1. These data and the probability distributions used in the model
are reported in Table 10.
TABLE 10 The clinical and utility data entered in the economic model
Effectiveness (HDSS response) results utilised in the model
Comparison Median ORa
Iontophoresis sponge vs. placebo 3.03b (95% CI 1 to 9.2)
Medication vs. placebo 7.21 (95% CI 1.56 to 53.83)
BTX vs. placebo 9.207 (95% CI 4.73 to 18.10)
Curettage vs. BTX 6.391 (95% CI 1.20 to 27.61)
ETS 1
Probability of stopping treatment due to adverse effects
Intervention Mean Distribution
Antiperspirants 0.55 (95% CI 0.00 to 1.00) α = 0.611, β = 0.505
Medications 0.37 (95% CI 0.01 to 0.89) α = 0.962, β = 1.652
Iontophoresis (tap water) 0.16 (95% CI 0.00 to 0.63) α = 0.511, β = 2.709
Iontophoresis (glycopyrrolate) 0.25 (95% CI 0.00 to 0.77) α = 0.737, β = 2.212
Long-term effectiveness: ETS CS event rates by severity
No CS Mild CS Moderate CS Severe CS Incapacitating CS n
340 394 409 367 190 1700
HDSS level utility estimates
HDSS level EQ-5D mean (SD) of sample distribution
Distribution
(EQ-5D rescaled to 0–1 range)
HDSS 2 (n= 36) 0.85 (0.13) α = 416.6, β = 43.3
HDSS 3 (n= 69) 0.8 (0.15) α = 391, β = 55.8
HDSS 4 (n= 58) 0.69 (0.2) α = 276.2, β = 67
a Non-parametric simulation effectiveness data were actually entered in the model.
b The mean.
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Cost data
As stated in Overview, the analysis was undertaken from a NHS and PSS perspective. Costs relevant to the
NHS and PSS were identified for the analysis. Information on the precise description of resources required
for each individual treatment was partially based on data derived from the review, augmented when
necessary by clinical experts in the study group and published economic literature. Unit costs were taken
from appropriate routine sources, such as NHS Reference Costs 2014 to 2015,344 Personal Social Services
Research Unit345 and the British National Formulary 2016346 for medication. The price year of the analysis
was 2014/15. The monthly costs for each model state are reported in Table 11. See Resource use and unit
costs for the unit costs and assumptions made to derive these monthly costs.
TABLE 11 The monthly costs of the model states entered in the model
Model state Monthly cost (£)
Aluminium chloride (A) 8.72
Iontophoresis sponge (IS) 198.64
Iontophoresis sponge responder (ISR) 0.00
Medication month 1 (M1) 73.34
Medication month 2 (M2) 28.13
Medication month 3 (M3) 28.13
Medication responder (MR) 39.55
BTX month 1 (B1) 201.21
BTX 2 (B2) 0.00
BTX 3 (B3) 0.00
BTX 4 (B4) 0.00
BTX 5 (B5) 0.00
BTX 6 (B6) 0.00
BTX subsequent injections (BS) 156.00
Curettage (C) 1194.62
Curettage responder (CR) 0.00
ETS (E) 5750.89
ETS responder (ER) 0.00
ETS low CS (ELCS) 39.55
ETS moderate CS (EMCS) 39.55
ETS high CS (EHCS) 39.55
ETS regretful CS (ERCS) 39.55
Treatment failure (TF) Based on methods described in Summary of model data
Dead (D) 0.00
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Derivation of transition probabilities and reuse of treatments
Transition probabilities
Each treatment is associated with a probability of response, defined as a reduction in the HDSS score of
at least 2 points. Placebo is not a treatment option in the model; however, the baseline probability of
response is derived from the placebo probability of response. The relative risk of response for each
treatment is derived with placebo as the comparator. The derivation of the relative risk is described in Use of
the odds ratio of response in the model. If Ppr is the placebo probability of response, RRmp is the relative risk
of response for medication compared with placebo and Pmr is the medication probability of response, then:
Pmr = RRmpPpr . (3)
The potential transitions from the third month on medication after the follow-up visit to determine
response are presented in Figure 13. If there is another non-surgical treatment in the treatment sequence
then the option to retry previous treatments does not apply. A patient dies due to causes prevalent in the
general population, continues on medication or withdraws from the current treatment due to either lack
of effectiveness or sufficiently serious adverse effects to warrant progression to the next treatment.
There is a probability, Pmr, that a patient achieves adequate response and a probability, Pmae, that a patient
experiences adverse effects that result in the patient stopping treatment. There is a probability, Pd, that a
patient may die at any time from causes prevalent in the general population and the complement
probability, Pa, that a patient remains alive. The probability, Pmc, that a patient continues on medication is:
Pmc = Pmr (1 − Pmae)Pa. (4)
The probability, Pnt, that a patient moves on to the next treatment is:
Pmnt = 1 − Pmc − Pd. (5)
If medication was the last treatment in the sequence, then there is not another treatment to move on to
and the patient retries previous treatments. The probability, Pmrt, that a patient retries a previous treatment
is calculated in the same way as Pmnt in Equation 5.
Pmrt = 1 − Pmc − Pd. (6)
If the next treatment in the sequence is a surgical intervention, it is assumed that patients who are
non-responders, but have experienced a partial response and who have not experienced adverse effects
sufficiently serious to withdraw from the treatment previously, retry those treatments. Only patients who
have experienced no response at all from treatment, and those who have experienced a partial response
but also serious adverse effects, move on to have surgery.
Death Next treatment
Retries previous
treatment
Medication
Pmc
Pd
Pmnt
Pmrt
FIGURE 13 Medication treatment state transitions.
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It is useful to break down the population into five categories of response, which are presented in Table 12.
There are four possible response outcomes on the HDSS scale: from a zero-point reduction to a three-point
reduction. The probability of a zero-point reduction for medication is Pm0 and the probability of a one-point
reduction is Pm1.
When there is only one treatment in the sequence, the probability, Pmpb, of a partial benefit with no adverse
effects is:
Pmpb = Pm1(1 − Pmae), (7)
And the probability of a patient having no benefit (i.e. either zero response or has adverse effects) is:
Pmnb = Pm0 + Pm1Pmae + PmrPmae = Pm0 + Pm1 − Pmpb + PmrPmae. (8)
As:
(1 − PmrPmae) = Pmnb + Pmpb, (9)
Pmnb can also be expressed as:
Pmnb = (1 − PmrPmae)
Pmnb
Pmnb + Pmpb
. (10)
If medication occurs before surgery in the sequence, accounting for mortality, the four transition
probabilities are as presented in Table 13.
The expression of Pmnb stated in Equation 10 is used when there are multiple treatments in the sequence
before surgery. In the base case, it is assumed that treatment effects are independent. In the two
treatment cases (e.g. medication followed by BTX), the probability, Pbnb, of no benefit from any of the
previous treatments is the joint probability of no benefit from both treatments multiplied by the probability
of not continuing on BTX treatment.
Pbnb = (1 − PbrPbae)
Pbnb
Pbnb + Pbpb
×
Pmnb
Pmnb + Pmpb
. (11)
The frequency of treatment use after treatment failure
Treatment failure is when a patient has no adequate response to any of the treatments in the sequence.
When there is no ETS in the treatment sequence, all patients who (1) have not had an adequate response
of a reduction in HDSS score of at least 2 points and (2) have had an adequate response but have
withdrawn from treatment because adverse effects enter a treatment failure state. Once in this state,
a proportion of patients who achieved partial response on previous treatments retry those previous
treatments in accordance with an assumed hierarchy.
TABLE 12 Probabilities of response
Category of response Probability
Responders without adverse effects Pmr(1 – Pmae)
Responders with adverse effects PmrPmae
Partial responders without adverse effects Pm1(1 – Pmae)
Partial responders with adverse effects Pm1Pmae
Complete non-responders Pm0
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Assuming that patients retry treatments in the order of medication, iontophoresis then BTX, then
the proportions retrying each treatment is calculated as follows. The proportion, Pm, of patients in the
treatment-failure group that is assumed to retry medication is:
Pm =
Pm1(1 − Pmae)
Pm0 + Pm1 + PmrPmae
. (12)
The proportion, Pi, of patients assumed to retry iontophoresis is:
P i = (1 − Pm)
P i1(1 − P iae)
P i0 + P i1 + P irP iae
. (13)
The proportion, Pb, of patients assumed to retry BTX is:
Pb = (1 − Pm − P i)
Pb1(1 − Pbae)
Pb0 + Pb1 + PbrPbae
. (14)
The remaining patients, Panti, are assumed to remain in the failed treatment state in which patients use
antiperspirants:
Panti = 1 − Pm − P i − Pb. (15)
When there is ETS in the sequence, then no patients who have ETS enter the treatment failure state. They
either enter a successful ETS state or are in a state with different degrees of CS. Patients in the CS states
are assumed to retry oral medication.
Effectiveness evidence
The clinical effectiveness review reported in Chapters 2 and 3 searched for studies of clinical effectiveness
of treatments for different hyperhidrosis body sites. The two most common clinical outcomes were
gravimetry sweat rates and HDSS outcomes. HDSS was chosen as the clinical outcome to inform the
treatment outcomes in the model, as it enabled a treatment response model and estimates of EQ-5D utility
values for HDSS levels were available in the literature.
Clinical evidence with Hyperhidrosis Disease Severity Scale outcome
From the clinical review, nine of the included studies had a HDSS outcome for the axilla body
site.21,24,27,28,53,69,77,83,184 One study had a HDSS outcome for the hand body site.88 Intervention, comparator,
body site, time point and event data for these studies are reported in Table 14. The Leclere et al.24 study
was a four-armed study of two intensities of laser, one curettage arm and one curettage followed by laser.
The low-intensity laser was reported to be ineffectual and, therefore, only the results for the high-intensity
laser and curettage are included. Half of these studies, indicated by footnote b in Table 14, reported
mean HDSS data. Mean reduction in points on the HDSS scale cannot be easily converted into binary
response data. There is no unique response rate associated with a specific mean reduction. The possible
TABLE 13 Transition probabilities
Transition Probability
Dies Pd
Continues on medication Pmc = Pmr(1 – Pmae)Pa
Next treatment Pmnt = (Pm0 + Pm1Pmae + PmrPmae)Pa
Retries previous treatments Pmrt = 1 – Pd – Pmc – Pmnt
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TABLE 14 Included studies with interventions, body site and event data
Author Intervention Comparator Body site Time point
Eventsa
(intervention) n (intervention)
Eventsa
(comparator) n (comparator)
Mehrotra et al.53 Glycopyrrolate Placebo Axilla 4 weeks 10 24 1 14
bMüller et al.69 Methantheline bromide Placebo Axilla and
palm
4 weeks 4 128 1 139
bLeclere et al.24 Laser Curettage Axilla 1 month 10 25 8 25
Rajagopal and Mallya88 Iontophoresis BTX Palm 4 weeks 17 30 8 30
bIbrahim et al.21 Curettage BTX Axilla 3 months 1 20 4 20
Glaser et al.27 Microwave Placebo Axilla 3 months 54 81 5 39
Ohshima et al.83 BTX Placebo Axilla 3 months 45 78 10 74
bFatemi Naeini et al.28 Fractionated microneedle
radiofrequency
Placebo Axilla 9 weeks 7 25 1 25
Lowe et al.77 BTX Placebo Axilla 4 weeks 161 214 27 108
bVakili and Baker184 Curettage BTX Axilla 6 weeks 7 23 21 75
a An event is a responder to treatment defined as at least a two-point reduction on the HDSS scale.
b Reported continuous HDSS data: mean change from baseline.
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range of the number of events in each arm of each study was therefore derived through simulation.
This is described in The frequency of treatment use after treatment failure.
These studies form a network of evidence presented in Figure 14; the thickness of the lines represents the
relative weight of evidence for each comparison.
There are few studies, and most of these have small sample sizes. The quality assessment carried out as
part of the systematic review indicates a high risk of bias and poor reporting across studies. There is,
therefore, considerable uncertainty in the effectiveness evidence used in the NMA. One of the nine
studies is a non-RCT.184 It should be noted that a NMA was not included in the clinical evidence section
(see Chapter 3) owing to the high risk of bias and heterogeneity of the trials. However, establishing relative
effectiveness of the various treatments is essential for the economic model. The risk of bias should be
considered in interpreting the results for both meta-analyses and NMA. See Between-study variance,
inconsistency and bias for further discussion.
The advice provided by the project clinical experts was that time to response was short for iontophoresis
and oral medication as these are interventions that are used continually and the clinical studies in general
had short follow-up time points. Therefore, a time point closest to 4 weeks was selected as the optimal
follow-up time point in the studies evaluating the effectiveness of medication and iontophoresis. Clinical
studies investigating minor surgery generally had longer follow-up time points (as semi-permanent
treatments) and so a time point closest to a 3-month follow-up time point was selected in studies with
BTX and minor surgery, including curettage and laser. It is assumed that BTX is immediately effective so
the time point at follow-up depends on the comparator.
Derivation of response rates from continuous outcomes
The derivation of response rates from continuous outcomes comprised three steps:
1. Derive the plausible ranges of events for each study arm that are consistent with the continuous
outcomes reported in each study.
2. Derive the relative risk and standard error on the log-scale accounting for the uncertainty in the study
arm events represented by the ranges of plausible events obtained in step 1.
3. Derive the study arm events that are consistent with the relative risk and standard error obtained in step 2.
Curettage
BTX
Placebo
Oral medication
Microwave
Laser
Fraction
FIGURE 14 The network of effectiveness evidence for the axilla body site. Graph produced using published Stata
code.347 Fraction, fractionated microneedle radiofrequency.
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These steps are described below in turn.
Step 1
The likely distribution of possible responses (a reduction in HDSS score of 0, 1, 2 or 3 points) depends on
the skewness of the distribution across that range. If the population were evenly distributed across the
possible responses, then the mean change would be 1.5. The distance of the mean change from 1.5 is an
indication of the skewness of the distribution across the possible range of distributions.
There is no reason to think that there are differences for distinct populations in how they are likely to
respond to treatment, so a unimodal distribution was assumed. This was imposed as a constraint in the
simulation model by assuming that if the mean change is < 1.5 then:
E3 ≤ E2 and E2 ≤ E1, (16)
where Ex represents the number of events with X points of reduction on the HDSS scale. If the mean
change is > 1.5 then:
E0 ≤ E1 and E1 ≤ E2. (17)
If the SD of the mean change was available, this would narrow down the possible range of events. All of
the studies reporting mean HDSS data did not report mean change. Mean change was calculated from the
mean at baseline and the mean at follow-up. The SD of the mean change could be calculated from the SD
of the baseline scores and the SD of the follow-up scores if there was evidence for the correlation between
baseline and follow-up scores. No evidence for the correlation was identified.
Therefore, the possible range of events was simulated using two constraints:
1. a unimodal distribution
2. the mean of the distribution should be the mean from the study treatment group to within rounding
error in study reporting for one data point (e.g. 1.885 reported as 1.89).
In addition to rounding error in study reporting, a feasible mean may be different from the reported mean
(1) because of cumulative rounding error from both baseline and follow-up scores; (2) because of
misreporting by the study author; (3) because the reviewer misreported the study data; or (4) because the
scale of a study graph was not adequate for a reviewer to correctly identify. The range of the possible means
may therefore have had to be widened if no feasible mean was identified within the original range. This was
the case for one study: for a calculated mean change of 0.17, the nearest feasible mean was 0.16.28
The simulation required us to obtain 200,000 samples of combinations of numbers with responses of a
reduction in HDSS score of 0, 1, 2 and 3 points. Results that did not meet the defined constraints were
deleted. The R code is reported in Appendix 6.
Step 2
The relative risk was then derived for the studies reporting mean change in HDSS scores. It was assumed
that each feasible number of events in each study arm had an equal probability of being the true number
of events. The number of events was randomly sampled from a uniform distribution across these ranges
of feasible numbers of events and the relative risk was calculated from the sample values. This was a
reasonable assumption for many of the study arms. A total of 50,000 samples were drawn from the
feasible range of event numbers for both the intervention and the comparator. The mean and standard
error on the log-scale were also derived. Values of the log-RR were then sampled from a normal
distribution and converted back to the relative risk scale. The relative risk and the standard error on the
log-scale were derived to enable the event rates associated with these relative risk and standard errors to
be derived through solving simultaneous equations in the next step. The R code is reported in Appendix 7.
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Step 3
Finally, event rates were derived for each study arm; the uncertainty in the event rates was reflected by
solving a pair of simultaneous equations. The standard error of the relative risk on the log-scale derived in
Step 2 incorporates uncertainty in the event numbers for each study arm. The total number of patients in
each arm is known, so event rates can be derived from each arm corresponding to the relative risk and the
standard error of the relative risk on the log-scale, by solving the pair of simultaneous equations given by
the formulae for the relative risk and the standard error of the relative risk on the log-scale.
The formulae for the mean relative risk and the variance on the log-scale provide two simultaneous
equations to solve for a and b.
µ =
a/Na
b/Nb
. (18)
σ2 =
1
a
−
1
Na
+
1
b
−
1
Nb
. (19)
Solving these equations gives:
b =
Nb + µNa
µ(σ2Na + 1 +
Na /Nb )
. (20)
a =
µbNa
Nb
. (21)
If b is < 1, b is set to 1 and a is recalculated. Results are rounded to the nearest integer.
The results incorporate the uncertainty in the unknown study arm events. As a lower number of events
is associated with greater uncertainty in the effect estimate, the derived event numbers are quite low.
The final events are included in Table 12.
Network meta-analysis methods
A NMA was performed in order to derive the relative effectiveness estimates for the economic model.
Analyses
Network meta-analyses were conducted for the network presented in Figure 14 using the event data for
the axilla body site included in Table 14. The model code is reported in Appendix 8. The model adopted a
binomial likelihood and logit model. The model was based on the code reported in NICE Technical Support
Document 2.348 Random-effects models were specified assuming a normal distribution on the log-OR scale
for the between-study variance. Uninformative priors were given for the mean log-OR effects. Informative
priors were given for the between-study variances (see Between-study variance, inconsistency and bias).
Convergence was assessed using the Brooks–Gelman–Rubin diagnostic along with visual inspection of the
trace and density plots.349 The initial 100,000 simulations were discarded and the results were based on a
further sample of 50,000 simulations.
It is assumed that there is clinical and statistical heterogeneity in treatment effectiveness across the NHS for
reasons such as varying medication use, surgical experience and hyperhidrosis severity. Therefore, it is the
average treatment effect that is applicable to the decision problem rather than the treatment effect of
specific treatments in specific contexts.
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Between-study variance, inconsistency and bias
True variation in relative treatment effects across studies is known as between-study variance. There was
insufficient evidence to estimate a between-study variance from the variation in relative risks among
studies. However, a degree of between-study variance is highly likely. There is certainly heterogeneity
across studies: the estimated mean response rate for curettage was 0.15 in Ibrahim et al.21 compared with
0.64 in Leclere et al.24
Accounting for between-study variance is especially important in an evidence network in which there are
no loops (i.e. there is evidence for A vs. B and B vs. C but not for A vs. C, hence the effectiveness estimate
for A vs. C is an indirect estimate from the evidence of A vs. B and B vs. C). For example, Figure 14 shows
that the relative effectiveness of curettage compared with placebo is informed by an indirect chain of
evidence. If there were a characteristic of the Leclere et al.24 study that differs from the Ibrahim et al.21
study that affects curettage response more than the comparator, then the relative effectiveness of
curettage compared with placebo would be biased. Inconsistency cannot be quantified when direct and
indirect evidence are not both available for the same comparison, but the relative significance of
inconsistency is reduced if between-study variance is accounted for.
A priori, it is reasonable to expect that the between-study variance would differ between treatment effects
that compare non-pharmacological interventions with pharmacological interventions and treatment effects
that compare pharmacological interventions with placebo. For example, the experience and skill of a
surgeon is an additional factor associated with curettage that may contribute to between-study variance.
It is even reasonable to expect greater variation in treatment effects between placebo-controlled medication
studies than in placebo-controlled BTX studies, as it would appear that there is greater variation in the types
of medication than in BTX procedures. For example, the two medication studies included in the network
investigate methantheline bromide and topical glycopyrrolate wipes.
Table 15 presents the log-normal prior distributions for the between-study variances utilised within the
NMA. All treatment effects are assumed to be different. When there are no data to inform the
between-study variance in the data set, then the posterior distribution will simply be the same as the prior
distribution. The prior distributions for the quality-of-life outcomes were obtained from Turner et al.350
No estimate of inconsistency can be derived given the available evidence. This is because there are no
loops of evidence in the network presented in Figure 14; that is, there are no treatment comparisons that
are informed by both direct and indirect evidence. For example, if there were trials comparing A with B,
B with C and A with C, then the trials A comparing with B and B with C provide indirect evidence of A
compared with C, whereas the trial of A compared with C provides direct evidence for that comparison.
TABLE 15 Log-normal distribution parameters for different comparisons
Generic comparison Treatment effects
Log-normal
distribution
(mean, SD2)
Mean BSV on
log-odds scale
Pharmacological vs. placebo Medication vs. placebo LN(–2.54, 1.542) 0.245
BTX vs. placebo
Non-pharmacological vs. placebo Microwave vs. placebo LN(–2.77, 1.732) 0.324
Fractionated microneedle
radiofrequency vs. placebo
Pharmacological vs. non-pharmacological Curettage vs. BTX LN(–1.51, 1.272) 0.487
Non-pharmacological vs. non-pharmacological Laser vs. curettage LN(–2.1, 1.472) 0.371
BSV, between-study variance.
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Inconsistency refers to differences between direct and indirect evidence. It is not evident, based on the
available evidence, that there is a significant difference, on average, in population severity in terms of
HDSS score between pharmacological and non-pharmacological trials. The BTX response rates are similar in
BTX and placebo trials and BTX and curettage trials. The placebo response rates are slightly higher, on
average, in BTX and placebo trials than in minor surgery and placebo trials; however, this may be due to
either different populations or different placebo effects. The important consideration in NMA is the
difference in treatment effects. Given the considerable uncertainty within trials and in the between-study
variances, and the indirect nature of the evidence, it is likely that the effect of uncertainty in study
characteristics of different parts of the evidence chain on the relative effect estimates, and, therefore,
in the economic model, is relatively insignificant.
Treatment effect estimates and inconsistency may be affected by bias. The quality assessment of studies
included in the systematic review (see Chapter 3, Quality of studies included in the review) indicates that
the risk of bias of all of the studies included in the NMA is rated as high. The presence of bias in favour of
the intervention would mean that the effectiveness of the intervention compared with placebo may appear
greater than it should be. In turn, the direction of effect on relative effectiveness derived indirectly is
unclear. The effectiveness results have not been adjusted for bias in this NMA as further research would be
required to estimate the degree of bias.
Network meta-analysis results
The OR results of each intervention compared with placebo are presented in Table 16, including the
effects of different surgical procedures. The full set of results with every pairwise comparison is reported in
Appendix 4. The estimated between-study variances are reported in Appendix 9. The results indicate that
every treatment is effective compared with placebo, but there is considerable uncertainty as to how large
the effect is. The intervention with greatest precision in its effectiveness compared with placebo is BTX.
There was considerable uncertainty in the ORs comparing the interventions with each other. This was
particularly true for the comparisons between different minor surgery procedures which were informed
by longer indirect chains of evidence. For example, the OR of microwave compared with laser was 1.65
(95% CI 0.11 to 25.48).
Placebo response
The baseline probability of response in the model is the probability of response on placebo. The estimate
was derived by conducting a random-effects meta-analysis of the placebo probabilities of response for the
included studies. The meta-analysis was conducted in WinBUGS (1.4; MRC Biostatistics Unit, Cambridge,
UK) using a logit model and transforming the log-odds back to a probability within the model. The mean
was 0.13 and the SD was 0.05. The derived beta distribution was Beta (5.98, 38.4).
TABLE 16 Median ORs and 95% CIs (including different surgical procedures)
Intervention vs. placebo Median 95% CI
Medication 7.211 1.56 to 53.83
BTX 9.207 4.73 to 18.10
Curettage 6.391 1.20 to 27.61
Laser 9.126 0.90 to 84.68
Microwave 14.68 3.74 to 68.99
Fractionated microneedle radiofrequency 12.64 1.32 to 401.80
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Use of the odds ratio of response in the model
The model utilises log-ORs of each intervention compared with placebo, specifically the Convergence
Diagnostic and Output Analysis software output of the 50,000 simulation iterations used to estimate the
results in WinBUGS version 1.4.3 (MRC Biostatistics Unit, Cambridge, UK). A total of 10,000 samples are
then randomly drawn from these iterations across the treatment effects. The exponent is taken of these
samples and converted to a relative risk as follows:
RR =
OR
1 − ACR × (1 − OR)
, (22)
where assumed control risk (ACR) is the baseline risk.
The use of ORs in this way ensures that the probability of response for the intervention remains < 1.
The draw of random samples from the iterations across the treatment effects is important for two reasons.
First, any correlations induced by network loops or shared between study variance data are accounted for.
Second, a full Bayesian random-effects meta-analysis in WinBUGS results in a log-OR distribution that has
excess kurtosis. As the ratio of the between-study variance uncertainty to the within-study effect estimate
uncertainty increases from zero, the excess kurtosis increases from zero. The kurtosis of a standard normal
distribution is 3 with excess kurtosis of 0 (as it is defined in relation to the standard normal distribution).
For example, from the NMA the BTX effect estimate is the most precise, resulting in a high ratio of
uncertainty with an excess kurtosis of 2.92. The medication effect estimate is the least precise, resulting in
a low ratio of uncertainty with an excess kurtosis of 0.45.
Although log-ORs are utilised in the model, the OR estimates are summarised in Table 17 for axillae.
There are no studies providing appropriate evidence for iontophoresis sponge, so in the model the OR is
assumed to be 3.03, equivalent to half the log-OR of BTX compared with placebo. This is because clinical
experts advised that iontophoresis is not as effective as BTX for the axillae.
Treatment response
If the probability of response for placebo is Prp, then the probability of response for intervention i, Pri, with
a relative risk with a placebo comparator, RRrip, is:
Pri = PrpRRrip. (23)
For curettage, which links to placebo via BTX in the network, the probability, Prc, of response is:
Prc = PrpRRrbpRRrcb. (24)
TABLE 17 Effectiveness results utilised in the model
Comparison Median OR 95% CI
Iontophoresis sponge vs. placebo 3.03a Range 1 to 9.2
Medication vs. placebo 7.21 1.56 to 53.83
BTX vs. placebo 9.207 4.73 to 18.10
Curettage vs. BTX 6.391 1.20 to 27.61
ETSb 1
a Mean.
b There are no comparative data for ETS. It is assumed that it is perfectly effective in eliminating hyperhidrosis at the body
site targeted by the intervention, but CS may occur.
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In the model, it is assumed that the placebo response is a sustained response, which is part of the
treatment effect. The difference between a treatment sequence and no treatment includes the placebo
effect.
The mean estimates of the probability of response are reported in Table 18. There is uncertainty in these
estimates, which is accounted for in the analysis, but only the means are presented here to indicate the
levels of response. For aluminium chloride, no response estimate was available for this population so it was
assumed that patients using aluminium chloride would benefit from a 0.5-point reduction on the HDSS
sale (see Effectiveness evidence).
Derivation of different Hyperhidrosis Disease Severity Scale level responses
In Effectiveness evidence, it is explained that utility estimates are available for the different HDSS scores.
The model also assumes that previous treatments would be retried only in patients with a partial response
(a 1-point reduction on the HDSS). The outcome from the clinical studies is at least a 2-point reduction.
In order to incorporate model features related to different levels of HDSS response, the likelihood of a
reduction in the HDSS score of 2 or 3 points given a response of a reduction at least 2 points and
the likelihood of a reduction in HDSS score of 0 or 1 points given no response need to be calculated.
The NMA estimates the average response rate as a binary variable rather than a four-category variable; the
binary response outcome is the most important outcome for the economic model. Furthermore, it is a
simpler modelling process to convert all study outcomes into the same outcome first, incorporating the
uncertainty associated with the conversion, then to conduct the NMA on binary response, before finally
deriving the likelihood of different HDSS levels given response. Little information is lost because there were
no data on individual response levels.
The likelihood of these different degrees of response, given the binary classifications of response or
non-response, will depend on the skewness of the response distribution. There is no information on
skewness for the studies that report binary response data. There is information on skewness for the studies
that report mean HDSS data. For example, the BTX arm in Ibrahim et al.21 has a mean change of 1.55,
which is close to 1.5, and the ratio of the median number of patients with a reduction in HDSS score of
3 points to the median number of patients with a reduction in HDSS score of 2 points is 10 : 2. This is a
much higher ratio than the 11 : 6 for the laser arm in Leclere et al.,24 which has a mean change of 1.88,
which is further from 1.5.
As there is no evidence on skewness for half of the studies, estimates were obtained using simulation
methods. Both the ratio of the number of patients with a reduction in HDSS score of 3 points to the
number of patients with a reduction in HDSS score of 2 points (HDSS 3/2 ratio) and the ratio of the
number of patients with a reduction in HDSS score of 0 points to the number of patients with a reduction
in HDSS score of 1 point (HDSS 0/1 ratio) were estimated by simulating the feasible combination of
numbers across all possible levels of response.
TABLE 18 Mean estimates of the probability of response for each treatment
Intervention Response probability
Placebo 0.13
Medication 0.52
BTX 0.58
Curettage 0.49
Iontophoresis sponge 0.31a
ETS 1
a Based on the mean. All others are based on the median.
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The specific methods and graphic plots of the relationships between the HDSS response ratios and the
probability of response are presented in Appendix 10.
The coefficients on the log-scale are reported in Table 19. Predicted values are compared with the
simulated data in Table 20.
In the economic model, the sampled probability of response is an argument to one of the four linear
regressions. If the HDSS 3/2 ratio is r and the probability of response is Pr, then the probability of a HDSS 2
response is:
P2 =
Pr
1 + r
. (25)
The probability of a HDSS 3 response is:
P3 =
Prr
1 + r
. (26)
The probability of a HDSS 1 response is:
P1 =
(1 − Pr )
1 + r
. (27)
The probability of a HDSS 0 response is:
P0 =
(1 − Pr )r
1 + r
. (28)
The predicted distribution of HDSS response levels, given the mean probabilities of response presented in
Table 18, is presented in Table 21.
TABLE 20 Predicted ratios of numbers with different HDSS reductions compared with the simulated data
Model HDSS ratio
Response rate
0.1 0.2 0.4 0.6 0.8 0.9
Original simulated data 3/2 0.38 0.38 0.38 0.34 0.89 1.78
0/1 1.67 0.90 0.34 0.37 0.38 0.38
Predicted values 3/2 0.38 0.38 0.38 0.32 1.02 1.83
0/1 1.87 1.04 0.32 0.38 0.38 0.38
TABLE 19 The coefficients on the log-scale from the regressions of the HDSS 3/2 and HDSS 0/1 ratios on response
Explanatory variable
Response > 0.5 for HDSS 3/2 ratio Response < 0.5 for HDSS 0/1 ratio
Mean SE Mean SE
Intercept –4.6407 0.3113 1.2076 0.1145
Response probability 5.8278 0.4091 –5.8374 0.4069
SE, standard error.
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Withdrawal due to adverse effects
The probabilities of stopping treatment because of adverse effects were estimated for aluminium chloride
antiperspirants, medications and iontophoresis based on the responses collected from a survey of UK
dermatologists (see Appendix 5). The mean, µ, and SD, σ, of the survey responses were calculated.
A beta distribution can appropriately represent the uncertainty around a probability as a beta distribution
is bounded by 0 and 1. The parameters, α and β, of a beta distribution are calculated from the mean, µ,
and SD, σ, according to the following equations:
α =
µ2(1−µ)
(σ2−1)
. (29)
β =
µ(1−µ)2
(σ2−1)
. (30)
The mean and SD of the responses are reported in Table 22. The associated parameters of a beta
distribution are also presented. The 95% CI is derived through randomly sampling from the derived beta
distributions and taking 2.5th and 97.5th percentiles. Unfortunately, the dropout rate due to adverse
effects was not asked in the survey (see Appendix 5). However, the project clinical experts advised that
there is negligible dropout due to pain, and that this is true with, or without, the aid of a commonly
prescribed anaesthetic gel. As a result, the model assumes 0% dropout due to adverse effects. Some
patients may drop out due to lack of effectiveness after 1–2 months, possibly because of blocking
antibodies. A CEA of BTX compared with ETS based on an observational clinical study recorded 5 out of
77 patients dropped out because of adverse effects over 5 years.230 This represents a withdrawal
probability of 0.065. In order to test the impact on the results of withdrawal from BTX treatment because
of side effects, probabilities of withdrawal of 0.1 probability and 0.2 were included in sensitivity analyses.
A 0.2 probability is considered an extremely high estimate.
TABLE 21 Expected distribution of HDSS response given treatment-specific response rates of at least a two-point
reduction
Intervention Mean response
Reduction in HDSS
HDSS 0 HDSS 1 HDSS 2 HDSS 3
Medication 0.52 0.13 0.35 0.43 0.09
BTX 0.58 0.12 0.3 0.45 0.13
Curettage 0.49 0.08 0.43 0.36 0.13
Iontophoresis 0.31 0.24 0.45 0.22 0.09
TABLE 22 The mean, SD and 95% CI of the probability of stopping treatment due to adverse effects
Intervention Mean SD 95% CI Alpha Beta
Antiperspirants 0.55 0.3422 0.00 to 1.00 0.611 0.505
Medications 0.37 0.2537 0.01 to 0.89 0.962 1.652
Iontophoresis (tap water) 0.16 0.1779 0.00 to 0.63 0.511 2.709
Iontophoresis (glycopyrrolate) 0.25 0.2179 0.00 to 0.77 0.737 2.212
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Long-term effectiveness
It is assumed that if iontophoresis and BTX are effective, then they remain effective in the long term. There
is uncertainty over the long-term effectiveness for medication. Clinical opinion has suggested that there
may be declining effectiveness while following the manufacturer’s dose regime, but there was no evidence
to inform this.
In the base case, it is assumed that there is no decline in effectiveness. In sensitivity analysis, the impact of
different rates of decline in effectiveness on cost-effectiveness were evaluated through applying a monthly
probability of continued success. Figure 15 shows the decline in the proportion of originally successfully
treated patients still on treatment over time, assuming monthly continued success probabilities of 0.9975,
0.995 and 0.99. Probabilities of 0.9975 and 0.99 are used in sensitivity analysis.
Different levels of compensatory sweating following endoscopic
thoracic sympathectomy
Compensatory sweating outcomes following ETS were identified from studies in a rapid review of the
literature for clinical studies of ETS.351 Two studies had particularly useful classifications of CS. The first,
reported in Table 23, was used in the base-case model.16 This includes CS of such a degree that the
patient regrets having had the ETS. The second, reported in Table 24, was used in sensitivity analysis.252
Different utility assumptions associated with CS were made (see Network meta-analysis methods). The
treatment following CS followed the same guideline as that for inadequate treatment response across all
treatments.
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FIGURE 15 Decline in oral medication effectiveness over time.
TABLE 23 Endoscopic thoracic sympathectomy CS event rates by severity16
No CS Mild CS Moderate CS Severe CS Incapacitating/regret CS n
340 394 409 367 190 1700
TABLE 24 Alternative CS event rates252
No CS Mild CS Moderate CS Severe CS n
37 92 174 150 453
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Utility
Utility for different Hyperhidrosis Disease Severity Scale levels
The literature was searched specifically for utility estimates for hyperhidrosis. One study with EQ-5D utility
estimates for levels of HDSS response was identified from an abstract.204,228 No applicable utility values
were identified for other common hyperhidrosis outcomes. Means and SDs were reported for HDSS
responses 2 to 4. No sample sizes were reported. Although these descriptive statistics were not reported in
the PhD thesis on the development of the HidroQoL of Kamudoni et al.,232,261 it is highly likely that the data
originated from the study presented in chapter 8 of the thesis and these descriptive statistics were a
byproduct of that study. The sample sizes from that chapter were utilised.
Beta distributions of rescaled utilities were derived from the means and SDs of the HDSS levels. First, the
mean and SD were rescaled to the 0 to 1 scale from the –0.594 to 1 scale of the EQ-5D utility. Second,
beta distributions were derived from the rescaled mean and SDs. Third, sample means were bootstrapped
from the derived beta distributions, rescaling to the scale –0.594 to 1 for each sample. The bootstrap
technique uses the sample size to calculate the mean at each iteration. The simulated distribution is the
sampling distribution and its SD is the standard error of the mean. Fourth, beta distributions were specified
for these sampling distributions rescaled. The utility estimates and beta distribution parameters of the
rescaled utilities are reported in Table 25.
The sample and sampling distributions are presented in the Appendix 11.
Linking utility to treatment response
On the HDSS, 4 is the worst state and 1 is normal population health. The hypothetical model population is
assumed to be split equally across HDSS levels 4 and 3. The utility data available are for HDSS levels 2–4.
A patient who achieves a reduction in HDSS score of a specific number of points is assumed to have the
utility of the HDSS score that he or she achieves after the improvement. As the hypothetical population is a
mix of patients of HDSS levels 3 and 4, the final HDSS level is an average of two possible HDSS levels
unless a reduction of 3 points on the HDSS is achieved. The utility assumptions for different reductions in
HDSS scores are reported in Table 26.
TABLE 25 Hyperhidrosis Disease Severity Scale level utility estimates and beta distribution parameters of
rescaled utilities
EQ-5D distribution parameter HDSS 2 (n= 36) HDSS 3 (n= 69) HDSS 4 (n= 58)
EQ-5D mean (SD) of sample distribution 0.85 (0.13) 0.8 (0.15) 0.69 (0.2)
Beta parameters of sampling distribution α= 416.6, β= 43.3 α= 391, β = 55.8 α = 276.2, β = 67
TABLE 26 Utility assumptions for different HDSS point reductions
HDSS score reduction (points) Utility
3 HDSS level 1 (normal population health)
2 (HDSS 1+ HDSS 2)/2
1 (HDSS 2+ HDSS 3)/2
0 (HDSS 3+ HDSS 4)/2
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Utility for compensatory sweating, treatment failure and aluminium chloride
The different degrees of CS were reported in Different levels of compensatory sweating following
endoscopic thoracic sympathectomy. The HDSS response rates assumed for the different degrees of CS are
reported in Table 27. For mild CS, response was assumed to be a reduction in HDSS score of 1.5 points.
For moderate CS, response was assumed to be a reduction in HDSS score of 1 point. For severe CS,
response was assumed to be a reduction in HDSS score of 0 points, that is, no change. For the regret CS
outcome, the 16th percentile was identified from the sample distribution of the HDSS 4 level. This 16th
percentile corresponds to 1 SD from the mean for a normal distribution. However, a beta distribution is
used here. The 16th percentile corresponds to a utility of 0.49. Sensitivity analyses were conducted using
the 25th percentile (0.57 utility) and the 2.5th percentile (0.21 utility).
Having failed to achieve adequate response to all available treatments, treatments are retried if they have
resulted in a partial response and no adverse events sufficiently serious to cause the patient to withdraw
from treatment. A proportion of the patients in this treatment failure state who revert to previously tried
treatments are allocated utility gain associated with a reduction in the HDSS score of 1 point.
As no treatment response estimate was available for aluminium chloride for this population, it was
assumed that patients using aluminium chloride antiperspirants benefited from a 0.5-point reduction in the
HDSS score.
Resource use and unit costs
Health service costs
As stated in Overview, the analysis was undertaken from a NHS and PSS perspective. Costs relevant to the
NHS and PSS were identified for the analysis. Information on the precise description of resources required
for each individual treatment was partially based on data derived from the review, augmented when
necessary by clinical experts in the study group and published economic literature. Unit costs were taken
from appropriate routine sources, such as NHS Reference Costs 2014 to 2015,344 Unit Costs of Health and
Social Care 2015345 and the most recent British National Formulary346 for medication. The price year of the
analysis was 2014/15. British National Formulary prices for 2015 were not available, so prices obtained
from the British National Formulary 2016 were used. In addition, medical inflation indices beyond 2014/15
in the UK were unavailable.
Drug acquisition costs
The unit costs of aluminium chloride and medications were sourced from the British National Formulary.346
Doses were calculated in accordance with their licences, unless otherwise stated. Medication costs included
in the model were for propantheline bromide, based on expert clinical input. However, because multiple
medications are available, alternative medication costs were explored in sensitivity analyses. Table 28
summarises the drug acquisition costs and the licensed dosage for hyperhidrosis patients.
TABLE 27 Assumed HDSS response for different degrees of CS severity
Severity of CS Assumed HDSS response
Mild 1.5-point reduction
Moderate 1-point reduction
Severe 0-point reduction
Regret 16th percentile from the sample distribution of the HDSS 4 level
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Botulinum toxin procedure costs
The unit cost of a BTX procedure was based on the equivalent NHS reference cost (Healthcare Resource
Group code JC42A, Intermediate Skin Procedures, 13 years and over, General Surgery category).344 To
support inclusion of this NHS reference cost, an additional cost of £170.45 for a BTX procedure was
estimated based on the British National Formulary cost of 100 units of BTX and the cost of a nurse grade 5
delivering the procedure (as advised by clinical experts). Both the NHS reference cost and the estimated
cost for BTX are presented in Tables 29 and 30. It is assumed that BTX injections are given every 6 months.
This is because the clinical evidence suggests that the effectiveness of BTX may be sustained over a
6-month period.
Iontophoresis procedure cost
The total cost of iontophoresis for the axillae included the cost of the iontophoresis device and the costs of
associated electrodes and sponge pockets. Based on clinical advice, different types of iontophoresis device
are used depending on whether the procedure is carried out in a clinical or home setting. The unit costs of
iontophoresis devices for hospital and home use, as well as the costs of electrodes and sponge pockets,
are summarised in Table 31.
TABLE 28 Drug acquisition costs
Medication Dose Cost (£) Source
Aluminium chloride (Driclor 20% solution 75ml,
GlaxoSmithKline Consumer Healthcare)
One bottle
per montha
3.01 BNF, November 2016346
Propantheline bromide (Pro-Banthine
15mg × 84 tablets, Kyowa Kirin Ltd)
75 mg daily 20.74 BNF, November 2016346
Oxybutynin (Ditropan 2.5 mg × 84 tablets,
Sanofi-aventis)
12.5 mg daily 1.60 BNF, November 2016346
Glycopyrronium bromide 2mg × 30 tablets 2 mg dailyb 186.50 Significant Cost Changes – April 2016.
NHS, Midlands and Lancashire
Commissioning Support Unit352
BNF, British National Formulary.
a Source: clinical input.
b Source: Walling and Swick.353
TABLE 29 Botulinum toxin procedure cost based on NHS reference costs
Procedure Cost (£) Source
BTX 156 HRG code JC42A, Intermediate Skin Procedures, 13 years and over, General Surgery category
(NHS Reference Costs 2014 to 2015344)
HRG, Healthcare Resource Group.
TABLE 30 Cost components of the estimated cost of BTX procedure
Cost component Cost (£) Source
BTX 100-unit powder for solution for injection vials (Allergan Ltd) 138.20 BNF, November 2016346
Cost of delivery: 45 minutesa × hourly rate of nurse grade 5 32.25 Curtis and Burns, 2015345
Total cost (£) 170.45
BNF, British National Formulary.
a Source: clinical input.
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The monthly costs of iontophoresis at home and at hospital were estimated and are reported in Table 32. The
cost of hospital iontophoresis was derived by summing the discounted monthly machine running cost, the
cost of associated consumables and the cost of delivery and device maintenance. The main assumptions
underlying this cost estimate are that the device is used by 10 patients per month, that the device lasts for
15 years and that in the NHS the treatment is delivered in seven sessions over a 1-month period. It was also
assumed that sponge pockets are changed annually and that electrodes last for 15 years. It was assumed that
the procedure takes 20 minutes (plus 10 minutes cleaning time) and is delivered by a nurse (band 5) (based
on expert clinical advice).
The monthly cost of home iontophoresis includes the machine running costs and the cost of associated
consumables, as the procedure is self-administered. All assumptions for deriving costs were based on clinical
advice and are summarised in Table 32. In the base case, it is assumed that the patient has to pay for a
home iontophoresis device. In a scenario analysis, it is assumed that the NHS pays for home iontophoresis.
The effect of the cost to the patient on the uptake of iontophoresis is unclear. In both the base-case analysis
and the scenario analysis, it is assumed that a patient who responds to iontophoresis continues to use it.
Surgery costs
Surgery for hyperhidrosis varies from minimally to fully invasive. The unit costs of minimally and fully
invasive operations are reported in Tables 33 and 34, respectively. Curettage and fractionated microneedle
radiofrequency costs were obtained from NHS Reference Costs 2014 to 2015.344 For curettage, an estimate
based on clinical advice was also calculated in order to support the relatively generic NHS reference cost.
It was derived by summing the cost of utilising a surgical theatre at a dermatology unit for the duration of
the procedure, the cost of nurse and anaesthesiologist time to deliver the procedure and also the cost of
one overnight stay in hospital. The total estimated cost of curettage of £1460.25 was similar to the NHS
reference cost of £1126.10.
For laser, microwave and ultrasound, no appropriate NHS reference costs were identified; hence, the prices
for these procedures were obtained from UK private health-care providers.
The cost of ETS is reported in Table 34. According to clinical advice, owing to the risk of pneumothorax
(collapse of lung), ETS is a unilateral procedure; hence patients will need two procedures.
Consultancy visits
Medication, BTX and iontophoresis are all associated with an initial consultation with a dermatologist,
which is assumed to last 20 minutes. The associated resource use cost is £45 per visit. In the case of BTX
and iontophoresis, it was assumed that no follow-up visits are required. It was assumed that, the treatment
is unsuccessful, then the patient has another consultation with a dermatologist, which is considered to be
the initial consultation for the next treatment. For aluminium chloride, follow-up visits were assumed to
take place every 6, and for medication follow-up visits were assumed to take place every 3 months.
TABLE 31 Iontophoresis device types and unit costs
Setting Type of device
Device
cost (£)
Cost of electrodes
(for sponge) (£)
Cost of one pair of
sponge pockets (£) Source
Hospital Idrostar Pro pulse (Laboratories I2M,
Caen, France)
1290 47.23 1.98 Idrostar354
Home Idrostar+ (Laboratories I2M, Caen,
France)
504 47.23 1.98 Idrostar354
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Minor invasive surgery was assumed to involve one visit before surgery and one visit after, both lasting
15 minutes and led by a surgeon. For ETS, two visits before treatment and one visit after were assumed.
The associated resource use of both initial and follow-up visits is £34.50 per visit. All of these assumptions
were based on clinical advice. Details of, and unit costs for, initial consultations and follow-up visits for all
treatments are summarised in Tables 35 and 36.
Adverse effects
Compensatory sweating
The cost of experiencing CS following curettage and ETS depends on the cost of the treatments used to
treat it. These treatments depend on the treatment sequence. The proportion of patients trying each
treatment is described in The frequency of treatment use after treatment failure.
TABLE 33 Costs of minimally invasive surgery
Minimally invasive
surgery Cost (£) Source
Curettage 1126.10 HRG code JC42A, Intermediate Skin Procedures, 13 years and over,
General Surgery category (NHS Reference Costs 2014 to 2015344)
Fractionated microneedle
radiofrequency (outpatient)
591 NHS reference costs (AB157, Fractionated microneedle radiofrequency
Ablation or Cryoablation for Pain Management) Outpatient, Service
description: General Surgery (NHS Reference Costs 2014 to 2015344)
Fractionated microneedle
radiofrequency (inpatient)
1169.70 NHS reference costs (AB157, Fractionated microneedle radiofrequency
Ablation or Cryoablation for Pain Management) Inpatient (NHS
Reference Costs 2014 to 2015344)
Laser 3768 The Whiteley Clinic355
Microwave 1495 PHI Clinic356
Ultrasound 2749.41a Commons and Lim182
a The cost was converted from dollars and inflated to 2015 price level.
TABLE 34 Unit cost of a fully invasive surgery
Fully invasive surgery Cost (£) Source
ETS 2823.66 NHS Reference Costs 2014 to 2015 (YQ407, ETS)344
TABLE 35 Details and unit costs of initial consultations
Type of treatment Duration (minutes) Job title of health professional Unit cost (£)a
Medication 20 Consultant dermatologist 45.21
BTX 20 Consultant dermatologist 45.21
Iontophoresis 20 Consultant dermatologist 45.21
Minor invasive surgery 15 Consultant surgeon 34.50
ETS (two consultations) 15 × 2 Consultant surgeon 69.00
a The unit costs were calculated based on hourly rates for health professionals delivering the visits, obtained from Curtis
and Burns.345
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Wound infections
Based on clinical advice, it was assumed that 0.1% of patients receiving ETS will experience a wound
infection in month 1. A cost of £0.07 (based on 0.1% of the cost of ETS in month 1 prior to accounting
for adverse events) was added to this state to account for the probability of experiencing an adverse event.
Model state costs
Resource use associated with individual treatments, associated consultation costs and the probability of
experiencing adverse events for specific treatments were combined to estimate monthly costs for each
state included in the base-case model. Monthly costs are outlined in Table 37. The states correspond to
the states presented in Table 9.
Incremental cost-effectiveness analysis, and scenario and sensitivity
analyses
Incremental cost-effectiveness analysis
Incremental CEA was conducted involving the following steps:
1. Estimate the total costs and QALYs for each treatment sequence.
2. Calculate the difference in cost and QALYs for each sequence compared with the sequence with the
next highest cost.
3. Eliminate treatments/sequences where the incremental cost is positive and the incremental QALYs is
negative; these interventions/sequences are said to be dominated (repeat steps 2 and 3 until no more
are eliminated).
4. Calculate the ratio of incremental cost to incremental QALYs: this is the incremental cost-effectiveness
ratio (ICER).
5. Eliminate treatments/sequences when the ICER is higher than the ICERs of treatments/sequences with
higher costs; these interventions are said to be dominated by extension (repeat steps 4 and 5 until no
more are eliminated).
The incremental CEA was calculated for both deterministic and probabilistic analyses. A deterministic
analysis calculates the result using point estimates for all of the parameters in the model. A probabilistic
analysis is described later in Scenario and sensitivity analyses.
Scenario and sensitivity analyses
The base-case model included the following assumptions:
l The OR of response for iontophoresis sponge compared with placebo is 3.03 (half the OR of BTX
vs. placebo).
l There is no decline in medication effectiveness.
TABLE 36 Details and unit costs of follow-up visits
Type of treatment
Frequency of
follow-up visits
Duration
(minutes) Job title of health professional Unit cost (£)a
Aluminium chloride 6 monthly 15 Consultant dermatologist 34.25
Medication 3 monthly 15 Consultant dermatologist 34.25
Minor invasive surgery Single 15 Consultant surgeon 34.50
ETS Single 15 Consultant surgeon 34.50
a The unit costs were calculated based on hourly rates for health professionals delivering the visits, obtained from Curtis
and Burns.345
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l The cost of medication is the cost of propantheline bromide.
l Patients pay for the iontophoresis sponge home device if successful.
l BTX injections are given every 6 months and their effectiveness is sustained over 6 months.
l No patients withdraw from BTX treatment because of adverse effects.
l Only people who experienced no benefit from any of the previous non-surgical treatments take up the
option of a surgical treatment.
l Only people who experience no benefit from curettage go on to have ETS.
l Patients retry medication, then iontophoresis sponge, then aluminium chloride, in the event of
treatment failure if the treatments were in the strategy.
l Patients remain on the treatment that worked best for them for the remainder of the time that they
have hyperhidrosis.
A large number of the base-case model assumptions were varied in sensitivity analyses.
TABLE 37 Model states and associated costs
Model state Monthly cost (£)
Aluminium chloride (A) 8.72
Iontophoresis sponge (IS) 198.64
Iontophoresis sponge responder (ISR) 0.00
Medication month 1 (M1) 73.34
Medication month 2 (M2) 28.13
Medication month 3 (M3) 28.13
Medication responder (MR) 39.55
BTX month 1 (B1) 201.21
BTX 2 (B2) 0.00
BTX 3 (B3) 0.00
BTX 4 (B4) 0.00
BTX 5 (B5) 0.00
BTX 6 (B6) 0.00
BTX subsequent injections (BS) 156.00
Curettage (C) 1194.62
Curettage responder (CR) 0.00
ETS (E) 5750.89
ETS responder (ER) 0.00
ETS low CS (ELCS) 39.55
ETS moderate CS (EMCS) 39.55
ETS high CS (EHCS) 39.55
ETS regretful CS (ERCS) 39.55
Treatment failure (TF) Based on methods described in Summary of model data
Dead (D) 0.00
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Deterministic sensitivity analysis
One-way, two-way and multiway sensitivity analyses were performed to determine the impact of changing
key parameters on the model results. Sensitivity analyses were also carried out to test for the effect of
assumptions and variability. Although deterministic sensitivity analyses do not precisely estimate the
expected mean outcomes of a non-linear model, these were conducted initially in order to identify the
parameter and assumption changes that had a significant effect on the results. Probabilistic sensitivity
analyses (PSAs) were then conducted to evaluate scenarios of parameters and assumptions that had a
particularly important effect on the results.
Scenario and sensitivity analyses have been introduced throughout this section. These are summarised here
and listed in Box 1. For the iontophoresis sponge, threshold analysis was done around the response rate of
iontophoresis sponge as there is no evidence of the effectiveness of iontophoresis. Current practice is for
BOX 1 Scenario and sensitivity analyses
Scenario/sensitivity analysis
Iontophoresis sponge
1. Threshold analysis for the response rate of iontophoresis sponge.
2. Assume the NHS pays for the use of an iontophoresis device at home.
Medication
3. Glycopyrronium bromide medication cost.
4. Average cost of glycopyrronium bromide and propantheline bromide.
5. Moderate and considerable decline in medication effectiveness.
6. Use of medication only before important occasions (emergency use).
BTX
7. Increase the probability of withdrawal from BTX treatment due to adverse effects from 0 to 0.2.
8. Assume that BTX injections are given annually without any decline in effectiveness over the year.
Aluminium chloride
9. Increase the probability of withdrawal from aluminium chloride from 0.55 to 0.9.
CS
10. Change the distribution of severity of CS from that in Smidfelt and Drott16 to that of Wolosker et al.252
11. Reduce the utility of people who regret having ETS due to severe CS from 0.49 to 0.21.
Utility
12. Halve the utility gained from an improvement (reduction) in the HDSS score of 1 point.
Progression to minor surgery
13. All non-responders to non-surgical treatments move on to minor surgery.
Treatment failure
14. The order in which patients retry treatments after inadequate response to treatments is changed from
medication/iontophoresis/BTX/aluminium chloride to iontophoresis/BTX/medication/aluminium chloride.
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the NHS to provide a 1-month free trial of iontophoresis and then patients have to pay for a home
iontophoresis device if they want to continue to use it. As the analysis is undertaken from a NHS and PSS
perspective, the costs incurred by the patients paying for an iontophoresis device are not included in the
analysis. A sensitivity analysis assuming that the NHS pays for iontophoresis home devices that patients can
borrow free of charge was conducted.
The base-case analysis assumes that the medication is propantheline bromide. Although a class effect is
assumed for the effectiveness of medication (the two clinical studies investigated methantheline bromide
and topical glycopyrrolate wipes), the cost of propantheline was used. Scenario analyses used the cost of
glycopyrronium bromide or an average of the cost of glycopyrronium bromide and propantheline bromide
instead. No cost of glycopyrronium wipes was identified. As a clinical expert advised that medication could
be restricted to use only before particularly important occasions (emergency use), a scenario analysis was
conducted in which tablets were taken only four times a week with quality-of-life benefit reduced on a pro
rata basis (although that may not be the case). There is no evidence for the long-term effectiveness of
medication, so monthly probabilities of continued success of 0.9975 and 0.99 were used in sensitivity analysis.
The base case assumes that the probability of withdrawal due to adverse effects from BTX is zero.
Probabilities of 0.1 and 0.2 were used in a sensitivity analysis. There is very little evidence of withdrawal
from BTX treatment because of adverse effects, and 0.2 is considered a high value. In the base case, BTX
injections were given every 6 months. This was changed to annual injections, while assuming that there
was no decline in effectiveness. The probability of withdrawal because of adverse effects was increased
from 0.55 to 0.90 in another sensitivity analysis.
An alternative distribution of CS outcomes that represented a less severe outcome was evaluated. A more
severe outcome was evaluated using a lower utility value for regretting ETS. In a separate sensitivity
analysis, the utility gain for an improvement (reduction) in the HDSS score of 1 point was halved as a
conservative estimate of the benefit of a small (1-point) response to treatment. The original utility for
a 1-point gain improvement in HDSS was 0.825. The new, more conservative, utility was 0.8.
In the base case, only patients who experience no benefit at all from any of the non-surgical treatments
go on to have a surgical intervention. In a scenario analysis, patients who were non-responders (less than a
2-point reduction in HDSS) but had a partial response (a 1-point reduction in HDSS) also went on to have
a surgical intervention if there was one in the sequence. In another sensitivity analysis the order in which
patients retried previous non-surgical treatments was changed from medication/iontophoresis/BTX/aluminium
chloride to iontophoresis/BTX/medication/aluminium chloride to test if the order had a significant effect.
Probabilistic sensitivity analysis
When available, data were entered into the model as distributions in order to fully incorporate the
uncertainty around model parameters so that a PSA could be undertaken. In decision modelling, many of
the parameter values are often estimated with a degree of uncertainty. There is a need to propagate the
joint parameter uncertainty in terms of decision uncertainty; to achieve this, distributions are assigned to
input parameter values. Relevant distributions were informed by the systematic review, additional literature
and expert opinion. The PSA was run with 3000 simulations. Estimation of costs and QALYs were
calculated as the expectation over the joint distribution of the parameters. An incremental CEA was
conducted based on the estimated costs and QALYs as described in Health service costs.
The probability of the treatment sequence with the highest net benefit being cost-effective across a range
of willingness-to-pay (WTP) threshold values was estimated and presented through a cost-effectiveness
frontier. First, the net benefit for each intervention was calculated, where:
Net benefit = threshold e.g.
£20,000
QALY
 
× QALYs − Cost (£). (31)
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The proportion of the simulations in which the treatment sequence has the highest net benefit represents
the probability (p) that the treatment sequence is the most cost-effective. 1 – p is the error probability, the
probability that one of the other treatment sequences is in fact the most cost-effective. This can be calculated
at different thresholds.
This quantification of decision uncertainty also provided the starting point for assessing the value of
additional research.
Value-of-information analysis
In addition to assessing the relative effectiveness and cost-effectiveness of the alternative treatment
options, the economic model was used to quantify the main uncertainties facing decision-makers and to
help inform decisions about the direction of future research. Within the economic component of this
study, this was explored using variants of VOI analysis: EVPI and expected value of partial perfect
information (EVPPI).
Value-of-information analysis can quantify the expected gain in net benefit from obtaining further
information to inform a decision. A decision based on existing information will be uncertain and so may
turn out to be incorrect if more information becomes available in the future. If the decision turns out to be
incorrect, then there will be a cost in terms of lost health benefit and wasted resources. Quantifying the
value of an incorrect decision, alongside the probability of making an incorrect decision, allows us to
estimate EVPI. If the EVPI for a decision problem exceeds the cost of future research, additional
investigation may be worthwhile.
As well as determining EVPI around the decision as a whole, VOI approaches can also be used for
particular elements of the decision with the purpose of focusing research in areas where the elimination of
uncertainty might have the most value. EVPPI analysis can be used to estimate the expected value of
removing uncertainty surrounding specific parameters or groups of parameters to identify where future
research should focus on identifying more precise and reliable estimates of specific pieces of information
(e.g. relative effectiveness, costs or utilities). EVPI places an upper value on conducting further research
overall, whereas EVPPI places an upper value on conducting further research on a specific area of information.
Therefore, if the EVPI or EVPPI exceeds the expected costs of that additional research, then it is potentially
cost-effective to acquire more information by undertaking this research. However, although this additional
investigation may be worthwhile, calculation of the expected net gain of sample information (expected value
of sample information – cost of sampling) would ultimately be required to confirm this. The expected value of
sample information is computationally demanding and was not undertaken.
Population EVPI was calculated by multiplying the individual EVPI by the expected future population to
benefit from the interventions:
Population EVPI = EVPI ×∑
t
It /
(1 + r)
t . (32)
No reliable estimates for the prevalence of primary hyperhidrosis and primary hyperhidrosis of the axilla in
the UK were identified.3–6 The Hyperhidrosis Support Group website quotes a prevalence of 1%, but no
reference is provided. The largest survey of hyperhidrosis prevalence identified was conducted in the USA.226
As hyperhidrosis is a chronic condition, it was assumed that the annual incidence was an average of the
number of people with primary hyperdrosis for each 1-year age group in the age range 18–65 years. The
estimated percentage of axillary hyperhidrosis among the US population aged 18–65 years was 2.1%.
When adjusted for the entire population, resulting prevalence would be < 2.1%. The HSSS scores of the
model population are assumed to be equally split between 3 and 4. The same study reported that 32.4% of
patients with hyperhidrosis has a HDSS score of 3 or 4 points. The percentage of the population aged
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18–65 years that has axillary hyperhidrosis and a HDSS score of 3 or 4 points was therefore calculated to be
0.67%. The annual incidence (5275) was therefore calculated to be the average population for each
1-year age group across the age range 18–64 years within England and Wales, multiplied by 0.0067.
Using the England and Wales population statistics from the Office for National Statistics,343 a discount rate
of 3.5% and a 10-year useful life of the current interventions before a significant change in the treatment
options, the applicable population was estimated to be 49,122 using the summation expression in
Equation 32. This was multiplied by the EVPI estimates to obtain the population EVPI estimates.
For the EVPI, sensitivity analysis was performed around the incidence rate, varying the rate over the
following values: 2%, 1.5%, 1%, 0.5% and 0.1%.
The EVPPI for specific parameters were calculated for eight different scenarios. It was assumed the NHS
pays for home iontophoresis and the iontophoresis device has a life expectancy of 10 years. It is calculated
assuming an OR of iontophoresis compared with placebo of 3.03 and of 1. Furthermore, it is calculated for
the £20,000 and £30,000 cost-effectiveness thresholds and at a 2% axillary hyperhidrosis incidence and a
0.5% incidence.
The base-case model was structured with OR parameters for each treatment compared with placebo. In
order to conduct EVPPI analysis on BTX compared with medication, and curettage compared with BTX,
the model was recoded with the placebo-controlled OR replaced by an OR for the comparison of interest,
and also for any other effectiveness parameter in the same indirect chain of evidence connected to
placebo.
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Chapter 7 Cost-effectiveness, expected value of
perfect information and expected value of partial
perfect information results
As stated in Chapter 6, given limited evidence for treatment effectiveness for different body sites,CEA and VOI analysis were limited to axillary hyperhidrosis. Sixty-four different treatment sequences were
compared. The interventions included in the different sequences were iontophoresis sponge, medication,
BTX, curettage, ETS and aluminium chloride antiperspirants. Aluminium chloride antiperspirants represent
no secondary care treatment. In the base-case analysis, the medication was assumed to be propantheline
bromide. Treatment sequences are represented by abbreviations where each letter represents the first letter
of each treatment: iontophoresis (I), medication (M), BTX (B), curettage (C), ETS (E), aluminium chloride
antiperspirants (A). For example, the treatment sequence MBICE represents the following order in which
treatments would be offered by the NHS: medication, BTX, iontophoresis, curettage, ETS.
Base-case results
This section presents the results of the base-case CEA for the probabilistic model. The key assumptions of
the base-case model are presented in Chapter 6, Model state costs. The analyses set out to investigate the
value of further research in hyperhidrosis related to different body sites and different interventions. For the
axillae body site, sufficient evidence was identified to model iontophoresis, medication, BTX, curettage and
ETS in sequences. No other body sites were modelled.
Axilla probabilistic model
The probabilistic analysis, net benefit and cost-effectiveness acceptability frontier were calculated as
described in Chapter 6, Scenario and sensitivity analyses.
The total costs and QALYs for each of the 64 treatment sequences are reported in Appendix 5. The
base-case results for the probabilistic model shown in Table 38 indicate that the treatment sequence of I
is the least expensive, with a mean cost of £900. Compared with I, the sequence of ICE has an ICER of
£253. Although more expensive, the treatment sequence of IBMCE produces a higher QALY gain than ICE
and has an ICER of £9304, below the NICE threshold of £20,000–30,000 per QALY gained. Although
more costly than their rspective previous treatment sequences, the strategies of BMICE and MBICE also
produce higher QALY gains than their comparators. However, the incremental QALY gains are so small
that the ICERs for both strategies exceed the NICE threshold by a considerable margin. All other treatment
strategies were either dominated or extendedly dominated.
TABLE 38 Base-case CEA
Strategy Mean cost (£) Cost difference (£) Mean QALYs QALY difference ICER (cost per QALY) (£)
I 900 – 18.47 – –
ICE 1121 220 19.30 0.829 253
IBMCE 6091 4970 19.84 0.542 9304
BMICE 7468 1377 19.85 0.009 137,046
MBICE 8195 726 19.85 0.001 1,407,569
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The probability that the treatment sequence with the highest net benefit is cost-effective across a
range of WTP threshold values is presented in the cost-effectiveness acceptability frontier in Figure 16.
ICE is the most cost-effective treatment up to a threshold of £9304, and IBMCE is the most cost-effective
sequence when the threshold is between £10,000 and £50,000. The error probability that IBMCE is most
cost-effective at NICE cost-effectiveness thresholds of £20,000 and £30,000 is around 0.2. The error
probability is the probability that one of the treatments not identified as the most cost-effective is in fact
the most cost-effective. When the pairwise net benefit of the most cost-effective sequence compared with
every other sequence is calculated, then the comparator that has the highest probability of being the
most cost-effective is the sequence IMBCE. This reflects the considerable uncertainty in the estimate of
effectiveness for medication compared with placebo.
Scenario and sensitivity analysis results
Axilla deterministic model
Fourteen deterministic scenario/sensitivity analyses were undertaken in order to establish which parameters
had a significant impact on the results. The PSAs that follow evaluate scenarios with the parameters that
had the most impact. In each scenario, a key model parameter/assumption was varied with all other
parameters fixed at base-case values. A number of these analyses had no significant impact on the
base-case results. Each scenario is presented in turn, with either a statement of no significant impact
or a short summary of the impact that the analysis had on the base-case results.
Scenario 1
No evidence was identified on the relative effectiveness of iontophoresis sponge. In the base case, the
response rate of iontophoresis sponge was assumed to be 0.31, compared with a placebo response rate
of 0.13 used in the model (this corresponds to a relative risk of 2.4 and an OR of 3.03 of iontophoresis
sponge vs. placebo), half that of BTX compared with placebo. The response rate of iontophoresis sponge
was reduced in a threshold analysis to identify how ineffective iontophoresis needs to be to significantly
change the results. Reducing the iontophoresis response rate from 0.10 to 0.07 resulted in BMICE
becoming most cost-effective. At a response rate of 0.07, the most cost-effective treatment was BMICE,
with an ICER of £13,058. A response rate of 0.07 is less than the response rate for the placebo effect of
medication and BTX, and so the threshold for changing the decision is low.
Scenario 2
Scenario 2 assumed that the NHS pays for the use of the iontophoresis device at home. As the analysis is
undertaken from a NHS and PSS perspective, in the base case the costs incurred by the patients paying for
an iontophoresis device are not included in the analysis. This analysis had no significant impact on the ICER
results. The most cost-effective remained IBMCE, with an ICER of £9253.
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Scenarios 3 and 4
The base-case analysis assumes that propantheline bromide is the first choice of oral medication and the
cost of propantheline bromide is used in the model. When the cost of glycopyrronium bromide (£283.29
per month) is used instead of the cost of propantheline bromide (£28.13 per month), then IBCE becomes
the most cost-effective sequence, rather than IBMCE. The result is the same when the average cost of
propantheline bromide and glycopyrronium bromide was used. No cost of topical glycopyrrolate wipes was
identified. The cost of 500 ml of 0.05% glycopyrrolate solution was £325.04.357 It is likely that the monthly
cost of using this solution would be somewhere between the monthly cost of propantheline bromide and
that of glycopyrronium bromide. Using the cost of glycopyrronium bromide, the most cost-effective
sequence was IBCE, with an ICER of £10,742.
Scenario 5
When it was assumed that there is a considerable decline in medication effectiveness over time, IBCE
became the most cost-effective sequence at a threshold of £20,000, with an ICER of £10,742. At a
threshold of £30,000, the most cost-effective sequence was IBMCE with an ICER of £26,518. A moderate
decline in effectiveness did not have a significant effect.
Scenario 6
A clinical expert advised that oral medication may be taken sparingly in order to sustain long-term
effectiveness. To model this scenario, the daily medication dose was reduced from the manufacturer’s
recommendation to only four tablets a week to be taken at the most appropriate times. Cost and utility
were reduced on a pro rata basis. In this scenario analysis, IBCE again became the most cost-effective
sequence, with an ICER of £10,742. The relationship between utility and dose may not be linear, but is
unknown. This means that this scenario potentially underestimates the cost-effectiveness of medication as
the patients may get more benefit from the few occasions of medication use than assumed in this
scenario.
Scenario 7
Scenario 7 showed an increase in the probability of withdrawal from BTX treatment because of adverse
effects from 0 to 0.2. This analysis had no significant impact on the results. The most cost-effective
scenario remained IBMCE, with an ICER of £11,381.
Scenario 8
Giving botulinum toxin injections given annually, rather than every 6 months, had no significant impact on
the results. The most cost-effective secnario remained IBMCE, with an ICER of £11,978.
Scenario 9
Increasing in the probability of withdrawal from aluminium chloride treatment from 0.55 to 0.9 had no
significant impact on the results. The most cost-effective scenario remained IBMCE, with an ICER of
£10,242.
Scenario 10
Changing the distribution of severity of CS from that of Smidfelt and Drott16 to that of Wolosker et al.252
had no significant impact on the results. The most cost-effective scenario remained IBMCE, with an ICER of
£10,324.
Scenario 11
Reducing the utility of people who regret having ETS due to severe CS from 0.49 to 0.21 had no
significant impact on the results. The most cost-effective scenario remained IBMCE, with an ICER of £9745.
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Scenario 12
The utility gained from an improvement in one point on the HDSS score was halved. The original utility
for a 1-point improvement was 0.825. The new more conservative utility was 0.8. This analysis had no
significant impact on the results. The most cost-effective scenario remained IBMCE, with an ICER of £7318.
Scenario 13
The base-case model assumes that only people who receive no benefit at all from any of the previous
treatments move on to minor surgery if minor surgery is an option in the treatment sequence. In a scenario
analysis, it was assumed that all patients who did not respond to any of the previous non-surgical
treatments in the sequence moved on to minor surgery. In this scenario, ICE was the most cost-effective
treatment sequence, with an ICER of £330. This reflects the cost-effectiveness of the surgical interventions.
In this scenario, more patients have surgery, and, as curettage is more cost-effective than medication and
BTX given the assumptions made, curettage takes precedence over medication and BTX in the sequence.
Based on clinical expert advice, the model assumes that surgery is offered only after non-surgical
interventions available in the sequence, medication and BTX, are absent entirely from the optimal
sequence.
Scenario 14
The order in which patients retry treatments after inadequate response to treatments was changed from
MIBA to IBMA. This had no significant impact on the results. The most cost-effective scenario remained
IBMCE, with an ICER of £5720.
Table 39 presents the optimal treatment sequence and ICER results of those one-way sensitivity scenarios
in which the treatment decision changed as a result of the alternative assumption/data. Given a WTP
threshold of £30,000 per QALY, the most cost-effective option for each of the seven scenarios is
presented.
Two-way and multiway sensitivity analyses were also undertaken to assess the impact of changing more
than one key variable at the same time. Table 40 presents the results of the two-way and multiway
sensitivity analyses of key model parameters. Given a WTP threshold of £30,000 per QALY, the most
cost-effective option is presented following each analysis. When a NHS subsidy for using an iontophoresis
sponge at home was included, along with an adjusted response rate for iontophoresis sponge of 0.07,
the optimal strategy was BMICE. This held true when the duration of an iontophoresis was reduced to
10 years and this variation was combined with the NHS subsidy and adjusted relative risk.
TABLE 39 Results of scenario analyses
Analysis
Optimal
decision ICER (£)
Base case IBMCE 10,122
Scenario Analyses
Scenario 1 Response rate of 0.07 for iontophoresis sponge BMICE 13,058
Scenario 3 Glycopyrronium bromide medication cost IBCE 10,742
Scenario 4 Average cost of glycopyrronium bromide and propantheline bromide IBCE 10,742
Scenario 5 Considerable decline in medication effectiveness IBMCE; IBCEa 26,518; 10,742a
Scenario 6 Medication utility and cost reduced to emergency medication use only IBCE 10,742
Scenario 13 All non-responders to non-surgical treatments move on to minor surgery ICE 330
a IBCE optimal treatment at £20,000 threshold; IBMCE optimal treatment at £30,000 threshold.
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Axilla probabilistic model
Finally, PSAs were undertaken to further explore the parameters that appeared to have the potential to
have an impact on the overall treatment sequence decision. The parameters explored were the cost of
using iontophoresis sponge at home (a NHS subsidy vs. no subsidy), the durability of an iontophoresis
device (10 years instead of 15 years), the relative risk of iontophoresis sponge compared with placebo
(1 instead of 2.4 with a placebo response of 0.13) and the decline in effectiveness of medication over time
(from none to considerable decline; see Chapter 6, Long-term effectiveness). The four scenarios are as
follows.
1. A NHS subsidy of iontophoresis at home and a 10-year durability of an iontophoresis device
are assumed.
2. A relative risk of 1 for iontophoresis sponge compared with placebo is assumed.
3. A NHS subsidy of iontophoresis at home, a 10-year durability of an iontophoresis device and a relative
risk of 1 for iontophoresis sponge compared with placebo are assumed.
4. A considerable decline in the effectiveness of medication over time is assumed.
For scenarios 1–3, IBMCE remained the most cost-effective treatment sequence at the conventional
thresholds. The ICER ranged from £8352 to £10,210. The error probability for IBMCE in scenario 1 was
0.2, and this increased to 0.35 and 0.42 in scenarios 2 and 3, respectively, at a threshold of £20,000 per
QALY. In scenario 1, the comparator with the next highest probability of being most cost-effective was the
sequence IMBCE, reflecting the uncertainty in the effectiveness of medication. In scenarios 2 and 3, the
reduced effectiveness of iontophoresis increased the uncertainty in the position of iontophoresis within
the sequence. In theses scenarios, the comparator with the next highest probability of being most
cost-effective was the sequence BMICE with an ICER of £41,837 in scenario 2 and an ICER of £36,796
in scenario 3. In scenario 4, IBCE was the most cost-effective sequence at conventional thresholds with an
ICER of £10,058. The closest comparator was IBMCE, with an ICER of £30,170.
Expected value of perfect information results
Figure 17 presents population EVPI (number of patients) for all model parameters across a range of WTP
thresholds. In the base case, at a WTP threshold of £20,000, based on an incidence of axillary hyperhidrosis
in the adult population between the ages of 18 and 65 years of 2.1%, the cost of further research should
not exceed £4.5M if it is to be worthwhile. This figure is unchanged if the NHS pays for iontophoresis at
home, but increases to roughly £13.4M if the relative risk of iontophoresis compared with placebo is
reduced to 1 from 2.4. The EVPI is very sensitive to the threshold value between thresholds of £5000 and
£20,000 per QALY. If a considerable decline in effectiveness of oral medication is assumed, then the EVPI
rises significantly between thresholds £20,000 and £30,000. At £30,000 the EVPI is £35.5M.
TABLE 40 Results of two-way and multiway sensitivity analyses
Analysis
Optimal
decision ICER (£)
Base case IBMCE 10,122
Two-way sensitivity analyses
NHS subsidy and response rate of 0.07 for iontophoresis sponge BMICE 12,089
NHS subsidy and response rate of 0.07 for iontophoresis sponge and reduced duration of
iontophoresis device
BMICE 12,221
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The population EVPI assuming different population annual incidences is presented in Figure 18. The population
annual incidencess are 2%, 1.5%, 1%, 0.5% and 0.01%. At a threshold of £20,000 the population EVPI is
£4.4M at an annual incidence of 2%, £3.3M at an annual incidence of 1.5%, £2.2M at an annual incidence of
1%, £1.1M at an annual incidence of 0.5% and £0.2M at an annual incidence of 0.1%.
Population expected value of partial perfect information results
The population EVPPI of sets of parameters has been calculated based on the model assuming that the NHS
pays for home iontophoresis and the iontophoresis device has a life expectancy of 10 years. It is calculated
for two alternative ORs of iontophoresis compared with placebo: first, assuming OR = 3.03 and, second,
assuming OR = 1. Furthermore, it is calculated for both the £20,000 and £30,000 cost-effectiveness
thresholds and at a 2% axillary hyperhidrosis annual incidence and a 0.5% annual incidence. Combinations
of these factors result in eight different scenarios. The results are presented in Table 41.
Across all of the EVPPI analyses, the greatest VOI is associated with the parameter ‘medication versus
placebo’. The population EVPPI ranges from £0.26M to £5.8M. In contrast, the EVPPI for Botox compared
with placebo is negligible. This reflects the fact that the estimate of the effectiveness of BTX compared
with placebo (OR 9.21, 95% CI 4.73 to 18.10) is much more precise than the effectiveness of medication
compared with placebo (OR 7.21, 95% CI 1.56 to 53.83).
Reducing the annual incidence of axillary hyperhidrosis reduced the population EVPPI of all parameters
because the population EVPPI is the result of multiplying the EVPPI for an individual by a factor related to
the annual incidence of axillary hyperhidrosis.
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Incidence = 1%
Incidence = 0.5%
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FIGURE 18 Population EVPI for different values of axilla hyperhidrosis incidence.
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FIGURE 17 Population EVPI for the base-case model and four sensitivity analyses.
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TABLE 41 The population EVPI and population expected value of partial parameters at thresholds of £20,000 and £30,000, incidence rates of 2% and 0.5% and high and low
iontophoresis effect sizes
Threshold
(£/QALY) Incidence (%) IS effectiveness
PEVPI (£000) Expected value of partial parameter information (£000)
Total
All
effectiveness
parameters
All utility
parameters
All withdrawal due
to adverse effects
parameters
Botox vs.
medication
Curettage
vs. Botox
Medication
vs. placebo
Botox vs.
placebo
20,000 2 High 4206 836 0 58 564 597 1040 0
Low 10,850 6109 21 972 2225 3137 1660 29
0.5 High 1048 208 0 14 141 149 259 0
Low 2704 1523 5 242 555 782 414 7
30,000 2 High 6926 2901 0 137 3100 0 3628 63
Low 12,818 7250 183 2636 2711 2013 5786 374
0.5 High 1726 723 0 34 773 0 904 16
Low 3195 1807 46 657 676 502 1442 93
IS, iontophoresis sponge; PEVPI, population expected value of perfect information.
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The increase in the cost-effectiveness threshold from £20,000 per QALY to £30,000 per QALY increased
the EVPPI for all parameters except for ‘curettage versus BTX’ effectiveness. ‘Curettage versus BTX’ is the
exception because BTX and medication become more cost-effective relative to curettage as the threshold
increases; BTX and medication are more costly than curettage because they involve recurring annual
costs rather than the one-off cost of curettage. Therefore, there is less uncertainty about the position of
curettage in the sequence. For the other parameters, as the threshold increases from £20,000 to £30,000
it becomes less certain that IBMCE is the most cost-effective sequence; overall decision uncertainty has
increased and the value of further information has also correspondingly increased.
Reducing the effectiveness of iontophoresis sponge increases the EVPPI of all parameters because all of the
other interventions become relatively more cost-effective than iontophoresis as the effectiveness of
iontophoresis is reduced. Therefore, there is greater uncertainty as to which sequences are the most
cost-effective.
To place the population EVPPI results into context, a clinical trial of a medication or surgical intervention
may cost around £1.5M. This cost will vary considerably depending on a number of key factors, including
the sample size of the trial required to achieve a statistically significant outcome and the interventions
under investigation. An observational study of rates of withdrawal due to adverse effects can cost as little
as £200,000; however, a large RCT may cost upwards of £1M.
The population EVPPI is a maximum VOI for that parameter or for a group of related parameters, such as
effectiveness. Given that any further research is unlikely to achieve full perfect information – even the most
robust trials produce estimates with some uncertainty – the real value of further research will necessarily be
lower than the population EVPPI. Therefore, if a trial of two interventions cost £1.5M and we knew that it
would only reduce our uncertainty by half, then our EVPPI estimate would need to be at least £3M to
warrant conducting that study. Any further research needs to cost less than the EVPPI estimate; how much
less will depend on the studies undertaken.
Population EVPPI analysis was conducted for seven different subsets of parameters. The results are
summarised for each.
Effectiveness
This analysis investigated the EVPPI of the subset of parameters that inform the relative effectiveness of
medication, BTX and curettage. The population EVPPI ranged from £208,000 to £7,250,000 across the
different scenarios. As this subset of parameters covers three treatments and placebo, it is expected that
the population EVPPI will be higher than the population EVPPI of a single relative effectiveness parameter
for two interventions. For a threshold of £20,000 per QALY or £30,000 per QALY, the population EVPPI is
only > £4M in the scenario of low effectiveness of iontophoresis sponge compared with placebo and an
annual incidence of 2%. It would be useful to include the EQ-5D-5L instrument and a HDSS outcome,
as well any preferred outcome in a future trial, in order to allow the trial results to be used in a future
economic evaluation.
Medication compared with placebo effectiveness
This analysis investigated the EVPPI of the specific effectiveness parameter of medication compared with
placebo. The population EVPPI ranged from £259,000 to £5,786,000 across the different scenarios. For a
threshold of £20,000 per QALY, the population EVPPI is < £3M. For a threshold of £30,000 per QALY,
the population EVPPI is only > £3M when the annual incidence is 2%.
Botulinum toxin compared with placebo effectiveness
This analysis investigated the EVPPI of the specific effectiveness parameter of BTX compared with placebo.
The population EVPPI ranged from £0 to £374,000 across the different scenarios, so it is never > £3M.
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Botulinum toxin compared with medication effectiveness
This analysis investigated the EVPPI of the specific effectiveness parameter of BTX compared with
medication. The population EVPPI ranged from £141,000 to £3,100,000 across the different scenarios. For
a threshold of £20,000 per QALY, the population EVPPI is < £3M. For a threshold of £30,000 per QALY,
the population EVPPI is only > £3M in the scenario where the annual incidence of axillary hyperhidrosis is
2% and the OR of iontophoresis compared with placebo is assumed to be 3.03. The population EVPPI
values for BTX compared with medication effectiveness are related to the population EVPPI value for
medication compared with placebo effectiveness as the estimate of the effectiveness of BTX compared
with medication was derived from indirect evidence using placebo-controlled trials.
Curettage compared with botulinum toxin effectiveness
This analysis investigated the EVPPI of the specific effectiveness parameter of curettage compared with
BTX. The population EVPPI ranged from £0 to £3,137,000 across the different scenarios. For a threshold of
£20,000 per QALY, the population EVPPI is > £3M only if the annual incidence is 2% and the OR of
response of iontophoresis compared with placebo is 1. For a threshold of £30,000 per QALY, the
population EVPPI is < £3M.
Withdrawal rates due to adverse effects
This analysis investigated the EVPPI of the subset of parameters that inform the rates of withdrawals due
to adverse effects for medication and iontophoresis sponge. The population EVPPI ranged from £14,000 to
£2,636,000 across the different scenarios. Assuming that future research would be an observational study,
for a threshold of £20,000 per QALY the population EVPPI is > £400,000 in the scenario with an annual
incidence of 2% and where the OR of response of iontophoresis compared with placebo is 1. For a
threshold of £30,000 per QALY, the in which EVPPI is > £400,000 in the scenarios in which the OR of
response of iontophoresis compared with placebo is 1.
Utility
This analysis investigated the EVPPI of the subset of parameters that inform the utilities of the different
HDSS levels. The population EVPPI ranged from £0 to £183,000 across the different scenarios. Future
research may be an observational study with a cost of £400,000. The population EVPPI is never
> £400,000 for the utility parameters.
Summary of cost-effectiveness and value-of-information analysis
The base-case results indicated that IBMCE was the most cost-effective sequence with an ICER of £9304
per QALY. The first three treatments in this sequence are in order of annual cost: iontophoresis incurs the
lowest annual expenditure and medication incurs the highest annual expenditure. Curettage and ETS come
last because of the assumption that surgery would only be offered after a patient has tried the available
non-surgical options. Fifty-nine out of the 64 treatment sequences were either strictly dominated or
dominated by extension.
When pairwise net benefit comparisons between the most cost-effective sequence and the other
sequences were made, the highest error probabilities were associated with comparisons with IMBCE
(0.1 error probability) and then IBCE (0.05 error probability) at a threshold of £20,000 per QALY. At a
threshold of £30,000 per QALY, they are IMBCE (0.17 error probability) and MIBCE (0.07 error probability).
This indicates that the greatest uncertainty is associated with the effectiveness of medication compared
with placebo and this reflects the clinical evidence. Despite the fact that the annual costs of medication are
greater than the annual costs of BTX, the uncertainty in the effect estimate for medication means that it is
possible that medication is sufficiently more effective than BTX to come before it in the sequence at a
threshold of £20,000 per QALY. Equally, it may be sufficiently less effective than BTX so that it drops out
of the sequence altogether.
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Most sensitivity and scenario analyses had no effect on the results, with the exception of scenario analyses
1, 3, 4, 5, 6 and 13, which resulted in a significant change in the results.
Scenario 1
If the response rate of iontophoresis sponge is reduced to 0.07, BMICE becomes the most cost-effective
sequence, with an ICER of £13,058.
Scenarios 3 and 4
If the cost of medication increases from the cost of propantheline bromide to an average of the cost of
propantheline bromide and glycopyrrolate bromide, then it is no longer cost-effective to include
medication in the treatment sequence at a threshold of £30,000 per QALY.
Scenario 5
If the effectiveness of medication declines over time then it becomes significantly less cost-effective to
include medication in a treatment sequence.
Scenario 6
If the relative risk of iontophoresis sponge compared with placebo were only 0.5, then iontophoresis
would come after medication in the sequence and BTX would be first.
Scenario 13
If partial responders to non-surgical options as well as patients with no response at all had curettage,
instead of only those who had no response at all to previous treatments, then curettage comes after
iontophoresis in the treatment sequence as it is relatively cost-effective compared with BTX and medication
given the assumptions in the model.
The results of the EVPI and EVPPI analyses are very sensitive to the decision-maker’s cost-effectiveness
threshold, to the annual incidence rate of axillary hyperhidrosis and to the effectiveness of iontophoresis
sponge compared with placebo. There is uncertainty in the annual incidence rate because the study was
based on a US population. The population EVPPI results also reflected the uncertainty in the estimate of
effectiveness of medication compared with placebo. A conservative estimate of the expected VOI required
for a future trial is assumed to be £3M and £400,000 for an observational study.
The population EVPPI for medication compared with placebo effectiveness is < £3M when the threshold is
£20,000 per QALY, but is > £3M for a threshold of £30,000 per QALY and the annual incidence of axillary
hyperhidrosis is 2%. The population EVPPI for BTX compared with medication effectiveness is > £3M
when the OR of response of iontophoresis compared with placebo is 1, the annual incidence is 2% and
the threshold is £30,000 per QALY. The population EVPPI for curettage compared with BTX effectiveness
is > £3M when the OR of response of iontophoresis compared with placebo is 1, the annual incidence
is 2% and the threshold is £20,000 per QALY. The population EVPPI for BTX compared with placebo
effectiveness is very low in every scenario. The population EVPPI for withdrawal rates is > £400,000 when
the relative risk of response of iontophoresis compared with placebo is 1, except when the threshold is
£20,000 per QALY and the annual incidence of axillary hyperhidrosis is 0.5%. For utility parameters,
the population EVPPI is never > £400,000.
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Chapter 8 Patient and clinician perspective on
research findings
Background
The patients’ perspective was collected at various points through the project, including at the initial team
meetings and during protocol development (when Julie Halford acted as the patients’ representative).
The patients’ perspective was also required to complement the narrative review of quality-of-life measures
used in studies of hyperhidrosis and to guide the economic modelling by providing information on what is
important to patients in terms of outcomes, both beneficial and adverse, and to advise on the various tools
available for assessing HRQoL. The patients’ perspective was also required to help with the interpretation
of the results of the systematic review and economic evaluation, and the resultant recommendations for
research.
Methods
It should be noted that a ‘virtual workshop’ was originally planned to elicit the opinions of patients,
dermatologists and surgeons through an online survey on items that should be captured in tools assessing
HRQoL. However, our review of quality-of-life measures identified the literature describing the development
of a new tool: the HidroQoL, developed by Kamudoni et al.204,260,261 This development exercise was much
more comprehensive than could be achieved by our planned virtual workshop. Therefore, the workshop was
redesigned to be a smaller end-of-project event undertaken face to face with patients. This was submitted as
a protocol amendment in the research progress report. In addition, patients were consulted on the structure
and inputs of the economic model.
The end-of-project workshop was held at Harrogate District Hospital with four patient advisors and one
dermatologist (AL). Julie Halford and the other clinical advisors provided their advice during telephone
meetings or via e-mail.
Prior to the workshop the patient advisors were sent a short overview of the purpose of the project. They
were also sent copies of four HRQoL tools together with a short list of questions about the tools and asked
to consider these questions in preparation for the workshop (see Appendix 12).
At the workshop, an overview of the project was presented, along with a summary of findings from the
review of clinical effectiveness of treatments for hyperhidrosis. Gaps in the evidence base that warranted
further research were discussed and patients and the dermatologist attending the workshop were asked
for their opinions and any further comments. The cost-effectiveness model and results were also described,
along with results of VOI analyses relating to further research that would be cost-effective. Again, patients
and the dermatologist attending the workshop were asked for their opinions and any further comments.
Finally, the review of quality-of-life tools used in hyperhidrosis research was described and patients were
asked to comment on the most commonly used tools (HDSS, DLQI, HQLQ) and the new HidroQoL tool,
which patients had been sent in advance of the workshop.
The results of the clinical effectiveness review and cost-effectiveness modelling and the resultant
recommendations for research were discussed further by teleconference with Dr Nick Levell (clinical
advisor) and Julie Halford (nurse clinical advisor and patient representative).
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The notes from the various discussions were collated and incorporated into our interpretation of the
research findings and into the study’s conclusions and recommendations for research.
Results
Patient advisors
Patient advisors were not surprised by the finding of the review that there is evidence for effectiveness
of BTX for hyperhidrosis of the axilla; there was a consensus among patient advisors that BTX for
hyperhidrosis of the axilla was very effective. Interestingly, they stated that annual administration was
adequate. The annual use of BTX compared very favourably with frequent use required with iontophoresis
or frequent application of anticholinergic creams. BTX was considered to be a more effective treatment
than iontophoresis and patients expressed an interest in receiving BTX to the hands, as well as the axilla.
Patient advisors agreed that a trial of BTX (plus an anaesthetic) compared with iontophoresis for palmar
hyperhidrosis would be useful and that outcomes should include long-term impairment of hand sensitivity
and pain of BTX administration. Patient advisors did not think that it would be worth conducting further
research into iontophoresis for the axilla; they had limited knowledge of it but imagined it would be (even)
less effective than water bath iontophoresis for the hands. The patient advisors agreed that future trials of
treatments for hyperhidrosis of the axilla should compare new treatments against BTX, as an established
effective treatment.
Patients advisors commented that topical glycopyrrolate (to the hand and other areas) had fewer adverse
effects than oral anticholinergic medications. Oral medication was considered to have limited effectiveness,
along with troublesome adverse effects. There are adverse effects associated with long-term use of
anticholinergic medications; therefore, patients are often advised to use oral medications only when
necessary (e.g. when going to public events), rather than on a daily basis. They did not think it was
important to investigate which was the best anticholinergic medication: they were happy with the idea of
trying one and switching to another if the first did not work. It would be worthwhile researching a new
drug only if it had the potential to be effective and was associated with greatly reduced adverse effects
compared with the current medications available.
Patient advisors expressed an interest in a more permanent solution for their hyperhidrosis, such as
curettage or the newer, less invasive, energy-based ‘destructive’ technologies for hyperhidrosis of the
axilla. However, they believed that patients would need assurance that it really was a ‘one-off’ treatment,
otherwise they would rather continue with BTX. They also had significant concerns regarding scarring.
They expressed an interest in research comparing newer, ‘destructive’, technologies with BTX.
Patient advisors were happy with the sequence of treatments identified as being cost-effective in the
modelling exercise: iontophoresis, BTX, medication, curettage, ETS. They also considered that iontophoresis
machines should be supplied by the NHS (if they were effective for a patient), rather than having to be
purchased by patients.
When asked about the four quality-of-life tools they had been asked to consider, all patient advisors
agreed that the HidroQoL tool was superior to the other tools commonly used in hyperhidrosis research
(HDSS, DLQI, HQLQ) for assessing quality of life. They commented that it covers everything important to
patients with hyperhidrosis and is easy to complete. The DLQI was considered to be too general and too
focused on the skin, with questions that are not applicable to hyperhidrosis patients. The HDSS was
considered to be too basic and, depending on different situations, patients could easily fluctuate between
a HDSS score of 2 points and one of 3 points. They considered that measuring the actual amount of sweat
produced (e.g. by gravimetry) was less important than measuring quality of life and it should be considered
only a secondary outcome. Single measurements in time could give the wrong impression of the severity of
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hyperhidrosis and do not necessarily reflect the patient’s overall condition. The patient advisors considered
that the HidroQoL tool should be the primary outcome in future studies.
Clinical advisors
It was clear that there is regional variation in the treatments available for patients with hyperhidrosis.
Iontophoresis is widely used for hyperhidrosis of the hands and considered effective in a significant
proportion of patients, but is used for hyperhidrosis of the axilla much less in NHS trusts that allow access
to BTX. Clinical advisors commented that glycopyrrolate was more effective, with a better adverse event
profile, than the cheaper anticholinergic medication propantheline bromide. Given the much higher cost of
glycopyrrolate than propantheline bromide, it is reasonable to use the cheapest drug first. However, in reality
many clinicians use glycopyrrolate, believing it to be superior. The clinical advisors agreed that curettage is
not widely used and admitted that they had limited knowledge of the new sweat gland-destroying
(‘destructive’) technologies.
Like the patient advisors, the clinical advisors agreed that a trial of BTX (plus an anaesthetic) compared
with iontophoresis for palmar hyperhidrosis would be useful and that outcomes should include long-term
impairment of hand sensitivity and pain of BTX administration. Given the cost and potential complexity of
administering an anaesthetic, it was suggested that a CEA alongside such a trial would be warranted. The
clinical advisors also did not think that it would be worth conducting further research into iontophoresis
for the axilla and that future trials of treatments for hyperhidrosis of the axilla should compare new
treatments against BTX, as an established effective treatment.
Unlike the patients, clinicians did not think that a trial comparing BTX with curettage or newer ‘destructive’
technologies for axillary hyperhidrosis was warranted, at least not until there is clear evidence of benefit
with the new technologies, in terms of offering a permanent cure, with a low risk of scarring.
Regarding oral medications, it was considered by clinicians that it would be difficult to power a trial to find
statistically significant differences between anticholinergic medications, as effectiveness is considered to be
broadly similar between medications, although some medications work better for some patients than
others.
Like the patient advisors, the clinical advisors were happy with the sequence of treatments identified
as being cost-effective for hyperhidrosis of the axilla in the modelling exercise: iontophoresis, BTX,
medication, curettage, ETS. Clinical advisors were happy to try BTX before medication; although this is not
generally current standard practice, it reflects their belief in the order of effectiveness and acceptability of
the treatments.
It was stated that there is anecdotal evidence of patients being unable to purchase iontophoresis machines
because of the cost. In such cases, further clinic appointments are sometimes offered for further sessions
of hospital administered iontophoresis.
Conclusions from patient and clinician perspective
Patients and clinicians favoured BTX for hyperhidrosis of the axilla and did not consider that further research
on iontophoresis for the axilla would be worthwhile. A trial comparing the different anticholinergic
medications currently available for hyperhidrosis was also not considered to be worthwhile. Patients and
clinicians agreed that a trial of BTX (plus an anaesthetic) compared with iontophoresis for palmar
hyperhidrosis would be useful.
Patients and clinicians were happy with the sequence of treatments identified as being cost-effective in the
modelling exercise: iontophoresis, BTX, medication, curettage, ETS.
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All patient advisors agreed that the HidroQoL tool was superior to the other tools commonly used in
hyperhidrosis research (HDSS, DLQI, HQLQ) for assessing quality of life. Patients considered that the
HidroQoL tool should be the primary outcome in future studies and that measuring the actual amount of
sweat produced should be considered only as a secondary outcome.
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Chapter 9 Discussion
Summary of findings
The aim of this research was to establish the expected value of undertaking additional clinical studies
(such as RCTs) to determine the most clinically effective and cost-effective interventions for the management
of refractory primary hyperhidrosis in secondary care. The key objectives were to undertake an evidence
synthesis by systematic review to estimate clinical effectiveness and safety of treatments that would be
available in secondary care, to inform key clinical parameters for a decision model, to develop a decision
model to estimate cost-effectiveness and, using the decision model, to undertake a VOI analysis to
determine the need for further research and to help inform the design of future clinical studies.
Clinical effectiveness and safety of second-line treatments for primary hyperhidrosis
Fifty studies were included in the systematic review of secondary care interventions for the treatment of
primary hyperhidrosis. Despite the large number of studies, the evidence for the effectiveness and safety of
second-line treatments of primary hyperhidrosis is limited overall: most studies were small, rated as being
a high risk of bias and poorly reported. There were no studies assessing the clinical effectiveness of
propantheline bromide, oral glycopyrrolate or iontophoresis applied to the axilla. Evidence was very limited
regarding the newer, energy-based, ‘destructive’, technologies. Overall, there was insufficient evidence to
draw firm conclusions regarding the relative effectiveness and safety of any active second-line treatments
for hyperhidrosis.
There is moderate-quality evidence of a large effect of subcutaneous BTX on symptoms of axillary
hyperhidrosis in the short and medium term (up to 16 weeks), and of a small to moderate positive effect
on quality of life in the short term (4 weeks), compared with placebo. There is some limited evidence for
BTX for palmar hyperhidrosis and very low-quality but consistent evidence of a small treatment effect with
iontophoresis for palmar hyperhidrosis. Therefore, a trial of BTX compared with iontophoresis for palmar
hyperhidrosis may be warranted.
The evidence regarding the effectiveness of BTX injections to the axillae compared with curettage is very
low quality and uncertain, although there is no evidence to suggest that curettage is more effective than
BTX in the short to medium term and there is evidence to suggest a higher incidence of adverse events
with curettage. Trials are too short term to explore the potential curative nature of curettage, compared
with the retreatment needed with BTX.
Review of quality-of-life measures/tools
The narrative review of quality-of-life measures/tools commonly used in hyperhidrosis research included
184 studies, many of which used two or more tools. Twenty-two individual tools for measuring quality
of life were identified from the selected studies. In addition, 32 studies were identified that reported
quality-of-life outcomes although the method used to measure quality of life was not reported. The
DLQI, the HDSS and the HQLQ were used more often than any other tool for measuring quality of life
in hyperhidrosis. The HidroQoL is the most recent tool to be designed and validated for measuring the
quality of life of patients with hyperhidrosis.
Cost-effectiveness
The cost-effectiveness model considered only axillary hyperhidrosis, owing to a lack of evidence to support
modelling other body sites.
The probabilistic base case suggested that IBMCE is the most cost-effective treatment sequence. A number
of sensitivity analyses were conducted, and in general the model results were found to be quite robust.
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Although no clinical studies were identified to inform the effectiveness of iontophoresis sponge for the
axilla, sensitivity analysis for the base-case model demonstrated that iontophoresis needs to have very low
effectiveness for it to be displaced as a first-line treatment choice; the response rate of iontophoresis
sponge would need to be lower than 0.10, which is lower than the placebo response rate (0.13) for
medication and BTX. The monthly cost of iontophoresis is substantially lower than that of either BTX or
medication. In the base case, the patient has to pay for iontophoresis at home; however, even if the
NHS paid for the iontophoresis device, the monthly cost is around £5.60, compared with £39.55 for
propantheline bromide and £26 for BTX, assuming 6-monthly injections. Even if BTX injections were
annual, the cost would be £13 per month.
The greatest value to the NHS is to keep patients on the most cost-effective treatments if the patients
respond to that treatment. The most cost-effective treatments will be early in a treatment sequence.
Reducing the number of patients who move on to more expensive treatments will result in cost savings.
For the NHS, encouraging patients to remain on iontophoresis if they achieve a response will achieve this.
The only negative consequence of experimenting with a cheaper treatment is that it is possible that a patient
may not try a more cost-effective treatment later in the sequence. Current clinical practice, according to which
the patient is expected to purchase an iontophoresis machine, and the base-case model presented do not
account for patients being unable to pay for an iontophoresis device. In addition to the equity concerns of the
ability to pay for an iontophoresis home device, there are also cost implications to the NHS of patients who
elect not to purchase a machine, but rather move on to the next more costly treatment. Movement to the
next treatment is a consequence of affordability, rather than lack of response to first-line treatment. Sensitivity
analysis showed that in a scenario where the NHS loan individuals iontophoresis devices, rather than patients
incurring the costs of purchase, iontophoresis remains a cost-effective first-line treatment option.
After iontophoresis, BTX is the next most cost-effective option, being effective and the next cheapest option.
Further to the affordability and equity issues, there is regional inequity in access to treatments. In a survey
of dermatologists, 78% of respondents stated that iontophoresis was available and 58% of respondents
stated that BTX was available.
Although the structure of the model ensured that non-invasive treatments were considered first, curettage
was found to be cost-effective given the model assumptions. If future evidence demonstrates that newer
techniques, such as laser, are equally effective as but less invasive than curettage, these other options may
come to be considered a cost-effective option earlier in the treatment sequence offered to patients.
Value-of-information analysis and future research priorities
The lack of evidence available limited the modelling and subsequent VOI analysis to the axilla. The analysis
was undertaken to determine the expected cost of decision uncertainty predicted by the model and the
maximum value of further research undertaken to reduce that uncertainty. The population EVPI suggests that
further research is of potential value, ranging from £4.5M to £15.8M; dependent on the WTP threshold.
Further population EVPPI analysis found that the greatest VOI was associated with the parameter
‘medication versus placebo’, ranging from £0.3M to £5.8M, reflecting the high level of uncertainty in the
evidence base (OR 7.21, 95% CI 1.56 to 53.83).
The VOI analysis suggested that further research on medication compared with placebo effectiveness may be
of value only if the cost-effectiveness threshold is £30,000 per QALY and the annual incidence of axillary
hyperhidrosis is 2%. The impact that further research on medication compared with placebo effectiveness
might have on the first- or second-line treatment options is unclear. It is likely that, even if a trial of
medication compared with placebo were conducted, iontophoresis and BTX would retain their position
before medication in any cost-effective treatment sequence. It would be useful to include the EQ-5D-5L
instrument and a HDSS outcome, as well any preferred outcome in a future trial, in order to allow the trial
results to be incorporated into the wider evidence base and to be used in a future economic evaluation.
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The results of the population EVPI and EVPPI are very sensitive to the annual incidence rate of axilla
hyperhidrosis and to the assumed effectiveness of iontophoresis sponge compared with placebo.
Patient and clinician perspective on research findings
In order to elicit the opinions of patients with hyperhidrosis and clinicians treating patients, an end-of-
project workshop was held at Harrogate District Hospital with four patients and one dermatologist. Other
clinicians provided advice during telephone meetings.
Patients and clinicians were unsurprised by the positive findings regarding BTX for hyperhidrosis of the
axilla and did not consider that further research on iontophoresis for the axilla would be worthwhile.
Despite the weak evidence, they believed that iontophoresis is effective in reducing palmar hyperhidrosis in
some patients. Patients and clinicians agreed that a trial of BTX (plus an anaesthetic) compared with
iontophoresis for palmar hyperhidrosis would be useful.
Patients and clinicians were satisfied with the sequence of treatments identified as being cost-effective in
the modelling exercise: iontophoresis, BTX, medication, curettage, ETS.
A trial comparing the different anticholinergic medications currently available for hyperhidrosis was not
considered to be worthwhile. Although there was interest in the new energy-based ‘destructive’
technologies as potential cures, patients and clinicians agreed that better evidence was needed before a
comparative trial against BTX was warranted.
All patient advisors agreed that the HidroQoL tool is superior to the other tools commonly used in
hyperhidrosis research (HDSS, DLQI, HQLQ) for assessing quality of life. Patients considered that the
HidroQoL tool should be the primary outcome in future studies and that measuring the actual amount of
sweat produced should be considered only as a secondary outcome.
Strengths and limitations of the review
Strengths
The systematic review of the clinical effectiveness of second-line treatments for primary hyperhidrosis used
all of the best available evidence; 32 RCTs were included, as well as 17 non-RCTs and one case series for
interventions where RCT evidence was lacking. Extensive searches were undertaken to identify all of the
relevant research evidence. Five RCTs of subcutaneous injections of BTX compared with placebo for
hyperhidrosis of the axilla were sufficiently similar to be pooled in a meta-analysis, with no evidence of
significant statistical heterogeneity for most outcomes.
The clinical effectiveness results were combined with patient and clinical expertise in order to model the
cost-effectiveness of the different interventions and undertake a VOI analysis. The results were presented
to patients at an end-of-project workshop and their input was combined with the clinical and economic
results to inform the conclusions and recommendations for further research.
A strength of the cost-effectiveness and EVPI analyses is that the clinical effectiveness evidence was based
on studies identified through a systematic review of the literature. Sufficient data were available to model
treatment sequences for the most common treatments for axillary hyperhidrosis in the UK and to explore
the sensitivity of results to variation in parameters and assumptions for those based on little evidence. It
was concluded that there was insufficient information to warrant cost-effectiveness and EVPI analyses for
other body sites and for a comparison of minor surgery procedures (e.g. laser and microwave) with
curettage.
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Limitations
The protocol for this project included all treatments for hyperhidrosis prescribed in secondary care.
However, screening and selecting the relevant literature for the clinical effectiveness review revealed that
ETS, although used as part of the treatment pathway for hyperhidrosis, could not be included in a
comparative review as the position of ETS in the treatment pathway is uncontestable (ETS is considered
only as an intervention of last resort because of its significant risks). NICE recommends ETS for primary
hyperhidrosis of the upper limb, but only for those ‘suffering from severe and debilitating primary
hyperhidrosis that has been refractory to other treatments’.19 Therefore, ETS was excluded from the
systematic review of clinical effectiveness and safety of second-line treatments for hyperhidrosis, but
remained in the cost-effectiveness model as the final treatment in the sequence. Recent studies of ETS
have focused on the details of the surgical procedure. However, undertaking a systematic review of
different specific techniques for undertaking ETS was beyond the remit of this project. Therefore, although
further research on ETS may be warranted, recommendations for further research relating to ETS have not
been made.
There was substantial variation among the 32 RCTs, 17 non-RCTs and one case series that were included
in the systematic review of interventions for the treatment of primary hyperhidrosis. Studies were
conducted in a range of different countries. Therefore, some study populations may not be representative
of hyperhidrosis patients in the UK, notably because of differences in climate. In addition, the methods of
outcome assessment varied between studies. Methods used to assess sweat rate varied, with some studies
undertaking gravimetry under specific conditions, such as under stressful conditions or at a regulated room
temperature. This may affect the generalisability and reliability of results relating to sweat rate. In addition,
some studies used the iodine starch test as a primary measure of sweat rate; the iodine starch test is
limited by the fact that it measures sweat area, rather than volume of sweat. Absolute and relative
reductions in sweat rate may not necessarily correspond with improvement in a patient’s HRQoL. There
was considerable variation in the tools used to assess HRQoL, as described in Chapter 4. Many studies used
the HDSS for assessing treatment response, although there is limited evidence on the validity of this
specific tool, or the various cut-off points used for responders (i.e. a 2-point reduction in HDSS score, or an
improvement from HDSS 3 or 4 to HDSS 1 or 2). The evidence was considered too heterogeneous and
limited to perform a NMA to address the clinical review question.
Most studies were small, rated as being at a high risk of bias and poorly reported. Only one RCT was
judged to have a low overall risk of bias; 31 studies were judged to have a high overall risk of bias and for
18 studies the reporting was inadequate to judge the risk of bias.
There was a lack of long-term data for many of the interventions and, therefore, the long-term efficacy
and safety of the interventions is unclear. This is particularly pertinent for interventions requiring repeated
use over time and also for exploring the potential curative nature of minor surgical treatments, such as
curettage.
For many of the interventions, the available data were very limited. In particular, for the newer, energy-based,
‘destructive’, technologies and new formulations of anticholinergic medications, studies were either ongoing
or only recently completed. Research on two new medications, DRM04 and THVD-102, was presented at the
European Academy of Dermatology and Venereology conference in Vienna in September/October 2016, but
data were not available in time to be included in the review.358 In addition, there were no studies assessing
the clinical effectiveness of propantheline bromide, oral oxybutynin or iontophoresis applied to the axilla,
which are used in standard NHS practice.
Where stated, most of the included studies restricted inclusion criteria to patients with moderate to severe
hyperhidrosis (HDSS score of 3 or 4 points and/or a minimum sweat rate of 50 mg/5 minutes); therefore,
the results may not be generalisable to patients with milder disease, who may be less willing to undergo
more invasive or painful treatments.
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The limitations of the evidence base for treatments for hyperhidrosis result in limitations for the modelling
exercise. Only hyperhidrosis of the axilla could be modelled. In addition, HDSS and gravimetry sweating
measurements are two of the most common outcomes in clinical studies of hyperhidrosis. Lack of evidence
on the association between these two outcomes meant that, to facilitate modelling, the model had to be
structured around HDSS measurements only.
Robust evidence for a number of key model parameters was not available: no evidence for the
effectiveness of iontophoresis sponge, the long-term effectiveness of medication or the long-term toxicity
of medication was identified. Assumptions regarding the effectiveness of iontophoresis sponge have an
impact on the ICER results, although the ordering of treatment sequences remains the same. To inform
some evidence gaps, such as the rates of withdrawal due to adverse effects and resource use, a survey of
dermatologists was undertaken. It is possible that the findings of this survey are biased; however, it
currently represents the best available evidence for these data.
The relative treatment effects in the model were derived from the NMA. There was considerable
uncertainty in the effect estimates, which was reflected in the economic results. The quality assessment of
studies included in the systematic review indicates that all of the studies included in the NMA are at high
risk of bias. The presence of bias in favour of the intervention would mean that the effectiveness of the
intervention compared with placebo would appear greater than it should be, but the direction of effect on
relative effectiveness derived indirectly from medication and BTX placebo-controlled trials is unclear. The
effectiveness results have not been adjusted for bias in this NMA, as further research would be required
to estimate the degree of bias. As the direction of bias is unknown and there is already considerable
uncertainty in the effect estimates, it is unlikely that the probabilistic results would change greatly by
including an uninformative bias parameter. The potential for bias suggests that the EVPPI estimates for the
relative effectiveness parameters are likely to be overestimates. The effect estimates used in the CEA
ignored any effect of treatment order or failure on patient response to treatment as there was no evidence
to inform this.
Finally, there is uncertainty in the estimate of the incidence of axillary hyperhidrosis, which was based on a
US study.226 The population EVPI and EVPPI are calculated using this statistic and this adds another layer of
uncertainty, which was addressed by re-estimating the EVPI and EVPPI at different incidence rates.
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Chapter 10 Conclusions
The evidence for the effectiveness and safety of second-line treatments for primary hyperhidrosis islimited overall. Most studies were small, rated as being at a high risk of bias and poorly reported.
However, there is moderate-quality evidence of a large effect of BTX injections on symptoms of axillary
hyperhidrosis compared with placebo. Evidence for other interventions is of low or very low quality.
There was insufficient evidence to draw firm conclusions regarding the relative effectiveness and safety of
second-line treatments for hyperhidrosis.
The narrative review of quality-of-life measures found that the DLQI, HDSS and HQLQ were used most
frequently in hyperhidrosis research. All patients attending the end-of-project workshop preferred the
new HidroQoL tool over the DLQI, HDSS or HQLQ and agreed that it captured all hyperhidrosis-related
quality-of-life issues.
Although many of the data used to populate the model of axillary hyperhidrosis were derived from small
studies at a high risk of bias and poorly reported, when augmented by clinical opinion and other literature
the results are quite robust. Only when the effectiveness of iontophoresis sponge was reduced to less than
that of placebo did iontophoresis cease to be the optimal first-line treatment choice in a cost-effective
sequence at the £20,000 threshold. Only if medication were significantly more effective than BTX, would
BTX be displaced from second-line treatment in cost-effective treatment sequences at the £20,000
threshold. VOI analysis showed that, although there is some value in undertaking further research to
reduce decision uncertainty, it is unclear if the cost of the research would be offset by the reduction in
that uncertainty.
Implications for practice
The findings of the research undertaken suggest that the treatment sequence for axillary hyperhidrosis
(iontophoresis, BTX, medication, curettage, ETS) may be cost-effective within the NHS setting. When
using medication, propantheline should be used first, before trying more expensive alternatives such as
glycopyrrolate.
Implications for research
The VOI analysis showed that, although there is some value in undertaking further research to reduce
decision uncertainty, it is unclear if the cost of the research would be offset by the reduction in that
uncertainty. The VOI analysis also indicates that further research into the effectiveness of existing
medications might be worthwhile, but it is unclear if such trials are of clinical importance. Research that
established a robust estimate of the annual incidence of axillary hyperhidrosis in the UK population would
reduce the uncertainty in future VOI analyses.
The implications from the systematic review of clinical evidence were as follows.
Botulinum toxin for hyperhidrosis of the axilla
There is sufficient evidence demonstrating the clinical effectiveness of BTX for hyperhidrosis of the
axilla; therefore, there is little value in undertaking further studies of BTX compared with placebo for
hyperhidrosis of the axilla. Future trials of interventions for hyperhidrosis of the axilla should use BTX as
an active comparator.
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Iontophoresis for palmar/plantar hyperhidrosis
Iontophoresis studies consistently show that iontophoresis is more effective than placebo/no treatment for
hyperhidrosis of the palm; therefore, there is little value in undertaking further studies of iontophoresis
compared with placebo/no treatment for hyperhidrosis of the palm. Iontophoresis is currently standard
practice for palmar hyperhidrosis in many dermatology units.
Iontophoresis compared with botulinum toxin for palmar hyperhidrosis
A well-conducted, adequately powered, RCT of BTX (with anaesthesia) compared with iontophoresis
for palmar hyperhidrosis may be warranted. The new HidroQoL tool appears appropriate for capturing
hyperhidrosis-related quality-of-life issues. The cost of BTX plus anaesthesia is considerably higher than the
cost iontophoresis; therefore, cost-effectiveness would also need to be assessed.
Microwave, laser, fractionated microneedle radiofrequency and ultrasound
There are ongoing studies of microwave, laser, fractionated microneedle radiofrequency and ultrasound
therapies. If the results of this ongoing research are promising, then a trial comparing these new
energy-based technologies with BTX for hyperhidrosis of the axilla may be warranted; patients expressed
interest in a permanent treatment.
Curettage compared with botulinum toxin for hyperhidrosis of the axilla
In view of the ongoing research into less invasive energy-based technologies (microwave, laser,
fractionated microneedle radiofrequency and ultrasound), a trial comparing BTX with curettage for
hyperhidrosis of the axilla may not be warranted at this time. When further evidence is available on the
newer energy-based technologies, then it will be clearer whether or not further research on curettage is
warranted. Patients expressed interest in a permanent treatment, but were concerned about scar tissue
resulting from curettage.
Comparison of different oral/topical medications: propantheline bromide,
glycopyrrolate, oxybutynin, methantheline bromide and newer medications
There are ongoing/recently completed trials of new oral and topical anticholinergic medication
formulations and, therefore, it is unlikely to be worthwhile undertaking further research of the
anticholinergic medications currently available. Different medications may work better for some patients
than others, therefore it may be difficult to power a study to find any statistically significant differences
between treatments.
CONCLUSIONS
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Appendix 1 Literature search strategies
Hyperhidrosis effectiveness literature searching
3572 records identified after deduplication
Databases searched
AMED 17 records
British Nursing Index 35 records
CINAHL 276 records
CENTRAL 206 records
CDSR 1 record
DARE 4 records
EMBASE 3122 records
HTA database 4 records
MEDLINE 2162 records
NHS EED 2 records
PsycINFO 53 records
PubMed 1989 records
Allied and Complementary Medicine Database (via OvidSP)
Date range searched: 1985 to January 2016.
Date searched: 12 January 2016.
Search strategy
1. exp Hyperhidrosis/ (24)
2. hyperhidrosis.ti,ab. (31)
3. hyperhydrosis.ti,ab. (2)
4. (excess$ adj2 sweat$).ti,ab. (15)
5. (primary HH or secondary HH).ti,ab. (0)
6. 1 or 2 or 3 or 4 or 5 (45)
7. (aluminum adj2 (chloride or hydrochloride)).ti,ab. (2)
8. (aluminium adj2 (chloride or hydrochloride)).ti,ab. (4)
9. (antiperspirant$ or deodorant$).ti,ab. (4)
10. driclor.ti,ab. (0)
11. anhydrol forte.ti,ab. (0)
12. 7 or 8 or 9 or 10 or 11 (9)
13. 6 and 12 (1)
14. Iontophoresis/ (45)
15. (iontophoresis or iontophoreses).ti,ab. (74)
16. 14 or 15 (79)
17. 6 and 16 (6)
18. exp Botulinum Toxins/ (391)
19. botulinum toxin$.ti,ab. (415)
20. botox.ti,ab. (55)
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21. 18 or 19 or 20 (467)
22. 6 and 21 (6)
23. Cholinergic Blocking Drugs.ti,ab. (0)
24. cholinergic receptor blocking agent$.ti,ab. (0)
25. muscarinic antagonist$.ti,ab. (3)
26. muscarinic receptor blocking agent$.ti,ab. (0)
27. (quaternary ammonium adj (compound$ or derivative$)).ti,ab. (4)
28. glycopyrronium bromide.ti,ab. (1)
29. robinul.ti,ab. (1)
30. glycopyrrolate.ti,ab. (4)
31. propantheline.ti,ab. (0)
32. anticholinergic$.ti,ab. (79)
33. pro-banthine.ti,ab. (0)
34. oxybutynin.ti,ab. (4)
35. methantheline.ti,ab. (0)
36. vagantin.ti,ab. (0)
37. methantheliniumbromide.ti,ab. (0)
38. atropine.ti,ab. (134)
39. 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 (219)
40. 6 and 39 (0)
41. sympathectom$.ti,ab. (21)
42. sympathicotom$.ti,ab. (0)
43. sympathotom$.ti,ab. (0)
44. (sympathetic adj2 (ablation or surgery or block$ or excision$)).ti,ab. (19)
45. endoscopic thoracic sympathectom$.ti,ab. (1)
46. ETS.ti,ab. (14)
47. 41 or 42 or 43 or 44 or 45 or 46 (53)
48. 6 and 47 (5)
49. curettage.ti,ab. (63)
50. curretage.ti,ab. (2)
51. 49 or 50 (65)
52. 6 and 51 (0)
53. Lasers/ (285)
54. laser$.ti,ab. (906)
55. 53 or 54 (940)
56. 6 and 55 (0)
57. Microwaves/ (26)
58. microwave$.ti,ab. (86)
59. 57 or 58 (89)
60. 6 and 59 (0)
61. Ultrasonic therapy/ (259)
62. ultrasound.ti,ab. (1482)
63. 61 or 62 (1533)
64. 6 and 63 (0)
65. (lipectom$ or liposuction).ti,ab. (6)
66. 6 and 65 (0)
67. miraDry.ti,ab. (0)
68. bilateral axillae aspiration.ti,ab. (0)
69. shelley$ procedure$.ti,ab. (0)
70. ((remove$ or removal or removing) adj2 sweat gland$).ti,ab. (0)
71. 6 and 70 (0)
72. (clonidine or diltiazem or benzodiazepine$).ti,ab. (236)
73. 6 and 72 (1)
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74. 13 or 17 or 22 or 40 or 48 or 52 or 56 or 60 or 64 or 66 or 67 or 68 or 69 or 71 or 73 (17)
British Nursing Index (via ProQuest)
Date searched: 13 January 2016.
Search strategy
(Hyperhidrosis OR Hyperhydrosis) OR (excess* N2 sweat*) OR (“primary HH” OR “secondary HH”)
Cumulative Index of Nursing and Allied Health Literature (via EBSCOhost)
Date searched: 12 January 2016.
Search strategy
S1 hyperhidrosis OR hyperhidrosis OR excess* N2 sweat* OR primary HH OR secondary HH (564)
S2 ( aluminum N2 (chloride or hydrochloride) ) OR ( aluminium N2 (chloride or hydrochloride) )
OR ( antiperspirant* or deodorant* ) OR driclor OR anhydrol forte (222)
S3 iontophoresis or iontophoreses (509)
S4 botulinum toxin* OR botox (4080)
S5 cholinergic receptor blocking agent* OR muscarinic antagonist* OR muscarinic receptor blocking
agent* OR quaternary ammonium compound* OR quaternary ammonium derivative* OR glycopyrronium
bromide OR robinul OR glycopyrrolate* OR propantheline OR anticholinergic* OR pro-banthine OR
oxybutynin (3093)
S6 methantheline OR vagantin OR methantheliniumbromide OR atropine (1493)
S7 sympathectom* OR sympathicotom* OR sympathotom* OR ( sympathetic N2 (ablation or surgery or
block* or excision*) ) OR endoscopic thoracic sympathectom* OR ETS (1386)
S8 curettage OR curretage OR laser* OR microwave* OR ultrasound OR ultrasonic (47,577)
S9 ( lipectom* or liposuction ) OR miraDry OR bilateral axillae aspiration OR shelley* procedure*
OR ( (remove* or removal or removing) N2 (sweat gland*) ) (530)
S10 Clonidine OR diltiazem OR Benzodiazepine* (6750)
S11 S1 AND S2 (24)
S12 S1 AND S3 (46)
S13 S1 AND S4 (119)
S14 S1 AND S5 (27)
S15 S1 AND S6 (2)
S16 S1 AND S7 (114)
S17 S1 AND S8 (22)
S18 S1 AND S9 (4)
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S19 S1 AND S10 (10)
S20 S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 (276)
The Cochrane Library (via John Wiley)
Date searched: 12 January 2016.
Note, the same search strategy was used to search CDSR, DARE, CENTRAL, HTA database and NHS EED.
Search strategy
#1 MeSH descriptor: [Hyperhidrosis] explode all trees
#2 hyperhidrosis:ti,ab,kw (Word variations have been searched)
#3 hyperhydrosis:ti,ab,kw (Word variations have been searched)
#4 excess* near/2 sweat*:ti,ab,kw (Word variations have been searched)
#5 primary HH or secondary HH:ti,ab,kw (Word variations have been searched)
#6 #1 or #2 or #3 or #4 or #5
#7 MeSH descriptor: [Antiperspirants] explode all trees
#8 MeSH descriptor: [Deodorants] explode all trees
#9 MeSH descriptor: [Aluminum Compounds] explode all trees
#10 aluminum near/2 (chloride or hydrochloride):ti,ab,kw or aluminum near/2 (chloride or hydrochloride):
ti,ab,kw or antiperspirant* or deodorant*:ti,ab,kw or driclor:ti,ab,kw or anhydrol forte:ti,ab,kw (Word
variations have been searched)
#11 #7 or #8 or #9 or #10
#12 #6 and #11
#13 MeSH descriptor: [Iontophoresis] explode all trees
#14 iontophoresis or iontophoreses:ti,ab,kw (Word variations have been searched)
#15 #13 or #14
#16 #6 and #15
#17 MeSH descriptor: [Botulinum Toxins] explode all trees
#18 botulinum toxin:ti,ab,kw or botox:ti,ab,kw (Word variations have been searched)
#19 #17 or #18
#20 #6 and #19
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#21 MeSH descriptor: [Cholinergic Antagonists] explode all trees
#22 MeSH descriptor: [Muscarinic Antagonists] explode all trees
#23 MeSH descriptor: [Quaternary Ammonium Compounds] explode all trees
#24 MeSH descriptor: [Glycopyrrolate] explode all trees
#25 glycopyrronium bromide:ti,ab,kw or “Robinul”:ti,ab,kw or “glycopyrrolate”:ti,ab,kw or
“propantheline”:ti,ab,kw or anticholinergic*:ti,ab,kw (Word variations have been searched)
#26 pro-banthine:ti,ab,kw or “oxybutynin”:ti,ab,kw or “methantheline”:ti,ab,kw or vagantin:ti,ab,kw or
methantheliniumbromide:ti,ab,kw (Word variations have been searched)
#27 “atropine”:ti,ab,kw (Word variations have been searched)
#28 #21 or #22 or #23 or #24 or #25 or #26 or #27
#29 #6 and #28
#30 MeSH descriptor: [Sympathectomy] explode all trees
#31 sympathectom*:ti,ab,kw or sympathicotom*:ti,ab,kw or sympathotom*:ti,ab,kw or sympathetic
near/2 (ablation or surgery or block* or excision*):ti,ab,kw or (endoscopic thoracic sympathectom*) or ETS:
ti,ab,kw (Word variations have been searched)
#32 #30 or #31
#33 #6 and #32
#34 MeSH descriptor: [Curettage] explode all trees
#35 “curettage”:ti,ab,kw or curretage:ti,ab,kw (Word variations have been searched)
#36 #34 or #35
#37 #6 and #36
#38 MeSH descriptor: [Lasers] explode all trees
#39 laser*:ti,ab,kw (Word variations have been searched)
#40 #38 or #39
#41 #6 and #40
#42 MeSH descriptor: [Microwaves] explode all trees
#43 microwave*:ti,ab,kw (Word variations have been searched)
#44 #42 or #43
#45 #6 and #44
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#46 MeSH descriptor: [Ultrasonic Therapy] explode all trees
#47 “ultrasound”:ti,ab,kw (Word variations have been searched)
#48 #46 or #47
#49 #6 and #48
#50 MeSH descriptor: [Lipectomy] explode all trees
#51 lipectom* or liposuction:ti,ab,kw (Word variations have been searched)
#52 #50 or #51
#53 #6 and #52
#54 miraDry:ti,ab,kw or bilateral axillae aspiration:ti,ab,kw or shelley* procedure*:ti,ab,kw or (remove*
or removal or removing) near/2 (sweat gland*):ti,ab,kw (Word variations have been searched)
#55 MeSH descriptor: [Clonidine] explode all trees
#56 MeSH descriptor: [Diltiazem] explode all trees
#57 MeSH descriptor: [Benzodiazepines] explode all trees
#58 #55 or #56 or #57
#59 #6 and #58
#60 #12 or #16 or #20 or #29 or #33 or #37 or #41 or #45 or #49 or #53 or #59
EMBASE
Date range searched: 1974 to 8 January 2016.
Date searched: 12 January 2016.
Search strategy
1. Hyperhidrosis/ (6531)
2. hyperhidrosis.ti,ab. (3530)
3. hyperhydrosis.ti,ab. (352)
4. (excess$ adj2 sweat$).ti,ab. (778)
5. (primary HH or secondary HH).ti,ab. (13)
6. 1 or 2 or 3 or 4 or 5 (7562)
7. antiperspirant agent/ or deodorant agent/ (1077)
8. Aluminum Derivative/ (4496)
9. (aluminum adj2 (chloride or hydrochloride)).ti,ab. (1106)
10. (aluminium adj2 (chloride or hydrochloride)).ti,ab. (704)
11. (antiperspirant$ or deodorant$).ti,ab. (846)
12. driclor.ti,ab. (1)
13. anhydrol forte.ti,ab. (0)
14. 7 or 8 or 9 or 10 or 11 or 12 or 13 (7499)
15. 6 and 14 (260)
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16. Iontophoresis/ (9004)
17. (iontophoresis or iontophoreses).ti,ab. (4755)
18. 16 or 17 (10,143)
19. 6 and 18 (361)
20. Botulinum Toxin A/ (15,690)
21. botulinum toxin$.ti,ab. (14,121)
22. botox.ti,ab. (2489)
23. 20 or 21 or 22 (21,445)
24. 6 and 23 (1011)
25. exp Cholinergic Receptor Blocking Agent/ or exp Muscarinic Receptor Blocking Agent/ (158,851)
26. exp Quaternary Ammonium Derivative/ (69,462)
27. Glycopyrrolate/ (5067)
28. Glycopyrronium Bromide/ (5067)
29. glycopyrronium bromide.ti,ab. (140)
30. robinul.ti,ab. (18)
31. glycopyrrolate.ti,ab. (988)
32. propantheline.ti,ab. (451)
33. anticholinergic$.ti,ab. (14,310)
34. pro-banthine.ti,ab. (31)
35. oxybutynin.ti,ab. (1551)
36. methantheline.ti,ab. (54)
37. vagantin.ti,ab. (3)
38. methantheliniumbromide.ti,ab. (2)
39. atropine.ti,ab. (30,771)
40. 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 (221,161)
41. 6 and 40 (630)
42. exp Sympathectomy/ (9187)
43. sympathectom$.ti,ab. (7408)
44. sympathicotom$.ti,ab. (148)
45. sympathotom$.ti,ab. (26)
46. (sympathetic adj2 (ablation or surgery or block$ or excision$)).ti,ab. (3191)
47. endoscopic thoracic sympathectom$.ti,ab. (196)
48. ETS.ti,ab. (10895)
49. 42 or 43 or 44 or 45 or 46 or 47 or 48 (25,151)
50. 6 and 49 (1398)
51. Curettage/ (10,938)
52. curettage.ti,ab. (11,284)
53. curretage.ti,ab. (139)
54. 51 or 52 or 53 (16,384)
55. 6 and 54 (88)
56. exp Laser/ (96,883)
57. laser$.ti,ab. (201,279)
58. 56 or 57 (217,779)
59. 6 and 58 (138)
60. Microwave Radiation/ (17,993)
61. microwave$.ti,ab. (28,836)
62. 60 or 61 (31,972)
63. 6 and 62 (28)
64. exp Ultrasound Therapy/ (19,942)
65. ultrasonic therapy.ti,ab. (489)
66. ultrasound.ti,ab. (251,254)
67. 64 or 65 or 66 (264,491)
68. 6 and 67 (61)
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69. Lipectomy/ (1690)
70. (lipectom$ or liposuction).ti,ab. (3524)
71. 69 or 70 (4289)
72. 6 and 71 (58)
73. miraDry.ti,ab. (2)
74. bilateral axillae aspiration.ti,ab. (0)
75. shelley$ procedure$.ti,ab. (1)
76. ((remove$ or removal or removing) adj2 sweat gland$).ti,ab. (14)
77. 6 and 76 (9)
78. Clonidine/ (38,187)
79. Diltiazem/ (26,350)
80. Benzodiazepine/ (22,631)
81. 78 or 79 or 80 (84,820)
82. 6 and 81 (206)
83. 15 or 19 or 24 or 41 or 50 or 55 or 59 or 63 or 68 or 72 or 73 or 74 or 75 or 77 or 82 (3122)
MEDLINE(R) In-Process & Other Non-Indexed Citations [Ovid MEDLINE(R)]
Date range searched: 1946 to present.
Date searched: 12 January 2016.
Search strategy
1. exp Hyperhidrosis/ (3163)
2. hyperhidrosis.ti,ab. (2736)
3. hyperhydrosis.ti,ab. (181)
4. (excess$ adj2 sweat$).ti,ab. (526)
5. (primary HH or secondary HH).ti,ab. (10)
6. 1 or 2 or 3 or 4 or 5 (4434)
7. antiperspirants/ or deodorants/ (442)
8. Aluminum Compounds/ (4302)
9. (aluminum adj2 (chloride or hydrochloride)).ti,ab. (776)
10. (aluminium adj2 (chloride or hydrochloride)).ti,ab. (357)
11. (antiperspirant$ or deodorant$).ti,ab. (582)
12. driclor.ti,ab. (1)
13. anhydrol forte.ti,ab. (0)
14. 7 or 8 or 9 or 10 or 11 or 12 or 13 (5773)
15. 6 and 14 (173)
16. Iontophoresis/ (6927)
17. (iontophoresis or iontophoreses).ti,ab. (3962)
18. 16 or 17 (8461)
19. 6 and 18 (201)
20. exp Botulinum Toxins/ (13,444)
21. botulinum toxin$.ti,ab. (10,541)
22. botox.ti,ab. (1499)
23. 20 or 21 or 22 (16,204)
24. 6 and 23 (643)
25. exp Cholinergic Antagonists/ or exp Muscarinic Antagonists/ (75,966)
26. Quaternary Ammonium Compounds/ (22,384)
27. Glycopyrrolate/ (764)
28. glycopyrronium bromide.ti,ab. (67)
29. robinul.ti,ab. (17)
30. glycopyrrolate.ti,ab. (798)
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31. propantheline.ti,ab. (382)
32. anticholinergic$.ti,ab. (10,401)
33. pro-banthine.ti,ab. (31)
34. oxybutynin.ti,ab. (1148)
35. methantheline.ti,ab. (58)
36. vagantin.ti,ab. (3)
37. methantheliniumbromide.ti,ab. (2)
38. atropine.ti,ab. (26,989)
39. 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 (116,077)
40. 6 and 39 (229)
41. Sympathectomy/ (8186)
42. sympathectom$.ti,ab. (6642)
43. sympathicotom$.ti,ab. (122)
44. sympathotom$.ti,ab. (27)
45. (sympathetic adj2 (ablation or surgery or block$ or excision$)).ti,ab. (2523)
46. endoscopic thoracic sympathectom$.ti,ab. (165)
47. ETS.ti,ab. (9160)
48. 41 or 42 or 43 or 44 or 45 or 46 or 47 (22,526)
49. 6 and 48 (1158)
50. Curettage/ (3791)
51. curettage.ti,ab. (9465)
52. curretage.ti,ab. (89)
53. 50 or 51 or 52 (11,530)
54. 6 and 53 (70)
55. Lasers/ (33,355)
56. laser$.ti,ab. (205,410)
57. 55 or 56 (210,678)
58. 6 and 57 (69)
59. Microwaves/ (14,078)
60. microwave$.ti,ab. (24,745)
61. 59 or 60 (27,361)
62. 6 and 61 (15)
63. Ultrasonic therapy/ (8596)
64. ultrasound.ti,ab. (176,119)
65. 63 or 64 (180,393)
66. 6 and 65 (33)
67. Lipectomy/ (3579)
68. (lipectom$ or liposuction).ti,ab. (3378)
69. 67 or 68 (4803)
70. 6 and 69 (67)
71. miraDry.ti,ab. (0)
72. bilateral axillae aspiration.ti,ab. (0)
73. shelley$ procedure$.ti,ab. (1)
74. ((remove$ or removal or removing) adj2 sweat gland$).ti,ab. (12)
75. 6 and 74 (9)
76. Clonidine/ (13,027)
77. Diltiazem/ (6062)
78. Benzodiazepines/ (19,607)
79. 76 or 77 or 78 (38,568)
80. 6 and 79 (27)
81. 15 or 19 or 24 or 40 or 49 or 54 or 58 or 62 or 66 or 70 or 71 or 72 or 73 or 75 or 80 (2162)
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PsycINFO (via OvidSP)
Date range searched: 1806 to January week 1 2016.
Date searched: 12 January 2016.
Search strategy
1. hyperhidrosis.ti,ab. (145)
2. hyperhydrosis.ti,ab. (26)
3. (excess$ adj2 sweat$).ti,ab. (89)
4. (primary HH or secondary HH).ti,ab. (1)
5. 1 or 2 or 3 or 4 (236)
6. Aluminum/ (155)
7. (aluminum adj2 (chloride or hydrochloride)).ti,ab. (21)
8. (aluminium adj2 (chloride or hydrochloride)).ti,ab. (8)
9. (antiperspirant$ or deodorant$).ti,ab. (38)
10. driclor.ti,ab. (0)
11. anhydrol forte.ti,ab. (0)
12. 6 or 7 or 8 or 9 or 10 or 11 (206)
13. 5 and 12 (1)
14. (iontophoresis or iontophoreses).ti,ab. (172)
15. 5 and 14 (0)
16. exp Botulinum Toxin/ (794)
17. botulinum toxin$.ti,ab. (1052)
18. botox.ti,ab. (158)
19. 16 or 17 or 18 (1177)
20. 5 and 19 (26)
21. exp Cholinergic Blocking Drugs/ (14,427)
22. cholinergic receptor blocking agent$.ti,ab. (1)
23. muscarinic antagonist$.ti,ab. (350)
24. muscarinic receptor blocking agent$.ti,ab. (1)
25. (quaternary ammonium adj (compound$ or derivative$)).ti,ab. (13)
26. glycopyrronium bromide.ti,ab. (4)
27. robinul.ti,ab. (0)
28. glycopyrrolate.ti,ab. (40)
29. propantheline.ti,ab. (4)
30. anticholinergic$.ti,ab. (2470)
31. pro-banthine.ti,ab. (1)
32. oxybutynin.ti,ab. (52)
33. methantheline.ti,ab. (0)
34. vagantin.ti,ab. (0)
35. methantheliniumbromide.ti,ab. (0)
36. atropine.ti,ab. (1746)
37. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 (17,317)
38. 5 and 37 (12)
39. Sympathectomy/ (77)
40. sympathectom$.ti,ab. (289)
41. sympathicotom$.ti,ab. (3)
42. sympathotom$.ti,ab. (1)
43. (sympathetic adj2 (ablation or surgery or block$ or excision$)).ti,ab. (124)
44. endoscopic thoracic sympathectom$.ti,ab. (2)
45. ETS.ti,ab. (536)
46. 39 or 40 or 41 or 42 or 43 or 44 or 45 (949)
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47. 5 and 46 (15)
48. curettage.ti,ab. (33)
49. curretage.ti,ab. (0)
50. 48 or 49 (33)
51. 5 and 50 (0)
52. laser$.ti,ab. (2561)
53. 5 and 52 (0)
54. microwave$.ti,ab. (207)
55. 5 and 54 (0)
56. Ultrasound/ (1198)
57. ultrasound.ti,ab. (2502)
58. ultrasonic therapy.ti,ab. (4)
59. 56 or 57 or 58 (2865)
60. 5 and 59 (0)
61. (lipectom$ or liposuction).ti,ab. (29)
62. 5 and 61 (0)
63. miraDry.ti,ab. (0)
64. bilateral axillae aspiration.ti,ab. (0)
65. shelley$ procedure$.ti,ab. (0)
66. ((remove$ or removal or removing) adj2 sweat gland$).ti,ab. (0)
67. 5 and 66 (0)
68. Clonidine/ (1307)
69. diltiazem.ti,ab. (127)
70. Benzodiazepines/ (4610)
71. 68 or 69 or 70 (6025)
72. 5 and 71 (3)
73. 13 or 15 or 20 or 38 or 47 or 51 or 53 or 55 or 60 or 62 or 63 or 64 or 65 or 67 or 72 (53)
PubMed
URL: www.ncbi.nlm.nih.gov/pubmed
Date searched: 14 January 2016.
Search strategy
#1 Search (((((Hyperhidrosis[MeSH Terms]) OR hyperhidrosis[Title/Abstract]) OR hyperhydrosis[Title/Abstract]) OR
“excess* sweat*”[Title/Abstract]) OR “primary HH”[Title/Abstract]) OR “secondary HH”[Title/Abstract] (4147)
#2 Search ((((((((((Antiperspirants[MeSH Terms]) OR Deodorants[MeSH Terms]) OR Aluminum Compounds
[MeSH Terms]) OR “aluminum chloride”[Title/Abstract]) OR “aluminum hydrochloride”[Title/Abstract]) OR
“aluminium chloride”[Title/Abstract]) OR “aluminium hydrochloride”[Title/Abstract]) OR antiperspirant*
[Title/Abstract]) OR deodorant*[Title/Abstract]) OR driclor[Title/Abstract]) OR “anhydrol forte” [Title/ Abstract]
(27,492)
#3 Search (#1 AND #2) (180)
#4 Search ((Iontophoresis[MeSH Terms]) OR iontophoresis[Title/Abstract]) OR iontophoreses[Title/Abstract]
(8441)
#5 Search (#1 AND #4) (201)
#6 Search ((Botulinum Toxins[MeSH Terms]) OR “botulinum toxin*”[Title/Abstract]) OR botox[Title/
Abstract] (15,884)
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#7 Search (#1 AND #6) (624)
#8 Search ((((((((((((((Cholinergic Antagonists[MeSH Terms]) OR Muscarinic Antagonists[MeSH Terms]) OR
Quaternary Ammonium Compounds[MeSH Terms]) OR Glycopyrrolate[MeSH Terms]) OR “glycopyrronium
bromide”[Title/Abstract]) OR robinul[Title/Abstract]) OR glycopyrrolate[Title/Abstract]) OR propantheline
[Title/Abstract]) OR anticholinergic*[Title/Abstract]) OR pro-banthine[Title/Abstract]) OR oxybutynin[Title/
Abstract]) OR methantheline[Title/Abstract]) OR vagantin[Title/Abstract]) OR methantheliniumbromide[Title/
Abstract]) OR atropine[Title/Abstract] (156,869)
#9 Search (#1 AND #8) (221)
#10 Search (((((((((Sympathectomy/[MeSH Terms]) OR sympathectom*[Title/Abstract]) OR sympathicotom*
[Title/Abstract]) OR sympathotom*[Title/Abstract]) OR “sympathetic ablation”[Title/Abstract]) OR “sympathetic
surgery”[Title/Abstract]) OR “sympathetic block*”[Title/Abstract]) OR “sympathetic excision*”[Title/Abstract])
OR “endoscopic thoracic sympathectom*” [Title/Abstract]) OR ETS[Title/ Abstract] (17,469)
#11 Search (#1 AND #10) (993)
#12 Search ((Curettage[MeSH Terms]) OR curettage[Title/Abstract]) OR curretage[Title/Abstract] (13,080)
#13 Search (#1 AND #12) (67)
#14 Search (((Lasers[MeSH Terms]) OR Microwaves[MeSH Terms]) OR laser*[Title/Abstract]) OR
microwave*[Title/Abstract] (241,816)
#15 Search (#1 AND #14) (80)
#17 Search (Search ((((Ultrasonic therapy[MeSH Terms]) OR ultrasound[Title/Abstract]) OR Lipectomy [MeSH
Terms]) OR lipectom*[Title/Abstract]) OR liposuction[Title/Abstract]) (4668)
#18 Search (#1 AND #17) (49)
#19 Search ((((bilateral axillae aspiration[Title/Abstract]) OR “shelley* procedure*”[Title/Abstract]) OR
“remove* sweat gland*”[Title/Abstract]) OR “removal sweat gland*”[Title/Abstract]) OR “removing
sweat gland*”[Title/Abstract] (6)
#20 Search ((Clonidine[MeSH Terms]) OR Diltiazem[MeSH Terms]) OR Benzodiazepines[MeSH Terms]
(78,025)
#21 Search (#1 AND #20) (34)
#22 Search (#3 OR #5 OR #7 OR #9 OR #11 OR #13 OR #15 OR #18 OR #19 OR #21) (1989)
Hyperhidrosis quality-of-life literature searching
The searches for hyperhidrosis and quality of life combined the six initial lines of the effectiveness search
strategy with a published MEDLINE search filter (URL: www.yhec.co.uk/yhec-content/uploads/2015/06/
Poster-374-Sensitivity-Of-A-Search-Filter.pdf) designed to retrieve studies reporting health state utility
values. The search filter was adapted as required for each of the databases searched.
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Databases searched
AMED 5 records
British Nursing Index 2 records
CINAHL 55 records
EMBASE 646 records
MEDLINE 99 records
PsycINFO 19 records
PubMed 197 records
Three hundred and thirty-seven records identified after deduplication (against the other quality-of-life
search results and the effectiveness search results).
Allied and Complementary Medicine Database (via OvidSP)
Date range searched: 1985 to January 2016.
Date searched: 21 January 2016.
Search strategy
1. exp Hyperhidrosis/ (24)
2. hyperhidrosis.ti,ab. (31)
3. hyperhydrosis.ti,ab. (2)
4. (excess$ adj2 sweat$).ti,ab. (15)
5. (primary HH or secondary HH).ti,ab. (0)
6. 1 or 2 or 3 or 4 or 5 (45)
7. “Quality of Life”/ (7722)
8. (qaly$ or qald$ or qale$ or qtime$).ti,ab,kf. (71)
9. (quality adjusted or adjusted life year$).ti,ab,kf. (112)
10. disability adjusted life.ti,ab,kf. (13)
11. daly$1.ti,ab,kf. (10)
12. ((index adj3 wellbeing) or (quality adj3 wellbeing) or qwb).ti,ab,kf. (46)
13. (multiattribute$ or multi attribute$).ti,ab,kf. (19)
14. (utility adj3 (score$1 or scoring or valu$ or measur$ or evaluat$ or scale$1 or instrument$1 or weight
or weights or weighting or information or data or unit or units or health$ or life or estimat$ or elicit$
or disease$ or mean or cost$ or expenditure$1 or gain or gains or loss or losses or lost or analysis or
index$ or indices or overall or reported or calculat$ or range$ or increment$ or state or states or
status)).ti,ab,kf. (571)
15. utility.ab. /freq=2 (228)
16. utilities.ti,ab,kf. (123)
17. disutili$.ti,ab,kf. (5)
18. (HSUV or HSUVs).ti,ab,kf. (0)
19. health$1 year$1 equivalent$1.ti,ab,kf. (0)
20. (hye or hyes).ti,ab,kf. (0)
21. (hui or hui1 or hui2 or hui3).ti,ab,kf. (67)
22. (illness state$1 or health state$1).ti,ab,kf. (145)
23. (euro qual or euro qual5d or euro qol5d or eq-5d or eq5-d or eq5d or euroqual or euroqol or
euroqual5d or euroqol5d).ti,ab,kf. (302)
24. (eq-sdq or eqsdq).ti,ab,kf. (0)
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25. (short form$ or shortform$).ti,ab,kf. (1525)
26. (sf36$ or sf 36$ or sf thirtysix or sf thirty six).ti,ab,kf. (1524)
27. (sf6 or sf 6 or sf6d or sf 6d or sf six or sfsix or sf8 or sf 8 or sf eight or sfeight).ti,ab,kf. (55)
28. (sf12 or sf 12 or sf twelve or sftwelve).ti,ab,kf. (177)
29. (sf16 or sf 16 or sf sixteen or sfsixteen).ti,ab,kf. (0)
30. (sf20 or sf 20 or sf twenty or sftwenty).ti,ab,kf. (7)
31. (15D or 15-D or 15 dimension).ti,ab,kf. (37)
32. (standard gamble$ or sg).ti,ab,kf. (87)
33. (time trade off$1 or time tradeoff$1 or tto or timetradeoff$1).ti,ab,kf. (53)
34. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or
24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 (9833)
35. 6 and 34 (5)
36. dermatology life quality index.ti,ab. (3)
37. DLQI.ti,ab. (2)
38. Skindex$.ti,ab. (2)
39. Hyperhidrosis Disease Severity Scale.ti,ab. (0)
40. HDSS.ti,ab. (0)
41. Hyperhidrosis Scale.ti,ab. (0)
42. Hyperhidrosis Quality of Life Questionnaire.ti,ab. (0)
43. HQLQ.ti,ab. (1)
44. Illness Intrusiveness Rating Scale.ti,ab. (2)
45. IIRS.ti,ab. (2)
46. 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 (9)
47. 6 and 46 (1)
48. 35 or 47 (5)
British Nursing Index (via ProQuest)
Date searched: 21 January 2016.
Search strategy
(((SU.EXACT.EXPLODE(“Health and Quality of Life”) OR (qaly* OR qald* OR qale* OR qtime*) OR ((quality
adjusted) OR (adjusted life year*)) OR (disability adjusted life OR daly*) OR ((index N3 wellbeing) OR
(quality N3 wellbeing) OR qwb) OR (multiattribute* OR multi attribute*) OR (utility N3 (score* OR scoring
OR valu* OR measur* OR evaluat* OR scale* OR instrument* OR weight OR weights OR weighting OR
information OR data OR unit OR units OR health* OR life OR estimat* OR elicit* OR disease* OR mean OR
cost* OR expenditure* OR gain OR gains OR loss OR losses OR lost OR analysis OR index* OR indices OR
overall OR reported OR calculat* OR range* OR increment OR state OR states OR status)) OR (utilities OR
disutili*)) OR ((HSUV OR HSUVs) OR (health* year* equivalent*) OR (hye OR hyes) OR (hui OR hui1 OR
hui2 OR hui3) OR ((illness state*) OR (health state*))) OR (“euro qual” OR “euro qual5D” OR “euro qol5d”
OR eq-5d OR eq5-d OR eq5d OR euroqual OR euroquol OR euroqual5d OR euroqol5d) OR ((eq-sdq OR
eqsdq) OR (“short form*” OR shortform*) OR (sf36* OR “sf 36*” OR “sf thirtysix” OR “sf thirty six”) OR
(sf6 OR “sf 6” OR sf6d OR “sf 6d” OR “sf six” OR sfsix OR sf8 OR “sf 8” OR “sf eight” OR sfeight) OR
(sf12 OR “sf 12” OR “sf twelve” OR sftwelve) OR (sf16 OR “sf 16” OR “sf sixteen” OR sfsixteen)) OR
((sf20 OR “sf 20” OR “sf twenty” OR sftwenty) OR (15D OR 15-D OR “15 dimension”) OR (“standard
gamble*” OR sg) OR (“time trade off*” OR timetradeoff* OR tto))) OR (“dermatology life quality index”
OR DLQI OR (Skindex* OR HQLQ) OR (“Hyperhidrosis Disease Severity Scale” OR HDSS) OR (“Hyperhidrosis
Scale” OR “Hyperhidrosis Quality of Life Questionnaire”) OR (“Illness Intrusiveness Rating Scale” OR IIRS)))
AND (Hyperhidrosis OR Hyperhydrosis OR (excess* N2 sweat*) OR (“primary HH” OR “secondary HH”))
Cumulative Index of Nursing and Allied Health Literature (via EBSCOhost)
Date searched: 21 January 2016.
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Search strategy
S1 hyperhidrosis OR hyperhidrosis OR excess* N2 sweat* OR primary HH OR secondary HH
S2 (MH “Quality of Life”)
S3 (MH “Quality-Adjusted Life Years”)
S4 TX ( (qaly* or qald* or qale* or qtime*) ) OR TX ( (quality adjusted or adjusted life year*) ) OR TX
disability adjusted life OR TX daly* OR TX ( (index N3 wellbeing) or (quality N3 wellbeing) or qwb ) OR TX
( (multiattribute* or multi attribute*) ) OR TX ( utility N3 (score* or scoring or valu* or measur* or evaluat*
or scale* or instrument* or weight or weights or weighting or information or data or unit or units or
health* or life or estimat* or elicit* or disease* or mean or cost* or expendi . . .
S5 TX ( (hui or hui1 or hui2 or hui3) ) OR TX ( (illness state* or health state*) ) OR TX ( (euro qual or euro
qual5d or euro qol5d or eq-5d or eq5-d or eq5d or euroqual or euroqol or euroqual5d or euroqol5d) ) OR
TX ( (eq-sdq or eqsdq) ) OR TX ( (short form* or shortform*) ) OR TX ( (sf36* or sf 36* or sf thirtysix or sf
thirty six) ) OR TX ( (sf6 or sf 6 or sf6d or sf 6d or sf six or sfsix or sf8 or sf 8 or sf eight or sfeight) ) OR TX
( (sf12 or sf 12 or sf twelve or sftwelve) ) OR TX ( (sf16 or . . .
S6 TX (time trade off* or time tradeoff* or tto or timetradeoff*)
S7 “dermatology life quality index” OR DLQI OR Skindex* OR “Hyperhidrosis Disease Severity Scale”
OR HDSS OR “Hyperhidrosis Scale” OR “Hyperhidrosis Quality of Life Questionnaire” OR HQLQ OR “Illness
Intrusiveness Rating Scale” OR IIRS (175)
S8 S2 OR S3 OR S4 OR S5 OR S6 OR S7 (186,197)
S9 S1 AND S8 Search modes - Boolean/Phrase (55)
EMBASE (via OvidSP)
Date range searched: 1974 to 20 January 2016.
Date searched: 21 January 2016.
Search strategy
1. exp Hyperhidrosis/ (6552)
2. hyperhidrosis.ti,ab. (3538)
3. hyperhydrosis.ti,ab. (352)
4. (excess$ adj2 sweat$).ti,ab. (782)
5. (primary HH or secondary HH).ti,ab. (13)
6. 1 or 2 or 3 or 4 or 5 (7583)
7. Quality of Life/ (305,322)
8. Quality-Adjusted Life Year/ (15,384)
9. Quality of Life Index/ (2010)
10. exp Short Form 36/ (17,697)
11. (qaly$ or qald$ or qale$ or qtime$).ti,ab,kf. (11,511)
12. (quality adjusted or adjusted life year$).ti,ab,kf. (13,879)
13. disability adjusted life.ti,ab,kf. (2068)
14. daly$1.ti,ab,kf. (2103)
15. ((index adj3 wellbeing) or (quality adj3 wellbeing) or qwb).ti,ab,kf. (687)
16. (multiattribute$ or multi attribute$).ti,ab,kf. (728)
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17. (utility adj3 (score$1 or scoring or valu$ or measur$ or evaluat$ or scale$1 or instrument$1 or weight
or weights or weighting or information or data or unit or units or health$ or life or estimat$ or elicit$
or disease$ or mean or cost$ or expenditure$1 or gain or gains or loss or losses or lost or analysis or
index$ or indices or overall or reported or calculat$ or range$ or increment$ or state or states or
status)).ti,ab,kf. (31,947)
18. utility.ab. /freq=2 (16,325)
19. utilities.ti,ab,kf. (7320)
20. disutili$.ti,ab,kf. (499)
21. (HSUV or HSUVs).ti,ab,kf. (35)
22. health$1 year$1 equivalent$1.ti,ab,kf. (39)
23. (hye or hyes).ti,ab,kf. (98)
24. (hui or hui1 or hui2 or hui3).ti,ab,kf. (1508)
25. (illness state$1 or health state$1).ti,ab,kf. (7072)
26. (euro qual or euro qual5d or euro qol5d or eq-5d or eq5-d or eq5d or euroqual or euroqol or
euroqual5d or euroqol5d).ti,ab,kf. (9732)
27. (eq-sdq or eqsdq).ti,ab,kf. (0)
28. (short form$ or shortform$).ti,ab,kf. (27,842)
29. (sf36$ or sf 36$ or sf thirtysix or sf thirty six).ti,ab,kf. (25,379)
30. (sf6 or sf 6 or sf6d or sf 6d or sf six or sfsix or sf8 or sf 8 or sf eight or sfeight).ti,ab,kf. (2979)
31. (sf12 or sf 12 or sf twelve or sftwelve).ti,ab,kf. (4775)
32. (sf16 or sf 16 or sf sixteen or sfsixteen).ti,ab,kf. (35)
33. (sf20 or sf 20 or sf twenty or sftwenty).ti,ab,kf. (298)
34. (15D or 15-D or 15 dimension).ti,ab,kf. (4859)
35. (standard gamble$ or sg).ti,ab,kf. (9779)
36. (time trade off$1 or time tradeoff$1 or tto or timetradeoff$1).ti,ab,kf. (1878)
37. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or
24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 (400,530)
38. 6 and 37 (594)
39. dermatology life quality index.ti,ab. (1620)
40. DLQI.ti,ab. (1480)
41. Skindex$.ti,ab. (488)
42. Hyperhidrosis Disease Severity Scale.ti,ab. (67)
43. HDSS.ti,ab. (284)
44. Hyperhidrosis Scale.ti,ab. (0)
45. Hyperhidrosis Quality of Life Questionnaire.ti,ab. (0)
46. HQLQ.ti,ab. (22)
47. Illness Intrusiveness Rating Scale.ti,ab. (31)
48. IIRS.ti,ab. (75)
49. 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 (2767)
50. 6 and 49 (121)
51. 38 or 50 (646)
MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R)
(via OvidSP)
Date range searched: 1946 to present.
Date searched: 21 January 2016.
Search strategy
1. exp Hyperhidrosis/ (3213)
2. hyperhidrosis.ti,ab. (2673)
3. hyperhydrosis.ti,ab. (181)
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4. (excess$ adj2 sweat$).ti,ab. (518)
5. (primary HH or secondary HH).ti,ab. (10)
6. 1 or 2 or 3 or 4 or 5 (4375)
7. Quality-Adjusted Life Years/ (7896)
8. Value of Life/ (5469)
9. (qaly$ or qald$ or qale$ or qtime$).ti,ab,kf. (6327)
10. (quality adjusted or adjusted life year$).ti,ab,kf. (9728)
11. disability adjusted life.ti,ab,kf. (1716)
12. daly$1.ti,ab,kf. (1600)
13. ((index adj3 wellbeing) or (quality adj3 wellbeing) or qwb).ti,ab,kf. (434)
14. (multiattribute$ or multi attribute$).ti,ab,kf. (569)
15. (utility adj3 (score$1 or scoring or valu$ or measur$ or evaluat$ or scale$1 or instrument$1 or weight
or weights or weighting or information or data or unit or units or health$ or life or estimat$ or elicit$
or disease$ or mean or cost$ or expenditure$1 or gain or gains or loss or losses or lost or analysis or
index$ or indices or overall or reported or calculat$ or range$ or increment$ or state or states or
status)).ti,ab,kf. (21,810)
16. utility.ab. /freq=2 (10,938)
17. utilities.ti,ab,kf. (4656)
18. disutili$.ti,ab,kf. (275)
19. (HSUV or HSUVs).ti,ab,kf. (22)
20. health$1 year$1 equivalent$1.ti,ab,kf. (40)
21. (hye or hyes).ti,ab,kf. (57)
22. (hui or hui1 or hui2 or hui3).ti,ab,kf. (1051)
23. (illness state$1 or health state$1).ti,ab,kf. (4369)
24. (euro qual or euro qual5d or euro qol5d or eq-5d or eq5-d or eq5d or euroqual or euroqol or
euroqual5d or euroqol5d).ti,ab,kf. (5345)
25. (eq-sdq or eqsdq).ti,ab,kf. (0)
26. (short form$ or shortform$).ti,ab,kf. (21,115)
27. (sf36$ or sf 36$ or sf thirtysix or sf thirty six).ti,ab,kf. (15,765)
28. (sf6 or sf 6 or sf6d or sf 6d or sf six or sfsix or sf8 or sf 8 or sf eight or sfeight).ti,ab,kf. (2242)
29. (sf12 or sf 12 or sf twelve or sftwelve).ti,ab,kf. (2820)
30. (sf16 or sf 16 or sf sixteen or sfsixteen).ti,ab,kf. (19)
31. (sf20 or sf 20 or sf twenty or sftwenty).ti,ab,kf. (310)
32. (15D or 15-D or 15 dimension).ti,ab,kf. (4004)
33. (standard gamble$ or sg).ti,ab,kf. (7088)
34. (time trade off$1 or time tradeoff$1 or tto or timetradeoff$1).ti,ab,kf. (1349)
35. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or
24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 (95,049)
36. 6 and 35 (27)
37. dermatology life quality index.ti,ab. (914)
38. DLQI.ti,ab. (676)
39. Skindex$.ti,ab. (271)
40. Hyperhidrosis Disease Severity Scale.ti,ab. (40)
41. HDSS.ti,ab. (239)
42. Hyperhidrosis Scale.ti,ab. (0)
43. Hyperhidrosis Quality of Life Questionnaire.ti,ab. (0)
44. HQLQ.ti,ab. (10)
45. Illness Intrusiveness Rating Scale.ti,ab. (19)
46. IIRS.ti,ab. (51)
47. 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 (1544)
48. 6 and 47 (74)
49. 36 or 48 (99)
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PsycINFO (via OvidSP)
Date range searched: 1806 to January week 3 2016.
Date searched: 21 January 2016.
Search strategy
1. hyperhidrosis.ti,ab. (145)
2. hyperhydrosis.ti,ab. (26)
3. (excess$ adj2 sweat$).ti,ab. (89)
4. (primary HH or secondary HH).ti,ab. (1)
5. 1 or 2 or 3 or 4 (236)
6. “Quality of Life”/ (31,012)
7. (qaly$ or qald$ or qale$ or qtime$).ti,ab,kf. (785)
8. (quality adjusted or adjusted life year$).ti,ab,kf. (1212)
9. disability adjusted life.ti,ab,kf. (269)
10. daly$1.ti,ab,kf. (470)
11. ((index adj3 wellbeing) or (quality adj3 wellbeing) or qwb).ti,ab,kf. (309)
12. (multiattribute$ or multi attribute$).ti,ab,kf. (885)
13. (utility adj3 (score$1 or scoring or valu$ or measur$ or evaluat$ or scale$1 or instrument$1 or weight
or weights or weighting or information or data or unit or units or health$ or life or estimat$ or elicit$
or disease$ or mean or cost$ or expenditure$1 or gain or gains or loss or losses or lost or analysis or
index$ or indices or overall or reported or calculat$ or range$ or increment$ or state or states or
status)).ti,ab,kf. (6903)
14. utility.ab. /freq=2 (5182)
15. utilities.ti,ab,kf. (1544)
16. disutili$.ti,ab,kf. (158)
17. (HSUV or HSUVs).ti,ab,kf. (2)
18. health$1 year$1 equivalent$1.ti,ab,kf. (4)
19. (hye or hyes).ti,ab,kf. (13)
20. (hui or hui1 or hui2 or hui3).ti,ab,kf. (439)
21. (illness state$1 or health state$1).ti,ab,kf. (1170)
22. (euro qual or euro qual5d or euro qol5d or eq-5d or eq5-d or eq5d or euroqual or euroqol or
euroqual5d or euroqol5d).ti,ab,kf. (1298)
23. (eq-sdq or eqsdq).ti,ab,kf. (0)
24. (short form$ or shortform$).ti,ab,kf. (9682)
25. (sf36$ or sf 36$ or sf thirtysix or sf thirty six).ti,ab,kf. (3645)
26. (sf6 or sf 6 or sf6d or sf 6d or sf six or sfsix or sf8 or sf 8 or sf eight or sfeight).ti,ab,kf. (281)
27. (sf12 or sf 12 or sf twelve or sftwelve).ti,ab,kf. (807)
28. (sf16 or sf 16 or sf sixteen or sfsixteen).ti,ab,kf. (0)
29. (sf20 or sf 20 or sf twenty or sftwenty).ti,ab,kf. (42)
30. (15D or 15-D or 15 dimension).ti,ab,kf. (169)
31. (standard gamble$ or sg).ti,ab,kf. (750)
32. (time trade off$1 or time tradeoff$1 or tto or timetradeoff$1).ti,ab,kf. (308)
33. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 (53,974)
34. 5 and 33 (14)
35. dermatology life quality index.ti,ab. (23)
36. DLQI.ti,ab. (14)
37. Skindex$.ti,ab. (13)
38. Hyperhidrosis Disease Severity Scale.ti,ab. (3)
39. HDSS.ti,ab. (30)
40. Hyperhidrosis Scale.ti,ab. (0)
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41. Hyperhidrosis Quality of Life Questionnaire.ti,ab. (0)
42. HQLQ.ti,ab. (1)
43. Illness Intrusiveness Rating Scale.ti,ab. (12)
44. IIRS.ti,ab. (22)
45. 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 (100)
46. 5 and 45 (10)
47. 34 or 46 (19)
PubMed
URL: www.ncbi.nlm.nih.gov/pubmed
Date searched: 21 January 2016.
Search strategy
#11 Search (#4 and #10) (197)
#10 Search (#5 or #6 or #7 or #8 or #9) (687,290)
#9 Search (((((((((((((((((((((((“utility overall”) OR “utility reported”) OR “utility calculate*”) OR “utility
range*”) OR “utility increment*”) OR “utility state*”) OR “utility status”) OR (utilities OR disutilities)) OR
(hsuv OR hsu s)) OR “health* year* equivalent*”) OR ((hye OR hyes))) OR ((hui OR hui1 OR hui2 OR hui3)))
OR (“illness state*” OR “health state*”)) OR (“euro qual” OR “euro qual5d” OR “euro qol5d” OR eq-5d
OR eq5-d OR eq5d OR euroqol OR euroqol OR euroqual5d OR euroqol5d)) OR (eq sd OR eedq)) OR (“short
form*” OR shortform*)) OR (sf36* OR “sf 36*” OR “sf thirtysix” OR “sf thirty six”)) OR (sf6 OR “sf 6” OR
sf6d OR “sf 6d” OR “sf six” OR sifsix OR sf8 OR “sf 8” OR “sf eight” OR speight)) OR (sf12 OR “sf 12”
OR “sf twelve” OR twelve)) OR (sf16 OR “sf 16” OR “sf sixteen” OR s sixteen)) OR (sf20 OR “sf 20” OR
“sf twenty” OR twenty)) OR (15D OR 15-D OR 15 dimension)) OR standard gamble*) OR (“time trade
off*” OR “time tradeoff*” OR tto OR “timetradeoff*”) (662,265)
#8 Search (((((((((((((((((((((((“utility overall”) OR “utility reported”) OR “utility calculate*”) OR “utility
range*”) OR “utility increment*”) OR “utility state*”) OR “utility status”) OR (utilities or disutilities)) OR
(HSUV or HSUVs)) OR “health* year* equivalent*”) OR ((hye or hyes))) OR ((hui or hui1 or hui2 or hui3)))
OR (“illness state*” or “health state*”)) OR (“euro qual” or “euro qual5d” or “euro qol5d” or eq-5d or
eq5-d or eq5d or euroqual or euroqol or euroqual5d or euroqol5d)) OR (eq-sdq or eqsdq)) OR (“short
form*” or shortform*)) OR (sf36* or “sf 36*” or “sf thirtysix” or “sf thirty six”)) OR (sf6 or “sf 6” or sf6d
or “sf 6d” or “sf six” or sfsix or sf8 or “sf 8” or “sf eight” or sfeight)) OR (sf12 or “sf 12” or “sf twelve”
or sftwelve)) OR (sf16 or “sf 16” or “sf sixteen” or sfsixteen)) OR (sf20 or “sf 20” or “sf twenty” or
sftwenty)) OR (15D or 15-D or 15 dimension)) OR standard gamble*) OR (“time trade off*” or “time
tradeoff*” or tto or “timetradeoff*”) (219,267)
#7 Search (((((((((((((((“utility information”) OR “utility data”) OR “utility unit*”) OR “utility health*”) OR
“utility life”) OR “utility estimate*”) OR “Utility elicit*”) OR “utility disease*”) OR “utility mean*”) OR
“utility cost*”) OR “utility expenditure*”) OR “utility gain*”) OR “utility loss*”) OR “utility analysis”) OR
“utility index”) OR “utility indices” (68,284)
#6 Search (((((((((((((((((qaly* or qald* or qale* or qtime*))) OR “quality adjusted”) OR “adjusted life
year*”) OR “disability adjusted life”) OR Daly*) OR “index of wellbeing”) OR “quality of wellbeing”) OR
qwb) OR (multiattribute* or “multi attribute*”)) OR “utility score*”) OR “utility scoring”) OR “Utility
valu*”) OR “Utility measure*”) OR “Utility scale*”) OR “Utility instrument*”) OR “Utility weight*”
(53,715)
#5 Search (Quality-Adjusted Life Years[MeSH Terms]) OR value of life[MeSH Terms] (13,132)
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#4 Search (Hyperhidrosis[MeSH Terms]) OR hyperhidrosis[Title/Abstract]) OR hyperhydrosis[Title/Abstract])
OR “excess* sweat*”[Title/Abstract]) OR “primary HH”[Title/Abstract]) OR “secondary HH”[Title/Abstract])
(4148)
Hyperhidrosis cost-effectiveness literature searching
The searches for hyperhidrosis and cost-effectiveness combined the six initial lines of the effectiveness
search strategy with a published search (URL: www.crd.york.ac.uk/crdweb/searchstrategies.asp), designed
to retrieve studies reporting economic evaluations.
One hundred and forty-eight records identified after deduplication (against the effectiveness search results
and the quality-of-life search results).
Databases searched
EMBASE 167 records
MEDLINE 22 records
NHS EED 18 records
EMBASE (via OvidSP)
Date range searched: 1974 to 25 January 2016.
Date searched: 26 January 2016.
Note, the EMBASE search retrieved 321 records and of these 167 were downloaded (those not identified
by the effectiveness searches).
Search strategy
1. Hyperhidrosis/ (6556)
2. hyperhidrosis.ti,ab. (3538)
3. hyperhydrosis.ti,ab. (352)
4. (excess$ adj2 sweat$).ti,ab. (782)
5. (primary HH or secondary HH).ti,ab. (13)
6. 1 or 2 or 3 or 4 or 5 (7587)
7. antiperspirant agent/ or deodorant agent/ (1078)
8. Aluminum Derivative/ (4515)
9. (aluminum adj2 (chloride or hydrochloride)).ti,ab. (1117)
10. (aluminium adj2 (chloride or hydrochloride)).ti,ab. (711)
11. (antiperspirant$ or deodorant$).ti,ab. (846)
12. driclor.ti,ab. (1)
13. anhydrol forte.ti,ab. (0)
14. 7 or 8 or 9 or 10 or 11 or 12 or 13 (7535)
15. 6 and 14 (260)
16. Iontophoresis/ (9022)
17. (iontophoresis or iontophoreses).ti,ab. (4768)
18. 16 or 17 (10164)
19. 6 and 18 (362)
20. Botulinum Toxin A/ (15,762)
21. botulinum toxin$.ti,ab. (14,205)
22. botox.ti,ab. (2515)
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23. 20 or 21 or 22 (21,564)
24. 6 and 23 (1014)
25. exp Cholinergic Receptor Blocking Agent/ or exp Muscarinic Receptor Blocking Agent/ (159,313)
26. exp Quaternary Ammonium Derivative/ (69,657)
27. Glycopyrrolate/ (5099)
28. Glycopyrronium Bromide/ (5099)
29. glycopyrronium bromide.ti,ab. (142)
30. robinul.ti,ab. (18)
31. glycopyrrolate.ti,ab. (995)
32. propantheline.ti,ab. (455)
33. anticholinergic$.ti,ab. (14,385)
34. pro-banthine.ti,ab. (31)
35. oxybutynin.ti,ab. (1557)
36. methantheline.ti,ab. (55)
37. vagantin.ti,ab. (3)
38. methantheliniumbromide.ti,ab. (2)
39. atropine.ti,ab. (30,840)
40. 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 (221,819)
41. 6 and 40 (634)
42. exp Sympathectomy/ (9206)
43. sympathectom$.ti,ab. (7419)
44. sympathicotom$.ti,ab. (148)
45. sympathotom$.ti,ab. (26)
46. (sympathetic adj2 (ablation or surgery or block$ or excision$)).ti,ab. (3198)
47. endoscopic thoracic sympathectom$.ti,ab. (196)
48. ETS.ti,ab. (10,936)
49. 42 or 43 or 44 or 45 or 46 or 47 or 48 (25,220)
50. 6 and 49 (1398)
51. Curettage/ (10,955)
52. curettage.ti,ab. (11,307)
53. curretage.ti,ab. (139)
54. 51 or 52 or 53 (16,411)
55. 6 and 54 (88)
56. exp Laser/ (97,333)
57. laser$.ti,ab. (202,208)
58. 56 or 57 (218,773)
59. 6 and 58 (138)
60. Microwave Radiation/ (18,060)
61. microwave$.ti,ab. (28,965)
62. 60 or 61 (32,105)
63. 6 and 62 (28)
64. exp Ultrasound Therapy/ (20,005)
65. ultrasonic therapy.ti,ab. (489)
66. ultrasound.ti,ab. (252,978)
67. 64 or 65 or 66 (266,249)
68. 6 and 67 (62)
69. Lipectomy/ (1698)
70. (lipectom$ or liposuction).ti,ab. (3544)
71. 69 or 70 (4312)
72. 6 and 71 (58)
73. miraDry.ti,ab. (2)
74. bilateral axillae aspiration.ti,ab. (0)
75. shelley$ procedure$.ti,ab. (1)
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76. ((remove$ or removal or removing) adj2 sweat gland$).ti,ab. (14)
77. 6 and 76 (9)
78. Clonidine/ (38,239)
79. Diltiazem/ (26,392)
80. Benzodiazepine/ (22,687)
81. 78 or 79 or 80 (84,970)
82. 6 and 81 (207)
83. 15 or 19 or 24 or 41 or 50 or 55 or 59 or 63 or 68 or 72 or 73 or 74 or 75 or 77 or 82 (3131)
84. health economics/ (34,997)
85. exp economic evaluation/ (237,188)
86. exp health care cost/ (228,071)
87. exp pharmacoeconomics/ (176,482)
88. or/84-87 (525,121)
89. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
(696,142)
90. (expenditure$ not energy).ti,ab. (27,775)
91. (value adj2 money).ti,ab. (1645)
92. budget$.ti,ab. (27,781)
93. (or/89) or 90 or 91 or 92 (723,587)
94. 88 or 93 (1,013,374)
95. letter.pt. (921,279)
96. editorial.pt. (497,990)
97. note.pt. (625,236)
98. 95 or 96 or 97 (2,044,505)
99. 94 not 98 (918,417)
100. (metabolic adj cost).ti,ab. (1047)
101. ((energy or oxygen) adj cost).ti,ab. (3454)
102. ((energy or oxygen) adj expenditure).ti,ab. (23,336)
103. 100 or 101 or 102 (26,950)
104. 99 not 103 (912,855)
105. exp animal/ (21,031,187)
106. exp animal experiment/ (1,903,901)
107. nonhuman/ (4,670,037)
108. (rat or rats or mouse oor mice or hamster or hamsters or animal or animals or dog or dogs or cat or
cats or bovine or sheep).ti,ab,sh. (4,193,562)
109. 105 or 106 or 107 or 108 (22,606,867)
110. exp human/ (16,657,067)
111. exp human-experiment/ (346,578)
112. 110 or 111 (16,658,513)
113. 109 not (109 and 112) (5,949,324)
114. 104 not 113 (841,578)
115. 6 and 114 (321)
116. 115 not 83 (167)
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R)
(via Ovid SP)
Date range searched: 1946 to present.
Date searched: 26 January 2016.
The MEDLINE search retrieved 79 records and of these 22 were downloaded (those not identified by the
effectiveness searches).
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Search strategy
1. exp Hyperhidrosis/ (3213)
2. hyperhidrosis.ti,ab. (2674)
3. hyperhydrosis.ti,ab. (181)
4. (excess$ adj2 sweat$).ti,ab. (520)
5. (primary HH or secondary HH).ti,ab. (10)
6. 1 or 2 or 3 or 4 or 5 (4378)
7. antiperspirants/ or deodorants/ (473)
8. Aluminum Compounds/ (4356)
9. (aluminum adj2 (chloride or hydrochloride)).ti,ab. (778)
10. (aluminium adj2 (chloride or hydrochloride)).ti,ab. (352)
11. (antiperspirant$ or deodorant$).ti,ab. (584)
12. driclor.ti,ab. (1)
13. anhydrol forte.ti,ab. (0)
14. 7 or 8 or 9 or 10 or 11 or 12 or 13 (5816)
15. 6 and 14 (173)
16. Iontophoresis/ (7056)
17. (iontophoresis or iontophoreses).ti,ab. (3924)
18. 16 or 17 (8381)
19. 6 and 18 (199)
20. exp Botulinum Toxins/ (12,983)
21. botulinum toxin$.ti,ab. (10,074)
22. botox.ti,ab. (1412)
23. 20 or 21 or 22 (15,668)
24. 6 and 23 (618)
25. exp Cholinergic Antagonists/ or exp Muscarinic Antagonists/ (78,592)
26. Quaternary Ammonium Compounds/ (22,711)
27. Glycopyrrolate/ (774)
28. glycopyrronium bromide.ti,ab. (65)
29. robinul.ti,ab. (17)
30. glycopyrrolate.ti,ab. (786)
31. propantheline.ti,ab. (378)
32. anticholinergic$.ti,ab. (10,252)
33. pro-banthine.ti,ab. (33)
34. oxybutynin.ti,ab. (1131)
35. methantheline.ti,ab. (66)
36. vagantin.ti,ab. (3)
37. methantheliniumbromide.ti,ab. (2)
38. atropine.ti,ab. (26,905)
39. 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 (118,080)
40. 6 and 39 (231)
41. Sympathectomy/ (8586)
42. sympathectom$.ti,ab. (6783)
43. sympathicotom$.ti,ab. (121)
44. sympathotom$.ti,ab. (29)
45. (sympathetic adj2 (ablation or surgery or block$ or excision$)).ti,ab. (2509)
46. endoscopic thoracic sympathectom$.ti,ab. (162)
47. ETS.ti,ab. (8822)
48. 41 or 42 or 43 or 44 or 45 or 46 or 47 (22,433)
49. 6 and 48 (1132)
50. Curettage/ (3988)
51. curettage.ti,ab. (9354)
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52. curretage.ti,ab. (88)
53. 50 or 51 or 52 (11,399)
54. 6 and 53 (64)
55. Lasers/ (32,487)
56. laser$.ti,ab. (201,104)
57. 55 or 56 (206,239)
58. 6 and 57 (68)
59. Microwaves/ (14,045)
60. microwave$.ti,ab. (24,617)
61. 59 or 60 (27,181)
62. 6 and 61 (15)
63. Ultrasonic therapy/ (8490)
64. ultrasound.ti,ab. (172,434)
65. 63 or 64 (176,744)
66. 6 and 65 (32)
67. Lipectomy/ (2921)
68. (lipectom$ or liposuction).ti,ab. (2868)
69. 67 or 68 (4008)
70. 6 and 69 (62)
71. miraDry.ti,ab. (0)
72. bilateral axillae aspiration.ti,ab. (0)
73. shelley$ procedure$.ti,ab. (1)
74. ((remove$ or removal or removing) adj2 sweat gland$).ti,ab. (11)
75. 6 and 74 (9)
76. Clonidine/ (12,706)
77. Diltiazem/ (5969)
78. Benzodiazepines/ (19,158)
79. 76 or 77 or 78 (37,710)
80. 6 and 79 (27)
81. 15 or 19 or 24 or 40 or 49 or 54 or 58 or 62 or 66 or 70 or 71 or 72 or 73 or 75 or 80 (2110)
82. economics/ (26,624)
83. exp “costs and cost analysis”/ or Cost Allocation/ or Cost-Benefit Analysis/ or Cost Control/ or Cost of
Illness/ or Cost Sharing/ or Health Care Costs/ or Health Expenditures/ (193,082)
84. economics, dental/ (1874)
85. exp “economics, hospital”/ or Hospital Charges/ or Hospital Costs/ (20,991)
86. economics, medical/ (8839)
87. economics, nursing/ (3931)
88. economics, pharmaceutical/ (2597)
89. (economic$ or cost$ or price or prices or pricing or pharmacoeconomic$).tw. (559,861)
90. (expenditure$ not energy).tw. (20,734)
91. (value adj1 money).tw. (27)
92. budget$.tw. (21,258)
93. 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 (691,881)
94. ((energy or oxygen) adj cost).ti,ab. (3160)
95. (metabolic adj cost).ti,ab. (953)
96. ((energy or oxygen) adj expenditure).ti,ab. (18,671)
97. or/94-96 (21,995)
98. 93 not 97 (686,861)
99. letter.pt. (898,943)
100. editorial.pt. (391,868)
101. historical article.pt. (325,476)
102. 99 or 100 or 101 (1,600,318)
103. 98 not 102 (655,996)
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104. exp animals/ not humans/ (4,173,052)
105. 103 not 104 (609,814)
106. 6 and 105 (79)
107. 106 not 81 (22)
NHS Economic Evaluation Database
Via CRD website URL: www.crd.york.ac.uk/CRDWeb/HomePage.asp
Date searched: 26 January 2016.
Search strategy
1. MeSH DESCRIPTOR Hyperhidrosis EXPLODE ALL TREES (18)
2. (hyperhidrosis) OR (hyperhydrosis) IN NHSEED (2)
3. (“excessive sweating”) IN NHSEED (0)
4. (primary HH) OR (secondary HH) IN NHSEED (0)
5. #1 OR #2 OR #3 OR # 4 (18)
Ongoing and/or unpublished studies
To identify ongoing and/or unpublished studies we searched the Conference Proceedings Citation Index:
Science (ISI), the ClinicalTrials.gov and World Health Organization International Clinical Trials Registry
Platform Portal trials registries. Details of the search strategies and results are as follows:
Conference Proceedings Citation Index: Science (ISI) via Web of Science
Date searched: 12 July 2016.
Records retrieved n = 335.
Search strategy
#1 253 TOPIC: (Hyperhidrosis)
Indexes=CPCI-S Timespan=All years
#2 17 TOPIC: (hyperhydrosis)
Indexes=CPCI-S Timespan=All years
#3 31 TOPIC: (excess* NEAR/2 sweat*)
Indexes=CPCI-S Timespan=All years
#4 51 TOPIC: (primary HH) OR TOPIC: (secondary HH)
Indexes=CPCI-S Timespan=All years
#5 335 #4 OR #3 OR #2 OR #1
Indexes=CPCI-S Timespan=All years
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Searching for “hyperhidrosis” using ClinicalTrials.gov (URL: https://clinicaltrials.gov/) identified
66 records, whereas using the World Health Organization International Clinical Trials Registry Platform
(URL: www.who.int/ictrp/en/) the same search term identified 106 records. Both searches were conducted
on 12 July 2016.
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Appendix 2 Study details and results tables
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TABLE 42 Iontophoresis vs. placebo: study details and results
Study details
Sample size;
study
location
Patient
characteristics
Hyperhidrosis
severity inclusion
criteria
Body
site Intervention 1 Intervention 2 Results Risk of bias
Dahl and
Glent-Madsen
1989;37 RCT
(half-side
comparison)
11; Denmark Age range:
18–44 years
Male: 27%
NR Palm Iontophoresis (DC
administration, tap water),
0–20mA (median 4mA),
15 minutes, one to five
times per week until ‘good
subjective effect’ was
reported. After the initial
treatments (length NR), six
patients continued on
maintenance treatment
(n= 11)
Sham iontophoresis
(circuit disconnected)
(n= 11)
Sweating (gravimetry): median reduction in
sweat production in iontophoresis-treated
hand: 38% (p< 0.01) (baseline sweating
NR). Median difference between treated
and placebo hand: 32% (p< 0.01). Six
patients continued maintenance treatment
every second week and achieved an 81%
(median) reduction at 3 months (p< 0.05).
AEs: none observed
Unclear
Karakoc et al.
2004;40
interrupted
time series
15; Turkey Age range:
15–26 years
Male: 47%
NR Palm Sham iontophoresis, low
AC current (9–12mA,
10–15 V and 8–10 Hz),
15 minutes, eight times
over 28 days, followed by
iontophoresis (DC
administration with tap
water), DC: 18–22mA and
40–60 V, 15 minutes, eight
times over 28 days (n= 15)
N/A Sweating (gravimetry): reduced by mean
88% in both hands (from mean 3.1± 0.4
g/hour to 0.4± 0.1 g/hour in the right hand
and from 3.2± 0.3 g/hour to 0.4± 0.1
g/hour in the left hand); p< 0.001 at 1
week. No significant change at 1 week for
placebo
High
Stolman
1987;42 RCT
(half-side
comparison)
18; USA Age range:
20–46 years
Male: 44%
Excessive sweating
resulting in a social
or occupational
handicap
Palm Iontophoresis (tap water),
12–20mA, 20 minutes
(polarity reversed after
10 minutes), three times
per week for 3 weeks
(n= 18)
Placebo (tap water
tray without
electrode) (n= 18)
Sweating (iodine starch test): 15/18 patients
experienced a marked reduction in
sweating in the treated hand 5 days after
treatment. There was no change in the
untreated hand. Two patients did not
improve subjectively or by iodine starch test
AEs: one patient dropped out because of
transient erythema of the foot. Three
patients reported slight transient
vesiculation of the skin of the hand,
12 patients noticed redness of the skin for
a number of hours after treatment, two
patients reported intermittent tingling in
the treated hand
Unclear
AE, adverse event; N/A, not applicable.
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TABLE 43 Iontophoresis vs. no treatment: study details and results
Study
details
Sample size;
study location
Patient
characteristics
Hyperhidrosis
severity inclusion
criteria
Body
site Intervention 1 Intervention 2 Results
Risk of
bias
Choi et al.
2013;44 non-
RCT (half-side
comparison)
23; South Korea Age range:
13–64 years
Male: 30%
NR Palm Iontophoresis (dry type),
20 mA, 20 minutes daily
for 4 weeks (left palm;
n= 23)
No treatment
(right palm;
n= 23)
IGA and hydration capacitance:
statistically significant difference
favouring treatment group in
improvement from baseline (data NR)
from 2 to 8 weeks’ follow-up and
after 8 weeks (p< 0.05)
Gravimetry and patient satisfaction:
no statistically significant differences
between hands after 4 weeks of
treatment
AEs: mild local events in two patients
in treated palm [pruritic erythematous
macules (n= 1), hyperpigmentation
(n= 1)]
High
Na et al.
2007;43 non-
RCT (half-side
comparison)
10; South Korea Age range:
18–34 years
Male: 70%
NR Palm Iontophoresis (dry type),
5–25mA/30 minutes
daily for 1 week, then
every other day for 1
week (one palm; n= 10)
No treatment
(contralateral
palm; n = 10)
Sweating (gravimetry): after-treatment
treatment group: mean 42%
reduction from baseline (from mean
4.3 ± 0.4 g/hour to 2.5± 0.4 g/hour);
control group: 2% reduction from
baseline (from 4.2 ± 0.3 g/hour to
4.0 ± 0.3 g/hour). At 2 weeks after
treatment discontinuation treatment
group: mean 19% reduction from
baseline (3.5± 0.4 g/hour); control
group: 2% reduction from baseline
(4.1± 0.4 g/hour). All differences with
control group were statistically
significant (p< 0.001)
Patient satisfaction: 9/10 patients were
satisfied with the therapy
AEs: erythema, mild local burning in
treated hands (number NR)
High
AE, adverse event; NR, not reported.
D
O
I:
1
0
.3
3
1
0
/h
ta
2
1
8
0
0
H
E
A
LT
H
T
E
C
H
N
O
LO
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
7
V
O
L.
2
1
N
O
.
8
0
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
7
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
W
a
d
e
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
1
9
5
TABLE 44 Iontophoresis vs. BTX: study details and results
Study details
Sample
size; study
location
Patient
characteristics
Hyperhidrosis
severity
inclusion
criteria Body site Intervention 1 Intervention 2 Intervention 3 Results
Risk of
bias
Rajagopal and
Mallya 2014;88
RCT (crossover)
60; India Age range:
10–43 years
Male: 65%
HDSS 3–4 Palm Iontophoresis,
2 × 10 minutes+ topical
aluminium chloride
(20% lotion) three times
per week for 4 weeks
(n= 30)
BTX-A (100 U) with
local anaesthesia
(n= 30)
N/A HDSS: response (≥ 2 points reduction):
57% of BTX-A patients vs. 27% in the
iontophoresis group (p= 0.037) at
4 weeks from baseline. Improvement
(≥ 1-point reduction): higher in BTX-A
group (80%) than in iontophoresis
group (47%) and higher in more severe
cases (HDSS 4 at baseline) with BTX-A
than with iontophoresis (p= 0.005).
In non-responders, significantly higher
rates of improvement in those switching
from iontophoresis to BTX-A compared
with those switching from BTX-A to
iontophoresis
Sweating (patient reported): statistically
significant difference favouring BTX-A
in proportion of patients rating
improvement as excellent or good
(80% vs. 47%; p= 0.037)
Effect duration: maintained in all
24 BTX-A responders for approximately
≥ 4 months and all 11 iontophoresis
responders approximately ≥ 1 month
after end of treatment
AEs: none severe; mild-to-moderate pain
(n= 8) and mild temporary motor
weakness (n= 1) in BTX-A group
High
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Study details
Sample
size; study
location
Patient
characteristics
Hyperhidrosis
severity
inclusion
criteria Body site Intervention 1 Intervention 2 Intervention 3 Results
Risk of
bias
Wachal et al.
2009;92 non-RCT
86; Poland Age range:
18–43 years
Male: 28%
NR Palm and
possibly
other
upper limb
Iontophoresis DC,
12–25mA, 20 minutes
every 2–3 days (n= 28)
BTX-A (50 U Botox),
topical anaesthesia
(EMLA) (n= 22)
Sympathectomy
(n= 36)
Sweating (patient reported, VAS):
percentage of patients assessing as good/
very good, VAS score: higher in BTX group
vs. iontophoresis at 1 month (90.9% vs.
35.7%, statistically significant), 6 months
(36.3% vs 28.5%, NS) and 12 months
(14.2% vs. 7.1%, NS)
Willingness to undergo retreatment:
higher for BTX vs. iontophoresis at
1 month (81.8% patients vs. 42.8%,
statistically significant), 6 months
(54.4% vs. 21.4%, NS) and 12 months
(18.1% vs. 7.1%, NS)
AEs: iontophoresis: none; BTX-A: NR
High
AE, adverse event; EMLA, eutectic mixture of local anaesthetics; N/A, not applicable; NR, not reported; NS, non-significant.
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TABLE 45 Iontophoresis with anticholinergics vs. iontophoresis alone: study details and results
Study details
Sample
size; study
location
Patient
characteristics
Hyperhidrosis
severity
inclusion
criteria Body site Intervention 1 Intervention 2 Intervention 3 Results
Risk of
bias
Shimizu et al.
2003;
41
RCT
52; Japan Age range: NR
Male: 44%
NR Palm and
feet
Iontophoresis (AC)
with tap water,
0–20 V, 4.3 kHz,
30 minutes, once
per week (n= 24)
Iontophoresis
(AC)+ oxybutynin,
0–20 V, 4.3 kHz,
30 minutes, once
per week.
Oxybutynin oral
4mg/day (n= 19)
Iontophoresis
(DC), 5–10mA,
30 minutes, once
a week (n= 9)
Sweating (gravimetry): statistically
significant mean reduction from baseline
in all three treatment groups from after
the second treatment (p< 0.05); no
significant difference in effectiveness
between treatment groups. AC group:
reduced by > 32%
a
(from mean
0.73± 0.06mg/cm2/minute at baseline to
below 0.5 mg/cm2/minute) by treatment 2
and reduced by > 66%
a
(from baseline
and to below 0.25mg/cm2/minute) by
treatment 12. AC+ oxybutynin group:
reduced by > 38%
a
(from mean
0.81± 0.07 mg/cm2/minute at baseline to
below 0.5 mg/cm2/minute) by treatment 2
and reduced by > 69%
a
(from baseline to
below 0.25mg/cm2/minute) by treatment
six. DC group: NR
AEs: small vesicles on palms in DC group
(n= 5), dry mouth and eyes in oxybutynin
group (n= 2)
Unclear
Dolianitis et al.
2004;
38
non-RCT
(half-side
comparison)
20; Australia Age range:
12–50 years
Male: 30%
Moderate to
severe (patient
rated)
Palm
(n= 20),
feet (n= 1)
Iontophoresis
(glycopyrrolate
0.05%), 3–20mA
(median 10mA),
once weekly for
10 minutes
(interval based
on response).
Unilateral (n= 20)
Iontophoresis (tap
water), 3–20mA
(median 10mA),
once weekly for
10 minutes.
Unilateral (n= 20)
Iontophoresis
(glycopyrrolate
0.05%), 3–20mA
(median 10mA),
once weekly for
10 minutes.
Unilateral, then
other side treated
2–3 weeks after
(n= 20)
Median number of dry hand days:
following treatment: tap water 3 days
(range 0–15 days), unilateral
glycopyrrolate 5 days (range 0–17 days)
and bilateral glycopyrrolate 11 days (range
0–31 days). Unilateral vs. tap water,
bilateral vs. unilateral, bilateral vs. tap
water all statistically significant (p≤ 0.001)
AEs: dry/sore throat (n= 8) with
glycopyrrolate (increased in bilateral vs.
unilateral)
High
AE, adverse event; NR, not reported.
a Calculated by the CRD.
A
P
P
E
N
D
IX
2
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
1
9
8
TABLE 46 Iontophoresis: non-comparative study details and results
Study
details
Sample
size; study
location
Patient
characteristics
Hyperhidrosis
severity
inclusion
criteria
Body
site Intervention 1 Intervention 2 Results
Risk of
bias
Karakoç
et al. 2002;39
case series
112; Turkey Age range:
8–32 years
Male: 45%
NR Palm Iontophoresis (DC
administration, tap
water), DC: 0–30mA and
0–90 V, 15 minutes each
side, eight times over
28 days (n = 112)
N/A Sweating (gravimetry): 81% with statistically
significant reduction in sweat from baseline.
Right hand: baseline 3.0 ± 1.2 g/hour, final for
responders (n= 91) 0.4 ± 0.1 g/hour, final for
non-responders (n = 21) 2.8 ± 1.0 g/hour. Left
hand: baseline 3.0 ± 1.3 g/hour, final for
responders (n= 91) 0.5 ± 0.2 g/hour, final for
non-responders (n = 21) 2.9 ± 1.0 g/hour.
Difference between baseline and final sweat
intensity for responders was statistically
significant in both hands (p < 0.001)
Effect duration: mean first remission period
35± 6 days
AEs: erythema (n= 12), vesicle (n= 8), discomfort
from burning (n = 20)
High
AE, adverse event; N/A, not applicable; NR, not reported.
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TABLE 47 Glycopyrrolate vs. placebo: study details and results
Study
details
Sample
size;
study
location
Patient
characteristics
Hyperhidrosis
severity
inclusion
criteria
Body
site
Intervention
details Comparators Results
Risk of
bias
Mehrotra
et al. 2015;53
RCT
38; USA Age range:
17–68 years
Male: 42%
HDSS 3–4;
≥ 50mg/
5 minutes
Axilla Glycopyrrolate
wipes 4%; once
daily for 4 weeks
(n = 12)
Glycopyrrolate
wipes 2%; once
daily for 4 weeks
(n = 12)
Placebo
(n = 14)
Gravimetry: mean reduction in sweat rate was larger with
4% glycopyrrolate (59% reduction,a from mean 384
mg/5 minutes to 157mg/5 minutes) than 2% glycopyrrolate
(48% reduction,a from mean 370mg/5 minutes to
191mg/5 minutes) or placebo (16% reduction,a from mean
367mg/5 minutes to 310mg/5 minutes) at the end of
treatment (data extracted from graph)
HDSS: the proportion of patients with reduction of ≥ 2
points was greater in patients receiving glycopyrrolate 4%
(50%) than glycopyrrolate 2% (35%) and placebo (9%) at
the end of treatment (data extracted from graph)
AEs: rates were similar between groups. Three AE were
reported in ≥ 2 patients per group: blurred vision (n= 2) in
glycopyrrolate 4% group, dry mouth and application site
discomfort in at least one glycopyrrolate group (group and n
NR)
High
Hyun et al.
2015;51 RCT
(half-side)
39;
South
Korea
Age range:
20–66 years
Male: 77%
HDSS 3–4 and
≥ 100mg/
20 minutes on
each side of
forehead
Face Glycopyrrolate
wipes (2%),
nine times over
10 days (n= 39)
Placebo
(n = 39)
Gravimetry: statistically significant difference of 37%
(± 11.4) in reduction of sweat production rate favouring
intervention vs. placebo at day 10 (p< 0.025). Baseline
sweat production NR
HDSS: mean (SD) change from baseline on day 10 in HDSS
was 1.08 (0.98) in intervention group vs. 0.90 (0.97) in the
control group (NS, p> 0.025)
AEs: transient headache after intervention (n = 1), no other
AE
Unclear
(gravimetry);
high (HDSS)
AE, adverse event; NR, not reported; NS, non-significant.
a Calculated by the CRD.
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TABLE 49 Oxybutynin vs. placebo: study details and results
Study details
Sample size;
study location
Patient
characteristics
Hyperhidrosis severity
inclusion criteria Body site Intervention Comparator Results
Risk of
bias
Schollhammer
et al. 2015;
59
RCT
62; France Age range:
18–62 years
Male: 43%
HDSS ≥ 2 Generalised
(83%); localised
(17%)
Oxybutynin, starting
dose 2.5 mg daily,
increased to maximum
7.5mg daily, for
6 weeks (n= 32)
Placebo for
6 weeks
(n= 30)
HDSS: ≥ 2-point reduction in HDSS score
oxybutynin: 43%, placebo, 7% at 6 weeks
(p-value NR). ≥ 1-point reduction in HDSS
score: oxybutynin: 60%, placebo, 27%
(p< 0.01) at 6 weeks
DLQI: mean improvement: oxybutynin
6.9 points (from baseline 11.4± 4.1 to
4.5±NR),
a
placebo 2.3 points (from
10.8± 4.7 to 8.5±NR)
a
at 6 weeks.
Statistically significant difference between
groups (p< 0.01)
AEs: dry mouth (43% oxybutynin patients
vs. 11% placebo patients) (p< 0.01),
‘severe intensity’ in two oxybutynin patients
Unclear
Wolosker et al.
2012;
60
RCT
50; Brazil Age range:
18–50 years
Male: 27%
NR Axilla and palm
b
Oxybutynin, starting
dose 2.5 mg daily,
increased to maximum
10mg daily, for
6 weeks (n= 25)
Placebo for
6 weeks
(n= 25)
Sweating (bespoke questionnaire):
moderate or great improvement in palmar
or axillary symptoms: 74% oxybutynin
patients vs. 27% placebo patients
(difference p< 0.001). Moderate or great
improvement in plantar symptoms: 92%
oxybutynin patients vs. 13% placebo
patients (difference p< 0.001)
Quality of life: improved in 74% oxybutynin
patients vs. 14% placebo patients
(p< 0.001)
AEs: moderate or severe dry mouth:
35% oxybutynin patients vs. 9% placebo
patients (p= 0.038, measured during
10-mg dose phase)
Unclear
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Study details
Sample size;
study location
Patient
characteristics
Hyperhidrosis severity
inclusion criteria Body site Intervention Comparator Results
Risk of
bias
Costa et al.
2014
57
and
Costa et al.
2015;
58
RCT
32; Brazil Age range: NR
Male: 0%
Persistent plantar
hyperhidrosis despite
sympathectomy
≥ 6 months earlier
Feet
b
Oxybutynin, starting
dose 2.5 mg daily,
increased to maximum
10mg daily, for
30 days (n= 16)
Placebo for
30 days
(n= 16)
Sweating (evaporimetry): significantly
improved from baseline (p= 0.01) in the
oxybutynin group (right foot: mean 38%
a
reduction, from 140.3± 40.3 g/m2/hour to
87.6± 70.2 g/m2/hour after treatment; right
hand: 54%
a
reduction, from 61.7± 43.9
g/m2/hour to 28.6± 20.5 g/m2/hour; back:
72%
a
reduction, from 38.2± 64.3 g/m2/
hour to 10.8± 8.7 g/m2/hour; abdomen:
58%
a
reduction, from 39.7 ± 46.0 g/m2/
hour to 16.5± 19.2 g/m2/hour), but not the
placebo group (right foot: 9%
a
reduction,
from 112.6± 49.3 g/m2/hour to
102.2± 55.9 g/m2/hour after placebo; right
hand: 14%
a
reduction, from 58.3± 39.3
g/m2/hour to 50.4± 37.8 g/m2/hour; back:
4%
a
increase, from 18.2± 19.0 g/m2/hour
to 19.0± 27.9 g/m2/hour; abdomen: 12%
a
increase, from 24.0± 18.1 g/m2/hour to
26.8± 31.4 g/m2/hour)
Quality of life: significantly improved in the
oxybutynin group from baseline from ‘very
good’ (adjusted quality-of-life mean
40.4± 14.4) at baseline to ‘excellent’
(17.5± 11.9) at follow-up (p= 0.001), but
not the placebo group (‘very good’ at both
time points)
AEs: dry mouth (100% vs. 44%),
constipation (31% vs. 6%) and drowsiness
(18% vs. 6%) more common with
oxybutynin than placebo
Unclear
AE, adverse event; NR, not reported.
a Calculated by the CRD.
b Primarily targeted, although other areas also assessed (see Results column).
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TABLE 50 Methantheline bromide vs. placebo: study details and results
Study
details
Sample size;
study
location
Patient
characteristics
Hyperhidrosis
severity
inclusion
criteria
Body
site Intervention Comparator Results Risk of bias
Müller et al.
2013;
69
RCT
339;
Germany
Age range: NR
Male: NR
≥ 50mg/
5 minutes
Axilla
and/or
palm
Methantheline
bromide,
3 × 50mg daily
for 28 days
(n= 171)
Placebo, three
times per day for
28 days (n= 168)
Sweating (gravimetry, axillae): reduced by 41% (from 168± 146mg/
5 minutes at baseline to 99± 98mg/5 minutes on day 28) in intervention
group vs. 19% (161± 119mg at baseline to 130± 119mg/5 minutes on
day 28) in placebo group (p= 0.0013)
Sweating (gravimetry, palms): no significant difference between groups at
follow-up
HDSS: statistically significant reduction in intervention group vs. placebo
(0.8 vs. 0.5 points reduction, p= 0.002) at day 28
DLQI: statistically significant improvement from baseline favouring
intervention: 6.9 points
a
(±NR) reduction, from 16.6± 5.3 at baseline
to 9.7± 6.8 at day 28; placebo: 4.2 points
a
(±NR) reduction, from
16.4± 5.6 to 12.2± 6.9 at day 28. Difference between groups
statistically significant (p= 0.003)
AEs: more frequent in intervention group: 147 events in 101 patients in
the treatment group vs. 61 events in 50 patients in the placebo group.
Most common: dry mouth, 88 events in treatment group vs. 28 events in
placebo group. 19 methantheline patients dropped out of study because
of AEs or were lost to follow-up. 17 placebo patients dropped out of the
study
Unclear (HDSS,
DLQI, axilla
gravimetry); high
(palm gravimetry)
Hund et al.
2004;
68
RCT
42; Germany Age range:
18–54 years
Male: 25%
≥ 50mg/minute Axilla
and/or
palm
Methantheline
bromide,
2 × 50mg daily
for 4 weeks
(n= 23)
Placebo for
4 weeks (n= 19)
Sweating (gravimetry, axillae): intervention group: 40%
a
reduction in
sweating from baseline [from 89.2± 73.4mg/minute to 53.3± 48.7
mg/minute, (p= 0.02)], compared with no change from baseline for the
placebo group at 4 weeks
Sweating (gravimetry, palms): no differences between intervention and
placebo in palmar hyperhidrosis at 4 weeks. NS difference in number of
patients with overall sweat reduction from baseline to < 50mg/minute
at 4 weeks (treatment: 16/23, placebo 9/18)
AEs: dry mouth (47.8% at week 2 and 34.8% at week 4 in intervention
group vs. 11.1% and 5.6% in placebo group; significant between group
difference p< 0.02). No other differences in AEs reported
High
AE, adverse event; NR, not reported; NS, non-significant.
a Calculated by the CRD.
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TABLE 51 Topical BTX vs. placebo: study details and results
Study details
Sample
size; study
location
Patient
characteristics
Hyperhidrosis
severity
inclusion
criteria
Body
site Intervention 1 Intervention 2 Results
Risk of
bias
Glogau
2007;71 RCT
(half-side
comparison)
12; USA Age range: NR
Male: 50%
≥ 50mg/
5 minutes
Axilla Topical BTX-A
(200 U Botox),
60 minutes
(n= 12)
Placebo
(n = 12)
Sweating (gravimetry): 40% difference in mean sweat
reduction between groups favouring treated axillae at
4 weeks: 65% (± 22%) reduction from baseline in the
BTX-A group (from 89.8mg/5 minutes to 31.4mg/5 minutes)
vs. 25% (± 66%) reduction in the placebo group (from
96.8 mg/5 minutes to 72.6 mg/5 minutes); p< 0.05.
Results confirmed by iodine starch test
AEs: all local, none severe (n= 4; all in placebo group)
Unclear
NR, not reported.
D
O
I:
1
0
.3
3
1
0
/h
ta
2
1
8
0
0
H
E
A
LT
H
T
E
C
H
N
O
LO
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
7
V
O
L.
2
1
N
O
.
8
0
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
7
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
W
a
d
e
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
2
0
5
TABLE 52 Botulinum toxin injection for axillary hyperhidrosis vs. placebo: study details and results
Study details
Sample size;
study
location
Patient
characteristics
Hyperhidrosis
severity
inclusion
criteria Intervention 1 Intervention 2 Results
Risk of
bias
Balzani et al.
2001;72 RCT
4; Italy Age range:
23–65 years
Male: 0%
NR BTX-A (250 U)
(n= 2)
Placebo (n= 2) Sweating (minor test): BTX group: near total reduction from
baseline at 26–28 weeks; placebo: no effect
AE: none
Unclear
Baumann et al.
2005;73 RCT
20; USA Age range: NR
Male: 35%
NR BTX-B (2500 U)
(n= 15)
Placebo (n= 5) Quality of life (Axillary Hyperhidrosis Quality of Life): score
reduction from baseline across groups statistically significant
up to 180 days’ follow-up. Differences between groups NR
AE: 16 events definitely or probably related to BTX-B,
including bruising (four events), pain at injection site (one
event), dry eyes (three events), dry mouth (five events),
indigestion (three events). All were mild–moderate events
High
Heckmann
et al. 2001;75
RCT (half-side
comparison)
145;
Germany
Age range: NR
Male: 52%
≥ 50mg/minute BTX-A (200 U)
(n= 145)
Placebo
(n = 145)+ BTX-A
(100 U) 2 weeks
later
Sweating (gravimetry): statistically significant reduction in
sweat production from baseline (192± 136mg/minute)
in treated axilla compared with control at 2 weeks
(24 ± 27mg/minute in the axillae treated with BTX-A vs.
144 ± 113mg/minute with placebo, MD between groups:
111 mg/minute; 95% CI 91 to 132 mg/minute; p< 0.001).
At 2 weeks, 86.9% of BTX-A group had ≤ 50mg/minute
vs. 4.8% of placebo group
AEs: none major at 14 weeks’ follow-up. Headache (four
patients), soreness at injection site (two patients), increased
facial sweating (one patient). Further longer-term results
(post crossover) reported. Tolerance: patient rated as
excellent (81.4%), good (17.2%), fair (1.4%)
Low
A
P
P
E
N
D
IX
2
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
2
0
6
Study details
Sample size;
study
location
Patient
characteristics
Hyperhidrosis
severity
inclusion
criteria Intervention 1 Intervention 2 Results
Risk of
bias
Lowe et al.
2007;77 RCT
322; USA Age range:
18–69 years
Male: 55%
HDSS 3–4,
≥ 50mg/
5 minutes room
temperature
BTX-A (50 U
Botox) (n= 104)
BTX-A (75 U
Botox) (n= 110)
Placebo (n= 108) HDSS: median effect duration (time to return to HDSS score
of 3 or 4 points) after first treatment (responders subgroup):
75-U group – 197 days; 50-U group – 205 days; placebo
group – 96 days; p< 0.001 for both treatment groups vs.
placebo
Sweating: gravimetry (% with ≥ 90% reduction in sweat at
4 weeks post first treatment) – 75-U group, 60%; 50-U
group, 59%; placebo group, 9%; p = 0.001 for both
treatment groups vs. placebo
Quality of life: all reported in Figure 9
AEs: none significant; most common: injection site pain
(75-U group 9%, 50-U group 12%, placebo group 8%);
injection site bleeding (75-U group 6%, 50-U group 5%,
placebo group 3%); non-axillary sweating (75-U group 6%,
50-U group 10%, placebo group 4%)
Unclear
(HDSS,
gravimetry);
high (DLQI)
continued
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TABLE 52 Botulinum toxin injection for axillary hyperhidrosis vs. placebo: study details and results (continued )
Study details
Sample size;
study
location
Patient
characteristics
Hyperhidrosis
severity
inclusion
criteria Intervention 1 Intervention 2 Results
Risk of
bias
Naumann and
Lowe 2001,79
Naumann et al.
200286 and
Lowe et al.
2002;78 RCT
320;
Germany,
Belgium and
the UK
Age range:
17–74 years
Male: 46%
≥ 50mg/
5 minutes
BTX-A (50 U)
(n= 242)
Placebo (n= 78) Sweating: all reported in Figure 6
Quality of life (SF-12): statistically significant difference in
mean change from baseline in quality of life in physical (PCS)
but not mental (MCS) scores at 16 weeks favouring
BTX-A-treated patients. PCS: improvement from baseline
(52.2 points) by 0.9 points in BTX-A group vs. decrease from
baseline (52.8 points) by 1.2 points in placebo group
(p= 0.019). MCS: improvement from baseline (49.1 points)
by 1.7 points in BTX-A group vs. improvement from baseline
(46.4 points) by 0.89 points in placebo group (p= 0.247)
Patient satisfaction (HHIQ): BTX-A treatment resulted in a
greater level of overall treatment satisfaction than previous
(mostly failed) hyperhidrosis treatments (p < 0.001)
Patient satisfaction (Patients’ Global Assessment of
Treatment Satisfaction Scale): significant difference favouring
BTX group in mean (SD) scores at 4 weeks (3.3 ± 0.9 vs.
0.8 ± 1.4) and 16 weeks (2.6± 1.6 vs. 0.3 ± 1.2); p < 0.001
AEs: increase in treatment-related non-axillary sweating in
BTX group (5% patients) vs. none in placebo. No clinically
important changes in vital signs or findings on physical
examination observed. No other treatment-related AEs
Unclear
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Study details
Sample size;
study
location
Patient
characteristics
Hyperhidrosis
severity
inclusion
criteria Intervention 1 Intervention 2 Results
Risk of
bias
Naumann et al.
2003;80 open
label extension
of Naumann
and Lowe
200179
207;
Germany,
Belgium and
the UK
Age range:
17–74 years
Male: NR
≥ 50mg/
5 minutes
BTX-A (50 U)
(n= 80)
BTX-A (50 U,
two treatments,
spaced by at least
16 weeks)
(n= 93)
BTX-A (50 U,
three treatments,
spaced by at least
16 weeks)
(n= 30)
Placebo (n= 4) Sweating (gravimetry): significantly greater difference in mean
(SD) % change from baseline in BTX groups at 4 weeks and
at 16 weeks after each treatment and placebo; p< 0.047.
Higher rate of responders (≥ 50% reduction in spontaneous
sweating, gravimetry) in BTX groups vs. placebo at 4 weeks
after first treatment (96.1%), second treatment (91.1%)
and third treatment (83.3%) vs. placebo (34.7%), and at
16 weeks after first treatment (85.7%), second treatment
(87.3%) and third treatment (80.5%) vs. placebo (20.6%)
(data from graph)
Quality of life: percentage very or somewhat satisfied with
ability to perform daily tasks) at 4 and 16 weeks higher in
treatment groups; first treatment (4 weeks 94%, 16 weeks
92%); second treatment (4 weeks 95%, 16 weeks 89%); third
treatment (4 weeks 85%, 16 weeks 78%) vs. placebo (4 weeks
44%, 16 weeks 18%)
Patient satisfaction (Patients’ Global Assessment of Treatment
Satisfaction Scale): higher scores in BTX groups in mean (SD)
scores at 4 and 16 weeks after first treatment (3.5± 0.9 at
4 weeks; 2.8± 1.3 at 16 weeks), second treatment (3.4± 0.8 at
4 weeks; 2.9± 1.1 at 16 weeks) and third treatment (3.3± 1.0
at 4 weeks; 1.9± 2.3 at 16 weeks) compared with placebo
(1.4± 1.5 at 4 weeks; 0.4± 1.1 at 16 weeks). Statistical
significance NR. Proportion of patients satisfied with BTX-A
compared with prior treatments was consistently higher in
treatment groups (83% to 99%) compared with placebo
(21% to 40%) at 4 and 16 weeks
AEs (treatment related): 9.9% of patients after first treatment,
4.9% after second treatment, 3.3% after third treatment,
4.1% after placebo. None serious. Most common: non-axillary
sweating (3.4% patients after first treatment, 1.6% after second
treatment, 0 post third treatment and placebo), pain at injection
site (1.5% after first treatment, 0.8% after second treatment,
0 post third treatment and placebo)
High
continued
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TABLE 52 Botulinum toxin injection for axillary hyperhidrosis vs. placebo: study details and results (continued )
Study details
Sample size;
study
location
Patient
characteristics
Hyperhidrosis
severity
inclusion
criteria Intervention 1 Intervention 2 Results
Risk of
bias
Odderson
2002;82 RCT
18; USA Age range:
16–50 years
Male: 61%
NR BTX-A (50 U)
(n= 12)
Placebo (n= 6) Sweating (gravimetry): average reduction in sweating in
BTX-A group of 91.6% at 2 weeks and 88.2% over
5 months. Placebo group experienced a smaller average
reduction in sweating (NR)
AEs: one event (mild compensatory hyperhidrosis of thighs)
Unclear
Ohshima et al.
2013;83,359 RCTa
152; Japan Age range: NR
Male: 24%
HDSS 3–4 BTX-A (50 U)
(n= 78)
Placebo (n= 74) HDSS response (HDSS ≥ 2-point reduction from baseline):
proportion of responders was higher for BTX-A group at all
time points: 8 weeks – 66.7% vs. 12.3%, difference 54.3%
(95% CI 41.4% to 67.2%); 12 weeks – 57.9% vs. 13.7%,
difference 44.2% (95% CI 30.6% to 57.8%); 16 weeks –
57.9% vs. 9.6%, difference 48.3% (95% CI 35.3% to
61.3%)
Mean change from baseline in HDSS (values < 0 indicate
greater response for BTX-A group): week 8, –1.7 (SD 0.8) vs.
–0.5 (SD 0.8), MD –1.1; week 12, –1.6 (SD 0.8) vs. –0.7
(SD 0.8), MD –0.9; week 16, –1.6 (SD 0.75) vs. –0.6 (SD 0.71)
Sweating (gravimetry): mean weight (mg/5 minutes) of axillary
sweating was lower in the BTX-A group compared with
placebo at all time points (LOCF). Baseline: mean 125.2
(± 85.4) for BTX group, 137.5 (± 128.2) for placebo group;
week 8 – 15.5 (24.5) vs. 80.4 (121.2), MD –65.0; week 12
– 18.0 (28.4) vs. 68.3 (67.5); week 16 – 18.6 (26.8) vs. 115.4
(157.7), MD –96.8
Duration of effect (from first treatment to first recording of
> 50% of baseline sweat production): median (95% CI) 273.0
(95% CI 171.0 to NR) days for BTX-A group vs. 35.0 (95% CI
28.0 to 56.0) days for placebo
Unclear
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Study details
Sample size;
study
location
Patient
characteristics
Hyperhidrosis
severity
inclusion
criteria Intervention 1 Intervention 2 Results
Risk of
bias
DLQI: greater mean reduction from baseline in DLQI scores for
BTX-A group at all time points. 8 weeks: –6.9 (SD 4.7)
vs. –2.0 (SD 3.9), MD –4.9 (SD NR). 12 weeks: –6.9 (SD 4.4)
vs. –2.5 (SD 4.3), MD –4.4 (SD NR). 16 weeks: –6.9 (SD 4.5)
vs. –2.5 (SD 4.3), MD –4.4 (SD NR). Baseline scores NR
Patient satisfaction (Global Assessment Treatment
Satisfaction): greater improvement for BTX-A group.
Week 4: 2.6 ± 1.1 vs 0.5± 1.1, MD 2.2. Week 8: 2.7± 1.2
vs.0.3± 1.0. Week 12: 2.6± 1.3 vs 0.4± 0.9, MD 2.2.
Week 16: 2.6± 1.2 vs. 0.4± 0.8, MD 2.2
AEs: 54% AEs in BTX group vs. 30% in placebo group.
Similar overall incidence of treatment-related AEs with BTX-A
and placebo (3% in both groups). CS 3% in BTX-A group vs.
0% in placebo. No treatment-related SAEs in either groups.
No patients withdrew due to AEs. Further data from open-
label second treatment phase reported
Schnider et al.
1999;85 RCT
(half-side
comparison)
13; Austria Age range:
21–55 years
Male: 31%
Socially
handicapped by
condition
BTX-A (200 U)
(n= 13)
Placebo (n= 13) Sweating (digitised ninhydrin-stained sheets): statistically
significant MD in sweating favouring BTX-A vs. placebo at
3 weeks (–34.5%), 8 weeks (–36.9%) and 13 weeks
(–28.4%) (p< 0.001)
Sweating (subjective rating, VAS): statistically significant MD
in sweating favouring BTX-A vs. placebo at 3 weeks
(–56.5%), 8 weeks (–67.4%) and 13 weeks (–62.5%)
(p< 0.001)
AEs: no SAEs reported, transient increase in palm sweating
for 1 week (15%)
Unclear
AE, adverse event; LOCF, last observation carried forward; NR, not reported; SAE, serious adverse event.
a The initial treatment phase (16–24 weeks) was followed by an open-label second treatment phase, which lasted until 40 weeks after first treatment. Participants initially allocated to BTX
received either a reinjection of BTX-A 50 U per axilla, or no reinjection. Participants initially allocated to placebo received either one injection of BTX-A 50 U per axilla, or no injection.
Patients received a BTX-A injection during the second treatment phase if they met ‘re-injection criteria’: mean sweat production beyond 50% of baseline at any time between weeks 16
and 24.
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TABLE 53 Botulinum toxin injection for axillary hyperhidrosis vs. no treatment: study details and results
Study details
Sample
size;
study
location
Patient
characteristics
Hyperhidrosis
severity
inclusion
criteria Intervention Control Results
Risk of
bias
Heckmann et al.
1999;89 non-RCT
(half-side
comparison)
12;
Germany
Age range:
21–42 years
Male: 42%
≥ 100mg/axilla/
minute
BTX-A (250 U Dysport)
(n= 12)
No treatment
(n= 12), followed
by BTX-A (250 U)
14 days later
Sweating (gravimetry): treated axillae had ≤ 10% of the untreated
axilla at 7 days and ≤ 50mg/minute in each patient
Iodine starch test: sweat secretion only observed on untreated side
Patient satisfaction: 10/12 ‘completely satisfied’; 2/12 ‘almost
completely satisfied’
Effect duration (patient reported): patients were symptom free for
12 months (seven patients), 9 months (three patients) or between
3 and 6 months (two patients)
AEs: stinging on first day after treatment (n= 4). No other AEs
reported
High
Naver et al. 2000;81
non-RCT (half-side
comparison)
28;
Sweden
Age range:
19–57 years
Male: 38%
NR BTX-A [Botox, mean
104 U (axilla), 56 U
(palm) once or twice],
local anaesthesia (palmar
hyperhidrosis only)
(n= 28; palmar, n= 19;
axillary, n= 13)
No treatment
(n= 28)
Sweating (iodine starch test): NR (not quantifiable by investigators)
Sweating (evaporimetry): significant evaporation reduction in
treated side vs. untreated. Reduced by 46% in treated axillae at
1–2 weeks
Sweating (patient reported): 13/13 axilla patients reported marked
reduction or complete disappearance of sweating at 1–2 weeks
AE: intense pain from injection (n= 2) with axillary hyperhidrosis
High
Wakugawa et al.
2001;185 non-RCT
(half-side
comparison)
20; Japan Age range: NR
Male: NR
NR BTX-A (50 U Dysport)
one side only (n= 7)
BTX-A (50 U Dysport)
both sides (n= 13)
No treatment
(n= 7)
Sweating: Sakurai–Montagna sweating paper test:188 Reduced to
16.4% (± 11.7%) of the pre-treatment level at 1 month and
45.8% (± 39.4%) of the pre-treatment level at 3 months in the
treated group (p< 0.05) vs. 94.9% (± 19.8) at 1 month and 93.6
(± 38.1) in the untreated side (NS)
Need for retreatment: further BTX-A administrations were needed
in two of seven cases after 3 months
AEs: none serious
High
AE, adverse event; NR, not reported; NS, non-significant.
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TABLE 54 Botulinum toxin vs. curettage for axillary hyperhidrosis: study details and results
Study details
Sample size;
study
location
Patient
characteristic
Hyperhidrosis
severity
inclusion criteria Intervention 1 Intervention 2 Results
Risk of
bias
Ibrahim et al. 201321
and Ibrahim et al.
2013;87 RCT (half-side
comparison)
20; USA Age range:
19–50 years
Male: 65%
Haider 2005
criteria187
Tumescent suction
curettage
(tumescent
anaesthesia)
(n = 20)
BTX-A (50 U)
injection
(n= 20)
HDSS: significantly greater reduction in mean HDSS score
in BTX-A-treated axillae compared with curettage at
3 months [BTX-A: from mean 3 points at baseline to
1.45 points at 3 months and 1.85 points at 6 months
(p < 0.0001); curettage: from mean 3.05 points at baseline
to 2.25 points at 3 months and 2.75 points at 6 months
(p = 0.047)]. MD between groups: 0.80 (p= 0.0002) at
3 months and 0.90 (p = 0.0017) at 6 months
Sweating (gravimetry): 72.1% sweat reduction with BTX-A
(from 27.77 to 7.75 mg/minute) vs. 60.4% (from 28.42 to
11.25 mg/minute) with suction curettage at 3 months
(non-significant difference of 11.7% between groups)
AEs: BTX-A none reported; curettage soreness for
≤ 1 week; hyperpigmentation (n= 3); dysaesthesia (n= 1)
High
Ottomann et al.
2007;155 non-RCT
88; Germany Age range:
17–39 years
Male: 16%
HDSS ≥ 2 Suction curettage
(n = 41);
anaesthesia NR
BTX-A (50 U)
(n= 47)
Sweating (gravimetry): non-significant differences between
groups in change from baseline (mean 171 ± 92mg/minute
across groups) at 2, 12 and 26 weeks
Quality of life: no significant differences between groups at
26 weeks (earlier follow-up NR)
AEs: higher rate of patients in curettage group [8.3%,
including epidermolysis (n= 2), scarring (n= 1) and
haematoma (n = 1)] than BTX-A [1.7%, hypoesthesia
(n = 1)]. None long term
High
Rompel and Scholz
2001;148 non-RCT
113; Germany Age range: NR
Male: 36%
‘Severely disabled
in regard to
occupation and
social activities’
Suction curettage
(subcutaneous)
under general
anaesthesia
(n = 90)
BTX-A
(40–50 U Botox
or 200–250 U
Dysport per
axilla) (n = 23)
Sweating (patient reported): curettage – reduced to mean
40% of baseline score at 6 months and mean 46% at end
of follow-up (median 28 months, n= 77a); BTX-A –
reduced to mean 49% of baseline score at 6 months and
mean 69% at end of follow-up (median 16 months,
n= 23). Mean duration of effect of BTX-A: 7.6 months
High
continued
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TABLE 54 Botulinum toxin vs. curettage for axillary hyperhidrosis: study details and results (continued )
Study details
Sample size;
study
location
Patient
characteristic
Hyperhidrosis
severity
inclusion criteria Intervention 1 Intervention 2 Results
Risk of
bias
Patient satisfaction: curettage – 36% ‘very good’, 30%
‘good’, 17% ‘satisfactory’, 16% ‘dissatisfied’ (n= 77);a
BTX-A – 39% ‘very good’, 22% ‘good’, 9% ‘satisfactory’,
30% ‘dissatisfied’ (n= 23); no significant difference
between treatment groups
AEs: curettage – 17.8% events [wound infection (n= 2),
partial epidermal necrosis (n= 2), bleeding/haematoma
requiring surgical revision (n= 12)]; BTX-A – transient
minimal superficial haematoma (n= NR). 4% curettage
patients judged the surgical scar to be ‘bothersome’
Vakili and Baker
2016;184 non-RCT
(abstract only)
98; UK Age range:
16–56 years
Male: 26%
NR mRAC (n = 23) BTX-A (Botox)
(n= 75)
HDSS: significant improvement from baseline in mean
HDSS score in both groups (p< 0.01) and no significant
difference between groups. mRAC group: reduced by
47%b (from 3.6 at baseline to 1.9) at 6 weeks. BTX-A
group: reduced by 48%b (from 3.3 at baseline to 1.7) at
6 weeks
Physical effects: (wearing bright clothes): significant
improvement from baseline (p < 0.01). mRAC group
reduced from 4.0 at baseline to 1.7 at 6 weeks, BTX-A
group reduced from 4.0 at baseline to 1.9 at 6 weeks. The
influence of psychological precipitating factors, such as
public speaking, were significantly and equally improved in
both groups (p < 0.05 from baseline)
AEs: NR
High
AE, adverse event; mRAC, microretrodermal axillary curettage; NR, not reported.
a 13/90 patients did not complete follow-up in the curettage group vs. 0 in the BTX-A group. The authors stated that postoperative follow-up was not achieved in 13 cases because they
lived too far or had moved without leaving a forwarding address.
b Calculated by the CRD.
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TABLE 55 Botulinum toxin injection for palmar hyperhidrosis vs. placebo: study details and results
Study details
Sample
size; study
location
Patient
characteristics
Hyperhidrosis
severity
inclusion
criteria Intervention Control Results
Risk of
bias
Baumann et al.
2005;74 RCT
20; USA Age range:
20–60 years
Male: 50%
NR BTX-B (5000 U),
local anaesthesia
(n= 15)
Placebo+ local
anaesthesia (n = 5)
Sweating (iodine starch test): no statistically significance
difference at 30 days. Mean time to return of baseline
sweating levels: 3.8 months (range 2.3–4.9 months)
Sweating (patient reported): statistically significant
difference in mean change from baseline in P-HI scores
(z= –4.1; p= 0.002) at 30 days favouring BTX-B vs.
placebo. Mean (SD) for each group NR
Quality of life: statistically significant difference in mean
change from baseline in P-HQOL scores (z= –2.6;
p= 0.010) at 30 days favouring BTX-B vs. placebo. Mean
(SD) for each group NR
AEs: 83 events definitely related, including decreased grip
strength (dynamometer) (50% of participants), muscle
weakness (60%), dry mouth (90%), excessively dry hands
(60%), indigestion/heartburn (60%). No statistically
significant difference with placebo in injection pain.
Number of severe AEs NR
High
Lowe et al. 2002;76
RCT (half-side
comparison)
19; USA Age range: NR
Male: 53%
≥ 40mg/minute BTX-A (100 U),
anaesthesia:
Lidocaine/Prilocaine
Cream and Cold
pack (n = 19)
Placebo (saline),
anaesthesia:
Lidocaine/Prilocaine
Cream and Cold
pack (n = 19)
Sweating (gravimetry): mean reduction of approximately
66%a (from approximately 290mg/5 minutes at baseline
to approximately 100 mg/5 minutes at 28 days) in BTX-A
hand and mean reduction of approximately 30%a (from
approximately 300 mg/5 minutes at baseline to
approximately 210 mg/5 minutes at 28 days) in placebo
hand; difference between hands: 33%a (p = 0.0027)
Physician assessment, patient assessment: significantly
greater improvement in BTX-A hand at 28 days (p< 0.01)
in physician (five-point scale) and patient assessment
(VAS). 17/17 patients (two lost to follow-up) rated the
treatment as successful in the BTX-A-treated palm
compared with 2/17 with the placebo-treated palm
(p < 0.0001)
Unclear
continued
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TABLE 55 Botulinum toxin injection for palmar hyperhidrosis vs. placebo: study details and results (continued )
Study details
Sample
size; study
location
Patient
characteristics
Hyperhidrosis
severity
inclusion
criteria Intervention Control Results
Risk of
bias
AEs: transient minor thumb and finger weakness
(n = 1 BTX-A), tingling/numbness in fingers (n= 1 BTX-A),
weakness (n= 1, placebo), pain (n = 1, both hands).
No significant difference between hands in grip strength
(dynamometer)
Schnider et al.
1997;84 RCT
(half-side
comparison)
11; Austria Age range:
23–54 years
Male: 64%
NR BTX-A (120 U
Dysport),
anaesthesia:
cold packs for
30 minutes (n= 11)
Placebo (saline),
anaesthesia: cold
packs for 3 minutes
(n= 11)
Sweating (digitised ninhydrin-stained sheets): BTX-A –
statistically significant mean reduction from baseline of
26% at 3 weeks and 8 weeks and 31% at 13 weeks
(p ≤ 0.002); placebo – NS reduction from baseline
(0.2% to 1.2%)
Subjective rating (VAS): BTX-A – mean improvement from
baseline 38–40% at 3, 8 and 13 weeks (p= 0.002);
placebo – NS improvement at any time point
AEs: minor handgrip weakness in the BTX-A-treated hand,
lasting 2–5 weeks (n= 3). Greater pain in BTX-A hand at
injection site vs. placebo (n = 3)
Unclear
AE, adverse event; NR, not reported; NS, non-significant.
a Extracted from graph and calculated by the CRD.
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TABLE 56 Botulinum toxin injection for palmar hyperhidrosis vs. no treatment: study details and results
Study details
Sample
size; study
location
Patient
characteristics
Hyperhidrosis
severity inclusion
criteria Intervention Control Results
Risk of
bias
Naver et al.
2000;81 non-RCT
(half-side
comparison)
28; Sweden Age range:
19–57 years
Male: 38%
NR BTX-A [Botox, mean 104 U
(axilla), 56 U (palm) once or
twice], local anaesthesia
(palmar hyperhidrosis only)
(n= 28; palmar n = 19;
axillary n= 13)
No treatment
(n= 28)
Sweating (iodine starch test): significant reduction
in area of colour reaction from the palms at
1–2 weeks (p= 0.0002), axilla could not be
quantified. 27/28 had marked reduction in
treated side vs. none in control side
Sweating (evaporimetry): significant evaporation
reduction in treated side vs. untreated. Reduced by
57% in treated palm at 1–2 weeks
Sweating (patient reported): 15/19 palm patients
reported marked reduction or complete
disappearance of sweating at 1–2 weeks
AEs: intense pain from injection (n= 2) with axillary
hyperhidrosis; intense skin dryness (n= 6) treated
with palmar hyperhidrosis; transient slight reduction
in power of fingers (n = 12) palmar patients
High
Yamashita et al.
2008;90 non-RCT
(half-side
comparison)
27; Japan Age range: NR
Male: 22%
14 severe
(> 1mg/cm2/minute),
13 mild
(< 1mg/cm2/minute)
BTX-A (60 U Botox), local
anaesthesia: ice packs (n= 27)
No treatment
(n= 27)
Sweating (gravimetry): statistically significant
reduction from baseline in both groups. Larger
reduction from baseline in right hand (BTX-A
group) compared with left hand (no treatment)
monthly at 1–6 months. Statistical significance of
between group difference NR
Iodine starch test: decreases observed
approximately 2 cm around each injection site
AE: NR
High
AE, adverse event; NR, not reported.
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TABLE 57 Curettage vs. other surgical interventions for axillary hyperhidrosis: study details and results
Study details
Sample size;
study
location
Patient
characteristic
Hyperhidrosis
severity inclusion
criteria Intervention 1 Intervention 2 Intervention 3 Intervention 4 Results Risk of bias
Bechara et al.
2008;
150
RCT
40; Germany Age range:
19–57 years
Male: 45%
≥ 50mg/minute Curettage
(liposuction), local
anaesthesia (n= 15)
Shelley (SST), local
anaesthesia (n= 11)
Radical skin excision
(modified
Bretteville–Jensen
technique with
Y-plasty closure),
local anaesthesia
(n= 14)
N/A Sweating (gravimetry): significantly reduced
sweat rates from baseline (ranging from
mean 76.1mg/minute to 81mg/minute
across groups) to 12 months in all groups
[reduction of: LC 66.4%; SST 62.9%; RSE
65.3% (p< 0.05)], no significant difference
between groups
Aesthetic outcome (patient reported from
1 ‘very good’ to 5 ‘not good at all’): mean
score was 3.2 (range 2–5) in the RSE
group, 2.3 (range 1–3) in the SST group
and 1.5 (range 1–2) in the LC group.
Significantly better for LC compared with
other interventions (p< 0.05) (follow-up
duration NR)
AEs: haematoma (LC, n= 3, including 1
moderate to severe, resolved over 4 weeks;
SST, n= 2; RSE, n= 3); paraesthesia (LC,
n= 4; SST, n= 3; RSE, n= 5); focal hair loss
(LC, n= 9; SST, n= 11; RSE, n= 14);
subcutaneous fibrotic bridles (LC, n= 8;
SST, n= 3; RSE, n= 0); seroma (LC, n= 1;
SST, n= 3; RSE, n= 0); skin erosion (LC,
n= 3; SST, n= 4; RSE, n= 0); flap necrosis
(LC, n= 1; SST, n= 2; RSE, n= 0); infection
(LC, n= 0; SST, n= 1; RSE, n= 2); and
suture dehiscence (LC, n= 0; SST, n= 1;
RSE, n= 2). No signs of movement
impairment. Other outcomes (histology)
were reported
High
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Study details
Sample size;
study
location
Patient
characteristic
Hyperhidrosis
severity inclusion
criteria Intervention 1 Intervention 2 Intervention 3 Intervention 4 Results Risk of bias
Jemec 1975;
149
non-RCT
41; Denmark Age range: NR
Male: NR
NR Curettage
(liposuction), local
or general
anaesthesia (n= 20)
Radical excision
(complete excision
and relieving
Z-plasty), local or
general anaesthesia
(n= 21)
N/A N/A Patient satisfaction: curettage – 12/20
patients were entirely satisfied, four were
partly satisfied, three were dissatisfied and
one lost to follow-up. No patients reported
troublesome scars; excision – 10/21
patients were entirely satisfied, six were
partly satisfied, three were dissatisfied and
two lost to follow-up. Four patients
reported troublesome scars. Follow-up
6–9 months
AEs: there were no abscesses, haematomas
or wound defects
High
Bechara et al.
2008;
154
non-
RCT (half-side
comparison)
4; Germany Age range: NR
Male: NR
≥ 50mg/minute Curettage
(liposuction) (n= 4)
Curettage
(liposuction)+
aggressive manual
shaving (n= 4)
N/A N/A Sweating (gravimetry): no significant
difference in sweat reduction between
surgical methods at 15 weeks
AEs: 4/4 in aggressive shaving group
had moderate to severe complications,
extensive skin damage, not tolerable.
Trial stopped early due to complications
High
Tronstad et al.
2014;
147
RCT
(half-side
comparison)
22; Norway Age range:
20–44 years
Male: 18%
NR Curettage
(anaesthesia: 50/50
mixture of lidocaine
1% with adrenaline
and saline,
maximum volume
40ml) (n= 22)
Tumescent suction
curettage
(anaesthesia:
200ml 0.9% saline
with 8ml lidocaine
2% and 0.2mg
adrenaline) (n= 22)
N/A N/A Sweating (gravimetry, skin conductance
and VAS score): reduced significantly at
6 and 12 months compared with baseline
in both treatment groups (p< 0.05) and
was significantly more reduced with
tumescent suction curettage than curettage
alone (p< 0.05)
DLQI: NR
AEs: postoperative neuropathic pain lasting
through the observation period (n= 1 in
tumescent suction curettage group). No
infection requiring antibiotics, haematoma
or scarring
Unclear
(gravimetry);
high (DLQI)
continued
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TABLE 57 Curettage vs. other surgical interventions for axillary hyperhidrosis: study details and results (continued )
Study details
Sample size;
study
location
Patient
characteristic
Hyperhidrosis
severity inclusion
criteria Intervention 1 Intervention 2 Intervention 3 Intervention 4 Results Risk of bias
Leclere et al.
2015;
24
RCT
100; France,
Germany and
Spain
Age range: NR
Male: NR
HDSS 3–4 (mean
3.86, SD 0.35
across groups)
Laser alone
(924/975 nm
simultaneous) once
(n= 25), LA
Laser (924/
975 nm)+ curettage
once (n= 25), LA
Laser alone
(975 nm) once
(n= 25), LA
Suction
curettage alone
once (n= 25),
LA
HDSS: laser+ curettage group had the
greatest reduction in mean score at
12 months, with 3.4 points reduction from
baseline (baseline 3.88± 0.33; 1 month
1.24± 0.44; 12 months 0.48± 0.51),
followed by laser 924/975 nm only, with
1.88 points reduction (baseline 3.84± 0.37;
1 month 1.96± 0.68; 12 months
1.96± 0.61), curettage only (1.52 points
reduction, baseline 3.84± 0.37; 1 month
2.20± 0.41; 12 months 2.32± 0.48) and
laser 975 nm (0.44 points reduction,
baseline 3.88± 0.33; 1 month 3.40± 0.50;
12 months 3.44± 0.51)
Starch-Iodine Scale improvement: largest
mean change from baseline at 12 months
with laser+ curettage (–2.2),
a
followed by
laser 924/975 nm only (–1.1),
a
curettage
(–0.8)
a
and laser 975 nm (increase of 0.2)
a
GAIS: highest mean (SD) scores at
12 months in laser+ curettage group
(3.8± 0.4), followed by laser 924/975 nm
[2.7 (SD 0.5)], curettage [2.6 (SD 0.5)] and
laser 924/975 nm [0.9 (SD 0.3)]. Results at
1 month follow-up were similar to the
12-month result for all three outcomes
ANOVA results comparing all interventions
NR
AEs: transient burns (n= 2, laser 975 nm
group), bruising (n= 3, curettage group)
and temporary loss of sensation (n= 1,
laser 924/975 nm)
High
AE, adverse event; ANOVA, analysis of variance; LA, local anaesthesia; LC, liposuction curettage; N/A, not applicable; NR, not reported; RSE, radical skin excision; SST, skin-sparing technique.
a Calculated by the CRD.
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TABLE 58 Laser epilation vs. other active treatments for axillary hyperhidrosis: study details and results
Study
details
Sample size;
study
location
Patient
characteristic
Hyperhidrosis
severity
inclusion
criteria Intervention 1 Intervention 2 Intervention 3 Intervention 4 Results
Risk of
bias
Leclere et al.
2015;24 RCT
100; France,
Germany
and Spain
Age range: NR
Male: NR
HDSS 3–4
(mean 3.86,
SD 0.35 across
groups)
Laser alone
(924/975 nm
simultaneous)
once (n= 25),
LA
Laser (924/975 nm)+
curettage once
(n= 25), LA
Laser alone
(975 nm) once
(n= 25), LA
Suction
curettage
alone once
(n= 25), LA
HDSS: laser+ curettage group had the
greatest reduction in mean score at
12 months, with 3.4 points reduction from
baseline (baseline 3.88± 0.33; 1 month
1.24± 0.44; 12 months 0.48± 0.51), followed
by laser 924/975 nm only, with 1.88 points
reduction (baseline 3.84± 0.37; 1 month
1.96± 0.68; 12 months 1.96± 0.61),
curettage only, 1.52 points reduction (baseline
3.84± 0.37; 1 month 2.20± 0.41; 12 months
2.32± 0.48) and laser 975 nm, with 0.44
points reduction (baseline 3.88± 0.33;
1 month 3.40± 0.50; 12 months 3.44± 0.51)
Starch-Iodine Scale improvement: largest mean
change from baseline at 12 months with
laser+ curettage (–2.2),a followed by laser
924/975 nm only (–1.1),a curettage (–0.8)a and
laser 975 nm (increase of 0.2)a
GAIS: highest mean (SD) scores at 12 months
in laser+ curettage group (3.8± 0.4), followed
by laser 924/975 nm [2.7 (SD 0.5)], curettage
[2.6 (SD 0.5)] and laser 975 nm [0.9 (SD 0.3)].
Results at 1 month follow-up were similar to
the 12-month result for all three outcomes
ANOVA results comparing all interventions NR
AEs: transient burns (n= 2, laser 975 nm
group), bruising (n= 3, curettage group) and
temporary loss of sensation (n= 1, laser
924/975 nm)
High
AE, adverse event; ANOVA, analysis of variance; LA, local anaesthesia; NR, not reported.
a Calculated by CRD.
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TABLE 59 Laser epilation for axillary hyperhidrosis vs. no treatment: study details and results
Study details
Sample
size; study
location
Patient
characteristic
Hyperhidrosis
severity
inclusion
criteria Intervention details Comparator Results
Risk of
bias
Bechara et al.
2012;25 RCT
(half-side
comparison)
21;
Germany
Age range:
24–66 years
Male: 24%
Hornberger
2004189
Long-pulsed laser
(800 nm). Five
treatments at 4-week
intervals
Anaesthesia: NR
No
treatment
Sweat rate (gravimetry): significant reduction in both axillae:
treated axillae from median 89mg/minute, range 42–208mg/
minute at baseline to 48mg/minute, range 17–119mg/minute
after treatment (p< 0.001); untreated axillae from median
78mg/minute, range 25–220mg/minute at baseline to median
65mg/minute, range 24–399mg/minute after treatment
(p = 0.04); no significant difference in reduction between
treated and non-treated side after treatment (p = 0.1)
Patient satisfaction (VAS): 5.9/10 after treatment and 4.1/10 at
12 months
Histology: no significant changes in sweat glands
AEs: none serious
High
Letada et al.
2012;26 RCT
(half-side
comparison)
6; USA Age range: NR
Male: 17%
NR Long-pulsed laser
(1064 nm). Six
treatments at monthly
intervals
Anaesthesia: NR
No
treatment
Sweating (iodine starch test): ‘visibly reduced’ in 6/6 vs. control
at 1 month
Sweating (GAQ): 6/6 reported good or excellent improvement
in GAQ at 1 month. 2/3 reported good or excellent and 1/3
reported fair to good at 3 months
Histology: no difference between groups.
AEs: none
High
AE, adverse event; GAQ, Global Assessment Questionnaire; NR, not reported.
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TABLE 60 Fractionated microneedle radiofrequency for axillary hyperhidrosis vs. placebo: study details and results
Study details
Sample
size; study
location
Patient
characteristics
Hyperhidrosis
severity
inclusion
criteria Intervention Comparator Results
Risk of
bias
Fatemi Naeini et al.
201528 and Abtahi-Naeini
et al. 2015;170 non-RCT
(half-side comparison
25; Iran Age range: NR
Male: 32%
HDSS 3–4 FMR (1MHz of
radiofrequency
current), three
sessions at 3-week
intervals (n= 25)
Local topical
anaesthesia
Sham FMR
(n = 25)
Local topical
anaesthesia
HDSS: mean score at 21 weeks – FMR reduced by
1.59 pointsa (from 3.46± 0.5 to 1.87± 0.61); placebo
reduced by 0.08 pointsa (from 3.46 ± 0.5 to
3.38 ± 0.49) (p< 0.001)
Sweating intensity (iodine starch test, VAS): mean
sweating intensity score at 21 weeks (out of 10,
higher scores = greater intensity) – FMR from 9 ± 1.55
to 3.92 ± 1.31; placebo from 9± 1.55 to 8.44 ± 1.55
(p< 0.001)
Patient satisfaction: 80% of patients reported > 50%
satisfaction at 21 weeks
AEs: most patients experienced temporary swelling
(% NR), pain (% NR), erythema (68%) and pin-point
bleeding (56%) in the treated areas. Transient post-
inflammatory hyperpigmentation (44%), resolved in
2 months. Tingling/numbness in the group (4%),
discontinued and resolved after 2 months
High
AE, adverse event; FMR, fractionated microneedle radiofrequency; NR, not reported.
a Calculated by CRD.
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TABLE 61 Microwave therapy for axillary hyperhidrosis vs. placebo: study details and results
Study details
Sample
size; study
location
Patient
characteristics
Hyperhidrosis
severity
inclusion
criteria Intervention details Comparator Results
Risk of
bias
Glaser et al.
201227 and
Kilmer et al.
2011;172 RCT
120; USA Age range: NR
Male: 43%
HDSS 3–4;
≥ 50mg/
5 minutes
Microwave, two
sessions approximately
2 weeks apart. Third
procedure allowed for
10 non-responders
(total n = 81)
Local anaesthesia
Sham microwave
(n= 39)
Local
anaesthesia
HDSS: percentage with reduction from baseline by
≥ 2 points significantly greater for microwave vs. placebo
at 30 days (67% vs. 13%; p< 0.001), 3 months (57% vs.
13%; p< 0.001) and 6 months (47% vs. 13%; p < 0.001)
Sweating (gravimetry): 50% reduction in sweat rate: no
statistically significant difference between groups at
30 days, 3 or 6 months. ≥ 75% reduction in sweat rate:
62% for treatment group vs. 39% for placebo at 30 days
(p = 0.01), but not significant difference between groups at
3 or 6 months
AEs (treatment related): 28% microwave patients and 13%
placebo patients; mostly mild; most frequent were transient
altered sensation in skin of upper group (10% for
microwave vs. 3% placebo) and pain (6% vs. 5%).
Persistent compensatory facial hyperhidrosis at 6 months
(n = 1, microwave group). Seven patients did not receive
second microwave treatment due to AEs: two dropped out
due to pain, five had ongoing side effects (swelling,
pustules or blisters)
High
AE, adverse event; NR, not reported.
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TABLE 62 Ultrasound therapy for axillary hyperhidrosis vs. placebo: study details and results
Study details
Sample
size;
study
location
Patient
characteristics
Hyperhidrosis
severity
inclusion
criteria Intervention Comparator Anaesthesia Results
Risk of
bias
Nestor and Park
201429 and Nestor
and Park 2012;178
RCT (half-side
comparison n= 11)a
Study 1
14; USA Age range: NR
Male: 21%
HDSS 3–4;
≥ 50mg/
5 minutes
Microfocused
ultrasound (4 MHz,
4.5-mm depth; then
7MHz, 3.0-mm depth),
two treatments 30 days
apart (n= 14)
Placebo, two
treatments
30 days apart
(n= 14)
Local (only
for subgroup
n= 3)a
Response (gravimetry): 13/14 had ≥ 50%
reduction in sweating from baseline
(difference between groups NR) at
90 days’ follow-up
AEs: 93% intervention group had ≥ 1
treatment related vs. 9% for placebo.
Most AEs were mild. No serious AEs.
Most common axilla tenderness/soreness
(86% in intervention group). Less
discomfort in axilla pre-treated with
lidocaine+ adrenaline compared with
lidocaine alone (n= 3)
High
Nestor and Park
201429 and Nestor
and Park 2012;178
RCT
Study 2
20; USA Age range:
21–52 years
Male: 65%
HDSS 3–4;
≥ 50mg/
5 minutes
Microfocused
ultrasound (4 MHz,
4.5-mm depth; then
7MHz, 3.0-mm depth),
two treatments 30 days
apart (n= 12)
Placebo, two
treatments
30 days apart
(n= 8)
Local Response (HDSS): from 3 or 4 at baseline
to 1 or 2 – 30 days’ follow-up 67% vs.
27% in placebo group (p = 0.005);
60 days 59% vs. 17%; 90 days 73% vs.
24%; 335 days 81% vs. 7%b
Response (gravimetry): 83% patients in
intervention group had ≥ 50% sweat
reduction from baseline vs. 0% in
placebo group across all time points
(p < 0.0001 at all follow-up points)
AEs: 92% intervention group had ≥ 1 AE
vs. 50% for placebo. Most AEs were mild
and none serious. Most common AE was
axilla tenderness/soreness (83% in
intervention group)
High
AE, adverse event; NR, not reported.
a Three patients received treatment in both axilla under local anaesthesia, with one axilla receiving pre-treatment with subcutaneous lidocaine and adrenaline and the other receiving
lidocaine alone.
b All data from graph, except 30 days’ follow-up.
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Appendix 3 Studies excluded at full-paper stage
with rationale
Study details Reason for exclusion
Abrams and Hallett 2013360 Not a SR or primary prospective study
Adar et al. 1977361 Not a SR or primary prospective study
Aguilar-Ferrandiz et al. 2011283 Not relevant comparator (psychological techniques)
Ak et al. 2013362 No intervention
Ak et al. 2013363 No intervention
Aksu et al. 2011281 Not a SR or primary prospective study
Alvarez et al. 2013231 Not a SR or primary prospective study
Alvarez et al. 2013224 Not a SR or primary prospective study
Ambrogi et al. 2009272 Not relevant comparator (sympathectomy)
Amini et al. 2008217 Not a SR or primary prospective study
Amir et al. 2000186 No intervention
Andrade et al. 2012208 Not dermatology study: sympathectomy
Andrews and Rennie 1997364 Not dermatology study: sympathectomy
Anonymous 2004365 Not a SR or primary prospective study
Araujo et al. 2009366 Not dermatology study: sympathectomy
Atkinson et al. 2010367 Not a SR or primary prospective study
Attia and Salah 2011219 Not relevant intervention (photodynamic therapy)
Awad et al. 2010368 Not dermatology study: sympathectomy
Aydemir and Toh 2006369 Not relevant intervention (comparison of specific techniques)
Bachmann et al. 2009317 Not a SR or primary prospective study
Bandeira et al. 2009370 Not a SR or primary prospective study
Basra et al. 2008275 Not primary hyperhidrosis
Baumgartner and Toh 2003371 Not a SR or primary prospective study
Baumgartner et al. 2009372 Not a comparative study (treatments undertaken sequentially)
Bechaux 2009373 Not a SR or primary prospective study
Bell et al. 2014374 Not a SR or primary prospective study
Benohanian et al. 1998375 Not relevant intervention (aluminium chloride)
Birnie and Motley 2009268 Not a SR or primary prospective study
Bischof et al. 2005376 Not dermatology study: sympathectomy
Bisseriex et al. 2012377 Not primary hyperhidrosis
Boas 2000378 Not a SR or primary prospective study
Boley et al. 2007319 Not dermatology study: sympathectomy
Bryan et al. 2012379 Not a SR or primary prospective study
Bygstad et al. 2013380 Not dermatology study: sympathectomy
Cameron and Ojimba 2004381 Not a SR or primary prospective study
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Study details Reason for exclusion
Cardoso et al. 2009320 Not a SR or primary prospective study
Cerfolio et al. 201115 Not a SR or primary prospective study
Chan et al. 2007321 Not dermatology study: sympathectomy
Chen et al. 1996382 Not a SR or primary prospective study
Chen et al. 2001383 Not dermatology study: sympathectomy
Chen et al. 2013384 Not dermatology study: sympathectomy
Cheng et al. 2015334 Not dermatology study: sympathectomy
Chia et al. 2012385 Not relevant intervention (glycopyrronium bromide iontophoresis)
Cho et al. 1994386 Not relevant comparator (aluminium chloride and sympathectomy)
Cinà and Clase 1999292 No intervention
Clerico et al. 2014387 Not a SR or primary prospective study
Coelho et al. 2014388 Not dermatology study: sympathectomy
Copleymerriman et al. 2015389 Not primary hyperhidrosis
Coveliers et al. 2011215 Not dermatology study: sympathectomy
Currie et al. 2011322 Not a SR or primary prospective study
Davarian et al. 2008264 Not relevant intervention (BTX iontophoresis vs. saline)
de Campos et al. 2003238 Not dermatology study: sympathectomy
de Campos et al. 2005390 Not dermatology study: sympathectomy
Delaplace et al. 2015211 Not dermatology study: sympathectomy
Deng et al. 2011391 Not dermatology study: sympathectomy
Dickmann and Dickmann 20102 Not a SR or primary prospective study
Divisi et al. 2013323 Not dermatology study: sympathectomy
Doolabh et al. 2004392 Not a SR or primary prospective study
Dressler et al. 2002393 Not relevant intervention (comparing different doses of BTX)
Drott et al. 1995394 Not a SR or primary prospective study
Drott and Claes 1996395 Not a SR or primary prospective study
Duarte et al. 2003396 Not dermatology study: sympathectomy
Dumont et al. 1997397 Not dermatology study: sympathectomy
Ebrahim 2011398 Not dermatology study: sympathectomy
Edmondson et al. 1992399 Not dermatology study: sympathectomy
Elia et al. 2005299 Not dermatology study: sympathectomy
Ellis 1977400 Not a SR or primary prospective study
Ellis and Scurr 1979401 Not relevant intervention (aluminium chloride)
Ellis 1982402 Not a SR or primary prospective study
Farahmand and Toolabi 2011403 Not dermatology study: sympathectomy
Fatemi Naeini et al. 2015404 Not a SR or primary prospective study
Flanagan et al. 2008218 Not relevant comparator (aluminium chloride)
Flørenes 2003405 Not dermatology study: sympathectomy
Flores 2012335 Not a SR or primary prospective study
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Study details Reason for exclusion
Fuentes et al. 2012207 Not dermatology study: sympathectomy
Furlan et al. 2000406 Not primary hyperhidrosis
Galati and Raposio 2010407 Not a SR or primary prospective study
Garcia Franco et al. 2011210 Not dermatology study: sympathectomy
Geddoa et al. 2008267 Not a SR or primary prospective study
George et al. 2014408 Not a SR or primary prospective study
Ghisletta et al. 1999409 Not dermatology study: sympathectomy
Gibbons et al. 2014274 Not a SR or primary prospective study (CEA)
Glent-Madsen and Dahl 1988410 Not primary hyperhidrosis
Goh 1990411 Not relevant intervention (aluminium chloride)
Goh and Yoyong 1996412 Not relevant comparator (tannic acid)
Goh et al. 2000413 Not dermatology study: sympathectomy
Goldman 2000414 Not a SR or primary prospective study
Gorouhi et al. 2009220 Not relevant comparator (aluminium chloride)
Gossot et al. 2001415 Not a SR or primary prospective study
Grabham et al. 1998416 Not dermatology study: sympathectomy
Gracia et al. 2011324 Not dermatology study: sympathectomy
Greenhalgh et al. 1971417 Not a SR or primary prospective study
Grimalt et al. 2006418 Not relevant intervention (atropine)
Grootens and Hartong 2011419 Not primary hyperhidrosis
Guérin et al. 1990420 Not dermatology study: sympathectomy
Hasche et al. 1997156 Duplicate report of Hasche et al. 1997156
Hashmonai 2011421 Not a SR or primary prospective study
Hecht et al. 2004422 Not relevant intervention (comparing different doses of BTX)
Heidemann and Licht 2013423 Not a SR or primary prospective study
Hekmat et al. 2010297 Not a SR or primary prospective study
Henriques et al. 2014424 Not a SR or primary prospective study
Henteleff and Kalavrouziotis 2008425 Not dermatology study: sympathectomy
Hoorens and Ongenae 2012426 Not a SR or primary prospective study
Hornberger et al. 2004189 Not a SR or primary prospective study
Hsu et al. 1998427 Not a SR or primary prospective study
Ibrahim et al. 2013245 Not dermatology study: sympathectomy
Ibrahim et al. 2013428 Not a SR or primary prospective study
Innocenzi et al. 2008429 Not relevant intervention (aluminium sesquichlorhydrate foam)
Ishy et al. 2011239 Not dermatology study: Ssympathectomy
Isla-Tajera et al. 2013230 Not a dermatology study: quality of life/economics only
Ismail and El Samadoni 2015213 Not a SR or primary prospective study
Jaffer et al. 2007336 Not dermatology study: sympathectomy
Jani 2009430 Not dermatology study: sympathectomy
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Study details Reason for exclusion
Jeganathan et al. 2008325 Not dermatology study: sympathectomy
Jog et al. 2010431 Not primary hyperhidrosis
Kamudoni et al. 2012204 No intervention
Kamudoni et al. 2014228 No intervention
Kamudoni et al. 2015261 No intervention
Kavanagh et al. 2004432 Not a SR or primary prospective study
Kavanagh and Shams 2006433 Not relevant intervention (BTX iontophoresis vs. saline)
Khademi Kalantari et al. 2011434 Not relevant intervention (aluminium chloride)
Kim et al. 2005435 Not dermatology study: sympathectomy
Kim et al. 200818 Not a SR or primary prospective study
Kim et al. 2008436 Not primary hyperhidrosis
Kopelman et al. 1996437 Not a SR or primary prospective study
Koskinen et al. 2012308 Not dermatology study: sympathectomy
Kravarusic and Freud 2012438 Not a SR or primary prospective study
Krogstad et al. 2006439 No intervention
Kuijpers et al. 2013282 Not dermatology study: sympathectomy
Kumar et al. 2014440 Not a SR or primary prospective study
Kuo et al. 2004259 No intervention
Lakraj et al. 2013441 Not a SR or primary prospective study
Lau et al. 2014442 Not dermatology study: sympathectomy
Law and Ellis 1989443 Not a SR or primary prospective study
Lawrence and Lonsdale Eccles 2006444 Not a SR or primary prospective study
Leão et al. 2003445 Not a SR or primary prospective study
Lecouflet et al. 2014446 Not a SR or primary prospective study
Lee et al. 2004447 Not dermatology study: sympathectomy
Lee and Ryman 2005448 Not a SR or primary prospective study
Lee et al. 2006449 Not primary hyperhidrosis
Lee et al. 2008450 Not a SR or primary prospective study
Lessa et al. 2014284 No intervention
Lewis et al. 1998451 Not a SR or primary prospective study
Li et al. 201222 Not primary hyperhidrosis
Licht and Pilegaard 2004452 Not a SR or primary prospective study
Lin and Fang 1999453 Not a SR or primary prospective study
Lin et al. 2000454 Not a SR or primary prospective study
Lin 2001455 Not dermatology study: sympathectomy
Little 2004456 Not a SR or primary prospective study
Lladó et al. 2005457 Not dermatology study: sympathectomy
Loureiro et al. 2008246 Not dermatology study: sympathectomy
Lupin and Hong 2012209 Duplicate report Lupin et al. 2011175
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Study details Reason for exclusion
Malmivaara et al. 2007458 Not dermatology study: sympathectomy
Malone et al. 1986459 Not dermatology study: sympathectomy
Marcella et al. 2011221 Not a SR or primary prospective study
Masters and Rennie 1992460 Not a SR or primary prospective study
McAleer et al. 2009265 Not a SR or primary prospective study
Mehrotra et al. 2014229 Not a SR or primary prospective study
Menna et al. 2012461 Not dermatology study: sympathectomy
Micali et al. 2013266 Not relevant intervention (aluminium chloride)
Misiak et al. 2012462 Not dermatology study: sympathectomy
Montaser-Kouhsari et al. 2014463 Not relevant intervention (BTX iontophoresis)
Mordant et al. 2010464 Not a SR or primary prospective study
Moya et al. 2006465 Not dermatology study: sympathectomy
Muhammad and Allam 2014466 Not dermatology study: sympathectomy
Muller and Augustin 2013340 Not dermatology study: quality of life/economics only
Munia et al. 2007328 Not dermatology study: sympathectomy
Munia et al. 2008327 Not dermatology study: sympathectomy
Nakamura et al. 2008467 Not a SR or primary prospective study
Naumann and Hamm 2002468 Not a SR or primary prospective study
Neidhardt et al. 2010469 Not a SR or primary prospective study
Neumayer et al. 2003470 Not dermatology study: sympathectomy
Neumayer et al. 2005471 Not dermatology study: sympathectomy
Neumayer et al. 2005257 Not dermatology study: sympathectomy
Neves et al. 2012247 Not dermatology study: sympathectomy
Nicholson et al. 1994472 Not dermatology study: sympathectomy
Nieuwenhuis 2015473 Not a SR or primary prospective study
Odderson 1998474 Not a SR or primary prospective study
Ojimba and Cameron 2004475 Not a SR or primary prospective study
Oncel et al. 2012476 Not dermatology study: sympathectomy
Panhofer et al. 2005233 Not a SR or primary prospective study
Panhofer et al. 2006248 Not dermatology study: sympathectomy
Panhofer et al. 2011242 Not dermatology study: sympathectomy
Panhofer et al. 2013249 Not dermatology study: sympathectomy
Panhofer et al. 2013241 Not dermatology study: sympathectomy
Panhofer et al. 2014240 Not dermatology study: sympathectomy
Pastorelli and Plasmati 2013214 Not relevant intervention (comparison of BTX brands)
Pastorelli et al. 2014223 Not relevant intervention (comparison of BTX brands)
Paul et al. 2010273 Not relevant intervention (effect of laser hair removal on effectiveness of BTX)
Penna et al. 2007477 No effectiveness or quality-of-life outcome
Phadke et al. 1995478 Not relevant comparator (topical methenamide and glutaraldehyde)
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Study details Reason for exclusion
Ponce-Olivera et al. 2014479 Not a SR or primary prospective study
Prasad et al. 2010250 Not dermatology study: sympathectomy
Purtuloglu et al. 2013480 Not a SR or primary prospective study
Purtuloglu et al. 2013481 Not a SR or primary prospective study
Raja and Campbell 2000482 Not a SR or primary prospective study
Rameshkannan et al. 2010269 Not relevant intervention (clonidine vs. propranolol)
Ramos et al. 2006483 Not dermatology study: sympathectomy
Ramos et al. 2007484 Not a SR or primary prospective study
Ramos et al. 2009485 Not dermatology study: sympathectomy
Ramos et al. 2012486 Not dermatology study: sympathectomy
Ramsaroop et al. 2004487 Not dermatology study: sympathectomy
Rantanen and Telaranta 2013313 Not dermatology study: sympathectomy
Rathinam et al. 2008329 Not a SR or primary prospective study
Rayner et al. 1980488 Not relevant intervention (aluminium chloride)
Rezai 2009489 Not a SR or primary prospective study
Rezende and Luz 2014490 Not a SR or primary prospective study
Rieger and Pedevilla 2007491 Not dermatology study: sympathectomy
Rieger et al. 200917 Not dermatology study: sympathectomy
Rieger et al. 2011492 Not a SR or primary prospective study
Rieger et al. 2015251 Not dermatology study: sympathectomy
Roddy 2012493 Not a SR or primary prospective study
Rodriguez et al. 2008300 Not dermatology study: sympathectomy
Rodriguez-Lopez et al. 2010494 Not dermatology study: sympathectomy
Rzany et al. 2012227 Not a dermatology study: quality of life/economics only
Saadia et al. 2001495 Not relevant intervention (comparison of BTX doses)
Salek et al. 2015260 Not primary hyperhidrosis
Sanli et al. 2010216 Not a SR or primary prospective study
Scheer et al. 2014271 Not a SR or primary prospective study
Scheer et al. 2014270 Not dermatology study: sympathectomy
Schestatsky et al. 2009496 Not dermatology study: sympathectomy
Scholes et al. 1978497 Not relevant intervention (aluminium chloride)
Sciuchetti et al. 2008498 Not dermatology study: sympathectomy
Shalaby et al. 2012330 Not dermatology study: sympathectomy
Sharpe et al. 2013222 Not a SR or primary prospective study
Shen et al. 1990499 Not relevant intervention (aluminium chloride iontophoresis vs. tap water)
Shi et al. 2015331 Not dermatology study: sympathectomy
Simonyi et al. 2010500 Not primary hyperhidrosis
Simonyi et al. 2010303 Not a SR or primary prospective study
Simonyi et al. 2011304 Not a SR or primary prospective study
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Study details Reason for exclusion
Solish et al. 200712 Not a SR or primary prospective study
Solish 2008501 Not a SR or primary prospective study
Stefaniak et al. 2009502 Not dermatology study: sympathectomy
Stefaniak and C´wigon´ 2013503 Not dermatology study: sympathectomy
Stefaniak and C´wigon´ 2013504 Not dermatology study: sympathectomy
Steiner et al. 2007332 Not dermatology study: sympathectomy
Streker et al. 2010505 Not relevant intervention (aluminium chloride)
Streker et al. 2012506 Not relevant intervention (aluminium chloride)
Strutton et al. 2004226 No intervention
Suh et al. 2014507 Not a SR or primary prospective study
Swaile et al. 2012508 Not primary hyperhidrosis
Swinehart 2000509 Not a SR or primary prospective study
Tan and Solish 2002263 Not a SR or primary prospective study
Tang et al. 2013510 Not dermatology study: sympathectomy
Teivelis et al. 2014253 Not a SR or primary prospective study
Toolabi et al. 2015511 Not dermatology study: sympathectomy
Umezawa et al. 2011512 Not dermatology study: sympathectomy
Ureña et al. 2009513 Not a SR or primary prospective study
Van Schil 2005514 Not dermatology study: sympathectomy
Vazquez et al. 2011305 Not dermatology study: sympathectomy
Vorkamp et al. 2010515 Not a SR or primary prospective study
Wein et al. 2010516 Not primary hyperhidrosis
Weiss et al. 2010517 Not dermatology study: sympathectomy
Wollina et al. 2002146 Not relevant intervention (comparing different doses of BTX)
Wollina and Konrad 2004518 Not a SR or primary prospective study
Wollina et al. 200820 Not a SR or primary prospective study
Wolosker et al. 2007519 Not dermatology study: sympathectomy
Wolosker et al. 2010244 Not dermatology study: sympathectomy
Wolosker et al. 2010234 Not dermatology study: sympathectomy
Wolosker et al. 2012252 Not dermatology study: sympathectomy
Wolosker et al. 2013254 Not a SR or primary prospective study
Wolosker et al. 2013243 Not dermatology study: sympathectomy
Wolosker et al. 2014237 Not a SR or primary prospective study
Wolosker et al. 2015255 Duplicate report of Wolosker et al. 201567
Woolery-Lloyd and Valins 2009520 Not a SR or primary prospective study
Woolery-Lloyd and Valins 2009521 Not a SR or primary prospective study
Wörle et al. 2007522 Not a SR or primary prospective study
Xiao et al. 2015333 Not dermatology study: sympathectomy
Yanagishita et al. 2012523 Not relevant intervention (aluminium chloride)
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Study details Reason for exclusion
Yazbek et al. 2005235 Not dermatology study: sympathectomy
Yazbek et al. 2009236 Not dermatology study: sympathectomy
Young et al. 2003298 Not dermatology study: sympathectomy
Youssef and Soliman 2015524 Not dermatology study: sympathectomy
Yuncu et al. 2013212 Not dermatology study: sympathectomy
Zaba et al. 2013525 Not relevant comparator (aluminium chloride and sodium chloride)
Zackrisson et al. 2008526 Not relevant intervention (comparing different doses of BTX)
SR, systematic review.
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Appendix 4 The results of the network
meta-analysis
The full NMA results of all pairwise comparisons are reported in Table 63.
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TABLE 63 The ORs for each pairwise comparison of the interventions included in the NMA
Intervention
Placebo Medication Botox Curettage Laser Microwave Radiofrequency
Median
OR 95% CI
Median
OR 95% CI
Median
OR 95% CI
Median
OR 95% CI
Median
OR 95% CI
Median
OR 95% CI
Median
OR 95% CI
Placebo N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Medication 7.21 1.56 to 53.83 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Botox 9.21 4.73 to 18.10 1.26 0.15 to 6.88 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Curettage 6.39 1.20 to 27.61 0.85 0.07 to 7.52 0.70 0.15 to 2.54 N/A N/A N/A N/A N/A N/A N/A N/A
Laser 9.13 0.90 to 84.68 1.20 0.06 to 19.50 0.99 0.11 to 8.25 1.45 0.28 to 7.62 N/A N/A N/A N/A N/A N/A
Microwave 14.68 3.74 to 68.99 2.01 0.18 to 17.98 1.60 0.34 to 18.60 2.36 0.30 to 21.79 1.65 0.11 to 25.48 N/A N/A N/A N/A
N/A, not applicable.
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Appendix 5 Survey of UK dermatologists
Introduction
The purpose of the survey was to obtain information on current clinical practice to help inform the
economic modelling assumptions. The survey was conducted by means of an online survey tool: ‘Qualtrics’
version 2016 (Provo, UT, USA). It was circulated to > 1000 dermatologists in various NHS units across the
UK. The questionnaire dealt with treatments typically administered, effectiveness of treatments, adverse
events related to treatments and resource use associated with each individual treatment.
Forty-five respondents from 42 different dermatology units completed the survey at least partially (i.e. not all
respondents answered every question and, therefore, most of the questions had different response rates).
Methods
Each type of treatment (medication, Botox, iontophoresis, curettage and alternative minor non-invasive
surgery) was assigned a separate section in the survey. It was assumed that all dermatologists prescribe
medication, including aluminium chloride, for hyperhidrosis and so respondents were asked to list all
prescribed medications, their dosages and recommended frequencies. For all other treatments, a filter
question was included whereby respondents were simply asked to choose ‘yes’ or ‘no’ depending on the
availability of that treatment at their individual unit. If they chose ‘yes’, they were asked to answer further
questions on the effectiveness of, and resource use associated with, that treatment. If they chose ‘no’,
respondents were asked to move to the next section. The full survey can be seen at the end of Appendix 5.
NB, questions about ETS were not included in the survey as sufficient evidence for the model had already
been obtained.
Results
Treatment availability
Medications
When asked what medications were available at their units, 42 dermatologists (93% of the total sample)
mentioned at least one type of medication. The total number of responses, or medications listed (n = 114),
was greater than the total number of respondents (n = 42), as the majority of clinicians (83%) listed more
than one type of medication. Seventy-one per cent of these included oxybutynin and 55% included
propantheline bromide.
Table 64 shows the medications prescribed by dermatologists and the percentage delivering each type of
medication.
In terms of combinations of the medications outlined in Table 64, 22 different combinations were reported
by the 42 respondents. This suggests that there is no unique combination of medications that is prescribed.
However, 19 out of the 22 combinations (86%) included oxybutynin and/or propantheline bromide. Use of
these two medications only combined was also notably more frequent than use of any other combination
(reported by 19% of respondents). All medication combinations are presented in Table 65.
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Other treatments
Regarding the availability of other treatments (Botox, iontophoresis, curettage and alternative minor
non-invasive surgery), all 45 dermatologists (100%) indicated the availability of one or more procedures.
Responses are summarised in Table 66.
As shown in Table 66, the vast majority of respondents (84%) indicated that iontophoresis (tap water) was
available at their dermatology unit, and over half of the sample (58%) stated that their unit offered Botox,
but no respondents indicated that alternative minor non-invasive surgery procedures were available.
In terms of combinations of the available treatments, the most commonly offered combination was Botox
and iontophoresis (tap water) – reported by 33% of the sample. Slightly fewer dermatologists (22%)
indicated iontophoresis (tap water) only. The remaining combinations of treatments varied across the
sample, but most included Botox and/or iontophoresis (tap water). All combinations of other treatments
can be seen in Table 67.
It can be concluded that there are a variety of medications and other treatments available for hyperhidrosis
from dermatologists in the UK. The most prevalent medications are oxybutynin and propantheline bromide
and the most common clinical procedures are Botox injections and iontophoresis (tap water), according to
the survey results. No respondents indicated availability of the alternative minor non-invasive surgery
procedures, suggesting that they are not yet available on the NHS.
Resource use associated with treatments
The survey respondents were asked to provide additional information about available treatments. For
medications, they were asked to indicate dosage, frequency and details about follow-up visits. For other
treatments, they were asked to indicate duration of the procedure, job title of the treatment provider and
details about monitoring visits. Dermatologists that provided iontophoresis (tap water) were additionally
asked to indicate the type of machine that would be used in the clinic, the type of machine that would be
used at home and the proportion of patients that would continue this treatment at home.
Medications
Nineteen out of 30 dermatologists who prescribe oxybutynin indicated the dose. Responses ranged from
2.5 to 30 mg daily, but the most common minimum and maximum values were 5 mg and 15 mg daily,
indicated by eight and six respondents respectively. This is largely consistent with the British National
Formulary recommendation, which is, on average, 12.5 mg per day. For propantheline bromide, 21 out of
23 respondents indicated the dose. Responses ranged from 15 to 125 mg daily. The most frequently
indicated value was 45 mg daily, which is lower than the British National Formulary recommendation of
75 mg daily. Only 6 out of 12 respondents indicated the dose for glycopyrronium bromide, out of which
the most common recommendation was 1–4 mg daily and four indicated the dose for propranolol (120 mg
per day).
TABLE 64 Available medications
Medication Number of respondents % of respondents
Aluminium chloride 10 24
Oxybutynin 30 71
Propantheline bromide 23 55
Propranolol 4 10
Clonidine 2 5
Oral glycopyrrolate 12 29
Topical glycopyrrolate 8 19
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Thirty-three dermatologists out of 42 who prescribe medication specified the frequency of, length of and
the title of health professional present at monitoring visits. More than a third of them (n = 12) stated that
follow-up visits take place every 3 months, over a half of them (n = 18) said it would last for 10 minutes
and the majority of respondents (n = 25) indicated that it would be led by a consultant dermatologist.
According to four clinicians, there are no follow-up visits; patients would be discharged back to their GP.
Botox
According to 13 out of 26 dermatologists who indicated that Botox was available at their unit, the
procedure is delivered by a consultant dermatologist. The other half responded that it would be carried out
by specialist nurse. In terms of duration of the procedure, 22 out of 24 dermatologists who responded to
this question stated values of < 1 hour (mostly 30 minutes). Only 5 of the 26 respondents who indicated
that they provide the procedure reported frequency of follow-up visits. In the majority of cases (four),
these were every 6 months.
Iontophoresis (tap water)
The treatment details for iontophoresis (tap water) are summarised in Table 68 (the most frequent
responses are shown), based on the responses from the 35 dermatologists who indicated that they provide
this treatment.
The results presented in Table 68 highlight the uncertainty and variability in responses among
dermatologists in relation to iontophoresis (tap water) treatment. This could potentially be explained
by the fact that the survey was completed by dermatologists, whereas the procedure is normally carried
out by a nurse.
TABLE 66 Availability of other treatments
Procedure
Number of respondents who said
that the procedure was available
% of
respondents
Iontophoresis (tap water) 35 78
Botox 26 58
Iontophoresis (glycopyrrolate) 10 22
Curettage 2 4
Laser/microwave/ultrasound/radiofrequency 0 0
TABLE 67 Combinations of other treatments
Botox
Iontophoresis
(tap water)
Iontophoresis
(glycopyrrolate) Curettage
Number of
combinations
% of
respondents
✓ ✓ 15 33
✓ 10 22
✓ ✓ ✓ 7 16
5 11
✓ ✓ 3 7
✓ 3 7
✓ 1 2
✓ ✓ 1 2
Total 45 100
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Iontophoresis (glycopyrrolate)
Eight of the 10 respondents that indicated that they provide iontophoresis (glycopyrrolate) reported the job
title of the health professional. According to all eight, the procedure is delivered by a specialist nurse. Six
of the 10 clinicians stated that the procedure could be done at home. Five of the six respondents who
reported the length of the procedure said that the procedure would last for up to 1 hour (varied between
15 and 60 minutes).
Curettage
Only one dermatologist provided treatment details about curettage surgery. According to the respondent,
the procedure would last for 30 minutes, it would be delivered by a consultant dermatologist and there
would be one follow-up visit that would last for 5 minutes.
Adverse events and treatment effectiveness
Dropout rates due to adverse events and lack of effectiveness
The survey respondents were asked to indicate the dropout rates for each type of treatment due to both
lack of effectiveness and adverse events. The percentage of who drop out, according to the respondents,
was recorded. Results are presented in Tables 69 and 70.
TABLE 68 Most frequent responses on resource use associated with iontophoresis (tap water)
Details provided Iontophoresis (tap water)
Number of
respondents
Type of machine used at hospital ‘Not sure’ 18/24
Type of machine for home use ‘Not sure’ 17/19
Proportion of patients who would carry out the
treatment at home
‘Not sure’ (other responses vary between
5% and 100%)
8/28
TABLE 69 Dropout rates due to lack of effectiveness
Treatment type Percentage of patients who drop out SD (%) Number of respondents
Antiperspirants 68.57 26.13 21
Medications 36.46 25.09 15
Iontophoresis (tap water) 47.17 15.58 15
Iontophoresis (glycopyrrolate) 36.67 10.33 6
TABLE 70 Dropout rates due to adverse events
Treatment type Percentage of patients who drop out SD (%) Number of respondents
Aluminium chloride 54.76 34.22 22
Medications 36.80 25.37 18
Iontophoresis (tap water) 15.88 17.79 18
Iontophoresis (glycopyrrolate) 25 21.79 5
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In the case of aluminium chloride and iontophoresis (tap water and glycopyrrolate), dropout rates due to
lack of effectiveness were higher than dropout rates due to side effects. For medications, the dropout rates
were similar in both categories. Overall, the dropout rates are relatively high for both of the reasons.
Time to effectiveness
As sufficient clinical advice on time to effectiveness had already been obtained for all types of treatment except
for medications, data were only collected for medications. The responses varied significantly, from ‘immediate’
to ‘up to 3 months’. The most common response was ‘variable’ (stated by 8 out of 38 respondents).
Survey questions
1. What is the name of the town/city to which your responses relate?
2. What is the name of the hospital trust(s) to which your responses relate?
3. What medications, and with what dose and frequency, do you prescribe to hyperhidrosis patients?
4. What is the time to effectiveness of medication for hyperhidrosis?
5. If a hyperhidrosis patient is on medication:
i. How frequently would a monitoring visit (follow-up visit following the prescription of medication)
be required?
ii. What is the duration of one monitoring visit? (In minutes.)
iii. Job title of the health professional(s) that is present at the monitoring visit.
6. Is there an ongoing risk of dropout due to adverse events related to medication use beyond 1 month?
7. Is Botox procedure available at your dermatology unit?
8. What is the job title of the health professional(s) that delivers the procedure?
9. What is the duration of the procedure (in minutes)?
10. How many monitoring visits following Botox treatment and how often do they occur?
11. Is curettage surgery (for hyperhidrosis) available at your dermatology unit?
12. What is the duration of the surgery? (In minutes.)
13. What is the job title of the health professional(s) that delivers the procedure?
14. What is the duration of monitoring visits? (In minutes.)
15. What is the frequency of monitoring visits?
16. What are the side effects?
17. What are the treatments of side effects?
18. Is laser surgery available at your dermatology unit?
19. What is the duration of the surgery? (In minutes.)
20. What is the job title of the health professional(s) that delivers the procedure?
21. What is the duration of monitoring visits? (In minutes.)
22. What is the frequency of monitoring visits?
23. What are the side effects?
24. What are the treatments of side effects?
25. Is microwave surgery available at your dermatology unit?
26. What is the duration of the surgery? (In minutes.)
27. What is the job title of the health professional(s) that delivers the procedure?
28. What is the duration of monitoring visits? (In minutes.)
29. What is the frequency of monitoring visits?
30. What are the side effects?
31. What are the treatments of side effects?
32. Is ultrasound treatment of hyperhidrosis available in your unit/hospital?
33. What is the duration of the surgery? (In minutes.)
34. What is the job title of the health professional(s) that delivers the procedure?
35. What is the duration of monitoring visits? (In minutes.)
36. What is the frequency of monitoring visits?
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37. What are the side effects?
38. What are the treatments of side effects?
39. Is radiofrequency treatment of hyperhidrosis available in your unit/hospital?
40. What is the duration of the surgery? (In minutes.)
41. What is the job title of the health professional(s) that delivers the procedure?
42. What is the duration of monitoring visits? (In minutes.)
43. What is the frequency of monitoring visits?
44. What are the side effects?
45. What are the treatments of side effects?
46. Is iontophoresis (with tap water) available at your dermatology unit?
47. What is the model of the iontophoresis machine used at the hospital?
48. Approximately, what is the proportion (%) of patients who would carry on with the treatment at home?
49. What is the model of the iontophoresis machine recommended for home use?
50. What are the side effects?
51. What are the treatments of the side effects?
52. Is iontophoresis (with glycopyrrolate) available at your dermatology unit?
53. What is the job title of the health professional(s) that delivers the procedure?
54. What is the duration of the procedure? (In minutes.)
55. What are the side effects?
56. What are the treatments of the side effects?
57. Can the patient have the procedure at home?
58. Approximately what proportion of patients (%) would carry on with the treatment at home?
59. Approximately, please indicate the dropout rates (%) due to lack of effectiveness for the
following treatments:
i. antiperspirants
ii. medication
iii. iontophoresis (tap water)
iv. iontophoresis (glycopyrrolate).
60. Approximately, please indicate the dropout rates (%) due to side effects for the following treatments:
i. antiperspirants
ii. medication
iii. iontophoresis (tap water)
iv. iontophoresis (glycopyrrolate).
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Appendix 6 R code for deriving event ranges for
continuously reported outcome measure for the
Hyperhidrosis Disease Severity Scale
dist<-function(temp,res,mu_Su,mu_Sl,n){
for (i in 1:400000){
x1<-seq(1:n)
x1
x<-c(0,x1)
x
a<-sample(x,1)
a
if (a<n){
y1<-seq(1:(n-a))
y1
y<-c(0,y1)
y
b <- sample(y,1)
b
} else {
b<-0  
}
if ((a+b)<n){
z1<-seq(1:(n-a-b))
z1
z<-c(0,z1)
z
c<- sample(z,1)
c  
} else{
c<-0
}
d<-n-a-b-c
d
s<-seq(1:24)
ss<-sample(s,1)
if (ss==1){
e<-a;
f<-b;
g<-c;
h<-d
} else if (ss==2){
e<-a;
f<-b;
g<-d;
h<-c
} else if (ss==3){
e<-a;
f<-c;
g<-b;
h<-d
} else if (ss==4){
e<-a;
f<-c;
g<-d;
h<-b
}else if (ss==5){
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e<-a;
f<-d;
g<-b;
h<-c
} else if (ss==6){
e<-a;
f<-d;
g<-c;
h<-b
} else if (ss==7){
e<-b;
f<-a;
g<-c;
h<-d
} else if (ss==8){
e<-b;
f<-a;
g<-d;
h<-c
} else if (ss==9){
e<-b;
f<-c;
g<-a;
h<-d
} else if (ss==10){
e<-b;
f<-c;
g<-d;
h<-a
} else if (ss==11){   
e<-b;
f<-d;
g<-a;
h<-c
} else if (ss==12){     
e<-b;
f<-d;
g<-c;
h<-a      
} else if (ss==13){
e<-c;
f<-b;
g<-a;
h<-d      
} else if (ss==14){
e<-c;
f<-b;
g<-d;
h<-a
} else if (ss==15){
e<-c;
f<-a;
g<-b;
h<-d
} else if (ss==16){
e<-c;
f<-a;
g<-d;
h<-b
} else if (ss==17){
e<-c;
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f<-d;
g<-b;
h<-a
} else if (ss==18){
e<-c;
f<-d;
g<-a;
h<-b
} else if (ss==19){
e<-d;
f<-b;
g<-c;
h<-a
} else if (ss==20){
e<-d;
f<-b;
g<-a;
h<-c
} else if (ss==21){
e<-d;
f<-c;
g<-b;
h<-a
} else if (ss==22){
e<-d;
f<-c;
g<-a;
h<-b
} else if (ss==23){
e<-d;
f<-a;
g<-b;
h<-c
} else {
e<-d;
f<-a;
g<-c;
h<-b
}
mu<-(f+2*g+3*h)/n
v<-(0-mu)^2
w<-(1-mu)^2
p<-(2-mu)^2
q<-(3-mu)^2
var<-(e*v + f*w + g*p + h*q)/n
sd<-sqrt(var)
temp[,"a"]<-e
temp[,"b"]<-f
temp[,"c"]<-g
temp[,"d"]<-h
temp[,"mu"]<-mu
temp[,"sd"]<-sd
if (i == 1){
res<-temp
} else {
if (mu_Su<1.5){
if (mu<mu_Su & mu>mu_Sl & (h==g | h<g) & (g==f | g<f)){
res<-rbind(res,temp)  
} else {
res<-res
}
}else {
if (mu<mu_Su & mu>mu_Sl & (e==f | e<f) & (f==g | f<g)){
res<-rbind(res,temp)  
} else {
res<-res 
}   
}      
}    
}
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(res);
}
#Muller grp 1
res<-dist(temp,mu_Su=0.805,mu_Sl=0.795,n=128)
res
#Muller grp 2
res<-dist(temp,mu_Su=0.605,mu_Sl=0.595,n=139)
res
#Ibrahim grp 1
res<-dist(temp,mu_Su=1.555,mu_Sl=1.545,n=20)
res
#Ibrahim grp 2
res<-dist(temp,mu_Su=0.805,mu_Sl=0.795,n=20)
res
#Leclere grp 2
res<-dist(temp,mu_Su=1.885,mu_Sl=1.875,n=25)
res
#Leclere grp 3
res<-dist(temp,mu_Su=1.645,mu_Sl=1.635,n=25)
res
#Fatemi grp 1
res<-dist(temp,mu_Su=1.49,mu_Sl=1.43,n=25)
res
#Fatemi grp 2
res<-dist(temp,mu_Su=0.19,mu_Sl=0.15,n=25)
res
#Vakili grp 1
res<-dist(temp,mu_Su=1.705,mu_Sl=1.695,n=23)
res
#Vakili grp 2
res<-dist(temp,mu_Su=1.605,mu_Sl=1.595,n=75)
res
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Appendix 7 Derivation of the relative risk from
the event ranges
RRsim <- function(rep,minTe,maxTe,Tn,minCe,maxCe,Cn){
for (i in 1:rep){
re<-seq(from=minTe,to=maxTe)
xe <- sample(re,1);
rc<-seq(from=minCe,to=maxCe)
xc <- sample(rc,1);
if (xe==0){
xen <- Tn + 2
} else {
xen <- Tn
}
if (xc==0){
xcn <- Cn + 2
} else {
xcn <- Cn
}
if (xe==0){
xe <- 1
} else {
xe <- xe
}
if (xc==0){
xc <- 1
} else {
xc <- xc
}
RR<-(xe/xen)/(xc/xcn)
LNRR<-log(RR)
LNVAR<-(1/xe)-(1/xen)+(1/xc)-(1/xcn)
LNSE<-sqrt(LNVAR)
LNres<-rnorm(1,LNRR,LNSE)
res<-exp(LNres)
if (i==1){
RRres <- res
} else {
RRres <- c(RRres,res)
}
}
(RRres);
}
#Muller
RRres <- RRsim(rep=50000,minTe=0,maxTe=34,Tn=128,minCe=0,maxCe=28,Cn=139)
RRres
#Ibrahim
RRres <- RRsim(rep=50000,minTe=0,maxTe=5,Tn=20,minCe=11,maxCe=14,Cn=20)
RRres
#Leclere
RRres <- RRsim(rep=50000,minTe=16,maxTe=22,Tn=25,minCe=14,maxCe=19,Cn=25)
RRres
#Fatemi
RRres <- RRsim(rep=50000,minTe=0,maxTe=7,Tn=25,minCe=0,maxCe=1,Cn=25)
RRres
#Vakili
RRres <- RRsim(rep=50000,minTe=13,maxTe=18,Tn=23,minCe=40,maxCe=55,Cn=75)
RRres
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Appendix 8 Network meta-analysis assuming
individual surgery effects
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
delta[i,1] <- 0 # treatment effect is zero for control arm
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:2) { # LOOP THROUGH ARMS
r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood
logit(p[i,k]) <- mu[i] + delta[i,k] # model for linear predictor
rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k])) #Deviance contribution
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k])))
}
resdev[i] <- sum(dev[i,]) # summed residual deviance contribution for this trial
delta[i,2] ~ dnorm(md[i,2],prec[t[i,2],t[i,1]]) # trial-specific LOR distributions
md[i,2]<-d[t[i,2]] - d[t[i,1]]
}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<- 0 # treatment effect is zero for reference treatment
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
#sd ~ dunif(0,5) # vague prior for between-trial SD
priorprec1<-pow(1.54,-2)
priorprec2<-pow(1.73,-2)
priorprec4<-pow(1.27,-2)
priorprec5<-pow(1.47,-2)
tau1~dlnorm(-2.54,priorprec1)
tau4~dlnorm(-1.51,priorprec4)
tau5~dlnorm(-2.1,priorprec5)
tau2~dlnorm(-2.77,priorprec2)
tau[2,1]<-tau1
tau[3,1]<-tau1
tau[4,3]<-tau4
tau[5,4]<-tau5
tau[6,1]<-tau2
tau[7,1]<-tau2
prec[2,1]<-1/tau[2,1]
prec[3,1]<-1/tau[3,1]
prec[4,3]<-1/tau[4,3]
prec[5,4]<-1/tau[5,4]
prec[6,1]<-1/tau[6,1]
prec[7,1]<-1/tau[7,1]
# pairwise ORs and LORs for all possible pair-wise comparisons, if nt>2
for (c in 1:(nt-1)) {
for (k in (c+1):nt) {
or[c,k] <- exp(d[k] - d[c])
lor[c,k] <- (d[k]-d[c])
}
}
# ranking on relative scale
for (k in 1:nt) {
rk[k] <- nt+1-rank(d[],k) # assumes events are “good”
# rk[k] <- rank(d[],k) # assumes events are “bad”
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
}
# Provide estimates of treatment effects T[k] on the natural (probability) scale
# Given a Mean Effect, meanA, for ‘standard’ treatment 1, with precision (1/variance) precA
#A ~ dnorm(meanA,precA)
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#for (k in 1:nt) { logit(T[k]) <- A + d[k] }
# Provide estimates of number needed to treat NNT[k], Risk Difference RD[k],
# and Relative Risk RR[k], for each treatment, relative to treatment 1
#for (k in 2:nt) {
#NNT[k] <- 1/(T[k] - T[1]) # assumes events are “good”
# NNT[k] <- 1/(T[1]- T[k]) # assumes events are “bad”
#RD[k] <- T[k] - T[1]
#RR[k] <- T[k]/T[1]
#}
}
list(
d=c( NA,-0.5,-0.5,-0.5,-0.5,-0.5,-0.5),
tau1=0.1,
tau2=0.1,
tau4=0.1,
tau5=0.1,
)
list(
d=c( NA,0.5,0.5,0.5,0.5,0.5,0.5),
tau1=0.5,
tau2=0.5,
tau4=0.5,
tau5=0.5,
)
list(nt=7, ns=9)
r[,1] n[,1] r[,2] n[,2] t[,1] t[,2] 
1 14 10 24 1 2
1 129 4 140 1 2
8 25 10 25 4 5
4 20 1 20 3 4
5 39 54 81 1 6
10 74 45 78 1 3
1 26 7 26 1 7
27 108 161 214 1 3
21 75 7 23 3 4
END
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Appendix 9 Between-study variance estimates
Mean between-study variance estimates assuming individual surgery effects (Table 71).
TABLE 71 Between-study variance estimates from the NMA
Comparison Mean between-study variance
Medication vs. placebo 0.13
Botox vs. placebo 0.13
Curettage vs. Botox 0.48
Laser vs. curettage 0.37
Microwave surgery vs. placebo 0.29
Radiofrequency vs. placebo 0.29
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Appendix 10 Methods and graphic plots of the
relationships between the Hyperhidrosis Disease
Severity Scale level response ratios and the
probability of response
Specifically, 200,000 random combinations of numbers of different responses were drawn. These werecategorised into 21 response categories: < 2.5%, ≥ 97.5% and nineteen 5% bins in between.
The ratio of the numbers with a HDSS 3-point reduction to the numbers with a HDSS 2-point reduction,
and of the numbers with a HDSS 0-point reduction to the numbers with a HDSS 1-point reduction, were
calculated for each category for each simulation and then the average calculated. The lowest and highest
categories and the middle category were discarded. The relationship between the response rate and each
of the ratios was explored for a response rate < 0.5 and > 0.5.
For the ratio of numbers with a HDSS 3-point reduction to the numbers with a HDSS 2-point reduction,
the ratio is plotted against response levels for response > 0.5 in Figure 19a. The HDSS 3/2 ratio for
response > 0.5 is log-transformed before fitting a linear regression in Figure 19b.
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FIGURE 19 (a) Ratio of HDSS 3 to HDSS 2 at high response; and (b) ratio log-transformed with regression line.
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For the ratio of numbers with a HDSS 0 reduction to the numbers with a HDSS 1-point reduction, the ratio
is plotted against response levels for response < 0.5 in Figure 20a. The HDSS 0/1 ratio for response < 0.5 is
log-transformed before fitting a linear regression in Figure 20b.
The HDSS 3 : 2 ratio is plotted against response levels for response < 0.5 in Figure 21a. There is no
discernible relationship between the HDSS 3 : 2 ratio and response when response is < 0.5. The average
ratio is taken to be 0.38. The HDSS 0 : 1 ratio is plotted against response levels for response > 0.5 in
Figure 21b. Again, there is no discernible relationship between the HDSS 0 : 1 ratio and response when
response is < 0.5 and the average ratio is taken to be 0.38.
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FIGURE 20 (a) Ratio of HDSS 0 to HDSS 1 at low response; and (b) ratio log-transformed with regression line.
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FIGURE 21 (a) Ratio of HDSS 3 to HDSS 2 at low response; and (b) ratio of HDSS 0 to HDSS 1 at high response.
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Appendix 11 Sample and sampling distributions
for Hyperhidrosis Disease Severity Scale-level
EuroQol-5 Dimensions index
F igure 22a presents the sample distribution of the utilities for the HDSS level 2 on the EQ-5Drange (–0.594 to 1) simulated from a beta distribution derived from EQ-5D index mean and SDs
rescaled to the range of 0 to 1. Figure 22b presents the sampling distribution of the EQ-5D index
estimates rescaled as a beta distribution. Figures 23 and 24 present the same results for HDSS levels 3 and
4 respectively.
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FIGURE 22 (a) HDSS 2 sample distribution; and (b) sampling distribution.
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FIGURE 23 (a) HDSS 3 sample distribution; and (b) sampling distribution.
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FIGURE 24 (a) HDSS 4 sample distribution; and (b) sampling distribution.
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Appendix 12 Summary cost and quality-adjusted
life-year estimates for each treatment sequence
T able 72 presents the mean QALYs and costs for each of the 64 treatment sequences from thebase-case probabilistic model. In the results in Chapter 7, the treatment sequences that were either
dominated or dominated by extension were not presented.
TABLE 72 The mean QALYs and costs for each of the 64 treatment sequences
Strategy Mean QALYs Mean cost (£) Strategy Mean QALYs Mean cost (£)
I 18.48 1457 IMBE 19.82 6898
IC 18.84 1640 BIMC 19.81 7082
ICE 19.30 1813 BIM 19.80 7111
A 14.33 1914 BIMCE 19.85 7248
C 16.42 2056 MIE 19.36 7308
CE 16.81 2667 BIME 19.83 7325
IE 18.89 3467 BMIC 19.82 7424
IMC 19.27 5020 BMI 19.80 7461
IM 19.16 5096 MIBC 19.81 7535
IBC 19.64 5271 MIB 19.80 7576
IB 19.61 5337 BMICE 19.85 7593
E 16.20 5406 BMIE 19.83 7693
IBCE 19.71 5583 MIBCE 19.85 7704
IMCE 19.53 5622 MIBE 19.82 7813
IBE 19.66 5800 MBIC 19.82 8151
MIC 19.32 5935 MBI 19.81 8188
MI 19.17 6012 MBICE 19.85 8320
IBMC 19.80 6130 BC 19.45 8330
IBM 19.79 6159 MBIE 19.83 8420
IME 19.39 6177 BMC 19.68 8680
BIC 19.65 6231 B 19.36 8720
BI 19.62 6289 BM 19.65 8800
IBMCE 19.84 6297 BMCE 19.76 9288
IBME 19.82 6373 MBC 19.69 9344
MC 18.79 6442 BME 19.72 9491
BICE 19.72 6543 MB 19.66 9527
MICE 19.56 6564 BCE 19.61 9630
IMBC 19.81 6620 MCE 19.39 9657
IMB 19.80 6661 MBCE 19.77 9934
M 18.42 6706 MBE 19.71 10,240
BIE 19.67 6741 BE 19.47 10,250
IMBCE 19.84 6788 ME 19.02 10,733
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Appendix 13 Economic model
mStates <- c("A", "IS",  "ISR",  "M", "MR", "B1", "B2", "B3", "B4", "B5", "B6", "BS", "C", "CR", "CCS"
"E", "ER", "ELCS", "EMCS", "EHCS", "ERCS", "TF", "D");
qcStates <- c("Q1", "Q2", "Q3", "Q4", "Q5", "Q6", "Q7", "Q8", "Q9", "Q10", "Q11", "Q12", "Q13", "Q14", "Q15",
"Q16", "Q17", "Q18", "Q19", "Q20", "Q21", "Q22", "Q23", "Q24", "Q25", "Q26", "Q27", "Q28", "Q29", "Q30",
"Q31", "Q32", "Q33", "Q34", "Q35", "Q36", "Q37", "Q38", "Q39", "Q40", "Q41", "Q42", "Q43", "Q44", "Q45",
"Q46", "Q47", "Q48", "Q49", "Q50", "Q51", "Q52", "Q53", "Q54", "Q55", "Q56", "Q57", "Q58", "Q59", "Q60",
"Q61", "Q62", "Q63", "Q64",
"C1", "C2", "C3", "C4", "C5", "C6", "C7", "C8", "C9", "C10", "C11", "C12", "C13", "C14", "C15",
"C16", "C17", "C18", "C19", "C20", "C21", "C22", "C23", "C24", "C25", "C26", "C27", "C28", "C29", "C30",
"C31", "C32", "C33", "C34", "C35", "C36", "C37", "C38", "C39", "C40", "C41", "C42", "C43", "C44", "C45",
"C46", "C47", "C48", "C49", "C50", "C51", "C52", "C53", "C54", "C55", "C56", "C57", "C58", "C59", "C60",
"C61", "C62", "C63", "C64");
nTX <- 64
nStates <- 25; 
cohort <- 1000
nCycles  <- 58;
#nSims <- 1;
YrCycles <- 12; ##used to convert annual utilties to cycle length utilities
mcmcdf <- function (pnStates, n){
emcmc <- matrix(data=rep(0, (n*(length(pnStates)+1))), nrow=n, ncol=(length(pnStates)+1));  ##SR: creates a matrix of zero values
## where the number of rows is the cohort, and the number of columns is the number of states + 1 (not sure yet why there
## needs to be a column of 1 to n)
colnames(emcmc) <- c("ID", pnStates); 
emcmc[,1] <-seq(1,n);
(data.frame(emcmc));  
}
rmdf <- function (pnStates, n){
rmd <- matrix(data=rep(0, (n*(length(pnStates)+1))), nrow=n, ncol=(length(pnStates)+1));  ##SR: creates a matrix of zero values
## where the number of rows is the cohort, and the number of columns is the number of states + 1 (not sure yet why there
## needs to be a column of 1 to n)
colnames(rmd) <- c("ID", pnStates); 
rmd[,1] <-seq(1,n);
(rmd);  
}
df <- function (c, r){
pm <- matrix(data=rep(0, r*c), nrow=r, ncol=c);  ##SR: creates a matrix of zero values
## where the number of rows is the cohort, and the number of columns is the number of states + 1 (not sure yet why there
## needs to be a column of 1 to n)
#colnames(pm) <- c(pnStates); 
(pm);
}
################################################################
################################################################
dft<-df(10500,nSims)
#dft<-MMcreateMatrix2(df, 5389, 10)
df1<-df(10500,nSims)
dfe<-df(10500,nSims)
rmd<-rmdf(qcStates, nSims)
mcmc <- mcmcdf(qcStates, nSims)
#trans<-tab.datTnames(mStates)
#mModel <- MMcreateMatrix(trans, nStates, mStates)
################################################################
#antiperspirants drop out rate
dft[,70]<-rbeta(nSims,0.611,0.505)
P_R <- rbeta(nSims,5.977938,38.40171)   ##Placebo response
dft[,1]<-P_R
lor<-tab.datCU[sample(nrow(tab.datCU),size=nSims,replace=TRUE),]
if (sap1==7){
lor<-tab.datMSU[sample(nrow(tab.datMSU),size=nSims,replace=TRUE),]
}
#write.csv(lorCU, file = "lor.csv")
logISP_ORm<-1.11
if (det==1){}
if (det==2){
logISP_ORm<-1.11
if (sap1==9){
logISP_ORm<-runif(nSims,0,2.22)
}
}
ISP_ORm<-exp(logISP_ORm)
#ISP_ORm <- 0.4 ##relative risk mean of Iontophoresis sponge vs botox. Vary this in sensitivity analysis.
dft[,2]<-ISP_ORm
#ISB_RR <- exp(ISB_lnRR) ##convert back to RR from LN(RR)
ISP_OR <- ISP_ORm
ISP_RR<-ISP_OR/(1-dft[,1]*(1-ISP_OR))
if (sap6==1){}
if (sap6==2){
ISP_RR<-isrr
}
IS_R <- dft[,1]*ISP_RR
dft[,3]<-IS_R
dft[,3]<-ifelse(dft[,3]>1,1,dft[,3])
#IS_NR <- 1-IS_R
dft[,4]<-1-dft[,3]
IS_SE<-0.16
if (det==2){
IS_SE <- rbeta(nSims,0.511,2.709) ##drop out rate due to side effects
}
dft[,5]<-IS_SE
#IS_NSE <- 1-IS_SE
dft[,6]<-1-dft[,5]
dft[,7]<-exp(2.064)
if (det==2){
#MP_orCU<-exp(lor$mp)
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dft[,7]<-exp(lor$mp)
}
#MP_RR<-MP_OR/(1-P_R*(1-MP_OR))
dft[,8]<-dft[,7]/(1-dft[,1]*(1-dft[,7]))
#MP_RR <- exp(MP_lnRR) ##convert back to RR from LN(RR)
#dft[,8]<-dft[,7]
#M_R <- P_R*MP_RR
dft[,9]<-dft[,1]*dft[,8]
dft[,9]<-ifelse(dft[,9]>1,1,dft[,9])
#M_NR <- 1-M_R
dft[,10]<-1-dft[,9]
M_SE<-0.37
if (det==2){
M_SE <- rbeta(nSims,0.962,1.652) ##drop out rate due to side effects
}
dft[,11]<-M_SE
#M_NSE <- 1-M_SE
dft[,12]<-1-dft[,11]
M_SR <- 1  ##Sustained response: change in sensitivity analysis
if (sap1==5){
M_SR <- 0.9975 #moderate decline in effectiveness over time
}
if (sap1==6){
M_SR <- 0.99    #considerable decline in effectiveness over time
}
dft[,13]<-M_SR
################
dft[,14]<-exp(2.218)
if (det==2){
#BP_orCU<-exp(lor$bp)
dft[,14]<-exp(lor$bp)
}
#BP_RR<-BP_OR/(1-P_R*(1-BP_OR))
dft[,15]<-dft[,14]/(1-dft[,1]*(1-dft[,14]))
#BP_RR <- exp(BP_lnRR) ##convert back to RR from LN(RR)
#dft[,15]<-dft[,14]
#B_R <- P_R*BP_RR
dft[,16]<-dft[,1]*dft[,15]
dft[,16]<-ifelse(dft[,16]>1,1,dft[,16])
#B_NR <- 1-B_R
dft[,17]<-1-dft[,16]
B_SE<-0
if (sap5==1){}
if (sap5==2){
B_SE<-0.1
}
if (sap5==3){
B_SE<-0.2
}
#B_SE <- 0 ##drop out rate due to side effects
#if (det==2){
# B_SE<-dunif(nSims,0,0.5)
#}
dft[,18]<-B_SE
#B_NSE <- 1-B_SE
dft[,19]<-1-dft[,18]
################
dft[,20]<-exp(1.417)
if (det==2){
#CP_orCU<-exp(lor$cp)
dft[,20]<-exp(lor$cp)
}
if (sap4==1){}
if (sap4==2){
dft[,20]<-exp(2.198)
if (det==2){
#CP_orCU<-exp(lor$cp)
dft[,20]<-exp(lor$lp)    
}
}
if (sap4==3){
dft[,20]<-exp(2.705)
if (det==2){
#CP_orCU<-exp(lor$cp)
dft[,20]<-exp(lor$micp)    
}
}
if (sap4==4){
dft[,20]<-exp(2.728)
if (det==2){
#CP_orCU<-exp(lor$cp)
dft[,20]<-exp(lor$rp)    
}
}
#CP_RR<-CP_OR/(1-P_R*(1-CP_OR))
dft[,21]<-dft[,20]/(1-dft[,1]*(1-dft[,20]))
#CB_RR <- exp(CB_lnRR) ##convert back to RR from LN(RR)
#dft[,21]<-dft[,20]
#C_R <- P_R*CP_RR
dft[,22]<-dft[,1]*dft[,21]
dft[,22]<-ifelse(dft[,22]>1,1,dft[,22])
#C_NR <- 1-C_R
dft[,23]<-1-dft[,22]
#CCS <- 0.02
dft[,24]<-0
E_R <- 340/1700
ELCS <- 394/1700
EMCS <- 409/1700
EHCS <- 367/1700
ERCS <- 190/1700
if (sap1==8){
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E_R <- 37/453
ELCS <- 92/453
EMCS <- 174/453
EHCS <- 150/453
ERCS <- 0
}
if (det==2){
draws <- rdirichlet(nSims, c(340,394,409,367,190) ) #compensatory sweating random draw: smidfelt 2011
E_R <- draws[,1]
ELCS <- draws[,2]
EMCS <- draws[,3]
EHCS <- draws[,4]
ERCS <- draws[,5]
}
if (sap1==1){}
if (sap1==2){
draws <- rdirichlet(nSims, c(37,92,174,150) ) #compensatory sweating random draw: wolosker 2012
E_R <- draws[,1]
ELCS <- draws[,2]
EMCS <- draws[,3]
EHCS <- draws[,4]  
ERCS <- 0
}
dft[,25]<-E_R
dft[,26]<-ELCS
dft[,27]<-EMCS
dft[,28]<-EHCS
dft[,29]<-ERCS
#derive the HDSS0/1 and HDSS3/2 ratios
dft[,30]<-ifelse(dft[,3]<=0.5,exp(1.2076-5.8374*dft[,3]),0.38) #IS_R  HDSS_01_IS
dft[,31]<-ifelse(dft[,3]<=0.5,0.38,exp(-4.6407+5.8278*dft[,3])) #IS_R  HDSS_32_IS                
dft[,32]<-ifelse(dft[,9]<=0.5,exp(1.2076-5.8374*dft[,9]),0.38) #M_R  HDSS_01_M
dft[,33]<-ifelse(dft[,9]<=0.5,0.38,exp(-4.6407+5.8278*dft[,9])) #M_R  HDSS_32_M              
dft[,34]<-ifelse(dft[,16]<=0.5,exp(1.2076-5.8374*dft[,16]),0.38) #B_R  HDSS_01_B
dft[,35]<-ifelse(dft[,16]<=0.5,0.38,exp(-4.6407+5.8278*dft[,16])) #B_R  HDSS_32_B                
dft[,36]<-ifelse(dft[,22]<=0.5,exp(1.2076-5.8374*dft[,22]),0.38) #C_R  HDSS_01_C
dft[,37]<-ifelse(dft[,22]<=0.5,0.38,exp(-4.6407+5.8278*dft[,22])) #C_R  HDSS_32_C                
#determine the HDSS states conditional on response
#Ris0<-(IS_NR*HDSS_01_IS)/(1+HDSS_01_IS)
dft[,38]<-(dft[,4]*dft[,30])/(1+dft[,30])
#Ris1<-IS_NR/(1+HDSS_01_IS)
dft[,39]<-dft[,4]/(1+dft[,30])
#Ris2<-IS_R/(1+HDSS_32_IS)
dft[,40]<-dft[,3]/(1+dft[,31])
#Ris3<-(IS_R*HDSS_32_IS)/(1+HDSS_32_IS)
dft[,41]<-(dft[,3]*dft[,31])/(1+dft[,31])
#Rm0<-(M_NR*HDSS_01_M)/(1+HDSS_01_M)
dft[,42]<-(dft[,10]*dft[,32])/(1+dft[,32])
#Rm1<-M_NR/(1+HDSS_01_M)
dft[,43]<-dft[,10]/(1+dft[,32])
#Rm2<-M_R/(1+HDSS_32_M)
dft[,44]<-dft[,9]/(1+dft[,33])
#Rm3<-(M_R*HDSS_32_M)/(1+HDSS_32_M)
dft[,45]<-(dft[,9]*dft[,33])/(1+dft[,33])
#Rb0<-(B_NR*HDSS_01_B)/(1+HDSS_01_B)
dft[,46]<-(dft[,17]*dft[,34])/(1+dft[,34])
#Rb1<-B_NR/(1+HDSS_01_B)
dft[,47]<-dft[,17]/(1+dft[,34])
#Rb2<-B_R/(1+HDSS_32_B)
dft[,48]<-dft[,16]/(1+dft[,35])
#Rb3<-(B_R*HDSS_32_B)/(1+HDSS_32_B)
dft[,49]<-(dft[,16]*dft[,35])/(1+dft[,35])
#Rc0<-(C_NR*HDSS_01_C)/(1+HDSS_01_C)
dft[,50]<-(dft[,23]*dft[,36])/(1+dft[,36])
#Rc1<-C_NR/(1+HDSS_01_C)
dft[,51]<-dft[,23]/(1+dft[,36])
#Rc2<-C_R/(1+HDSS_32_C)
dft[,52]<-dft[,22]/(1+dft[,37])
#Rc3<-(C_R*HDSS_32_C)/(1+HDSS_32_C)
dft[,53]<-(dft[,22]*dft[,37])/(1+dft[,37])
#determine partial responders with adverse events and no responders with or without adverse events. For the purpose
#of calcuating the probability of minor surgery
#Ris_partial<-Ris1*IS_NSE
dft[,61]<-dft[,39]*dft[,6]
#Ris_noresp<-Ris0+Ris1-Ris_partial+IS_R*IS_SE
dft[,62]<-dft[,38]+dft[,39]-dft[,61]+dft[,3]*dft[,5]
#Ris_ratio<-Ris_noresp/(Ris_noresp+Ris_partial)
dft[,63]<-dft[,62]/(dft[,62]+dft[,61])
#Rm_partial<-Rm1*M_NSE
dft[,64]<-dft[,43]*dft[,12]
#Rm_noresp<-Rm0+Rm1-Rm_partial+M_R*M_SE
dft[,65]<-dft[,42]+dft[,43]-dft[,64]+dft[,9]*dft[,11]
#Rm_ratio<-Rm_noresp/(Rm_noresp+Rm_partial)
dft[,66]<-dft[,65]/(dft[,65]+dft[,64])
#Rb_partial<-Rb1*B_NSE
dft[,67]<-dft[,47]*dft[,19]
#Rb_noresp<-Rb0+Rb1-Rb_partial+B_R*B_SE
dft[,68]<-dft[,46]+dft[,47]-dft[,67]+dft[,16]*dft[,18]
#Rb_ratio<-Rb_noresp/(Rb_noresp+Rb_partial)
dft[,69]<-dft[,68]/(dft[,68]+dft[,67])
##Utilities
avpop_utility1<-tab.datU
avpop_utility<-as.numeric(avpop_utility1)
#dft[,54]<-avpop_utility
HDSS2_draw <- 0.906
if (det==2){
HDSS2_draw <- rbeta(nSims,416.6093,43.27513)
}
dft[,55]<-HDSS2_draw
#HDSS2_utility <- 1-((1-HDSS2_draw)*1.594)
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dft[,56]<-1-((1-dft[,55])*1.594)
HDSS3_draw <- 0.875
if (det==2){
HDSS3_draw <- rbeta(nSims,391.017,55.77788)
}
dft[,57]<-HDSS3_draw
#HDSS3_utility <- 1-((1-HDSS3_draw)*1.594)
dft[,58]<-1-((1-dft[,57])*1.594)
HDSS4_draw <- 0.805
if (det==2){
HDSS4_draw <- rbeta(nSims,276.24,66.96217)
}
dft[,59]<-HDSS4_draw
#HDSS4_utility <- 1-((1-HDSS4_draw)*1.594)
dft[,60]<-1-((1-dft[,59])*1.594)
##Costs
#cost-to-charge ratio distribution
dft[,71]<-rnorm(nSims,0.648,0.167)
cp<-tab.datC
cp["A"]<-cp["A"]*(1-dft[70])
if (sap1==10){
#cp["ISR"]<-5.64: 10 year time horizon
cp["ISR"]<-5.64
cp["IS"]<-153.81
}
if (sap4==2){
cp<-tab.datClaser
cp[,"C"]<-69+3.72+3768
}
if (sap4==3){
cp<-tab.datCmicro
cp[,"C"]<-69+3.72+(1495*2)
}
if (sap4==4){
cp<-tab.datCradio
cp[,"C"]<-69+3.72+1169.7
}
#if (sap2==2){
# cp[,"C"]<- 1006.94*(1/0.63) #cost of radiofrequency 
#}
#if (sap2==3){  
# cp[,"C"]<- 1010.85*2 #cost of two microwave visits 
#}
if (sap2==4){
cp[,"ISR"]<- 3.37 #Cost of NHS subsidising home iontophoresis 
}
if (sap2==5){ 
cp[,"M1"]<- 283.39+45.21+11.42 #sensitivity analysis of glycopyrrolate medication costs 
cp[,"M2"]<- 283.39+45.21+11.42 #sensitivity analysis of glycopyrrolate medication costs 
cp[,"M3"]<- 283.39+45.21+11.42 #sensitivity analysis of glycopyrrolate medication costs 
cp[,"MR"]<- 283.39+11.42
}
if (sap2==6){
cp[,"M1"]<- 45.21+11.42+(283.39+28.13)/2 #sensitivity analysis of half taking glycopyrrolate and half taking propantheline costs
cp[,"M2"]<- 45.21+11.42+(283.39+28.13)/2 #sensitivity analysis of half taking glycopyrrolate and half taking propantheline costs
cp[,"M3"]<- 45.21+11.42+(283.39+28.13)/2 #sensitivity analysis of half taking glycopyrrolate and half taking propantheline costs
cp[,"MR"]<- 11.42+(283.39+28.13)/2
}
if (sap2==7){
cp[,"M1"]<- 45.21+11.42+283.39*(4/35) #sensitivity analysis of emergency glycopyrrolate medication costs
cp[,"M2"]<- 45.21+11.42+283.39*(4/35) #sensitivity analysis of emergency glycopyrrolate medication costs
cp[,"M3"]<- 45.21+11.42+283.39*(4/35) #sensitivity analysis of emergency glycopyrrolate medication costs
cp[,"MR"]<- 11.42+283.39*(4/35)
}
if (sap2==8){  
cp[,"C"]<- 1195.1+3.72  #sensitivity analysis of infection rate of 10%
}
rt<-as.numeric(cp)
for (i in 1:nStates){
dft[,(100+i)]<-rt[i]
}
#Account for private-to-NHS cost ratio uncetainty
if (sap4==2){
dft[,115]<-dft[,115]*dft[,71]
}
if (sap4==3){
dft[,115]<-dft[,115]*dft[,71]
}
##mortality risk
mr <- tab.datMR
rtrisk<-as.numeric(mr)
########################
##CAll prob functions
#b<-20
for (b in 1:64){
#  dft1<-nTreat(b,dft,sap2)
#######################################
#derive the probabilitites of receiving either medication, iontophoresis or antiperspirants following
#treatment failure or compensatory sweating.These are conditional on the treatment sequence
#######################################
dfe<-dft
if (b == 49|b == 50|b == 51|b == 52|b == 61|b == 62|b == 63|b == 64|
b == 41|b == 42|b == 43|b == 44|b == 53|b == 54|b == 55|b == 56|
b == 47|b == 48|b == 59|b == 60|
b == 46|b == 58|b == 45|b == 57){
#tfMED<-(RM1/(RM0+RM1+M_R*M_SE))*M_NSE
dfe[,86]<-(dfe[,43]/(dfe[,43]+dfe[,42]+dft[,9]*dft[,11]))*dfe[,12]
#tfION<-(1-tfMED)*(RIS1/(RIS0+RIS1+IS_R*IS_SE))*IS_NSE
dfe[,87]<-(1-dfe[,86])*(dfe[,39]/(dfe[,39]+dfe[,38]+dft[,3]*dft[,5]))*dfe[,6]
#tfBOT<-(1-tfMED)*(1-tfION)*((RB1/(RB0+RB1+B_R*B_SE))*B_NSE
dfe[,88]<-(1-dfe[,86]-dfe[,87])*(dfe[,47]/(dfe[,47]+dfe[,46]+dft[,16]*dft[,18]))*dfe[,19]
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#tfANTI<-1-tfMED-tfION-tfBOT
dfe[,89]<-1-dfe[,86]-dfe[,87]-dfe[,88] 
#noben<-Ris_ratio*Rm_ratio*Rb_ratio
dfe[,90]<- dfe[,63]*dfe[,66]*dfe[,69]
#maxben<-min(Ris_ratio,Rm_ratio,Rb_ratio)
dfe[,91]<- min(dfe[,63],dfe[,66],dfe[,69])
} else if (b == 17| b == 18|b == 19|b == 20|b == 23|b == 24|b == 22|b == 21)  {
#tfMED<-(RM1/(RM0+RM1+M_R*M_SE))*M_NSE
dfe[,86]<-(dfe[,43]/(dfe[,43]+dfe[,42]+dft[,9]*dft[,11]))*dfe[,12]
#tfION<-(1-tfMED)*((RIS1/(RIS0+RIS1+IS_R*IS_SE))*IS_NSE)
dfe[,87]<-0
#tfBOT<-(1-tfMED)*(1-tfION)*((RB1/(RB0+RB1+B_R*B_SE))*B_NSE
dfe[,88]<-(1-dfe[,86]-dfe[,87])*(dfe[,47]/(dfe[,47]+dfe[,46]+dft[,16]*dft[,18]))*dfe[,19]
#tfANTI<-1-tfMED-tfION
dfe[,89]<-1-dfe[,86]-dfe[,87]-dfe[,88]
#noben<-Rm_ratio*Rb_ratio
dfe[,90]<- dfe[,66]*dfe[,69]
#maxben<-min(Rm_ratio,Rb_ratio)
dfe[,91]<- min(dfe[,66],dfe[,69])
} else if (b == 25| b == 26|b == 27|b == 28|b == 29|b == 30|b == 31|b == 32)  {
#tfMED<-(RM1/(RM0+RM1+M_R*M_SE))*M_NSE
dfe[,86]<-0
#tfION<-(1-tfMED)*(RIS1/(RIS0+RIS1+IS_R*IS_SE))*IS_NSE
dfe[,87]<-(1-dfe[,86])*(dfe[,39]/(dfe[,39]+dfe[,38]+dft[,3]*dft[,5]))*dfe[,6]
#tfBOT<-(1-tfMED)*(1-tfION)*((RB1/(RB0+RB1+B_R*B_SE))*B_NSE
dfe[,88]<-(1-dfe[,86]-dfe[,87])*(dfe[,47]/(dfe[,47]+dfe[,46]+dft[,16]*dft[,18]))*dfe[,19]
#tfANTI<-1-tfMED-tfION-tfBOT
dfe[,89]<-1-dfe[,86]-dfe[,87]-dfe[,88]
#noben<-Ris_ratio*Rb_ratio
dfe[,90]<- dfe[,63]*dfe[,69]
#maxben<-min(Ris_ratio,Rb_ratio)
dfe[,91]<- min(dfe[,63],dfe[,69])
} else if (b == 33| b == 34|b == 35|b == 36|b == 37|b == 38|b == 39|b == 40)  {
#tfMED<-(RM1/(RM0+RM1+M_R*M_SE))*M_NSE
dfe[,86]<-(dfe[,43]/(dfe[,43]+dfe[,42]+dft[,9]*dft[,11]))*dfe[,12]
#tfION<-(1-tfMED)*(RIS1/(RIS0+RIS1+IS_R*IS_SE))*IS_NSE
dfe[,87]<-(1-dfe[,86])*((dfe[,39]/(dfe[,39]+dfe[,38]+dft[,3]*dft[,5]))*dfe[,6])
#tfBOT<-(1-tfMED)*(1-tfION)*((RB1/(RB0+RB1+B_R*B_SE))*B_NSE
dfe[,88]<-0
#tfANTI<-1-tfMED-tfION-tfBOT
dfe[,89]<-1-dfe[,86]-dfe[,87]-dfe[,88]
#noben<-Ris_ratio*Rm_ratio
dfe[,90]<- dfe[,63]*dfe[,66]
#maxben<-min(Ris_ratio,Rm_ratio)
dfe[,91]<- min(dfe[,63],dfe[,66])
} else if (b == 13| b == 14|b == 15|b == 16)  {
#tfMED<-(RM1/(RM0+RM1+M_R*M_SE))*M_NSE
dfe[,86]<-0
#tfION<-(1-tfMED)*(RIS1/(RIS0+RIS1+IS_R*IS_SE))*IS_NSE
dfe[,87]<-(1-dfe[,86])*((dfe[,39]/(dfe[,39]+dfe[,38]+dft[,3]*dft[,5]))*dfe[,6])
#tfBOT<-(1-tfMED)*(1-tfION)*((RB1/(RB0+RB1+B_R*B_SE))*B_NSE
dfe[,88]<-0
#tfANTI<-1-tfMED-tfION-tfBOT
dfe[,89]<-1-dfe[,86]-dfe[,87]-dfe[,88]
#noben<-Ris_ratio
dfe[,90]<- dfe[,63]
#maxben<-Ris_ratio
dfe[,91]<- dfe[,63]
} else if (b == 9| b == 10|b == 11|b == 12)  {
#tfMED<-(RM1/(RM0+RM1+M_R*M_SE))*M_NSE
dfe[,86]<-(dfe[,43]/(dfe[,43]+dfe[,42]+dft[,9]*dft[,11]))*dfe[,12]
#tfION<-(1-tfMED)*(RIS1/(RIS0+RIS1+IS_R*IS_SE))*IS_NSE
dfe[,87]<-0
#tfBOT<-(1-tfMED)*(1-tfION)*((RB1/(RB0+RB1+B_R*B_SE))*B_NSE
dfe[,88]<-0
#tfANTI<-1-tfMED-tfION-tfBOT
dfe[,89]<-1-dfe[,86]-dfe[,87]-dfe[,88]
#noben<-Rm_ratio
dfe[,90]<- dfe[,66]
#maxben<-Rm_ratio
dfe[,91]<- dfe[,66]
} else if (b == 5| b == 6|b == 7|b == 8)  {
#tfMED<-(RM1/(RM0+RM1+M_R*M_SE))*M_NSE
dfe[,86]<-0
#tfION<-(1-tfMED)*(RIS1/(RIS0+RIS1+IS_R*IS_SE))*IS_NSE
dfe[,87]<-0
#tfBOT<-(1-tfMED)*(1-tfION)*((RB1/(RB0+RB1+B_R*B_SE))*B_NSE
dfe[,88]<-(1-dfe[,86]-dfe[,87])*(dfe[,47]/(dfe[,47]+dfe[,46]+dft[,16]*dft[,18]))*dfe[,19]
#tfANTI<-1-tfMED-tfION-tfBOT
dfe[,89]<-1-dfe[,86]-dfe[,87]-dfe[,88]
#noben<-Rb_ratio
dfe[,90]<- dfe[,69]
#maxben<-Rb_ratio
dfe[,91]<- dfe[,69]
} else   {
#tfMED<-(RM1/(RM0+RM1+M_R*M_SE))*M_NSE
dfe[,86]<-0
#tfION<-(1-tfMED)*(RIS1/(RIS0+RIS1+IS_R*IS_SE))*IS_NSE
dfe[,87]<-0
#tfBOT<-(1-tfMED)*(1-tfION)*((RB1/(RB0+RB1+B_R*B_SE))*B_NSE
dfe[,88]<-0
#tfANTI<-1-tfMED-tfION-tfBOT
dfe[,89]<-1-dfe[,86]-dfe[,87]-dfe[,88]
}
##cost of treatment failure/treating compensatory sweating
#cpTF<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)*(1-ANTI drop out)
dfe[,124]<-dfe[,86]*(28.13+11.42)+dfe[,87]*0+dfe[,88]*dfe[,114]/6+dfe[,89]*(3.01+11.42)*(1-dfe[,70])
#cpELCS<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
dfe[,120]<-dfe[,86]*(28.13+11.42)+dfe[,87]*0+dfe[,88]*dfe[,114]/6+dfe[,89]*(3.01+11.42)
#cpEMCS<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
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dfe[,121]<-dfe[,86]*(28.13+11.42)+dfe[,87]*0+dfe[,88]*dfe[,114]/6+dfe[,89]*(3.01+11.42)
#cpEHCS<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
dfe[,122]<-dfe[,86]*(28.13+11.42)+dfe[,87]*0+dfe[,88]*dfe[,114]/6+dfe[,89]*(3.01+11.42)
#cpERCS<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
dfe[,123]<-dfe[,86]*(28.13+11.42)+dfe[,87]*0+dfe[,88]*dfe[,114]/6+dfe[,89]*(3.01+11.42)
if (b == 6|b == 8|b == 10|b == 12|b == 14|b == 16|b == 18|b == 20|b == 22|b == 24|b == 26|
b == 28|b == 30|b == 32|b == 34|b == 36|b == 38|b == 40|b == 42|b == 44|b == 46|b == 48|b == 50|
b == 52|b == 54|b == 56|b == 58|b == 60|b == 62|b == 64){
#cpTF<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
dfe[,124]<-(dfe[,86]/(dfe[,86]+dfe[,87]+dfe[,88]))*(28.13+11.42)+(dfe[,87]/(dfe[,86]+dfe[,87]+dfe[,88]))*0+
(dfe[,88]/(dfe[,86]+dfe[,87]+dfe[,88]))*dfe[,114]/6
}
if  (b == 2| b == 3 | b == 4){
dfe[,124]<-dfe[,101]
dfe[,120]<-dfe[,101]
dfe[,121]<-dfe[,101]
dfe[,122]<-dfe[,101]
dfe[,123]<-dfe[,101]
}
if (sap2==1){}
#sensitivity analysis of NHS subsidising home iontophoresis
if (sap2==4){    
cpISR<- 3.37 #Cost of NHS subsidising home iontophoresis 
dfe[,103]<-cpISR
#cpTF<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
dfe[,124]<-dfe[,86]*(28.13+11.42)+dfe[,87]*3.37+dfe[,88]*dfe[,14]/6+dfe[,89]*(3.01+11.42)
#cpELCS<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
dfe[,120]<-dfe[,86]*(28.13+11.42)+dfe[,87]*3.37+dfe[,88]*dfe[,14]/6+dfe[,89]*(3.01+11.42)
#cpEMCS<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
dfe[,121]<-dfe[,86]*(28.13+11.42)+dfe[,87]*3.37+dfe[,88]*dfe[,14]/6+dfe[,89]*(3.01+11.42)
#cpEHCS<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
dfe[,122]<-dfe[,86]*(28.13+11.42)+dfe[,87]*3.37+dfe[,88]*dfe[,14]/6+dfe[,89]*(3.01+11.42)
#cpERCS<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
dfe[,123]<-dfe[,86]*(28.13+11.42)+dfe[,87]*3.37+dfe[,88]*dfe[,14]/6+dfe[,89]*(3.01+11.42)
if (b == 6|b == 8|b == 10|b == 12|b == 14|b == 16|b == 18|b == 20|b == 22|b == 24|b == 26|
b == 28|b == 30|b == 32|b == 34|b == 36|b == 38|b == 40|b == 42|b == 44|b == 46|b == 48|b == 50|
b == 52|b == 54|b == 56|b == 58|b == 60|b == 62|b == 64){     
#cpTF<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
dfe[,124]<-(dfe[,86]/(dfe[,86]+dfe[,87]+dfe[,88]))*(28.13+11.42)+(dfe[,87]/(dfe[,86]+dfe[,87]+dfe[,88]))*3.37+
(dfe[,88]/(dfe[,86]+dfe[,87]+dfe[,88]))*dfe[,114]/6
}
}
#initial population sequence (cols: 87 to 109)  
if (b == 1){    
dfe[,301]<-1
dfe[,302:325]<-0
} else if (b == 13| b == 14|b == 15|b == 16|b == 25|b == 26|b == 27|b == 28|b == 33|b == 34|b == 35|b == 36|b == 41|
b == 42|b == 43|b == 44|b == 45|b == 46|b == 47|b == 48){    
dfe[,302]<-1
dfe[,301]<-0
dfe[,303:325]<-0
} else if (b == 9| b == 10|b == 11|b == 12|b == 17|b == 18|b == 19|b == 20|b == 37|b == 38|b == 39|b == 40|b == 49|
b == 50|b == 51|b == 52|b == 53|b == 54|b == 55|b == 56){    
dfe[,304]<-1
dfe[,301:303]<-0
dfe[,305:325]<-0
} else if (b == 5| b == 6|b == 7|b == 8|b == 21|b == 22|b == 23|b == 24|b == 29|b == 30|b == 31|b == 32|b == 57|
b == 58|b == 59|b == 60|b == 61|b == 62|b == 63|b == 64){    
dfe[,308]<-1
dfe[,301:307]<-0
dfe[,309:325]<-0
} else if (b == 3| b == 4){   
dfe[,315]<-0.5
dfe[,301]<-0.5
dfe[,302:314]<-0
dfe[,316:325]<-0
} else { #if (b == 2)   
dfe[,318]<-0.5
dfe[,301]<-0.5
dfe[,302:317]<-0
dfe[,319:325]<-0
}
dfe[,4001:4025]<-dfe[,301:325]
df1<-dfe
# write.csv(df1, file = "df1.csv")
##set utilities so that they don't exceed average population   
av_pop_utility <- avpop_utility[1]
df1[,251]<-av_pop_utility  
base_utility <- (df1[,58] + df1[,60])/2  
HDSS1response_utility <- (df1[,56] + df1[,58])/2  
halfHDSSresponse_utility <- (base_utility + HDSS1response_utility)/2    
HDSS2response_utility <- (df1[,56]+df1[,251])/2 #correct to ensure that utility isn't higher than population average for older persons
threeqrtsHDSSresponse_utility <- (HDSS1response_utility + HDSS2response_utility)/2  
HDSS3response_utility <- df1[,251]    
df1[,201]<- halfHDSSresponse_utility*(1-df1[70])/YrCycles
df1[,202]<-((HDSS2response_utility*df1[,40]) + (HDSS3response_utility*df1[,41]) + (base_utility*df1[,38]) + (HDSS1response_utility*df1[,39])) /YrCycles##Assumption of complete
utility gain in first month
df1[,204]<-((HDSS2response_utility*df1[,44]) + (HDSS3response_utility*df1[,45]) + (base_utility*df1[,42]) + (HDSS1response_utility*df1[,43]))/YrCycles ##Assumption of complete 
utility gain in first month
df1[,205]<-((HDSS2response_utility*df1[,44]) + (HDSS3response_utility*df1[,45]) + (base_utility*df1[,42]) + (HDSS1response_utility*df1[,43]))/YrCycles ##Assumption of complete 
utility gain in first month
df1[,206]<-((HDSS2response_utility*df1[,44]) + (HDSS3response_utility*df1[,45]) + (base_utility*df1[,42]) + (HDSS1response_utility*df1[,43]))/YrCycles ##Assumption of complete 
utility gain in first month
df1[,208]<-((HDSS2response_utility*df1[,48]) + (HDSS3response_utility*df1[,49]) + (base_utility*df1[,46]) + (HDSS1response_utility*df1[,47]))/YrCycles ##Assumption of complete 
utility gain in first month
df1[,215]<-((HDSS2response_utility*df1[,52]) + (HDSS3response_utility*df1[,53]) + (base_utility*df1[,50]) + (HDSS1response_utility*df1[,51]))/YrCycles ##Assumption of complete 
utility gain in first month
df1[,218]<-((df1[,25]*df1[,251])+(df1[,26]*threeqrtsHDSSresponse_utility)+(df1[,27]*HDSS1response_utility)+(df1[,28]*base_utility)+(df1[,29]*0.487))/YrCycles
df1[,224]<-(((df1[,86]+df1[,87]+df1[,88])*HDSS1response_utility)+((df1[,89])*base_utility))/YrCycles 
if (b == 2| b == 4|b == 6|b == 8|b == 10|b == 12|b == 14|b == 16|b == 18|b == 20|b == 22|b == 24|b == 26|
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b == 28|b == 30|b == 32|b == 34|b == 36|b == 38|b == 40|b == 42|b == 44|b == 46|b == 48|b == 50|
b == 52|b == 54|b == 56|b == 58|b == 60|b == 62|b == 64){  
df1[,224]<-HDSS1response_utility/YrCycles
}
df1[,225]<-0 ##zero utility when dead  
df1[,203]<-((HDSS2response_utility*df1[,40]/(df1[,40]+df1[,41])) + (HDSS3response_utility*df1[,41]/(df1[,40]+df1[,41])))/YrCycles ##Assumption of complete utility gain from 
second month
df1[,207]<-((HDSS2response_utility*df1[,44]/(df1[,44]+df1[,45])) + (HDSS3response_utility*df1[,45]/(df1[,44]+df1[,45])))/YrCycles ##Assumption of complete utility gain from 
second month
df1[,209]<-((HDSS2response_utility*df1[,48]/(df1[,48]+df1[,49])) + (HDSS3response_utility*df1[,49]/(df1[,49]+df1[,48])))/YrCycles ##Assumption of complete utility gain from 
second month
df1[,210]<-((HDSS2response_utility*df1[,48]/(df1[,48]+df1[,49])) + (HDSS3response_utility*df1[,49]/(df1[,49]+df1[,48])))/YrCycles ##Assumption of complete utility gain from
second month
df1[,211]<-((HDSS2response_utility*df1[,48]/(df1[,48]+df1[,49])) + (HDSS3response_utility*df1[,49]/(df1[,49]+df1[,48])))/YrCycles ##Assumption of complete utility gain from 
second month
df1[,212]<-((HDSS2response_utility*df1[,48]/(df1[,48]+df1[,49])) + (HDSS3response_utility*df1[,49]/(df1[,49]+df1[,48])))/YrCycles ##Assumption of complete utility gain from 
second month
df1[,213]<-((HDSS2response_utility*df1[,48]/(df1[,48]+df1[,49])) + (HDSS3response_utility*df1[,49]/(df1[,49]+df1[,48])))/YrCycles ##Assumption of complete utility gain from 
second month
df1[,214]<-((HDSS2response_utility*df1[,48]/(df1[,48]+df1[,49])) + (HDSS3response_utility*df1[,49]/(df1[,49]+df1[,48])))/YrCycles ##Assumption of complete utility gain from 
second month
df1[,216]<-((HDSS2response_utility*df1[,52]/(df1[,52]+df1[,53])) + (HDSS3response_utility*df1[,53]/(df1[,53]+df1[,52])))/YrCycles ##Assumption of complete utility gain from 
second month
df1[,219]<-df1[,251]/YrCycles ##Assumption of complete utility gain from second month  
##Need to put in the CS utility scores  
df1[,217]<-base_utility/YrCycles ##Assumption of no utility gain with CS following curettage
df1[,220]<-threeqrtsHDSSresponse_utility/YrCycles ##Assumption of 1.5 HDSS utility gain with low/mild CS following ETS
df1[,221]<-HDSS1response_utility/YrCycles ##Assumption of 1 HDSS utility gain with moderate CS following ETS
df1[,222]<-base_utility/YrCycles ##Assumption of no utility gain with  high/severe CS following ETS
df1[,223]<-0.487/YrCycles ##Assumption of negative utility gain with  intervention regret CS following ETS.
#16th percentile of beta sample distribution of HDSS 4 in Base-case
if (sap3==1){}
if (sap3==2){
df1[,223]<-0.571/YrCycles #25th percentile of beta sample distribution of HDSS 4 in Base-case
df1[,218]<-((df1[,25]*df1[,251])+(df1[,26]*threeqrtsHDSSresponse_utility)+(df1[,27]*HDSS1response_utility)+(df1[,28]*base_utility)+(df1[,29]*0.571))/YrCycles
}
if (sap3==3){ 
df1[,223]<-0.21/YrCycles #2.5th percentile of beta sample distribution of HDSS 4 in Base-case
df1[,218]<-((df1[,25]*df1[,251])+(df1[,26]*threeqrtsHDSSresponse_utility)+(df1[,27]*HDSS1response_utility)+(df1[,28]*base_utility)+(df1[,29]*0.21))/YrCycles
}
#sensitivity analysis for emergency medication use
if (sap3==4){    
df1[,204]<-(HDSS2response_utility*df1[,44] + HDSS3response_utility*df1[,45] + base_utility*df1[,42] + HDSS1response_utility*df1[,43])*(4/35)/YrCycles
df1[,205]<-(HDSS2response_utility*df1[,44] + HDSS3response_utility*df1[,45] + base_utility*df1[,42] + HDSS1response_utility*df1[,43])*(4/35)/YrCycles
df1[,206]<-(HDSS2response_utility*df1[,44] + HDSS3response_utility*df1[,45] + base_utility*df1[,42] + HDSS1response_utility*df1[,43])*(4/35)/YrCycles
df1[,207]<-(HDSS2response_utility*df1[,44] + HDSS3response_utility*df1[,45])*(4/35)/YrCycles
}
##Define new initial population- first row of trace matrix
df1[,6001:6025]<-df1[,4001:4025]*df1[,201:225] #QALYs
df1[,8001:8025]<-df1[,4001:4025]*df1[,101:125] #Costs
#Sum the QALYs across the states for each cycle
df1[,10001]<-rowSums(df1[,6001:6025])    
#Sum the costs across the states for each iteration
df1[,10101]<-rowSums(df1[,8001:8025])
#write.csv(df1, file = "df1.csv") 
#i<-3
for (i in 2:12){  
##set utilities so that they don't exceed average population  
av_pop_utility <- avpop_utility[i]
df1[,251]<-av_pop_utility  
base_utility <- (df1[,58] + df1[,60])/2  
HDSS1response_utility <- (df1[,56] + df1[,58])/2  
if (sap3==8){
HDSS1response_utility <- df1[,58]   
}
halfHDSSresponse_utility <- (base_utility + HDSS1response_utility)/2  
HDSS2response_utility <- (df1[,56]+df1[,251])/2 #correct to ensure that utility isn't higher than population average for older persons
threeqrtsHDSSresponse_utility <- (HDSS1response_utility + HDSS2response_utility)/2  
HDSS3response_utility <- df1[,251]  
df1[,201]<- base_utility*(1-df1[70])/YrCycles
df1[,202]<-((HDSS2response_utility*df1[,40]) + (HDSS3response_utility*df1[,41]) + (base_utility*df1[,38]) + (HDSS1response_utility*df1[,39])) /YrCycles##Assumption of complete 
utility gain in first month
df1[,204]<-((HDSS2response_utility*df1[,44]) + (HDSS3response_utility*df1[,45]) + (base_utility*df1[,42]) + (HDSS1response_utility*df1[,43]))/YrCycles ##Assumption of complete 
utility gain in first month
df1[,205]<-((HDSS2response_utility*df1[,44]) + (HDSS3response_utility*df1[,45]) + (base_utility*df1[,42]) + (HDSS1response_utility*df1[,43]))/YrCycles ##Assumption of complete 
utility gain in first month
df1[,206]<-((HDSS2response_utility*df1[,44]) + (HDSS3response_utility*df1[,45]) + (base_utility*df1[,42]) + (HDSS1response_utility*df1[,43]))/YrCycles ##Assumption of complete 
utility gain in first month
df1[,208]<-((HDSS2response_utility*df1[,48]) + (HDSS3response_utility*df1[,49]) + (base_utility*df1[,46]) + (HDSS1response_utility*df1[,47]))/YrCycles ##Assumption of complete 
utility gain in first month
df1[,215]<-((HDSS2response_utility*df1[,52]) + (HDSS3response_utility*df1[,53]) + (base_utility*df1[,50]) + (HDSS1response_utility*df1[,51]))/YrCycles ##Assumption of complete 
utility gain in first month
df1[,218]<-((df1[,25]*df1[,251])+(df1[,26]*threeqrtsHDSSresponse_utility)+(df1[,27]*HDSS1response_utility)+(df1[,28]*base_utility)+(df1[,29]*0.487))/YrCycles
df1[,224]<-(((df1[,86]+df1[,87]+df1[,88])*HDSS1response_utility)+((df1[,89])*base_utility))/YrCycles 
df1[,225]<-0 ##zero utility when dead  
df1[,203]<-((HDSS2response_utility*df1[,40]/(df1[,40]+df1[,41])) + (HDSS3response_utility*df1[,41]/(df1[,40]+df1[,41])))/YrCycles ##Assumption of complete utility gain from 
second month
df1[,207]<-((HDSS2response_utility*df1[,44]/(df1[,44]+df1[,45])) + (HDSS3response_utility*df1[,45]/(df1[,44]+df1[,45])))/YrCycles ##Assumption of complete utility gain from 
second month
df1[,209]<-((HDSS2response_utility*df1[,48]/(df1[,48]+df1[,49])) + (HDSS3response_utility*df1[,49]/(df1[,49]+df1[,48])))/YrCycles ##Assumption of complete utility gain from 
second month
df1[,210]<-((HDSS2response_utility*df1[,48]/(df1[,48]+df1[,49])) + (HDSS3response_utility*df1[,49]/(df1[,49]+df1[,48])))/YrCycles ##Assumption of complete utility gain from 
second month
df1[,211]<-((HDSS2response_utility*df1[,48]/(df1[,48]+df1[,49])) + (HDSS3response_utility*df1[,49]/(df1[,49]+df1[,48])))/YrCycles ##Assumption of complete utility gain from 
second month
df1[,212]<-((HDSS2response_utility*df1[,48]/(df1[,48]+df1[,49])) + (HDSS3response_utility*df1[,49]/(df1[,49]+df1[,48])))/YrCycles ##Assumption of complete utility gain from
second month
df1[,213]<-((HDSS2response_utility*df1[,48]/(df1[,48]+df1[,49])) + (HDSS3response_utility*df1[,49]/(df1[,49]+df1[,48])))/YrCycles ##Assumption of complete utility gain from 
second month
df1[,214]<-((HDSS2response_utility*df1[,48]/(df1[,48]+df1[,49])) + (HDSS3response_utility*df1[,49]/(df1[,49]+df1[,48])))/YrCycles ##Assumption of complete utility gain from 
second month
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df1[,216]<-((HDSS2response_utility*df1[,52]/(df1[,52]+df1[,53])) + (HDSS3response_utility*df1[,53]/(df1[,53]+df1[,52])))/YrCycles ##Assumption of complete utility gain from 
second month
df1[,219]<-df1[,251]/YrCycles ##Assumption of complete utility gain from second month  
##Need to put in the CS utility scores  
df1[,217]<-base_utility/YrCycles ##Assumption of no utility gain with CS following curettage
df1[,220]<-threeqrtsHDSSresponse_utility/YrCycles ##Assumption of 1.5 HDSS utility gain with low/mild CS following ETS
df1[,221]<-HDSS1response_utility/YrCycles ##Assumption of 1 HDSS utility gain with moderate CS following ETS
df1[,222]<-base_utility/YrCycles ##Assumption of no utility gain with  high/severe CS following ETS
df1[,223]<-0.487/YrCycles ##Assumption of negative utility gain with  intervention regret CS following ETS.
#16th percentile of beta sample distribution of HDSS 4 in Base-case
if (sap3==1){}
if (sap3==2){   
df1[,223]<-0.571/YrCycles #25th percentile of beta sample distribution of HDSS 4 in Base-case
df1[,218]<-((df1[,25]*df1[,251])+(df1[,26]*threeqrtsHDSSresponse_utility)+(df1[,27]*HDSS1response_utility)+(df1[,28]*base_utility)+(df1[,29]*0.571))/YrCycles
}
if (sap3==3){    
df1[,223]<-0.21/YrCycles #2.5th percentile of beta sample distribution of HDSS 4 in Base-case
df1[,218]<-((df1[,25]*df1[,251])+(df1[,26]*threeqrtsHDSSresponse_utility)+(df1[,27]*HDSS1response_utility)+(df1[,28]*base_utility)+(df1[,29]*0.21))/YrCycles
}
#sensitivity analysis for emergency medication use
if (sap3==4){ 
df1[,204]<-(HDSS2response_utility*df1[,44] + HDSS3response_utility*df1[,45] + base_utility*df1[,42] + HDSS1response_utility*df1[,43])*(4/35)/YrCycles
df1[,205]<-(HDSS2response_utility*df1[,44] + HDSS3response_utility*df1[,45] + base_utility*df1[,42] + HDSS1response_utility*df1[,43])*(4/35)/YrCycles
df1[,206]<-(HDSS2response_utility*df1[,44] + HDSS3response_utility*df1[,45] + base_utility*df1[,42] + HDSS1response_utility*df1[,43])*(4/35)/YrCycles
df1[,207]<-(HDSS2response_utility*df1[,44] + HDSS3response_utility*df1[,45])*(4/35)/YrCycles
}
MORT <- rtrisk[i]
df1[,401]<-MORT
df1[,(1000+24*25+1):(1000+24*25+24)]<-df1[,401]  
#ALIVE <- 1-MORT
df1[,402] <- 1-df1[,401]    
##Transition probabilities grouped by original state, excluding transition to the next treatment and mortality  
#mModel["A","A"] <- ALIVE
df1[,1001]<-df1[,402]  
#IS_CONTINUE <- IS_R*ALIVE*IS_NSE
df1[,403] <- df1[,3]*df1[,402]*df1[,6]  
#IS_DROP <- 1-MORT-IS_CONTINUE ## drop out rate due to non-response and side effects
df1[,404] <- 1-df1[,401]-df1[,403] ## drop out rate due to non-response and side effects  
#mModel["IS","ISR"] <- IS_CONTINUE
df1[,(1000+2*25+2)]<-df1[,403]  
#mModel["IS","IS"] <- 0
df1[,(1000+1*25+2)]<-0
#mModel["ISR","ISR"] <- ALIVE
df1[,(1000+2*25+3)]<-df1[,402]  
#ISC_DROP <- (1-IS_R)*noben*ALIVE 
df1[,426] <- (1-df1[,3])*df1[,90]*df1[,402] ##Probability of progression following 
if (sap3==7){
#ISC_DROP <- (1-IS_R)*maxben*ALIVE   
df1[,426] <- (1-df1[,3])*df1[,91]*df1[,402] ##Probability of progression following   
}
#ISTF_DROP <- 1-MORT-IS_CONTINUE-ISC_DROP  #Progress to TF instead of minor surgery if medication partially successful
df1[,425] <- 1-df1[,401]-df1[,403]-df1[,426]  
#M_CONTINUE <- M_R*ALIVE*M_NSE
df1[,405] <- df1[,9]*df1[,402]*df1[,12]  
#M_DROP <- 1-MORT-M_CONTINUE ## drop out rate due to non-response and side effects
df1[,406] <- 1-df1[,401]-df1[,405] ## drop out rate due to non-response and side effects
#MC_DROP <- (1-M_R)*noben*ALIVE 
df1[,424] <- (1-df1[,9])*df1[,90]*df1[,402] ##Probability of progression following 
if (sap3==7){  
#MC_DROP <- (1-M_R)*maxben*ALIVE   
df1[,424] <- (1-df1[,9])*df1[,91]*df1[,402] ##Probability of progression following   
}
#MTF_DROP <- 1-MORT-M_CONTINUE-MC_DROP  #Progress to TF instead of minor surgery if medication partially successful
df1[,423] <- 1-df1[,401]-df1[,405]-df1[,424]  
#mModel["M3","MR"] <- M_CONTINUE
df1[,(1000+6*25+6)]<-df1[,405]
if (sap3==5){
#mModel["M3","MR"] <- 0
df1[,(1000+6*25+6)]<-0
}
#mModel["M1","M2"] <- ALIVE
df1[,(1000+4*25+4)]<-df1[,402]
if (sap3==5){    
df1[,(1000+4*25+4)]<-0
}
#mModel["M2","M3"] <- ALIVE
df1[,(1000+5*25+5)]<-df1[,402]  
if (sap3==5){    
df1[,(1000+5*25+5)]<-0
}
#mModel["M1","M1"] <- 0
df1[,(1000+3*25+4)]<-0
#mModel["M2","M2"] <- 0
df1[,(1000+4*25+5)]<-0
#mModel["M3","M3"] <- 0
df1[,(1000+5*25+6)]<-0
#MR_CONTINUE <- M_SR*ALIVE
df1[,407] <- df1[,13]*df1[,402]    
#mModel["MR","MR"] <- MR_CONTINUE ##Can vary this in SA to allow for decling effectiveness over time
df1[,(1000+6*25+7)]<-df1[,407]
#MR_DROP <- 1- MORT - MR_CONTINUE
df1[,432] <- 1 - df1[,401] - df1[,407]  
#M_SR_DROP <- 1-MORT-MR_CONTINUE
df1[,429] <- 1-df1[,401]-df1[,407]
#MC_SR_DROP <- noben*ALIVE 
df1[,430] <- df1[,90]*(1-df1[,13])*df1[,402] ##Probability of progression following 
if (sap3==7){  
#MC_SR_DROP <- maxben*ALIVE   
df1[,430] <- df1[,91]*(1-df1[,13])*df1[,402] ##Probability of progression following   
}
#MTF_SR_DROP <- 1-MORT-MR_CONTINUE-MC_SR_DROP  #Progress to TF instead of minor surgery if medication partially successful
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df1[,431] <- 1-df1[,401]-df1[,407]-df1[,430]      
#B_CONTINUE <- B_R*ALIVE*B_NSE
df1[,409] <- df1[,16]*df1[,402]*df1[,19]  
#B_DROP <- 1-MORT-B_CONTINUE ## drop out rate due to non-response and side effects. Assumption that botox
df1[,410] <- 1-df1[,401]-df1[,409] ## drop out rate due to non-response and side effects. Assumption that botox
#BC_DROP <- (1-B_R)*noben*ALIVE 
df1[,428] <- (1-df1[,16])*df1[,90]*df1[,402] ##Probability of progression following 
if (sap3==7){  
#BC_DROP <- (1-B_R)*maxben*ALIVE   
df1[,428] <- (1-df1[,16])*df1[,91]*df1[,402] ##Probability of progression following 
}
#BTF_DROP <- 1-MORT-B_CONTINUE-BC_DROP  #Progress to TF instead of minor surgery if medication partially successful
df1[,427] <- 1-df1[,401]-df1[,409]-df1[,428]
##drop outdue to side effects and lack of effectiveness occurs at the end of the first month and immediately
##move on to next treatment after 1st month
#mModel["B1","B2"] <- B_CONTINUE
df1[,(1000+8*25+8)]<-df1[,409]
#mModel["B1","B1"] <- 0
df1[,(1000+7*25+8)]<-0
#mModel["B2","B3"] <- ALIVE
df1[,(1000+9*25+9)]<-df1[,402]
#mModel["B3","B4"] <- ALIVE
df1[,(1000+10*25+10)]<-df1[,402]
#mModel["B4","B5"] <- ALIVE
df1[,(1000+11*25+11)]<-df1[,402]
#mModel["B5","B6"] <- ALIVE
df1[,(1000+12*25+12)]<-df1[,402]
#mModel["B6","BS"] <- ALIVE
df1[,(1000+13*25+13)]<-df1[,402]
#mModel["BS","B2"] <- ALIVE
df1[,(1000+8*25+14)]<-df1[,402]  
#CCS_TRANS <- CCS*ALIVE
df1[,411] <- df1[,24]*df1[,402]
#mModel["C","CCS"]<-CCS_TRANS
df1[,(1000+16*25+15)]<-df1[,411]
#mModel["C","C"] <- 0
df1[,(1000+14*25+15)]<-0
#no_CCS <- 1-CCS
df1[,412]<-1-df1[,24]  
#C_SUCCESS <- C_R*ALIVE*no_CCS
df1[,413] <- df1[,22]*df1[,402]*df1[,412]
#mModel["C","CR"]<-C_SUCCESS
df1[,(1000+15*25+15)]<-df1[,413]  
#C_DROP <- 1-MORT-CCS_TRANS-C_SUCCESS
df1[,414] <- 1-df1[,401]-df1[,411]-df1[,413]
#CC_DROP <- Rc0*ALIVE
df1[,434] <- df1[,50]*df1[,402]  
#CC_tf <- 1-MORT-CCS_TRANS-C_SUCCESS-CC_DROP
df1[,435] <- 1-df1[,401]-df1[,411]-df1[,413]-df1[,434]
#mModel["CR","CR"] <- ALIVE
df1[,(1000+15*25+16)]<-df1[,402]
#mModel["CCS","CCS"] <- ALIVE
df1[,(1000+16*25+17)]<-df1[,402]
#ELCS_TRANS <- ELCS*ALIVE
df1[,415] <- df1[,26]*df1[,402]
#mModel["E","ELCS"]<-ELCS_TRANS
df1[,(1000+19*25+18)]<-df1[,415]
#EMCS_TRANS <- EMCS*ALIVE
df1[,416] <- df1[,27]*df1[,402]
#mModel["E","EMCS"]<-EMCS_TRANS
df1[,(1000+20*25+18)]<-df1[,416]
#EHCS_TRANS <- EHCS*ALIVE
df1[,417] <- df1[,28]*df1[,402]
#mModel["E","EHCS"]<-EHCS_TRANS
df1[,(1000+21*25+18)]<-df1[,417]
#ERCS_TRANS <- ERCS*ALIVE
df1[,418] <- df1[,29]*df1[,402]
#mModel["E","ERCS"]<-ERCS_TRANS
df1[,(1000+22*25+18)]<-df1[,418]
#no_ECS <- 1-ELCS-EMCS-EHCS-ERCS
df1[,419] <- 1-df1[,26]-df1[,27]-df1[,28]-df1[,29]
#E_SUCCESS <- E_R*ALIVE*no_ECS
df1[,420] <- 1-df1[,415]-df1[,416]-df1[,417]-df1[,418]
#mModel["E","ER"]<-E_SUCCESS
df1[,(1000+18*25+18)]<-df1[,420]
#mModel["E","E"] <- 0
df1[,(1000+17*25+18)]<-0
#E_NR <- 1-MORT-ELCS_TRANS-EMCS_TRANS-EHCS_TRANS-ERCS_TRANS-E_SUCCESS
df1[,421] <- 1-df1[,401]-df1[,415]-df1[,416]-df1[,417]-df1[,418]-df1[,420]
#mModel["ER","ER"] <- ALIVE
df1[,(1000+18*25+19)]<-df1[,402]
#mModel["ELCS","ELCS"] <- ALIVE
df1[,(1000+19*25+20)]<-df1[,402]
#mModel["EMCS","EMCS"] <- ALIVE
df1[,(1000+20*25+21)]<-df1[,402]
#mModel["EHCS","EHCS"] <- ALIVE
df1[,(1000+21*25+22)]<-df1[,402]
#mModel["ERCS","ERCS"] <- ALIVE
df1[,(1000+22*25+23)]<-df1[,402]
#mModel["TF","TF"] <- ALIVE
df1[,(1000+23*25+24)]<-df1[,402]
#mModel["D","D"] <- 1
df1[,(1000+24*25+25)]<-1
###################################
#Set transition matrix for each sequence
###################################
if (b == 33| b == 34|b == 35|b == 36|b == 41|b == 42|b == 43|b == 44|b == 57|b == 58|b == 59|b == 60){   
#mModel["IS","M1"]<-IS_DROP
df1[,(1000+3*25+2)]<-df1[,404]
}
if (b == 25| b == 26|b == 27|b == 28|b == 45|b == 46|b == 47|b == 48|b == 49|b == 50|b == 51|b == 52){  
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#mModel["IS","B1"]<-IS_DROP
df1[,(1000+7*25+2)]<-df1[,404]
}
if (b == 15| b == 16|b == 31|b == 32|b == 39|b == 40|b == 55|b == 56|b == 63|b == 64){        
#mModel["IS","C"]<-ISC_DROP
df1[,(1000+14*25+2)]<-df1[,426]
#mModel["IS","TF"]<-ISTF_DROP
df1[,(1000+23*25+2)]<-df1[,425]    
}
if (sap3==6){
if (b == 15| b == 16|b == 31|b == 32|b == 39|b == 40|b == 55|b == 56|b == 63|b == 64){    
#mModel["IS","C"]<-IS_DROP
df1[,(1000+14*25+2)]<-df1[,404]    
}
}
if (b == 14| b == 30|b == 38|b == 54|b == 62){      
#mModel["IS","E"]<-ISC_DROP
df1[,(1000+17*25+2)]<-df1[,426]
#mModel["IS","TF"]<-ISTF_DROP
df1[,(1000+23*25+2)]<-df1[,425]    
}
if (sap3==6){    
if (b == 14| b == 30|b == 38|b == 54|b == 62){    
#mModel["IS","E"]<-IS_DROP
df1[,(1000+17*25+2)]<-df1[,404]
}
}
if (b == 13| b == 29|b == 37|b == 53|b == 61){    
#mModel["IS","TF"]<-IS_DROP
df1[,(1000+23*25+2)]<-df1[,404]
}
############################################
if (b == 37| b == 38|b == 39|b == 40|b == 49|b == 50|b == 51|b == 52|b == 61|b == 62|b == 63|b == 64){    
#mModel["M3","IS"]<-M_DROP
df1[,(1000+1*25+6)]<-df1[,406]
#mModel["MR","IS"]<-M_RSR
df1[,(1000+1*25+7)]<-df1[,432]
}
if (b == 17| b == 18|b == 19|b == 20|b == 41|b == 42|b == 43|b == 44|b == 53|b == 54|b == 55|b == 56){
#mModel["M3","B1"]<-M_DROP
df1[,(1000+7*25+6)]<-df1[,406]
#mModel["MR","B1"]<-MR-CONTINUE
df1[,(1000+7*25+7)]<-df1[,432]
}
if (b == 11| b == 12|b == 23|b == 24|b == 35|b == 36|b == 47|b == 48|b == 59|b == 60){
#mModel["M3","C"]<-MC_DROP
df1[,(1000+14*25+6)]<-df1[,424]   
#mModel["M3","TF"]<-MTF_DROP
df1[,(1000+23*25+6)]<-df1[,423]
#mModel["MR","C"]<-MC_SR_DROP
df1[,(1000+14*25+7)]<-df1[,431] 
#mModel["MR","TF"]<-MTF_SR_DROP
df1[,(1000+23*25+7)]<-df1[,430]
}
if (sap3==6){    
if (b == 11| b == 12|b == 23|b == 24|b == 35|b == 36|b == 47|b == 48|b == 59|b == 60){  
#mModel["M3","C"]<-M_DROP
df1[,(1000+14*25+6)]<-df1[,406]
#mModel["MR","C"]<-M_SR_DROP
df1[,(1000+14*25+7)]<-df1[,429]
}
}
if (b == 10| b == 22|b == 34|b == 46|b == 58){    
#mModel["M3","E"]<-MC_DROP
df1[,(1000+17*25+6)]<-df1[,424]    
#mModel["M3","TF"]<-MTF_DROP
df1[,(1000+23*25+6)]<-df1[,423]    
#mModel["MR","E"]<-MC_SR_DROP
df1[,(1000+17*25+7)]<-df1[,431]    
#mModel["MR","TF"]<-MTF_SR_DROP
df1[,(1000+23*25+7)]<-df1[,430]    
}
if (sap3==6){  
if (b == 10| b == 22|b == 34|b == 46|b == 58){    
#mModel["M3","E"]<-M_DROP
df1[,(1000+17*25+6)]<-df1[,406]    
#mModel["MR","E"]<-M_SR_DROP
df1[,(1000+17*25+7)]<-df1[,429]      
}
}
if (b == 9| b == 21|b == 33|b == 45|b == 57){    
#mModel["M3","TF"]<-M_DROP
df1[,(1000+23*25+6)]<-df1[,406]    
#mModel["MR","TF"]<-M_SR_DROP
df1[,(1000+23*25+7)]<-df1[,429]  
}
############################################
if (b == 29| b == 30|b == 31|b == 32|b == 53|b == 54|b == 55|b == 56|b == 57|b == 58|b == 59|b == 60){    
#mModel["B1","IS"]<-B_DROP
df1[,(1000+1*25+8)]<-df1[,410]
}
if (b == 21| b == 22|b == 23|b == 24|b == 45|b == 46|b == 47|b == 48|b == 61|b == 62|b == 63|b == 64){    
#mModel["B1","M1"]<-B_DROP
df1[,(1000+3*25+8)]<-df1[,410]  
}
if (b == 7| b == 8|b == 19|b == 20|b == 27|b == 28|b == 43|b == 44|b == 51|b == 52){  
#mModel["B1","C"]<-BC_DROP
df1[,(1000+14*25+8)]<-df1[,428]    
#mModel["B1","TF"]<-BTF_DROP
df1[,(1000+23*25+8)]<-df1[,427]    
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}
if (sap3==6){  
if (b == 7| b == 8|b == 19|b == 20|b == 27|b == 28|b == 43|b == 44|b == 51|b == 52){   
#mModel["B1","C"]<-B_DROP
df1[,(1000+14*25+8)]<-df1[,410]  
}
}
if (b == 6| b == 18|b == 26|b == 42|b == 50){    
#mModel["B1","E"]<-BC_DROP
df1[,(1000+17*25+8)]<-df1[,428]    
#mModel["B1","TF"]<-BTF_DROP
df1[,(1000+23*25+8)]<-df1[,427]    
}
if (sap3==6){  
if (b == 6| b == 18|b == 26|b == 42|b == 50){    
#mModel["B1","E"]<-B_DROP
df1[,(1000+17*25+8)]<-df1[,410]  
}
}
if (b == 5| b == 17|b == 25|b == 41|b == 49){    
#mModel["B1","TF"]<-B_DROP
df1[,(1000+23*25+8)]<-df1[,410]
}
##############################################
if (b == 4| b == 8|b == 12|b == 16|b == 20|b == 24|b == 28|b == 32|b == 36|b == 40|b == 44|b == 48|b == 52|
b == 56|b == 60|b == 64){  
#mModel["C","E"]<-CC_DROP
df1[,(1000+17*25+15)]<-df1[,434] 
#mModel["C","TF"]<-CC_tf
df1[,(1000+23*25+15)]<-df1[,435]  
}
if (sap3==6){
if (b == 4| b == 8|b == 12|b == 16|b == 20|b == 24|b == 28|b == 32|b == 36|b == 40|b == 44|b == 48|b == 52|
b == 56|b == 60|b == 64){   
#mModel["C","E"]<-C_DROP
df1[,(1000+17*25+15)]<-df1[,414]
}
}
if (b == 3| b == 7|b == 11|b == 15|b == 19|b == 23|b == 27|b == 31|b == 35|b == 39|b == 43|b == 47|b == 51|
b == 55|b == 59|b == 63){    
#mModel["C","TF"]<-C_DROP
df1[,(1000+23*25+15)]<-df1[,414]
}
##############################################
if (b == 2| b == 4|b == 6|b == 8|b == 10|b == 12|b == 14|b == 16|b == 18|b == 20|b == 22|b == 24|b == 26|
b == 28|b == 30|b == 32|b == 34|b == 36|b == 38|b == 40|b == 42|b == 44|b == 46|b == 48|b == 50|
b == 52|b == 54|b == 56|b == 58|b == 60|b == 62|b == 64){    
#mModel["E","TF"]<-0
df1[,(1000+23*25+18)]<-0
}
###########
##initial population cols: 87 to 109
for (j in 1:25){  
##define holding intermediate states: 1001:763 transition matrix; 789:1413 for intermediate states
df1[,(3001+(j-1)*25):(3025+(j-1)*25)]<-df1[,301:325]*df1[,(1001+(j-1)*25):(1001+24+(j-1)*25)]#A
}
for (j in 1:25){
##cols 89 to 113 becomes the holding vector for the initial population
df1[,(301+(j-1))]<-rowSums(df1[ ,(3001+(j-1)*25):(3025+(j-1)*25)])
}
##derive the population distirbutions from the second cycle onwards
df1[,(4001+(i-1)*25):(4025+(i-1)*25)]<-df1[,301:325]
##derive the QALYs from the second cycle onwards
df1[,(6001+(i-1)*25):(6025+(i-1)*25)]<-df1[,(4001+(i-1)*25):(4025+(i-1)*25)]*df1[,201:225]/(1+0.002871)^(i-0.5);
##derive the Costs from the second cycle onwards
df1[,(8001+(i-1)*25):(8025+(i-1)*25)]<-df1[,(4001+(i-1)*25):(4025+(i-1)*25)]*df1[,101:125]/(1+0.002871)^(i-0.5);
#Sum the QALYs across the states for each cycle
df1[,(10001+(i-1))]<-rowSums(df1[,(6001+(i-1)*25):(6025+(i-1)*25)])
#Sum the costs across the states for each iteration
df1[,(10101+(i-1))]<-rowSums(df1[,(8001+(i-1)*25):(8025+(i-1)*25)])
} #END OF i in 2:12 loop
#write.csv(df1, file = "df1.csv")
#adjust the costs to be annual costs
df1[,101:113]<-df1[,101:113]*12
df1[,115:125]<-df1[,115:125]*12
df1[,109:114]<-df1[,114]*2
#cpTF<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)*(1-ANTI drop out)
df1[,124]<-df1[,86]*(28.13+11.42)*12+df1[,87]*0*12+df1[,88]*df1[,114]*2+df1[,89]*(3.01+11.42)*12*(1-df1[,70])
#cpELCS<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
df1[,120]<-df1[,86]*(28.13+11.42)*12+df1[,87]*0*12+df1[,88]*df1[,114]*2+df1[,89]*(3.01+11.42)*12
#cpEMCS<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
df1[,121]<-df1[,86]*(28.13+11.42)*12+df1[,87]*0*12+df1[,88]*df1[,114]*2+df1[,89]*(3.01+11.42)*12
#cpEHCS<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
df1[,122]<-df1[,86]*(28.13+11.42)*12+df1[,87]*0*12+df1[,88]*df1[,114]*2+df1[,89]*(3.01+11.42)*12
#cpERCS<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
df1[,123]<-df1[,86]*(28.13+11.42)*12+df1[,87]*0*12+df1[,88]*df1[,114]*2+df1[,89]*(3.01+11.42)*12
if (b == 6|b == 8|b == 10|b == 12|b == 14|b == 16|b == 18|b == 20|b == 22|b == 24|b == 26|
b == 28|b == 30|b == 32|b == 34|b == 36|b == 38|b == 40|b == 42|b == 44|b == 46|b == 48|b == 50|
b == 52|b == 54|b == 56|b == 58|b == 60|b == 62|b == 64){  
#cpTF<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
df1[,124]<-(df1[,86]/(df1[,86]+df1[,87]+df1[,88]))*(28.13+11.42)*12+(df1[,87]/(df1[,86]+df1[,87]+df1[,88]))*0*12+
(df1[,88]/(df1[,86]+df1[,87]+df1[,88]))*df1[,114]*2    
}
if  (b == 2| b == 4){  
dfe[,124]<-0
}
#sensitivity analysis of NHS subsidising home iontophoresis
if (sap2==4){ 
cpISR<- 3.37 #Cost of NHS subsidising home iontophoresis 
dfe[,103]<-cpISR
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#cpTF<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)*(1-ANTI drop out)
df1[,124]<-df1[,86]*(28.13+11.42)*12+df1[,87]*3.37*12+df1[,88]*df1[,114]*2+df1[,89]*(3.01+11.42)*12*(1-df1[,70])
#cpELCS<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
df1[,120]<-df1[,86]*(28.13+11.42)*12+df1[,87]*3.37*12+df1[,88]*df1[,114]*2+df1[,89]*(3.01+11.42)*12
#cpEMCS<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
df1[,121]<-df1[,86]*(28.13+11.42)*12+df1[,87]*3.37*12+df1[,88]*df1[,114]*2+df1[,89]*(3.01+11.42)*12
#cpEHCS<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
df1[,122]<-df1[,86]*(28.13+11.42)*12+df1[,87]*3.37*12+df1[,88]*df1[,114]*2+df1[,89]*(3.01+11.42)*12
#cpERCS<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
df1[,123]<-df1[,86]*(28.13+11.42)*12+df1[,87]*3.37*12+df1[,88]*df1[,114]*2+df1[,89]*(3.01+11.42)*12  
if (b == 6|b == 8|b == 10|b == 12|b == 14|b == 16|b == 18|b == 20|b == 22|b == 24|b == 26|
b == 28|b == 30|b == 32|b == 34|b == 36|b == 38|b == 40|b == 42|b == 44|b == 46|b == 48|b == 50|
b == 52|b == 54|b == 56|b == 58|b == 60|b == 62|b == 64){ 
#cpTF<-tfMED*(28.13+11.42)+tfION*3.37+tfBOT*BScost+tfANTI*(3.01+11.42)
df1[,124]<-(df1[,86]/(df1[,86]+df1[,87]+df1[,88]))*(28.13+11.42)*12+(df1[,87]/(df1[,86]+df1[,87]+df1[,88]))*3.37*12+
(df1[,88]/(df1[,86]+df1[,87]+df1[,88]))*df1[,114]*2    
}
}
if (sap1==5){  
M_SR <- 0.970409082 #moderate decline in effectiveness over time  
}
if (sap1==6){
M_SR <- 0.886384872  #considerable decline in effectiveness over time  
}
df1[,13]<-M_SR
for (i in 13:58){   
##set utilities so that they don't exceed average population  
av_pop_utility <- avpop_utility[i]
df1[,251]<-av_pop_utility  
base_utility <- (df1[,58] + df1[,60])/2  
HDSS1response_utility <- (df1[,56] + df1[,58])/2
if (sap3==8){
HDSS1response_utility <- df1[,58]
}
halfHDSSresponse_utility <- (base_utility + HDSS1response_utility)/2
HDSS2response_utility <- (df1[,56]+df1[,251])/2 #correct to ensure that utility isn't higher than population average for older persons
df1[,252]<-HDSS2response_utility
df1[,252]<-ifelse(df1[,252]>df1[,251],df1[,251],df1[,252])  
threeqrtsHDSSresponse_utility <- (HDSS1response_utility + df1[,252])/2  
HDSS3response_utility <- df1[,251]
df1[,201]<- halfHDSSresponse_utility*(1-df1[70])
df1[,202]<-((df1[,252]*df1[,40]) + (HDSS3response_utility*df1[,41]) + (base_utility*df1[,38]) + (HDSS1response_utility*df1[,39]))##Assumption of complete utility gain in first month
df1[,204]<-((df1[,252]*df1[,44]) + (HDSS3response_utility*df1[,45]) + (base_utility*df1[,42]) + (HDSS1response_utility*df1[,43])) ##Assumption of complete utility gain in first 
month
df1[,205]<-((df1[,252]*df1[,44]) + (HDSS3response_utility*df1[,45]) + (base_utility*df1[,42]) + (HDSS1response_utility*df1[,43])) ##Assumption of complete utility gain in first 
month
df1[,206]<-((df1[,252]*df1[,44]) + (HDSS3response_utility*df1[,45]) + (base_utility*df1[,42]) + (HDSS1response_utility*df1[,43])) ##Assumption of complete utility gain in first 
month
df1[,208]<-((df1[,252]*df1[,48]) + (HDSS3response_utility*df1[,49]) + (base_utility*df1[,46]) + (HDSS1response_utility*df1[,47])) ##Assumption of complete utility gain in first 
month
df1[,215]<-((df1[,252]*df1[,52]) + (HDSS3response_utility*df1[,53]) + (base_utility*df1[,50]) + (HDSS1response_utility*df1[,51])) ##Assumption of complete utility gain in first 
month
df1[,218]<-((df1[,25]*df1[,251])+(df1[,26]*threeqrtsHDSSresponse_utility)+(df1[,27]*HDSS1response_utility)+(df1[,28]*base_utility)+(df1[,29]*0.487))
df1[,224]<-(((df1[,86]+df1[,87]+df1[,88])*HDSS1response_utility)+((df1[,89])*base_utility)) 
if (b == 2| b == 4|b == 6|b == 8|b == 10|b == 12|b == 14|b == 16|b == 18|b == 20|b == 22|b == 24|b == 26|
b == 28|b == 30|b == 32|b == 34|b == 36|b == 38|b == 40|b == 42|b == 44|b == 46|b == 48|b == 50|
b == 52|b == 54|b == 56|b == 58|b == 60|b == 62|b == 64){    
df1[,224]<-HDSS1response_utility
}
df1[,225]<-0 ##zero utility when dead  
df1[,203]<-((df1[,252]*df1[,40]/(df1[,40]+df1[,41])) + (HDSS3response_utility*df1[,41]/(df1[,40]+df1[,41]))) ##Assumption of complete utility gain from second month
df1[,207]<-((df1[,252]*df1[,44]/(df1[,44]+df1[,45])) + (HDSS3response_utility*df1[,45]/(df1[,44]+df1[,45]))) ##Assumption of complete utility gain from second month
df1[,209]<-((df1[,252]*df1[,48]/(df1[,48]+df1[,49])) + (HDSS3response_utility*df1[,49]/(df1[,49]+df1[,48]))) ##Assumption of complete utility gain from second month
df1[,210]<-((df1[,252]*df1[,48]/(df1[,48]+df1[,49])) + (HDSS3response_utility*df1[,49]/(df1[,49]+df1[,48]))) ##Assumption of complete utility gain from second month
df1[,211]<-((df1[,252]*df1[,48]/(df1[,48]+df1[,49])) + (HDSS3response_utility*df1[,49]/(df1[,49]+df1[,48]))) ##Assumption of complete utility gain from second month
df1[,212]<-((df1[,252]*df1[,48]/(df1[,48]+df1[,49])) + (HDSS3response_utility*df1[,49]/(df1[,49]+df1[,48]))) ##Assumption of complete utility gain from second month
df1[,213]<-((df1[,252]*df1[,48]/(df1[,48]+df1[,49])) + (HDSS3response_utility*df1[,49]/(df1[,49]+df1[,48]))) ##Assumption of complete utility gain from second month
df1[,214]<-((df1[,252]*df1[,48]/(df1[,48]+df1[,49])) + (HDSS3response_utility*df1[,49]/(df1[,49]+df1[,48]))) ##Assumption of complete utility gain from second month
df1[,216]<-((df1[,252]*df1[,52]/(df1[,52]+df1[,53])) + (HDSS3response_utility*df1[,53]/(df1[,53]+df1[,52]))) ##Assumption of complete utility gain from second month
df1[,219]<-df1[,251] ##Assumption of complete utility gain from second month  
##Need to put in the CS utility scores  
df1[,217]<-base_utility ##Assumption of no utility gain with CS following curettage
df1[,220]<-threeqrtsHDSSresponse_utility ##Assumption of 1.5 HDSS utility gain with low/mild CS following ETS
df1[,221]<-HDSS1response_utility ##Assumption of 1 HDSS utility gain with moderate CS following ETS
df1[,222]<-base_utility ##Assumption of no utility gain with  high/severe CS following ETS
df1[,223]<-0.487 ##Assumption of negative utility gain with  intervention regret CS following ETS.
#16th percentile of beta sample distribution of HDSS 4 in Base-case
if (sap3==1){}
if (sap3==2){
df1[,223]<-0.571 #25th percentile of beta sample distribution of HDSS 4 in Base-case
df1[,218]<-((df1[,25]*df1[,251])+(df1[,26]*threeqrtsHDSSresponse_utility)+(df1[,27]*HDSS1response_utility)+(df1[,28]*base_utility)+(df1[,29]*0.571))
}
if (sap3==3){  
df1[,223]<-0.21 #2.5th percentile of beta sample distribution of HDSS 4 in Base-case
df1[,218]<-((df1[,25]*df1[,251])+(df1[,26]*threeqrtsHDSSresponse_utility)+(df1[,27]*HDSS1response_utility)+(df1[,28]*base_utility)+(df1[,29]*0.21))
}
#sensitivity analysis for emergency medication use
if (sap3==4){  
df1[,204]<-(df1[,252]*df1[,44] + HDSS3response_utility*df1[,45] + base_utility*df1[,42] + HDSS1response_utility*df1[,43])*(4/35)
df1[,207]<-(df1[,252]*df1[,44] + HDSS3response_utility*df1[,45])*(4/35)
}
# df1[,114:138]<-df1[,201:225]  
#  df1[,639:(1000+24*25+25)]<-rtrisk[i]  
MORT <- rtrisk[i]
df1[,401]<-MORT
df1[,(1000+24*25+1):(1000+24*25+24)]<-df1[,401]
#ALIVE <- 1-MORT
df1[,402] <- 1-df1[,401]  
##Transition probabilities grouped by original state, excluding transition to the next treatment and mortality
#mModel["A","A"] <- ALIVE
df1[,1001]<-df1[,402]
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#IS_CONTINUE <- IS_R*ALIVE*IS_NSE
df1[,403] <- df1[,3]*df1[,402]*df1[,6]
#IS_DROP <- 1-MORT-IS_CONTINUE ## drop out rate due to non-response and side effects
df1[,404] <- 1-df1[,401]-df1[,403] ## drop out rate due to non-response and side effects
#mModel["IS","ISR"] <- IS_CONTINUE
df1[,(1000+2*25+2)]<-df1[,403]
#mModel["IS","IS"] <- 0
df1[,(1000+1*25+2)]<-0
#mModel["ISR","ISR"] <- ALIVE
df1[,(1000+2*25+3)]<-df1[,402]
#ISC_DROP <- (1-IS_R)*noben*ALIVE 
df1[,426] <- (1-df1[,3])*df1[,90]*df1[,402] ##Probability of progression following 
if (sap3==7){
#ISC_DROP <- (1-IS_R)*maxben*ALIVE   
df1[,426] <- (1-df1[,3])*df1[,91]*df1[,402] ##Probability of progression following   
}
#ISTF_DROP <- 1-MORT-IS_CONTINUE-ISC_DROP  #Progress to TF instead of minor surgery if medication partially successful
df1[,425] <- 1-df1[,401]-df1[,403]-df1[,426]
#M_CONTINUE <- M_R*ALIVE*M_NSE
df1[,405] <- df1[,9]*df1[,402]*df1[,12]
#M_DROP <- 1-MORT-M_CONTINUE ## drop out rate due to non-response and side effects
df1[,406] <- 1-df1[,401]-df1[,405] ## drop out rate due to non-response and side effects
#MC_DROP <- (1-M_R)*noben*ALIVE 
df1[,424] <- (1-df1[,9])*df1[,90]*df1[,402] ##Probability of progression following 
if (sap3==7){
#MC_DROP <- (1-M_R)*maxben*ALIVE   
df1[,424] <- (1-df1[,9])*df1[,91]*df1[,402] ##Probability of progression following 
}
#MTF_DROP <- 1-MORT-M_CONTINUE-MC_DROP  #Progress to TF instead of minor surgery if medication partially successful
df1[,423] <- 1-df1[,401]-df1[,405]-df1[,424]
#mModel["M3","MR"] <- M_CONTINUE
df1[,(1000+6*25+6)]<-df1[,405]
if (sap3==5){
#mModel["M3","MR"] <- 0
df1[,(1000+6*25+6)]<-0
}
#mModel["M1","M2"] <- ALIVE
df1[,(1000+4*25+4)]<-df1[,402]
if (sap3==5){  
df1[,(1000+4*25+4)]<-0
}
#mModel["M2","M3"] <- ALIVE
df1[,(1000+5*25+5)]<-df1[,402]
if (sap3==5){ 
df1[,(1000+5*25+5)]<-0
}
#mModel["M1","M1"] <- 0
df1[,(1000+3*25+4)]<-0
#mModel["M2","M2"] <- 0
df1[,(1000+4*25+5)]<-0
#mModel["M3","M3"] <- 0
df1[,(1000+5*25+6)]<-0
#MR_CONTINUE <- M_SR*ALIVE
df1[,407] <- df1[,13]*df1[,402]
#mModel["MR","MR"] <- MR_CONTINUE ##Can vary this in SA to allow for decling effectiveness over time
df1[,(1000+6*25+7)]<-df1[,407]
#MR_DROP <- 1- MORT - MR_CONTINUE
df1[,432] <- 1 - df1[,401] - df1[,407]
#M_SR_DROP <- 1-MORT-MR_CONTINUE
df1[,429] <- 1-df1[,401]-df1[,407]
#MC_SR_DROP <- noben*ALIVE 
df1[,430] <- df1[,90]*(1-df1[,13])*df1[,402] ##Probability of progression following 
if (sap3==7){ 
#MC_SR_DROP <- maxben*ALIVE   
df1[,430] <- df1[,91]*(1-df1[,13])*df1[,402] ##Probability of progression following   
}
#MTF_SR_DROP <- 1-MORT-MR_CONTINUE-MC_SR_DROP  #Progress to TF instead of minor surgery if medication partially successful
df1[,431] <- 1-df1[,401]-df1[,407]-df1[,430]  
#B_CONTINUE <- B_R*ALIVE*B_NSE
df1[,409] <- df1[,16]*df1[,402]*df1[,19]
#B_DROP <- 1-MORT-B_CONTINUE ## drop out rate due to non-response and side effects. Assumption that botox
df1[,410] <- 1-df1[,401]-df1[,409] ## drop out rate due to non-response and side effects. Assumption that botox
#BC_DROP <- (1-B_R)*noben*ALIVE 
df1[,428] <- (1-df1[,16])*df1[,90]*df1[,402] ##Probability of progression following 
if (sap3==7){ 
#BC_DROP <- (1-B_R)*maxben*ALIVE   
df1[,428] <- (1-df1[,16])*df1[,91]*df1[,402] ##Probability of progression following   
}
#BTF_DROP <- 1-MORT-B_CONTINUE-BC_DROP  #Progress to TF instead of minor surgery if medication partially successful
df1[,427] <- 1-df1[,401]-df1[,409]-df1[,428]
##drop outdue to side effects and lack of effectiveness occurs at the end of the first month and immediately
##move on to next treatment after 1st month
#mModel["B1","B2"] <- B_CONTINUE
df1[,(1000+8*25+8)]<-df1[,409]
#mModel["B1","B1"] <- 0
df1[,(1000+7*25+8)]<-0
#mModel["B2","B3"] <- ALIVE
df1[,(1000+9*25+9)]<-df1[,402]
#mModel["B3","B4"] <- ALIVE
df1[,(1000+10*25+10)]<-df1[,402]
#mModel["B4","B5"] <- ALIVE
df1[,(1000+11*25+11)]<-df1[,402]
#mModel["B5","B6"] <- ALIVE
df1[,(1000+12*25+12)]<-df1[,402]
#mModel["B6","BS"] <- ALIVE
df1[,(1000+13*25+13)]<-df1[,402]
#mModel["BS","B2"] <- ALIVE
df1[,(1000+8*25+14)]<-df1[,402]
#CCS_TRANS <- CCS*ALIVE
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df1[,411] <- df1[,24]*df1[,402]
#mModel["C","CCS"]<-CCS_TRANS
df1[,(1000+16*25+15)]<-df1[,411]
#mModel["C","C"] <- 0
df1[,(1000+14*25+15)]<-0
#no_CCS <- 1-CCS 
df1[,412]<-1-df1[,24]
#C_SUCCESS <- C_R*ALIVE*no_CCS
df1[,413] <- df1[,22]*df1[,402]*df1[,412]
#mModel["C","CR"]<-C_SUCCESS
df1[,(1000+15*25+15)]<-df1[,413]
#C_DROP <- 1-MORT-CCS_TRANS-C_SUCCESS
df1[,414] <- 1-df1[,401]-df1[,411]-df1[,413]
#CC_DROP <- Rc0*ALIVE
df1[,434] <- df1[,50]*df1[,402]
#CC_tf <- 1-MORT-CCS_TRANS-C_SUCCESS-CC_DROP
df1[,435] <- 1-df1[,401]-df1[,411]-df1[,413]-df1[,434]
#mModel["CR","CR"] <- ALIVE
df1[,(1000+15*25+16)]<-df1[,402]
#mModel["CCS","CCS"] <- ALIVE
df1[,(1000+16*25+17)]<-df1[,402]
#ELCS_TRANS <- ELCS*ALIVE
df1[,415] <- df1[,26]*df1[,402]
#mModel["E","ELCS"]<-ELCS_TRANS
df1[,(1000+19*25+18)]<-df1[,415]
#EMCS_TRANS <- EMCS*ALIVE
df1[,416] <- df1[,27]*df1[,402]
#mModel["E","EMCS"]<-EMCS_TRANS
df1[,(1000+20*25+18)]<-df1[,416]
#EHCS_TRANS <- EHCS*ALIVE
df1[,417] <- df1[,28]*df1[,402]
#mModel["E","EHCS"]<-EHCS_TRANS
df1[,(1000+21*25+18)]<-df1[,417]
#ERCS_TRANS <- ERCS*ALIVE
df1[,418] <- df1[,29]*df1[,402]
#mModel["E","ERCS"]<-ERCS_TRANS
df1[,(1000+22*25+18)]<-df1[,418]
#no_ECS <- 1-ELCS-EMCS-EHCS-ERCS
df1[,419] <- 1-df1[,26]-df1[,27]-df1[,28]-df1[,29]
#E_SUCCESS <- E_R*ALIVE*no_ECS
df1[,420] <- 1-df1[,415]-df1[,416]-df1[,417]-df1[,418]
#mModel["E","ER"]<-E_SUCCESS
df1[,(1000+18*25+18)]<-df1[,420]
#mModel["E","E"] <- 0
df1[,(1000+17*25+18)]<-0
#E_NR <- 1-MORT-ELCS_TRANS-EMCS_TRANS-EHCS_TRANS-ERCS_TRANS-E_SUCCESS
df1[,421] <- 1-df1[,401]-df1[,415]-df1[,416]-df1[,417]-df1[,418]-df1[,420]
#mModel["ER","ER"] <- ALIVE
df1[,(1000+18*25+19)]<-df1[,402]
#mModel["ELCS","ELCS"] <- ALIVE
df1[,(1000+19*25+20)]<-df1[,402]
#mModel["EMCS","EMCS"] <- ALIVE
df1[,(1000+20*25+21)]<-df1[,402]
#mModel["EHCS","EHCS"] <- ALIVE
df1[,(1000+21*25+22)]<-df1[,402]
#mModel["ERCS","ERCS"] <- ALIVE
df1[,(1000+22*25+23)]<-df1[,402]
#mModel["TF","TF"] <- ALIVE
df1[,(1000+23*25+24)]<-df1[,402]
#mModel["D","D"] <- 1
df1[,(1000+24*25+25)]<-1
###################################
#Set transition matrix for each sequence
###################################
if (b == 33| b == 34|b == 35|b == 36|b == 41|b == 42|b == 43|b == 44|b == 57|b == 58|b == 59|b == 60){  
#mModel["IS","M1"]<-IS_DROP
df1[,(1000+3*25+2)]<-df1[,404]
}
if (b == 25| b == 26|b == 27|b == 28|b == 45|b == 46|b == 47|b == 48|b == 49|b == 50|b == 51|b == 52){  
#mModel["IS","B1"]<-IS_DROP
df1[,(1000+7*25+2)]<-df1[,404]
}
if (b == 15| b == 16|b == 31|b == 32|b == 39|b == 40|b == 55|b == 56|b == 63|b == 64){  
#mModel["IS","C"]<-ISC_DROP
df1[,(1000+14*25+2)]<-df1[,426]  
#mModel["IS","TF"]<-ISTF_DROP
df1[,(1000+23*25+2)]<-df1[,425]  
}
if (sap3==6){  
if (b == 15| b == 16|b == 31|b == 32|b == 39|b == 40|b == 55|b == 56|b == 63|b == 64){    
#mModel["IS","C"]<-IS_DROP
df1[,(1000+14*25+2)]<-df1[,404]    
}
}
if (b == 14| b == 30|b == 38|b == 54|b == 62){  
#mModel["IS","E"]<-ISC_DROP
df1[,(1000+17*25+2)]<-df1[,426] 
#mModel["IS","TF"]<-ISTF_DROP
df1[,(1000+23*25+2)]<-df1[,425]
}
if (sap3==6){
if (b == 14| b == 30|b == 38|b == 54|b == 62){
#mModel["IS","E"]<-IS_DROP
df1[,(1000+17*25+2)]<-df1[,404]
}
}
if (b == 13| b == 29|b == 37|b == 53|b == 61){
#mModel["IS","TF"]<-IS_DROP
df1[,(1000+23*25+2)]<-df1[,404]
}
############################################
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if (b == 37| b == 38|b == 39|b == 40|b == 49|b == 50|b == 51|b == 52|b == 61|b == 62|b == 63|b == 64){
#mModel["M3","IS"]<-M_DROP
df1[,(1000+1*25+6)]<-df1[,406]
#mModel["MR","IS"]<-M_RSR
df1[,(1000+1*25+7)]<-df1[,432]
}
if (b == 17| b == 18|b == 19|b == 20|b == 41|b == 42|b == 43|b == 44|b == 53|b == 54|b == 55|b == 56){  
#mModel["M3","B1"]<-M_DROP
df1[,(1000+7*25+6)]<-df1[,406]
#mModel["MR","B1"]<-MR-CONTINUE
df1[,(1000+7*25+7)]<-df1[,432]
}
if (b == 11| b == 12|b == 23|b == 24|b == 35|b == 36|b == 47|b == 48|b == 59|b == 60){
#mModel["M3","C"]<-MC_DROP
df1[,(1000+14*25+6)]<-df1[,424]  
#mModel["M3","TF"]<-MTF_DROP
df1[,(1000+23*25+6)]<-df1[,423] 
#mModel["MR","C"]<-MC_SR_DROP
df1[,(1000+14*25+7)]<-df1[,431]
#mModel["MR","TF"]<-MTF_SR_DROP
df1[,(1000+23*25+7)]<-df1[,430]
}
if (sap3==6){  
if (b == 11| b == 12|b == 23|b == 24|b == 35|b == 36|b == 47|b == 48|b == 59|b == 60){    
#mModel["M3","C"]<-M_DROP
df1[,(1000+14*25+6)]<-df1[,406]
#mModel["MR","C"]<-M_SR_DROP
df1[,(1000+14*25+7)]<-df1[,429]
}
}
if (b == 10| b == 22|b == 34|b == 46|b == 58){  
#mModel["M3","E"]<-MC_DROP
df1[,(1000+17*25+6)]<-df1[,424]  
#mModel["M3","TF"]<-MTF_DROP
df1[,(1000+23*25+6)]<-df1[,423]  
#mModel["MR","E"]<-MC_SR_DROP
df1[,(1000+17*25+7)]<-df1[,431]  
#mModel["MR","TF"]<-MTF_SR_DROP
df1[,(1000+23*25+7)]<-df1[,430]  
}
if (sap3==6){  
if (b == 10| b == 22|b == 34|b == 46|b == 58){    
#mModel["M3","E"]<-M_DROP
df1[,(1000+17*25+6)]<-df1[,406]  
#mModel["MR","E"]<-M_SR_DROP
df1[,(1000+17*25+7)]<-df1[,429]    
}
}
if (b == 9| b == 21|b == 33|b == 45|b == 57){  
#mModel["M3","TF"]<-M_DROP
df1[,(1000+23*25+6)]<-df1[,406]  
#mModel["MR","TF"]<-M_SR_DROP
df1[,(1000+23*25+7)]<-df1[,429]
}
############################################
if (b == 29| b == 30|b == 31|b == 32|b == 53|b == 54|b == 55|b == 56|b == 57|b == 58|b == 59|b == 60){  
#mModel["B1","IS"]<-B_DROP
df1[,(1000+1*25+8)]<-df1[,410]
}
if (b == 21| b == 22|b == 23|b == 24|b == 45|b == 46|b == 47|b == 48|b == 61|b == 62|b == 63|b == 64){  
#mModel["B1","M1"]<-B_DROP
df1[,(1000+3*25+8)]<-df1[,410]  
}
if (b == 7| b == 8|b == 19|b == 20|b == 27|b == 28|b == 43|b == 44|b == 51|b == 52){  
#mModel["B1","C"]<-BC_DROP
df1[,(1000+14*25+8)]<-df1[,428]  
#mModel["B1","TF"]<-BTF_DROP
df1[,(1000+23*25+8)]<-df1[,427]
}
if (sap3==6){
if (b == 7| b == 8|b == 19|b == 20|b == 27|b == 28|b == 43|b == 44|b == 51|b == 52){    
#mModel["B1","C"]<-B_DROP
df1[,(1000+14*25+8)]<-df1[,410]
}
}
if (b == 6| b == 18|b == 26|b == 42|b == 50){  
#mModel["B1","E"]<-BC_DROP
df1[,(1000+17*25+8)]<-df1[,428]  
#mModel["B1","TF"]<-BTF_DROP
df1[,(1000+23*25+8)]<-df1[,427]  
}
if (sap3==6){
if (b == 6| b == 18|b == 26|b == 42|b == 50){    
#mModel["B1","E"]<-B_DROP
df1[,(1000+17*25+8)]<-df1[,410]
}
}
if (b == 5| b == 17|b == 25|b == 41|b == 49){
#mModel["B1","TF"]<-B_DROP
df1[,(1000+23*25+8)]<-df1[,410]
}
##############################################
if (b == 4| b == 8|b == 12|b == 16|b == 20|b == 24|b == 28|b == 32|b == 36|b == 40|b == 44|b == 48|b == 52|
b == 56|b == 60|b == 64){  
#mModel["C","E"]<-CC_DROP
df1[,(1000+17*25+15)]<-df1[,434]  
#mModel["C","TF"]<-CC_tf
df1[,(1000+23*25+15)]<-df1[,435]  
}
if (sap3==6){  
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if (b == 4| b == 8|b == 12|b == 16|b == 20|b == 24|b == 28|b == 32|b == 36|b == 40|b == 44|b == 48|b == 52|
b == 56|b == 60|b == 64){    
#mModel["C","E"]<-C_DROP
df1[,(1000+17*25+15)]<-df1[,414]
}
}
if (b == 3| b == 7|b == 11|b == 15|b == 19|b == 23|b == 27|b == 31|b == 35|b == 39|b == 43|b == 47|b == 51|
b == 55|b == 59|b == 63){  
#mModel["C","TF"]<-C_DROP
df1[,(1000+23*25+15)]<-df1[,414]
}
##############################################
if (b == 2| b == 4|b == 6|b == 8|b == 10|b == 12|b == 14|b == 16|b == 18|b == 20|b == 22|b == 24|b == 26|
b == 28|b == 30|b == 32|b == 34|b == 36|b == 38|b == 40|b == 42|b == 44|b == 46|b == 48|b == 50|
b == 52|b == 54|b == 56|b == 58|b == 60|b == 62|b == 64){  
#mModel["E","TF"]<-0
df1[,(1000+23*25+18)]<-0
}
########################################
for (j in 1:25){
##define holding intermediate states  
df1[,(3001+(j-1)*25):(3025+(j-1)*25)]<-df1[,301:325]*df1[,(1001+(j-1)*25):(1001+24+(j-1)*25)]#A      
}
for (j in 1:25){  
##holding vector for the initial population
df1[,(301+(j-1))]<-rowSums(df1[ ,(3001+(j-1)*25):(3025+(j-1)*25)])
}
##derive the population distirbutions from the second cycle onwards
df1[,(4001+(i-1)*25):(4025+(i-1)*25)]<-df1[,301:325]
df1[,(6001+(i-1)*25):(6025+(i-1)*25)]<-df1[,(4001+(i-1)*25):(4025+(i-1)*25)]*(df1[,201:225]/(1+0.035)^(i-11-0.5));
##derive the Costs from the second cycle onwards
df1[,(8001+(i-1)*25):(8025+(i-1)*25)]<-df1[,(4001+(i-1)*25):(4025+(i-1)*25)]*df1[,101:125]/(1+0.035)^(i-11-0.5);
#Sum the QALYs across the states for each cycle
df1[,(10001+(i-1))]<-rowSums(df1[,(6001+(i-1)*25):(6025+(i-1)*25)])
#Sum the costs across the states for each iteration
df1[,(10101+(i-1))]<-rowSums(df1[,(8001+(i-1)*25):(8025+(i-1)*25)])
} #END i in 13:58 loop
#Sum the QALYs across the cycles
df1[,10201]<-rowSums(df1[,10001:10058])
#Sum the Costs across the cycles
df1[,10202]<-rowSums(df1[,10101:10158])
rmd[,(1+b)]<-df1[,10201]
rmd[,(65+b)]<-df1[,10202]
}#end intervention loop
mcmc<-rmd
(mcmc);
}
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Appendix 14 End-of-project workshop documents
Research project to investigate the management and treatment
of hyperhidrosis
Health Technology Assessment project: 14/211/02 – interventional management of
hyperhidrosis: an evidence synthesis and value-of-information analysis
The emotional, psychosocial and physical impact of hyperhidrosis is substantial and the optimal
management of patients with this condition is essential. There is substantial variation in which treatments
are available in the NHS and access to treatments is limited for many patients. In addition, decisions about
which treatments to use are often made in a context of uncertainty.
The National Institute for Health Research have provided funding to thoroughly review the evidence for the
different treatments for hyperhidrosis. A team of researchers from the University of York and Newcastle
University have come together with clinicians in dermatology and surgery to carry out this research. The
focus of the project is to undertake a review of studies on all potentially useful treatments, supplemented
by patients’ view regarding important treatment effects, to establish which treatments are most potentially
effective and value for money to both the NHS and public. The results will help inform further research.
The research project started on 1 December 2015 and will be completed by 14 December 2016.
We will report the results of the project to our patient advisors at a workshop on 18 November 2016. We
would appreciate any feedback you can offer at that time regarding our findings and recommendations.
Workshop 18 November 2016
Outline
l Introduction and welcome.
l Short presentation of the project and its purpose.
l Review results:
¢ which treatments have been studied
¢ which ones definitely work (good evidence)
¢ which ones definitely do not work (good evidence)
¢ which look promising but more research needed.
l Economic modelling methods and results.
l Discussion of trials that might be recommended.
l Discussion of tools used for measuring quality of life.
Quality-of-life questionnaires
We would be very interested in hearing your thoughts and opinions regarding the attached quality-of-life
questionnaires and the ways quality of life are measured in patients with hyperhidrosis.
Please could you consider the following questions and we look forward to discussing your views at the
workshop.
l Which quality-of-life tool do you find the easiest to complete?
l Which tool is the most appropriate to capture quality-of-life issues for patients with hyperhidrosis?
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l Do you feel a combination of tools or questions would be best to address quality of life in patients
with hyperhidrosis?
l In your opinion do the questions in the new HidroQoL© tool address all the quality-of-life issues a
patient with hyperhidrosis may have? Is there anything you feel is lacking from the HidroQoL© tool?
l Do you have any further comments you wish to share?
Thank you for taking the time to consider these questions.
Links to the quality-of-life questionnaires
Dermatology Life Quality Index
URL: http://sites.cardiff.ac.uk/dermatology/quality-of-life/dermatology-quality-of-life-index-dlqi/
(accessed 18 November 2016).
Hyperhidrosis Disease Severity Scale
URL: www.sweathelp.org/pdf/HDSS.pdf (accessed 18 November 2016).
Hyperhidrosis Quality of Life Questionnaire
URL: www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-35862003000400003#at
(accessed 18 November 2016).
Hyperhidrosis Quality of Life Index
URL: www.ncbi.nlm.nih.gov/pmc/articles/PMC4366556/figure/Fig3/ (accessed 18 November 2016).
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